<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006196" GROUP_ID="SCHIZ" ID="538006031016370010" MERGED_FROM="" MODIFIED="2013-07-10 14:55:17 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.6">
<COVER_SHEET MODIFIED="2013-07-10 14:55:17 +0100" MODIFIED_BY="Claire Irving">
<TITLE MODIFIED="2009-12-10 15:12:11 +0000" MODIFIED_BY="[Empty name]">Intermittent drug techniques for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-07-10 14:55:17 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="47582939521085724166111208154807" ROLE="AUTHOR"><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Sampson</LAST_NAME><POSITION>Systematic Reviewer</POSITION><EMAIL_1>stephanie.sampson@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Jubilee Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441158231287</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-07-10 14:55:17 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="47582939521085724166111208154807" ROLE="AUTHOR"><FIRST_NAME>Stephanie</FIRST_NAME><LAST_NAME>Sampson</LAST_NAME><POSITION>Systematic Reviewer</POSITION><EMAIL_1>stephanie.sampson@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Jubilee Campus</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+441158231287</PHONE_1></ADDRESS></PERSON><PERSON ID="BB452EA382E26AA20047FC7157CD5ECF" ROLE="AUTHOR"><FIRST_NAME>Mouhamad</FIRST_NAME><LAST_NAME>Mansour</LAST_NAME><POSITION>Resident</POSITION><EMAIL_1>Pioneer_mmm@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Internal Medicine</DEPARTMENT><ORGANISATION>Henry Ford Hospital</ORGANISATION><ADDRESS_1>2799 W. Grand Blvd</ADDRESS_1><ADDRESS_2>CFP-1</ADDRESS_2><CITY>Detroit</CITY><ZIP>48202</ZIP><REGION>MI</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 313 695-3371</PHONE_1></ADDRESS></PERSON><PERSON ID="32829627489460063558100414114554" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Nicola</FIRST_NAME><LAST_NAME>Maayan</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>Nicola@enhance-reviews.com</EMAIL_1><ADDRESS><ORGANISATION>Enhance Reviews Ltd</ORGANISATION><ADDRESS_1>Central Office, Cobweb Buildings</ADDRESS_1><ADDRESS_2>The Lane, Lyford</ADDRESS_2><CITY>Wantage</CITY><ZIP>OX12 0EE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 589 687</PHONE_1></ADDRESS></PERSON><PERSON ID="12341" ROLE="AUTHOR"><FIRST_NAME>Karla</FIRST_NAME><LAST_NAME>Soares-Weiser</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>CEO</POSITION><EMAIL_1>karla@enhance-reviews.com</EMAIL_1><EMAIL_2>ksoaresweiser@gmail.com</EMAIL_2><URL>www.enhance-reviews.com</URL><ADDRESS><ORGANISATION>Enhance Reviews Ltd</ORGANISATION><ADDRESS_1>Central Office, Cobweb Buildings</ADDRESS_1><ADDRESS_2>The Lane, Lyford</ADDRESS_2><CITY>Wantage</CITY><ZIP>OX12 0EE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 589687</PHONE_1></ADDRESS></PERSON><PERSON ID="8746" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Clive</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Adams</LAST_NAME><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>clive.adams@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8231274</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-18 12:08:29 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="9" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="4" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="8" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-06-12 14:18:56 +0100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2013-05-23 12:01:59 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2013-05-01 11:24:43 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-05-01 11:24:43 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-05-01 11:24:43 +0100" MODIFIED_BY="[Empty name]">
<NAME>Rida Saeed Centre, Damascus University</NAME>
<COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-02-05 11:04:51 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-02-05 11:04:51 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Cochrane Collaboration Programme Grant 2011, Reference number: 10/4001/15</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-07-10 14:53:13 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-08-30 13:45:50 +0100" MODIFIED_BY="[Empty name]">Intermittent drug techniques for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>Antipsychotic medication is the main treatment for schizophrenia and helps people cope with positive symptoms such as hearing voices, seeing things and having strange beliefs. However, long-term exposure to these drugs has been associated with serious side effects, such as: weight gain; uncontrollable shaking of the head, body or hands; tremors; muscle stiffness; difficulties with walking and balance; sleepiness or apathy; and even death. Some people stop taking their medication as these side effects limit people&#8217;s quality of life. Not taking medication can be a contributory factor that leads to relapse and hospitalisation. Against this backdrop, there is cause to consider the role of intermittently administering antipsychotic medication compared to the continuous use of antipsychotic medication.</P>
<P>Intermittent drug techniques refer to the use of medication only during periods close to relapse of symptoms rather than continuously taking antipsychotic drugs all the time. Intermittent drug techniques include: prodrome-based intervention (which assesses the risk or early stage of relapse); crisis intervention during an acute episode or downturn in mental health; gradually increased drug-free periods; and drug holidays. The aim is to reduce exposure to drugs and decrease side effects.</P>
<P>This review assesses different intermittent drug techniques compared with maintenance treatment in people with schizophrenia or related disorders. Seventeen studies with 2252 participants compared intermittent drug techniques with standard maintenance on medication. Relapse was significantly higher in people receiving intermittent drug treatment. Hospitalisation was higher for people receiving intermittent drug treatment.</P>
<P>Results suggest that intermittent treatment is not as effective as continuous or maintained treatment in preventing relapse. Although information favours maintenance and continuous treatment, this is not always the case in real settings, where people may stop their medication due to debilitating side effects that affect their quality of life. More research is needed to assess any potential benefits or harm of intermittent treatment, particularly regarding the side effects commonly associated with maintained antipsychotic treatment. There was no exploration of economic/money savings, specifically relating to the potential cost-effectiveness of intermittent techniques.</P>
<P>Until further evidence is available concerning the potential benefits or harms of intermittent treatment, managers, psychiatrists and policy makers should consider it an experimental therapy.</P>
<P>This plain language summary has been written by a consumer Ben Gray, Service User and Service User Expert, Rethink Mental Illness.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-04-03 10:33:07 +0100" MODIFIED_BY="[Empty name]">
<P>Antipsychotic medication is considered the mainstay of treatment for schizophrenia and is generally regarded as highly effective, especially in controlling positive symptoms. However, long-term antipsychotic exposure has been associated with a range of adverse effects, including extra-pyramidal symptoms (EPS), neuroleptic malignant syndrome (NMS), tardive dyskinesia and death. Intermittent drug techniques refers to the 'use of medication only during periods of incipient relapse or symptom exacerbation rather than continuously'. The aim is to reduce the risk of typical adverse effects of antipsychotics by 'reducing long-term medication exposure for patients who are receiving maintenance treatment while limiting the risk of relapse', with a further goal of improving social functioning resulting from the reduction of antipsychotic-induced side effects</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-05-14 11:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>To review the effects of different intermittent drug techniques compared with maintenance treatment in people with schizophrenia or related disorders.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-05-14 11:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>We searched The Cochrane Schizophrenia Group Trials Register (April 2012) and supplemented this by contacting relevant study authors, handsearching relevant intermittent drug treatment articles and manually searching reference lists.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-06-11 14:52:19 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) that compared intermittent drug techniques with standard maintenance therapy for people with schizophrenia. Primary outcomes of interest were relapse and hospitalisation. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>At least two review authors selected trials, assessed quality and extracted data. We calculated risk ratios (RR) and 95% confidence intervals (CI) of homogeneous dichotomous data and estimated the 95% confidence interval (CI) around this. For non-skewed continuous endpoint data extracted from valid scales, we estimated mean difference (MD) between groups with a 95% CI. Where data displayed heterogeneity, these were analysed using a random-effects model. Skewed data are presented in tables. We assessed overall quality for clinically important outcomes using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-05-14 11:12:10 +0100" MODIFIED_BY="[Empty name]">
<P>Of 241 records retrieved by the search, 17 trials conducted between 1961 and 2011, involving 2252 participants with follow-up from six weeks to two years, were included. Homogenous data demonstrated that instances of relapse were significantly higher in people receiving any intermittent drug treatment in the long term (n = 436, 7 RCTs, RR 2.46, 95% CI 1.70 to 3.54, <I>moderate quality evidence</I>). Intermittent treatment was shown to be more effective than placebo, however, and demonstrated that significantly less people receiving intermittent antipsychotics experienced full relapse by medium term (n = 290, 2 RCTs, RR 0.37, 95% CI 0.24 to 0.58, <I>very low quality evidence</I>). Hospitalisation rates were higher for people receiving any intermittent drug treatment by long term (n = 626, 5 RCTs, RR 1.65, 95% CI 1.33 to 2.06, <I>moderate quality evidence</I>). Results demonstrated little difference in instances of tardive dyskinesia in groups with any intermittent drug technique versus maintenance therapy, with equivocal results (displaying slight heterogeneity) at long term (n = 165, 4 RCTs, RR 1.15, 95% CI 0.58 to 2.30, <I>low quality evidence</I>).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>Results of this review support the existing evidence that intermittent antipsychotic treatment is not as effective as continuous, maintained antipsychotic therapy in preventing relapse in people with schizophrenia. More research is needed to assess any potential benefits or harm of intermittent treatment regarding adverse effects typically associated with maintained antipsychotic treatment, as well as any cost-effectiveness of this experimental treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-07-10 13:34:54 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>In 1896, Emil Kraepelin isolated the illness of schizophrenia under the name of 'dementia praecox', which was considered to lead to a 'deterioration of the personality' (<LINK REF="REF-Kraepelin-1896" TYPE="REFERENCE">Kraepelin 1896</LINK>). It was eventually reframed into a substantially different concept by Swiss psychiatrist Paul Eugen Bleuler, who identified a demonstrable 'splitting of psychic functions' and re-labelled the mental illness as schizophrenia (<LINK REF="REF-Bleuler-1908" TYPE="REFERENCE">Bleuler 1908</LINK>). It is widely accepted that schizophrenia encapsulates a range of clinical manifestations, which are typically categorised into positive and negative symptoms. Positive symptoms are based on active disturbance of cerebral function (including disorders of thought such as disorganised speech/behaviour; thought-flow disturbances; delusions and auditory and visual hallucinations). Negative symptoms reflect a reduction or loss of normal function, including deficits of normal emotional responses or other thought processes (including avolition; depression; blunted affect or emotion and poverty of speech). Schizophrenia is a debilitating mental disorder, with a lifetime prevalence of about 1% (<LINK REF="REF-Jablensky-1992" TYPE="REFERENCE">Jablensky 1992</LINK>). Although schizophrenia can occur as a single episode of illness, up to 41% of those who develop schizophrenia suffer a chronic and often disabling illness with remission and relapses (<LINK REF="REF-Prudo-1987" TYPE="REFERENCE">Prudo 1987</LINK>).</P>
<P>Before the discovery of antipsychotic medication, treatment for schizophrenia was found in numerous physical approaches aimed at promoting more specific benefits, including the inducement of insulin comas; electroconvulsive therapy (ECT) and prefrontal leucotomy (lobotomy) (<LINK REF="REF-Johnstone-1998" TYPE="REFERENCE">Johnstone 1998</LINK>); treatments that are now considered 'outdated' and have fallen into disuse. The discovery of chlorpromazine in 1952 paved the way for a pioneering approach for the treatment of schizophrenia, and the use of antipsychotic medication subsequently became one of the most comprehensively researched areas in psychiatry (<LINK REF="REF-Klein-1969" TYPE="REFERENCE">Klein 1969</LINK>). Antipsychotic medication (classified as first generation (typical) or second generation (atypical)) is now considered the mainstay of treatment for schizophrenia (<LINK REF="REF-Dencker-1980" TYPE="REFERENCE">Dencker 1980</LINK>) and is generally regarded as highly effective, especially in controlling positive symptoms such as abnormal perceptions (hallucinations), disordered thinking and fixed false beliefs (delusions) (<LINK REF="REF-Kane-1998" TYPE="REFERENCE">Kane 1998</LINK>).</P>
<P>Antipsychotic maintenance treatment is the current predominant approach to treatment of schizophrenia, and has been recognised for its efficacy in treating symptoms in previous controlled trials (<LINK REF="REF-Davis-1976" TYPE="REFERENCE">Davis 1976</LINK>). A study by Baldessarini and colleagues showed antipsychotic maintenance treatment to be adequate for 50% of patients when administered with low doses of chlorpromazine (50 to 100 mg/day or equivalent) (<LINK REF="REF-Baldessarini-1988" TYPE="REFERENCE">Baldessarini 1988</LINK>), and subsequent systematic reviews of randomised controlled trials have shown that relapse rates are lower with slightly higher doses of the same antipsychotic during maintenance treatment (200 to 500 mg) (<LINK REF="REF-Barbui-1996" TYPE="REFERENCE">Barbui 1996</LINK>). Other studies have shown that antipsychotic maintenance (prophylaxis) treatment may reduce the risk of relapse (<LINK REF="REF-Schooler-1993" TYPE="REFERENCE">Schooler 1993</LINK>), particularly with people who had recently recovered from an acute episode of schizophrenia (<LINK REF="REF-Leff-1971" TYPE="REFERENCE">Leff 1971</LINK>). However, long-term antipsychotic exposure has been associated with a range of adverse effects, including extra-pyramidal symptoms (EPS) (acute dystonia, akathisia, tardive dyskinesia, tardive dystonia and parkinsonism); neuroleptic malignant syndrome (NMS) (muscle rigidity, pyrexia, cognitive changes and autonomic disturbance) (<LINK REF="REF-Haddad-2008" TYPE="REFERENCE">Haddad 2008</LINK>), and death (<LINK REF="REF-Ray-2009" TYPE="REFERENCE">Ray 2009</LINK>). Randomised trials have demonstrated that participants with schizophrenia who had been assigned continued antipsychotic treatment tended to discontinue treatment owing to inefficacy of the treatment or as a result of intolerable side effects (<LINK REF="REF-Lieberman-2005" TYPE="REFERENCE">Lieberman 2005</LINK>) (antipsychotic discontinuation has also proven adverse effects for those with schizophrenia, including anxiety, delirium, motor restlessness, insomnia, nausea and vomiting (<LINK REF="REF-Borison-1998" TYPE="REFERENCE">Borison 1998;</LINK> <LINK REF="REF-Haddad-2008" TYPE="REFERENCE">Haddad 2008</LINK>)). Such adverse effects have been shown to impact negatively on the patient's quality of life and are a frequently cited reason for non-compliance with antipsychotic medication, which could be a contributing factor towards relapse, hospitalisation and persistent psychotic symptoms (<LINK REF="REF-Morken-2008" TYPE="REFERENCE">Morken 2008</LINK>).</P>
<P>Against this backdrop, there is cause to consider the role of intermittently administering antipsychotic medication (intermittent drug techniques) versus maintained/continued use of antipsychotic medication (maintenance treatment), in order to ascertain the extent of any beneficial effects for those with schizophrenia.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-04-03 10:35:01 +0100" MODIFIED_BY="[Empty name]">
<P>Intermittent drug techniques (or 'intermittent treatment') refers to the 'use of medication only during periods of incipient relapse or symptom exacerbation rather than continuously' (<LINK REF="REF-Schooler-2004" TYPE="REFERENCE">Schooler 2004</LINK>).The aim is to reduce the risk of typical adverse effects of antipsychotics (including tardive dyskinesia) by 'reducing long-term medication exposure for patients who are receiving maintenance treatment while limiting the risk of relapse', with a further goal of improving social functioning resulting from the reduction of antipsychotic-induced side effects (<LINK REF="REF-Schooler-2004" TYPE="REFERENCE">Schooler 2004</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>People with chronic schizophrenia very frequently discontinue and re-instigate their own antipsychotic medications, and few continue to take their medication for lengthy periods of time (<LINK REF="REF-Lieberman-2005" TYPE="REFERENCE">Lieberman 2005</LINK>); self-imposed 'drug holidays' are common. It is clear that antipsychotics have proven effects in controlling positive symptoms, but are accompanied with the caveat of causing potential adverse effects; research has turned to assessing the ways in which various 'intermittent' strategies may maximise the benefits and minimise the negative effects of long-term antipsychotic use; these strategies include dose reduction, antipsychotic cessation and intermittent drug techniques, such as drug holidays.</P>
<P>The focus of this review will be on the use of intermittent drug techniques, which include:</P>
<UL>
<LI>prodrome-based intervention;</LI>
<LI>crisis intervention;</LI>
<LI>gradually increased drug-free periods; and</LI>
<LI>drug holidays.</LI>
</UL>
<P>Intermittent treatment is a long-term strategy that is used 'only when needed', relying on:</P>
<UL>
<LI>the presence of a prodromal period that would allow for intervention with medication in order to prevent relapse; and</LI>
<LI>an effective strategy for clinical monitoring in order to accurately identify prodromal symptoms in time for medication to be introduced (<LINK REF="REF-Schooler-2004" TYPE="REFERENCE">Schooler 2004</LINK>).</LI>
</UL>
<P>Various methods of detecting early prodromal signs and symptoms have been developed (including the Early Signs Questionnaire, <LINK REF="REF-Herz-1980" TYPE="REFERENCE">Herz 1980</LINK>) in order to provide a higher standard of accurate judgement in determining when to introduce/reintroduce medication.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>Co-operation and adherence to medication is a further significant issue in the clinical management of schizophrenia. Early treatment discontinuation in patients with schizophrenia or schizophrenia-like disorders is strikingly common, with estimates of its prevalence in antipsychotic drug trials ranging from 25% to 75% (<LINK REF="REF-Nose-2003" TYPE="REFERENCE">Nose 2003</LINK>). Discontinuation of a prescribed antipsychotic drug is associated with symptom exacerbation, relapse, and increased hospitalisation (<LINK REF="REF-Perkins-2002" TYPE="REFERENCE">Perkins 2002</LINK>). A review that analysed 66 studies found a mean cumulative relapse rate of 53% in patients completely withdrawn from antipsychotic therapy compared to 16% for those maintained on a regimen of antipsychotic therapy over a mean follow-up period of 9.7 months (<LINK REF="REF-Gilbert-1995" TYPE="REFERENCE">Gilbert 1995</LINK>). Evidence also points to the fact that experiencing a relapse of schizophrenia lowers a person's level of social functioning and quality of life (<LINK REF="REF-Curson-1985" TYPE="REFERENCE">Curson 1985</LINK>).<BR/>
<BR/>There are proven adverse effects associated with continued exposure to antipsychotic medication, but the extent to which maintenance treatment prevents relapse is unclear. The employment of non-continuous antipsychotic treatment has been tested in practice, under the support of literature that implies that patients decompensating off medication are either more responsive to treatment and/or experience more benign decompensations than patients experiencing relapse on medication; either due to the barrier provided by continuous medication or any potential diminutive effects of medication owing to such prolonged, continued use (<LINK REF="REF-Carpenter-1983" TYPE="REFERENCE">Carpenter 1983</LINK>; <LINK REF="REF-Gardos-1976" TYPE="REFERENCE">Gardos 1976</LINK>).<BR/>
<BR/>An intermittent approach depends on the accurate identification of times when medication should be administered, as well as the creation of an effective treatment structure to incorporate ongoing therapeutic patient monitoring and support. The approach further employs the assumption that those people with schizophrenia require antipsychotic medication on an 'only when needed' basis (during symptom exacerbation) and that the development of florid symptoms can be averted through the introduction of medication during the prodromal period (<LINK REF="REF-Schooler-2004" TYPE="REFERENCE">Schooler 2004</LINK>). With an intermittent technique comes potential economic and practical advantages, and a key question is whether an 'intermittent' intervention would eliminate or merely ameliorate an impending psychotic episode. It is for these reasons that intermittent drug techniques merit a dedicated systematic review; as an approach to using antipsychotic medication, it is fundamental to assess its efficacy as a technique that seeks to maximise the benefits and minimise the problems associated with continued antipsychotic exposure.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-05-14 11:41:58 +0100" MODIFIED_BY="[Empty name]">
<P>To review the effects of different intermittent drug techniques compared with maintenance treatment (as defined by the trial authors) in people with schizophrenia or related disorders.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-07-10 13:34:54 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-05-14 11:42:09 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. Where a trial was described in such a way as to imply randomisation, we included such trials in a sensitivity analysis (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>). Had their inclusion not resulted in a substantive difference, they remained in the analyses. Had their inclusion resulted in statistically significant differences, we would not add the data from these lower quality studies to the results of the better trials, but would have presented such data within a subcategory. We excluded quasi-randomised studies, such as those allocating by alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-05-01 14:19:11 +0100" MODIFIED_BY="[Empty name]">
<P>We included people with schizophrenia and other types of schizophrenia-like psychoses (schizophreniform and schizoaffective disorders diagnosed by any criteria), irrespective of gender, age or nationality. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-05-14 14:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>Any type of intermittent drug technique versus maintenance therapy:</P>
<SUBSECTION>
<HEADING LEVEL="4">a. Any intermittent drug technique</HEADING>
<P>Including:</P>
<SUBSECTION>
<HEADING LEVEL="5">1. Prodrome-based/early intervention</HEADING>
<P>Defined as treatment given on the early signs of relapse.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Crisis intervention</HEADING>
<P>Defined as treatment given only in case of full relapse and discontinued again after re-stabilisation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Gradually increased drug-free period</HEADING>
<P>Defined as increasing the cessation period of the treatment constantly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Drug holiday</HEADING>
<P>Defined as stopping medication for fixed periods, and then reintroducing it (repeating this more than once).</P>
<P>Compared with:</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1. Maintenance therapy</HEADING>
<P>As defined in each study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Placebo</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">b. Any intermittent drug technique (specific named drug)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. High dose (as defined by each study)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Low or moderate dose (as defined by each study)</HEADING>
</SUBSECTION>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-05-14 14:45:09 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into the short term (up to 12 weeks), medium term (13 to 25 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-01-25 11:52:34 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Relapse (as defined in the individual studies)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Hospitalisation</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-05-14 14:45:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Death - suicide and natural causes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">2.1 Any clinically important change in global state (as defined by individual studies)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.2 Average endpoint global state score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2.3 Average change in global state scores</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Service outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.1 Time to hospitalisation</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">4.1 No clinically important change in general mental state</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.2 Average endpoint general mental state score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3 Average change in general mental state scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia, depression, mania)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.5 Average endpoint specific symptom score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.6 Average change in specific symptom scores</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. General functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">5.1 No clinically important change in general functioning</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.2 Average endpoint general functioning score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.3 Average change in general functioning scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.4 No clinically important change in specific aspects of functioning, such as social or life skills</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.5 Average endpoint specific aspects of functioning, such as social or life skills</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.6 Average change in specific aspects of functioning, such as social or life skills</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Behaviour</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">6.1 No clinically important change in general behaviour</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.2 Average endpoint general behaviour score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3 Average change in general behaviour scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.4 No clinically important change in specific aspects of behaviour</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.5 Average endpoint specific aspects of behaviour</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.6 Average change in specific aspects of behaviour</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Adverse effects - general and specific</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">7.1 Clinically important general adverse effects</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.2 Average endpoint general adverse effect score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.3 Average change in general adverse effect scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.4 Clinically important specific adverse effects</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.5 Average endpoint specific adverse effects</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.6 Average change in specific adverse effects</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Engagement with services</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Satisfaction with treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">9.1 Leaving the studies early</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">9.2 Recipient of care not satisfied with treatment</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">9.3 Recipient of care average satisfaction score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">9.4 Recipient of care average change in satisfaction scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">9.5 Carer not satisfied with treatment</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">9.6 Carer average satisfaction score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">9.7 Carer average change in satisfaction scores</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10. Quality of life</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">10.1 No clinically important change in quality of life</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">10.2 Average endpoint quality of life score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">10.3 Average change in quality of life scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">10.4 No clinically important change in specific aspects of quality of life</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">10.5 Average endpoint specific aspects of quality of life</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">10.6 Average change in specific aspects of quality of life</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Cognitive functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">11.1 No clinically important change in cognitive functioning</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">11.2 Average endpoint cognitive functioning score</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">11.3 Average change in cognitive functioning scores</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">11.4 No clinically important change in specific aspects of cognitive functioning</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">11.5 Average endpoint specific aspects of cognitive functioning</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">11.6 Average change in specific aspects of cognitive functioning</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12. Economic outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">12.1 Direct costs (as defined by each study)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">12.2 Indirect costs (as defined by each study)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">12.3 Cost-effectiveness (as defined by each study)</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">13. Leaving the study early/loss to follow-up</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">14. 'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used GRADE profiler (<A HREF="http://www.ims.cochrane.org/revman/gradepro/revman">GRADEPRO</A>) to import data from RevMan 5 (<A HREF="http://www.ims.cochrane.org/revman">Review Manager</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the summary of findings table.</P>
<OL>
<LI>Relapse</LI>
<LI>Hospitalisation</LI>
<LI>Adverse effects</LI>
<LI>Mental state</LI>
<LI>Quality of life</LI>
<LI>Economic outcomes</LI>
<LI>Leaving the study early/loss to follow-up</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-05-14 11:52:01 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-05-14 11:52:01 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cochrane Schizophrenia Group Trials Register</HEADING>
<P>An initial search of the Cochrane Schizophrenia Group Trials Register was carried out in 2006 (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) This register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Group Module</A>).</P>
<P>We additionally made a later search of the Cochrane Schizophrenia Group Trials Register in April 2012, using the phrase:</P>
<P>[((intermit* or drug?holiday* or drug?free* or internal?med*) in title, abstract and index fields OR *targeted* in title or *targeted medication* in abstract or *drug administration methods*  in indexing terms REFERENCE ) OR ((intermittent medication or drug-free period) in interventions field in STUDY].<BR/>
</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-04-03 11:57:28 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected references of all included studies for further relevant studies and sought additional relevant trials by searching reference lists of included and excluded trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Requests for additional data</HEADING>
<P>We attempted to contact authors of relevant trials to inquire about other sources of relevant information.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-10 13:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>Since the protocol for this review was published the Cochrane Schizophrenia Group has updated its methodology for data collection and analysis. We have updated the relevant sections below to incorporate these new methods. See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for information relating to data collection and analysis specified in the protocol.</P>
<STUDY_SELECTION MODIFIED="2013-06-27 14:23:09 +0100" MODIFIED_BY="[Empty name]">
<P>Review author SS independently inspected citations, with help from Kajal Joshi (<LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>) from the searches and identified relevant abstracts. A random 20% sample was independently re-inspected by CEA to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. Full reports of the abstracts meeting the review criteria were obtained and inspected by KJ and SS. Again, a random 20% of reports was re-inspected by CEA in order to ensure reliable selection. Had it not been possible to resolve disagreement by discussion, we would have attempted to contact the authors of the study for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-06-27 14:25:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>Review author SS extracted data with help from Kajal Joshi (<LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>) from all included studies. In addition, to ensure reliability, CEA independently extracted data from a random sample of these studies, comprising 10% of the total. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies were contacted for clarification. With remaining problems, CEA helped clarify issues and these final decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but included only if two review authors independently had the same result. We attempted to contact authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi-centre, where possible, we extracted data relevant to each component centre separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument were described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument had not been written or modified by one of the trialists for that particular trial.<BR/>Ideally, the measuring instrument was either i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK> we have noted if this was the case or not.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we to applied the following standards to all data before inclusion: a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; b) when a scale started from the finite number zero, the SD, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of less than 200 participants as 'Other data' within the <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> section rather than into a statistical analysis. Skewed endpoint data pose less of a problem when looking at mean if the sample size is large (over 200), we entered such data into statistical syntheses.</P>
<P>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not and we entered skewed change data into statistical analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we had intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). However, no such variables were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>; <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for intermittent drugs. If we had to enter data so the area to the left of the line indicated a favourable outcome for the control group, this was noted in the relevant graphs.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-07-10 13:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>Review authors KSW, NM and SS worked independently to assess risk of bias by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. If the raters disagreed, the final rating was made by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, authors of the studies were contacted in order to obtain further information. Non-concurrence in quality assessment was reported, but if disputes arose as to which category a trial was to be allocated, again, resolution was made by discussion. The level of risk of bias was noted in both the text of the review and in the 'Summary of findings' tables (see below).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-05-14 14:45:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). The Number Needed to Treat/Harm (NNT/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes, we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-05-14 14:34:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a unit of analysis error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This can cause Type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If clustering had not been accounted for in primary studies, we would have presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients (ICCs) of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering may be incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design effect. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1 + (m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported, it would be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, we would have synthesised these with other studies using the generic inverse variance technique. However, no cluster trials were identified in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we would only have used data of the first phase of cross-over studies. However, no cross-over trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involves more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. If data were binary, these have simply been added and combined within the two-by-two table. If data were continuous, we combined the data following the formula in section 7.7.3.8  (Combining groups) of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the additional treatment arms were not relevant, we did not use these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-05-14 14:45:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses, (except for the outcome 'leaving the study early') - this was the case for the <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK> study. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias. This was the case in <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK> and <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes the rate of those who stayed in the study - in that particular arm of the trial - were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the intention-to-treat analysis using the above assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we reproduced these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations (SDs) were not reported, we first would have tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either 'P' value or 't' value available for differences in mean, we would have calculated them according to the rules described in the<I>Cochrane Handbook for Systemic reviews of Interventions</I> (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1301151509010033757225938656556&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>). If only the SE was reported, SDs would have been calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systemic reviews of Interventions</I> (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1301151509010033757225938656556&amp;format=REVMAN#REF-Higgins-2011">Higgins 2011</A>) present detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics. If these formulae did not apply, we would have calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless would have examined the validity of the imputations in a sensitivity analysis excluding imputed values, however, no imputations were made regarding SDs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we presented and used these data and indicated that they were the product of LOCF assumptions.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-05-14 14:44:58 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups were noted, these were fully discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, these were fully discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>Heterogeneity between studies was investigated by considering the I<SUP>2</SUP> method alongside the Chi<SUP>2</SUP> 'P' value. The I<SUP>2</SUP> provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2</SUP> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'P' value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2</SUP> estimate greater than or equal to 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 - <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-05-14 14:44:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Protocol versus full study</HEADING>
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We intended to locate protocols of included randomised trials. If the protocol had been available, outcomes in the protocol and in the published report would have been compared. If the protocol was not available, outcomes listed in the methods section of the trial report were compared with actually reported results. No protocols were available for any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Funnel plot</HEADING>
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are again described in Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</SUBSECTION>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-05-14 14:41:11 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We therefore chose to use a fixed-effect method for all analyses and used a random-effects model where heterogeneity were found. For primary outcomes, we also synthesised data using a random-effects model, and where the estimate of the effect was notably changed, this was noted in the conclusion.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-05-14 14:45:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>Data were sub-grouped according to duration of follow-up (short term, medium term or long term). The data for one study were compared in a single subgroup independently of the main comparison. The review authors believed that the inclusion of this data from a three-armed intervention trial was required, as a direct comparison of the two intermittent drug techniques ('early-based' and 'crisis-based').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Investigation of heterogeneity</HEADING>
<P>If inconsistency were high, this was reported. First, we investigated whether data had been entered correctly. Second, if data were correct, the graph was visually inspected and outlying studies were successively removed to see if homogeneity was restored. For this review, we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, data would be presented. If not, data were pooled and issues were discussed. We know of no supporting research for this 10% cut-off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. When unanticipated clinical or methodological heterogeneity were obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-05-14 14:45:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We included trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with a better description of randomisation, then all data were employed from these studies. We undertook a sensitivity analysis excluding these studies from the primary outcomes to assess whether this affected the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.</P>
<P>Where assumptions would have had to be made regarding missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we would have compared the findings on primary outcomes when we used our assumption compared with completer data only. A sensitivity analysis would have been undertaken to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. However, no SD data were imputed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then data from these trials were included in the analysis. However, all included studies were rated as 'high' on risk of bias on one or more of the domains, therefore, the effects of excluding each study would have resulted in no data to compare.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>We had also intended to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials. If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but instead presented them separately. However, no cluster randomised trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Fixed and random effects</HEADING>
<P>All data have been synthesised using a fixed-effect model, however, we also synthesised data for the primary outcome using a random-effects model to evaluate whether this altered the significance of the results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Skewed data</HEADING>
<P>Where scale derived data were both skewed and not skewed, all data were synthesised together and then the skewed data removed. This process was described and where clinically meaningful changes resulted, only the non-skewed data were presented in the synthesis. Skewed data were presented in 'other' tables within the <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> section.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-05-15 10:40:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-05-14 14:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>Please also see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2012-06-13 10:50:04 +0100" MODIFIED_BY="[Empty name]">
<P>The initial search of the Cochrane Schizophrenia Group Trials Register, carried out in 2006 (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), identified 174 studies. We additionally made a later search of the same Trials Register in April 2012 (using a modified search, based on the search strategy from the original review), which identified 56 references. An additional 11 potentially relevant references were identified from the reference lists of published trials and reviews (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-05-14 14:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>The review includes 17 studies published between 1962 and 2011. All studies were described as randomised; however, only four trials provided adequate descriptions of randomisation (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK> <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>), the remaining majority of included studies did not provide any further details beyond describing their trial as 'randomised' (for more details, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and the accompanying 'Risk of bias' tables).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Setting</HEADING>
<P>Of the 17 included studies within the meta-analysis, six were large, multi-centre trials involving two 18-hospital collaborative studies (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>), two German multi-centre studies (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>), a study conducted at seven district mental health care centres and a University Department of Psychiatry (all in the Netherlands, <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>), and one multi-centre trial conducted in the US (<LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>). Two studies were conducted in hostel wards in Scotland (UK) (<LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>), four studies took place in psychiatric hospitals/institutes in the US (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>), and one in Germany (<LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>). One study took place in a London (UK) hospital (<LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>), and a further trial was conducted in a Centre for Addiction and Mental Health, Canada (<LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>). It is not clear exactly where the trial was conducted in <LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK> and <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Length of trials</HEADING>
<P>We included trials that varied in duration; from six weeks (<LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>), four months (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>), six months (<LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>) nine and ten months (<LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>), one year (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>), 18 months (<LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>) to two years (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>There were a total of n = 2252 participants in the 17 included studies that provided data for the meta-analyses. Participants in seven of the included trials appear to have been inpatients (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001)</LINK>, while in the remaining 10 studies, participants were outpatients (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>).</P>
<P>All participants had a diagnosis of schizophrenia using different operational diagnostic criteria; <LINK REF="REF-RDC-criteria-1978" TYPE="REFERENCE">RDC criteria 1978</LINK> (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>), ICD-9/10 (<LINK REF="REF-ICD_x002d_10" TYPE="REFERENCE">ICD-10</LINK>) (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>), DSM-III/IV (<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK>; <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>) (<LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>), 'definite schizophrenia' according to <LINK REF="REF-Feighner-1972" TYPE="REFERENCE">Feighner 1972</LINK> criteria (<LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>) - classification and diagnostic criteria were unclear in four studies (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>).</P>
<P>In total, there were more male (n = 1555) than female (n = 540) participants randomised. Ten studies included both male and female participants (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>), five studies included male participants only (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>), and two studies did not specify the sex of participants (<LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Trial Size</HEADING>
<P>The overall sample size in all the included trials was generally small. The total number of participants in each trial ranged from n = 29 (<LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>) to n = 375 (<LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>). Only seven studies had a sample size of 100+ participants (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Any Intermittent drug technique versus maintenance therapy</HEADING>
<P>Out of the included studies, each made use of different intermittent drug techniques and various antipsychotics, however, most dosages were classified as either low/moderate (apart from <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>, in which both trials employed high doses of pimozide). All trials included a maintenance group consisting of participants taking their usual dosage of medication as prescribed in the form of maintenance, continuous or long-term therapy (these are discussed in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>The majority of studies used a drug-holiday approach versus maintenance treatment (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>), followed by a prodrome-based (early) intervention approach versus maintenance treatment (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>) and gradually-increased drug-free periods versus maintenance treatment (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>). One trial employed three treatment arms and compared both prodrome-based (early) versus crisis-based intermittent intervention versus maintenance treatment (<LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>); the results for this study were presented in the main results as well as in a subgroup analysis, to compare the effects of each intermittent intervention with each other. Types of antipsychotics and dosages varied between studies, and where some trials did not describe the specific drugs used nor the dosage, mean dosages of chlorpromazine or haloperidol equivalents were frequently employed; these details have been addressed in order to account for differences between studies.</P>
<SUBSECTION>
<HEADING LEVEL="6">5.1.1. Prodrome-based/early interventions (defined as treatment given on the early signs of relapse).</HEADING>
<P>Five trials were included comparing an intermittent prodrome-based/early intervention to maintenance therapy. Two trials used the same approach of administering antipsychotic mediation on an 'as-needed' basis to participants who were otherwise drug-free, with moderate to high doses of antipsychotics given when prodromal symptoms occurred and discontinued when a stable state was achieved (mean daily dose 196 mg ± 163 mg chlorpromazine equivalents, <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; mean daily dose 4.4 mg ± 1.1 mg haloperidol/173 mg ± 69 mg chlorpromazine, <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>). Participants were treated within the context of a psychosocial intervention, which complemented the intermittent treatment strategy in <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK> (involving assignment to a primary therapist) and complemented both treatment strategies in <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK> (weekly individual therapy as well as an educational approach through involvement with family/significant others).<BR/>
<BR/>In <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>, participants received either placebo medication or their usual dose of maintenance antipsychotic medication, as well as weekly supportive group therapy sessions. When prodromal symptoms appeared, participants in the intermittent treatment group were given the active form of antipsychotic medication openly; dosage was at the discretion of the psychiatrist, depending on the severity of symptoms, but was usually twice the maintenance or baseline level (average cumulative antipsychotic drug dosage (mg chlorpromazine equivalents) over two years = 487.19 mg ± 370.68 mg). Once participants were clinically stabilised and considered in remission for two weeks, active medication was decreased again while placebo was simultaneously increased.<BR/>
<BR/>Participants in <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK> either received fluphenazine in pre-trial doses or equivalent doses of placebo injections. Upon the emergence of prodromal symptoms or relapse, participants were given 5 mg to10 mg haloperidol for up to four weeks, and continued for a further four weeks after remission of symptoms (average cumulative antipsychotic drug dosage (mg haloperidol equivalents) over two years = 298 mg ± 249 mg - participants were withdrawn if relapse exceeded eight weeks).<BR/>
<BR/>An intermittent, 'targeted, early intervention' was employed in <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>, in which stabilised participants were given an injection of sesame oil (or "miglioil vehicle", placebo) every two weeks, and when participants showed prodromal signs of relapse, open-label rescue medication was added. In addition, participants received either one of two psychosocial interventions; psychoeducation-supportive family management (SFM) or applied family management (AFM), which included psychoeducational workshops for participants and their families over a period of 24 months.<BR/>
<BR/>Participants in <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK> were assigned to one of three treatment arms, including a prophylactic early intervention technique, in which antipsychotic therapy resumed as soon as prodromal symptoms appeared and were discontinued once stabilised (average cumulative antipsychotic drug dosage (mg chlorpromazine equivalents) over two years = 90 mg); the other treatment arms included maintenance treatment and a crisis-based intervention, addressed below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.1.2. Crisis intervention (defined as treatment given only in case of full relapse and discontinued again after re-stabilisation).</HEADING>
<P>There was only one trial that employed a crisis-based intermittent technique (<LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>), classified as a 'antipsychotic crisis intervention', in which antipsychotic treatment was employed only when relapse occurred and was discontinued once stabilisation was achieved (average cumulative antipsychotic drug dosage (mg chlorpromazine equivalents) over two years = 110 mg).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.1.3. Gradually increased drug-free periods (defined as increasing the cessation period of the treatment constantly).</HEADING>
<P>The intermittent technique adopted in <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> involved stepwise removal of previously maintained antipsychotic treatment over a period of three months at the most, and was restarted at the occurrence of prodromal symptoms - mean daily dose of 1 mg/day haloperidol-equivalent (the mean dose covers an initial maintenance phase of about three to four weeks (mean daily dose 3 mg/day), a phase of about 10 weeks in which antipsychotics were tapered off (mean daily dose 1.7 mg/day), a phase of six months where antipsychotics were withdrawn completely (0 mg/day) and a two-week phase in which drug treatment was restarted).<BR/>
<BR/>Similarly, <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK> employed a 'targeted' medication approach, involving gradual decrease of antipsychotics after three months using a step-by-step discontinuation technique of 50% of antipsychotics every two weeks (mean daily dosage 201 mg ± 134 mg chlorpromazine (CPZ) equivalent). Where prodromal signs occurred, antipsychotic treatment was reintroduced and when re-stabilisation was attained, pharmacotherapy was tapered off once more. Participants in <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK> received a 'guided discontinuation' treatment, in which dosage was gradually tapered and discontinued 'if feasible'. Tapering was guided by symptom severity levels and the preferences of the participant; if early warning signs of relapse emerged or positive symptoms recurred, clinicians were to restart or increase the dosage of anti-psychotics (average cumulative antipsychotic drug dosage (mg haloperidol equivalents) over two years = 4.36 mg).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.1.4. Drug holiday (defined as stopping medication for fixed periods, and then reintroducing it (repeating this more than once)).</HEADING>
<P>
<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK> subdivided their intermittent experimental group into two further groups of n = 15, with participants receiving either placebo for the whole length of the study, or receiving placebo for the first eight weeks of the study then reinstating antipsychotic medication for the final eight weeks of the study (either prochlorperazine, perphenazine, chlorpromazine, promazine, trifluoperazine - dosages not stated). Participants in <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK> received a reduced total dosage of either chlorpromazine or thioridazine (administered in standard 100 mg tablets) on an intermittent-schedule; they received their usual daily dosage on Monday, Wednesday and Friday, resulting in a reduction of dosage to 3/7 of what it had been previously. In <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>, participants received intermittent pimozide (mean dose 8 mg/oral, maximum 32 mg every four days/week) and in <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>, participants also received intermittent pimozide once a week (mean dose 10 mg to 60 mg/oral, mean 40 mg/intramuscular (IM) weekly). <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK> 'alternated' either phenothiazine or chlorpromazine and nothing between participants in the intermittent strategy group (dosages not specified).<BR/>
<BR/>Participants were assigned to one of four intermittent interventions in <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>: (1) intermittent five-day schedule A, where participants received their pre-study dosage Monday through Friday and placebo on Saturday and Sunday; (2) intermittent five-day schedule B, where participants received their pre-study dosage Monday, Wednesday, Thursday, Friday and Sunday, and placebo on Tuesday and Saturday; (3) intermittent four-day schedule A: participants received their pre-study dosage Monday through Thursday and placebo on Friday through Sunday; or (4) intermittent four-day schedule B: participants received their pre-study dosage Monday, Wednesday, Friday and Sunday, and placebo on Tuesday, Thursday and Saturday. However, these strategies are analysed collectively as one 'intermittent technique', as individually study data for each group were not reported. All participants had received stable doses of antipsychotic medication during the six months preceding the study; 48% of participants were receiving chlorpromazine (mean daily dose 462 mg), 46% were receiving thioridazine (mean daily dose 362 mg), 27% were receiving trifluoperazine (mean daily dose 15 mg), and 4% were receiving perphenazine (mean daily dose 28 mg), 25% of participants were receiving more than one drug. The intermittent technique employed in <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK> required participants to receive the same daily dose administered every other day (either risperidone or olanzapine; dosages not specified). Participants in <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK> received a six-week drug discontinuation technique, in which they were given a placebo injection and were returned to their routine active medication at the end of the study (dosages not specified).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Maintenance therapy</HEADING>
<P>In each of the included studies, various antipsychotics were administered throughout maintenance therapy in comparison with the above mentioned intermittent strategies - all dosages were classified as either low/moderate. The majority of studies measured antipsychotic usage through chlorpromazine equivalents. <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK> involved minimum daily chlorpromazine equivalent doses of 300 mg, combined with brief visits with a pharmacotherapist on alternate weeks; the mean daily dose totaling 720 mg ± 732 mg chlorpromazine equivalents; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK> employed the same continuous dose technique, but with a mean daily dose of 433 mg ± 46 mg chlorpromazine equivalents; participants in <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK> received their usual dose of antipsychotic medication with an average cumulative antipsychotic drug dosage over two years of 424.84 mg ± 333.05 mg chlorpromazine equivalents; in <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>, the type and application of antipsychotic drugs used throughout the study was not restricted and participants received continuous administration of medication, with doses individually adjusted in accordance with the patient's clinical demands at a given time, minimal dosage of 100 mg chlorpromazine equivalents, with a mean over two years of 210 mg; and in <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>, the same antipsychotic dose level was maintained throughout the study period, with a mean daily dosage of 314 mg ± 150 mg chlorpromazine equivalents) and haloperidol equivalents. <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK> also presented a mean daily dose of 11.8 mg ± 4.4 mg haloperidol equivalent; participants in <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> were maintained on a specified drug regimen with a mean daily dose of 3 mg/day haloperidol equivalent; and participants in <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK> were continuously treated with low-dose second-generation antipsychotics, measured as a mean daily dose of 2.94 mg haloperidol equivalent.<BR/>
<BR/>Five trials employed the use of continuous fluphenazine decanoate (participants in <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK> continued to receive fluphenazine decanoate in clinically optimal (pre-trial) doses, but the average cumulative antipsychotic drug dosage was measured in haloperidol equivalents, which over two years equalled 1616 mg ± 598 mg; continued fluphenazine decanoate was employed in <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK> , with a mean dose of 12.5 mg/IM (maximum 50 mg weekly); similarly, <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK> continued participants on IM fluphenazine decanoate, with a mean dose of 2 mg to 25 mg; participants in <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK> were maintained on either a standard dose of fluphenazine decanoate of 12.5 mg to 50 mg every two weeks or a low-dose of 2.5 mg to 10 mg every two weeks; and participants in <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK> were 'continued on their regular medication' and received a mean dose of 39.3 mg fluphenazine decanoate).<BR/>
<BR/>Participants in <LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK> had received initial daily doses of either prochlorperazine (15 mg to 150 mg), perphenazine (12 mg to 24 mg), chlorpromazine (50 mg to 800 mg), promazine (200 mg to 44 mg), trifluoperazine (6 mg) - when assigned to maintenance therapy, participants continued on their pre-study regimen. The same procedure was followed in <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>, where participants had received stable doses of antipsychotic medication during the six months preceding the study; 48% of participants were receiving chlorpromazine (mean daily dose 462 mg), 46% were receiving thioridazine (mean daily dose 362 mg), 27% were receiving trifluoperazine (mean daily dose 15 mg), and 4% were receiving perphenazine (mean daily dose 28 mg); 25% of participants were receiving more than one drug.<BR/>
<BR/>Participants in <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK> continued to receive either chlorpromazine or thioridazine daily, administered in standard 100 mg tablets - participants on chlorpromazine had been receiving it for over two years at an average daily dose of 400 mg and participants on thioridazine had been receiving it for one year at an average daily dose of 350 mg.<BR/>
<BR/>Some trials did not describe the dosage or even the type of antipsychotic administered throughout maintenance treatment (participants were described in <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK> as having received medication 'in standard form'; and in <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>, the control group received "treatment as usual", receiving either risperidone, olanzapine or loxapine, without specifying the dosages).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3 Placebo</HEADING>
<P>Three trials included a placebo group in addition to an intermittent and maintenance group. Particpants assigned to intermittent treatment in <LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK> were further subdivided into two groups to receive either a placebo drug or placebo-placebo regimen (thiamine chloride). Those who received placebo-placebo were kept on this regimen for the full length of the study. Results for the individual subdivided groups are presented only by medium term; at short term, the results are combined. In <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>, there were two corresponding placebo groups for both the intermittent and maintenance; in the former, participants received the same number of tablets they had prior to the study in placebo form on a daily basis, and participants in the latter received the same number of tablets prior to the study in placebo form on an intermittent basis (Monday, Wednesday and Friday only). The placebo group in <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK> alternated monthly between the active drug (one half of the group received phenothiazine and one half received chlorpromazine) and placebo.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Outcomes: Scales providing useable data</HEADING>
<P>Rating scales that provided useful data are described below.</P>
<SUBSECTION>
<HEADING LEVEL="5">6.1. Global state</HEADING>
<P>6.1.1 Clinical Global Impression Scale (CGI, <LINK REF="REF-Guy-1970" TYPE="REFERENCE">Guy 1970</LINK>)<BR/>This scale is a three-item observer rated scale that measures severity of illness (CGI-S); global improvement or change (CGI-C); and therapeutic response. The CGI-S and CGI-C are rated on a seven-point scale from 1 = normal to 7 = extremely unwell; lower scores indicative of decreased severity and/or greater recovery, and the treatment response ratings take into account both therapeutic efficacy and treatment-related adverse effects, and range from 0 = marker improvement and no side effects, to 4 = unchanged or worse with side effects outweighing therapeutic effects. Each component of the CGI is rated separately, and the instrument does not provide a global score. <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> and <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK> both reported data using the CGI-S component; a factor contributing towards the definition of relapse in <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> was a CGI-S change score of six or more, as well as PANSS positive score of more than 10, and a decrease in GAF score of more than 20. <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK> also noted deterioration on the CGI-S indicated by a score of &gt; 7 as a determinant contributing towards their definition of relapse (see below).</P>
<P>6.1.2 Global Assessment Scale (GAS, <LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>)<BR/>This single-item rating scale assesses one's overall functioning whilst diagnosed with a mental disorder during a specific time period. The scale scores from 1 = extremely unwell to 100 = extremely well and is divided into 10 equal intervals and the lower the mean value the more constant the symptomology. <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK> each reported data using the GAS; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK> defined 'relapse' as a decrease of &#8804; 30 using GAS; and the definition of 'relapse' in <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK> included three criteria: i) an increase of &gt; 10 in the psychosis factor (HOST, THOT, ACTV) of the BPRS; ii) a decrease of &gt; 20 in the GAS; iii) and deterioration on the CGI scale indicated by a score of &gt; 7. Relapse predicted by prodromal symptoms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2. Mental state</HEADING>
<P>6.2.1 Brief Psychaitric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This scale measures positive symptoms and quantifies factors such as thought disorder, activation, hostility. somatic, hallucinatory, and depressive states. The original scale had 16 items, but a revised 18-item scale is more commonly used, with scores ranging from 0 - 126. Each item is defined on a seven-point scale from 0 = not present to 7 = extremely severe. Higher scores equate to severity of illness. In their study <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK> defined relapse as a 20% increase in overall symptoms using the BPRS; however, <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK> and <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK> were the only studies to report usable outcome data using this scale.</P>
<P>6.2.2 Positive and Negative Symptom Scale (PANSS, <LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>PANSS was developed from the BPRS and the Psychopathology Rating Scale. It is used to evaluate positive, negative and other symptom dimensions in schizophrenia. The scale has 30 items, each measured on a seven-point scoring system varying from 1 = absent to 7 = extreme. <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> and <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK> were the only studies that reported data measuring both positive and negative symptoms.</P>
<P>6.2.3 Scale for the Assessment of Negative Symptoms (SANS, <LINK REF="REF-Andreasen-1982" TYPE="REFERENCE">Andreasen 1982</LINK>)<BR/>The SANS measures the incidence and severity of negative symptoms using a 25-item scale, using a six-point scoring system, where 0 = better to 5 = worse, where a higher score equals a more severe experience of negative symptoms. <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> was the only study that reported data using this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3. General functioning</HEADING>
<P>6.3.1 Global Assessement of Functioning (GAF, <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>)<BR/>The GAF subjectively measures overall psychiatric disturbance over a specified time period on a continuum from psychological or psychiatric sickness to health. Psychological, social and occupational functioning is assessed using a rating scale of 0 - 90, where 0 = severe symptoms and 90 = no present symptoms. <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> was the only study to report data from this scale.</P>
<P>6.3.2 Groningen Social Disabilities Schedule (GSDS, <LINK REF="REF-Wiersma-1990" TYPE="REFERENCE">Wiersma 1990</LINK>)<BR/>This scale measures social disabilities through a semi-structured interview with observer ratings of functioning in eight social role domains: vocational functioning, community integration, peer relationships, relationship with family members, parental functioning, partner relationship, house-keeping and self-care. Disabilities are rated on a four-point scale from no disability to serious disability. Total disability scores range from 0 - 21 and are calculated combining seven domains, excluding parental functioning because of limited applicability. <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK> was the only study to report data from this scale, however data were skewed.</P>
<P>6.3.3 Level of Functioning Scale (LOFS, <LINK REF="REF-Hawk-1975" TYPE="REFERENCE">Hawk 1975</LINK>)<BR/>The LOFS was designed to assess work functioning (occupational and overall level of function), social functioning (quality and quantity of social relationships, fullness of life, ability to meet basic needs) and hospitalisation. Scores from each area of functioning range from 0 = worst outcome, to 36 = best outcome, which is calculated by adding the nine outcome item scores.<BR/>
</P>
<P>6.4 Problem Appraisal Scale (PAS, <LINK REF="REF-Spitzer-1971" TYPE="REFERENCE">Spitzer 1971</LINK>)<BR/>The PAS in a one-page form, designed for use in emergency room or outpatient settings where extensive and detailed mental status examinations are generally not done. This scale provides scaled judgements of 38 areas of psychiatric disturbance (broken down into physical function; intellectual development; social relations; social performance; and other signs and symptoms). These dimensions are rated on a five-point scale, with 1 = none and 5 = severe over a time period of the last two weeks. <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK> was the only study to report data using this scale.</P>
<P>6.3.5 Social Adjustment Scale (SAS, <LINK REF="REF-Weissman-1976" TYPE="REFERENCE">Weissman 1976</LINK>)<BR/>The SAS contains 42 questions that measure either instrumental or expressive role performance in six major areas of functioning: work as a worker, housewife or student; social and leisure activities; relationships with extended families; marital role as a spouse, a parent and a member of the family unit. Each question is rated on a five-point scale, with a higher score indicating impairment. <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK> was the only study to report data using this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4. Adverse effects</HEADING>
<P>6.4.1 Abnormal Involuntary Movement Scale (AIMS, <LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This scale measures the examination of involuntary movements (tardive dyskinesia) consisting of 12 items scored from 0 = none to 4 = severe, quantifying the severity of tardive dyskinesia. This trial used in short-term trials may also help to assess parkinsonian symptoms such as tremor. Only <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> and <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK> reported usable data with this scale - however the data from each of these studies are skewed.</P>
<P>6.4.2 Extrapyramidal Side Effects Scale (EPS, <LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This is an observer-rated scale designed for assessing parkinsonian and related extrapyramidal side effects. The scale has 10 items - including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor and salivation - each measured on a five-point scoring system from 0 = absent to 4 = severe). <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> and <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK> both reported data from this scale.</P>
<P>6.4.3 Hillside Akathisia Scale (HAS, <LINK REF="REF-Fleischhacker-1989" TYPE="REFERENCE">Fleischhacker 1989</LINK>)<BR/>The HAS was used to measure akathisia; the subjective subscale has two subjective and three objective items for which anchored rating points are provided. The subjective items take into account a patient's sensation of restlessness and urge to move, and the objective items assess physical signs of akathisia present in the head, trunk, hands, arms, feet and legs. There are a total of five items, which are measured on a five-point scoring system from 0 = absent to 4 = present and not controllable. <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> was the only trial to report data using this scale.</P>
<P>6.4.4 Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS, <LINK REF="REF-Day-1995" TYPE="REFERENCE">Day 1995</LINK>; <LINK REF="REF-Lambert-2003" TYPE="REFERENCE">Lambert 2003</LINK>)<BR/>LUNSERS is a self-rating scale to measure antipsychotic side effects with 41 items. These side effects are rated on a five-point scale, from 0 = absent, to 4 = very much. <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK> was the only trial to report data using this scale.<BR/>
</P>
<P>6.4.5 Udvalg for Kliniske Undersogelser Side Effects Rating Scale (UKU, <LINK REF="REF-UKU-1987" TYPE="REFERENCE">UKU 1987</LINK>)<BR/>The UKU is a clinician-rated scale developed to provide comprehensive side-effect ratings of psychopharmacological medications. There are 48 items to the scale, and each are defined by means of a four-point scale, starting from 0 = not or doubtfully present, ranging to 3 = severe. <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> was the only trial to report data using this scale, however, these data are skewed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.5. Quality of life</HEADING>
<P>6.5.1 Lancashire Quality of Life Profile (LQLP, <LINK REF="REF-Oliver-1991" TYPE="REFERENCE">Oliver 1991</LINK>)<BR/>This 27-item scale presents both objective quality of life indicators and subjective quality of life estimates; the subjective elements focus on five specific domains, including work and education, leisure and participation, religion, finances, living situation, legal and safety, family relations, social relations, and health. Participants rate their satisfaction with these factors on a seven-point scale (1 = 'can't be worse', to 7 = 'can't be better'), the higher the score indicating a better quality of life. This scale has been subject to thorough examination to assess its validity, but is nevertheless widely used in Europe as a measurement to assess quality of life (<LINK REF="REF-van-Nieuwenhuizen-2001" TYPE="REFERENCE">van Nieuwenhuizen 2001</LINK>). <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK> was the only trial to report data using this scale.</P>
<P>6.5.2 Quality of Life Scale (QLS, <LINK REF="REF-Heinrichs-1984" TYPE="REFERENCE">Heinrichs 1984</LINK>)<BR/>The QLS is a 21-item clinician-administered scale rated from a semi-structured interview to assess symptoms and functioning. Each item is rated on a seven-point scale and requires judgement by a clinician/interviewer on all but two cases. Each item is composed of three parts; (1) brief descriptive statement to focus the interviewer on the judgement to be made, (2) a set of suggestive probes, (3) the seven-point scale with descriptive anchors for every other point - with a low score 0 = severe impairment, and 6 = normal/unimpaired functioning.<BR/>
</P>
<P>6.5.3 World Health Organization Quality of Life Scale (WHOQoL-Bref, <LINK REF="REF-O_x0027_Carroll-2000" TYPE="REFERENCE">O'Carroll 2000</LINK>)<BR/>The WHOQoL-Bref is a 26-item self-report comprising satisfaction with health, psychological functioning, social relationships and environmental opportunities. Each item is scored on a five-point scale from 1 = poor to 5 = worse. <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK> was the only trial that reported data using this scale.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-04-03 10:37:30 +0100" MODIFIED_BY="[Empty name]">
<P>Eight studies were excluded altogether; <LINK REF="STD-Caffey-1975" TYPE="STUDY">Caffey 1975</LINK>; <LINK REF="STD-Hymowitz-1980" TYPE="STUDY">Hymowitz 1980</LINK> and <LINK REF="STD-Uchida-2008" TYPE="STUDY">Uchida 2008</LINK> were each excluded because they were not randomised. <LINK REF="STD-Engelhart-2002" TYPE="STUDY">Engelhart 2002</LINK>; <LINK REF="STD-Levine-1980" TYPE="STUDY">Levine 1980</LINK>; <LINK REF="STD-Newton-1989" TYPE="STUDY">Newton 1989</LINK> and <LINK REF="STD-Strauss-1990" TYPE="STUDY">Strauss 1990</LINK> were excluded because the trials delivered no usable data; and <LINK REF="STD-Docherty-2003" TYPE="STUDY">Docherty 2003</LINK> was excluded as there was no intermittent treatment group by which to draw comparison with continuous antipsychotic maintenance treatment.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>There is one known ongoing study (UMIN Clinical Trials Registry (UMIN-CTR) unique trial number: UMIN000006011, <LINK REF="STD-Uchida-2013" TYPE="STUDY">Uchida 2013</LINK>); as of January 2012, participants were in the process of recruitment, with a target date for completion of late 2013.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Awaiting assessment</HEADING>
<P>There are no studies awaiting assessment at the time of writing this review.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-05-14 15:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>For a graphical overview please see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. </P>
<ALLOCATION MODIFIED="2013-05-14 15:01:28 +0100" MODIFIED_BY="[Empty name]">
<P>All 17 included trials were described as randomised; the methods used to describe allocation and concealment, however, were poorly described. Only four trials provided an adequate description of 'randomisation' (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>), with six studies poorly describing the allocation methods used (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>) and the final seven provided no further description beyond stating that 'participants were randomised' or 'randomly assigned' (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>). One study was rated as having a high risk of bias (<LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>) because it was stated that the participating clinicians were requested to refer patients whom they thought might benefit from the brief intermittent treatment approach.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-05-14 15:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the description of blinding was poor throughout the records of the included studies; only five trials gave adequate description of methods used for blinding (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>). Three trials were rated as having a high risk of bias because, even though a double-blind method was expressed, treatment was open to some participants depending on their point of entry into the study ('lateral entry' participants in <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>) and when participants required active antipsychotic medication as an intervention (<LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>). Four studies did not employ blinding methods (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>) and one study was described as single (assessor) blind (<LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>). The remaining studies were rated as an unclear risk of bias, as there was little/no detail as to blinding (<LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-05-14 15:02:07 +0100" MODIFIED_BY="[Empty name]">
<P>For this review, high loss to follow-up was defined in trials where the number of participants lost exceeded 50% overall. Only one included study satisfied this criteria; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK> had a high loss to follow-up, with only 44% completing the study. Therefore, only the outcome of 'leaving the study early' was included in the data and analysis, as per our protocol, which stated that should more than 50% of data go unaccounted for, we would not reproduce these data or use them within analyses.<BR/>Several studies had a moderate level of participants lost to follow-up (ranging between 34% to 48%), including <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK> and <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>. As did <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK> and <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK> studies, which presented completer-only data in their results. In <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>, attrition was moderate, yet contentious, as the included participants were 're-randomised' following a previous trial by the same authors (one year of maintenance therapy comparing risperidone versus haloperidol); however, out of those randomised, n = 44 were treated and included in an intention-to-treat analysis.<BR/>
<BR/>Studies with low levels of attrition included <LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980;</LINK> <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>; each of these trials provided specific reasons why participants may have left the studies early. <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK> had a low attrition rate, and completer only data were used in their analysis, which included the participants in each group of the study that did not relapse, however, not all of the 'completer only' data were represented, making the results more susceptible to bias and therefore we rated this study as a 'high risk'. Follow-up data were not made clear in <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>.<BR/>
<BR/>Overall, poor reporting at each stage of the included studies made it difficult to ascertain the true numbers of participants who left the study early - use of a flow chart would have been an appropriate measure to accurately reflect these numbers. Two studies did not make clear the number of participants lost to follow-up (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>), and most studies either (i) did not indicate whether they reported completer analyses; (ii) did not specify whether completer or intention-to-treat analyses were employed; or (iii) presented highly skewed data.<BR/>
</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-05-14 14:56:45 +0100" MODIFIED_BY="[Empty name]">
<P>The majority of studies were rated as having a high risk of bias, as not all outcomes were reported, in particular, data from rating scales went unreported from the time intervals specified in the study protocols. Only one study reported all specified outcomes and was therefore rated as a low risk of bias (<LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>). Two studies were rated as an 'unclear' risk; <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK> reported scale data but only by two years, where it was specified that criterion instruments would be completed at six-month intervals; and <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>, as mentioned above, was ambivalent; it was stated that participants from 13 German psychiatric hospitals were included, however, participants from only eight hospitals were mentioned, with no reasons for this reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-05-14 14:57:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Funding:</HEADING>
<P>The majority of studies reported sources of funding, and included support grants from NIMH (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>); Department of Health and Social Services (<LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>); Netherlands Organisation for Health Research and Development (<LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>); the German Ministry of Research and Technology (<LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>); Dumfries and Galloway Health Board (<LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>); the German Federal Ministry for Education and Research BMBF (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>); and a National Alliance for Research on Schizophrenia and Depression (NARSAD) Independent Award (<LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>). No studies described direct funding from pharmaceutical companies, but several trials acknowledged study drugs donated by Sandoz and Smith, Kline &amp; French (<LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>); Janssen Cilag and Wyeth-Pharma (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>); Janssen Pharamceutical and ER Squibb Limited (<LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>); and Eli Lilly Nederland B.V. (<LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Rating scales:</HEADING>
<P>The majority of studies did not describe whether raters of measurement scales were independent (<LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>), and in two studies raters were not independent (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>). Only seven studies gave details on how ratings scales were administered and the extent to which raters were independent (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-05-15 10:40:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2012-12-06 06:01:44 +0000&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Under comparison 6 'There was significant favour for placebo' For what?&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Steph - clumsy sentence - has been re-phrased to read: &amp;quot;Significantly more people receiving placebo left the study early when receiving intermittent therapy.&amp;quot;&lt;/p&gt;" NOTES_MODIFIED="2013-05-15 10:40:37 +0100" NOTES_MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1. ANY INTERMITTENT DRUG TECHNIQUE versus MAINTENANCE THERAPY</HEADING>
<P>All 17 included studies were included in this comparison, which included any type of intermittent drug therapy, with a total n = 2252. Twelve of the included studies reported data for the primary outcome of relapse (n = 1327) and six reported data for the second primary outcome of hospitalisation (n = 661). All the remaining studies reported for outcomes of either death, global state, general functioning, service outcomes, adverse effects, quality of life and leaving the study early, with the primary objective of evaluating the effects of intermittent drug techniques on these outcomes - participants had to be clinically stabilised to some extent to participate in the study.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Relapse</HEADING>
<P>Data demonstrate that there was a significantly greater risk of relapse for participants receiving intermittent drug therapy; results were homogenous, clinically and statistically significant in favour of maintenance therapy at each short term (n = 396, 4 RCTs, risk ratio (RR) 1.68, 95% confidence interval (CI) 1.00 to 2.81), medium term (n = 774, 5 RCTs, RR 2.41, 95% CI 1.50 to 3.86) and long term (n = 436, 7 RCTs, RR 2.46, 95% CI 1.70 to 3.54, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Hospitalisation</HEADING>
<P>At medium term, there was little difference between groups receiving intermittent therapy or maintenance therapy (n = 136, 2 RCTs, RR 1.03, 95% CI 0.07 to 14.98), however, results displayed significant heterogeneity (Chi² = 3.19, P = 0.07, I² = 69%) and were displayed using a random-effects model. At long term, results were homogenous and statistically significant in favour of maintenance therapy, with a greater risk of hospitalisation for people receiving intermittent therapy (n = 626, 5 RCTs, RR 1.65, 95% CI 1.33 to 2.06, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Death</HEADING>
<P>People on maintenance treatment were less likely to die in the long term than those on intermittent treatment (1/77 versus 4/78), however the data were from only two trials, and did not rule out the effects of chance (n = 155, 2 RCTs, RR 0.34, 95% CI 0.05 to 2.08, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.4.1. Average score (CGI-S, high = worse)</HEADING>
<P>Symptom severity was measured using the CGI-S scale and did not significantly differ between intermittent treatment and maintenance treatment at medium term (n = 35, 1 RCT) or long term (n = 27, 1 RCT, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>); substantial heterogeneity was present (Chi² = 2.38, P = 0.12, I² = 58%) and therefore displayed using a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.2. Average score (GAS, low = worse)</HEADING>
<P>Symptomology was assessed using the GAS, and significantly favoured maintenance therapy in the short term (n = 31, 1 RCT, mean difference (MD) -3.61, 95% CI -5.67 to -1.55), but displayed little difference at both medium (n = 126, 2 RCTs, MD -0.45, 95% CI -4.55 to 3.66) and long term (n = 133, 3 RCTs, MD 1.32, 95% CI -2.75 to 5.39, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>); again, substantial heterogeneity was present (Chi² = 5.37, P = 0.07, I² = 62.7%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.3. Prodromal episodes</HEADING>
<P>By long term, people receiving intermittent treatment were at a significantly greater risk of experiencing prodromal episodes, with significant favour for maintenance therapy (n = 155, 2 RCTs, RR 3.19, 95% CI 1.87 to 5.44, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4.4. Significant improvement</HEADING>
<P>One study also measured 'significant improvement', which was significantly demonstrated in people receiving maintenance therapy at both short term (n = 60, 1 RCT, RR 0.40, 95% CI 0.18 to 0.89) and medium term (n = 60, 1 RCT, RR 0.32, 95% CI 0.15 to 0.68, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.5.1. Average score (BPRS, high = worse)</HEADING>
<P>Mental state did not significantly differ between Intermittent and maintenance treatment over the medium term (n = 51, 1 RCT) or long term (n = 77, 2 RCTs) in trials that measured this outcome with the BPRS (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.2. Negative symptom score (PANSS negative symptom subscale, high = worse)</HEADING>
<P>Negative symptoms were assessed in one RCT using the PANSS negative symptom subscale; there was no significant difference between intermittent and maintenance treatment groups by medium term (n = 128, 1 RCT) or long term (n = 128, 1 RCT, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.3. Negative symptom score (PANSS negative symptom subscale, high = worse, skew)</HEADING>
<P>There were also skewed data reported using the PANSS negative symptom subscale, and these are reported separately (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.4. Negative symptom score (SANS negative symptom subscale, high = worse, skew)</HEADING>
<P>This was also the case for assessing negative symptoms using SANS; these data are skewed and should be interpreted with caution (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.5. Positive symptom score (PANSS positive symptom subscale, high = worse)</HEADING>
<P>Positive symptoms were measured using the PANSS positive symptom subscale, the results of which significantly favoured intermittent treatment by medium term (n = 128, 1 RCT, MD -0.80, 95% CI -1.58 to -0.02) but demonstrated no significant difference at long term (n = 155, 2 RCTs, MD 0.40, 95% CI -0.79 to 1.59, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 General functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.6.1. Average endpoint (LOFS, low = worse)</HEADING>
<P>Overall functioning was measured using the LOFS by one RCT, however there was no significant difference between intermittent or maintenance therapy (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.2. Social functioning score (GAF, low = worse)</HEADING>
<P>Psychiatric disturbance was measured by one study using the GAF, which demonstrated significant favour of maintenance therapy by long term (n = 27, 1 RCT, MD -9.00, 95% CI -15.92 to -2.08, <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.3. Social functioning score (GSDS, high = worse, skew)</HEADING>
<P>The GSDS measured levels of social disabilities - note that these data are skewed and are presented in an additional table (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.4. Social functioning score (PAS, high = worse)</HEADING>
<P>Psychiatric disturbance was measured using the PAS, but results were no different at both medium term (n = 75, 1 RCT) and long term (n = 56, 1 RCT, <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6.5. Social functioning score (SAS, high = worse)</HEADING>
<P>Finally, social adjustment was measured in one RCT using the SAS, which again demonstrated no significant difference between interventions at both medium term (n = 51, 1 RCT) and long term (n = 51, 1 RCT, <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.7.1. Akathisia (HAS, high = worse, skew)</HEADING>
<P>The HAS was employed to measure akathisia. These results should be interpreted carefully, however, as only one study reported data using this scale, and the data displayed are skewed, with high standard deviations (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.2. Extrapyrimidal side effects</HEADING>
<P>Only one trial reported data for specific extrapyramidal side effects, which demonstrated a slightly higher (non-significant) instance of hypomimia (lack of facial expression) for maintenance therapy at medium term (n = 43, 1 RCT, RR 0.26, 95% CI 0.06 to 1.09) and long term (n = 43, 1 RCT, RR 0.17, 95% CI 0.02 to 1.33); no difference was found for rigidity between groups at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference between groups for instance of tremor at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference between groups for instance of akathisia at medium term (n = 43, 1 RCT), but with a significant difference favouring intermittent therapy at long term (n = 43, 1 RCT, RR 0.19, 95% CI 0.05 to 0.76); no significant difference between groups for instance of gait abnormality for maintenance therapy at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference between groups for instance of parkinsonism at medium term (n = 43, 1 RCT), but with a significant difference favouring intermittent therapy at long term (n = 43, 1 RCT, RR 0.13, 95% CI 0.02 to 0.96); and a significantly higher risk of global non-liveliness with maintenance therapy at both medium term (n = 43, 1 RCT, RR 0.24, 95% CI 0.08 to 0.73) and long term (n = 43, 1 RCT, RR 0.09, 95% CI 0.01 to 0.61, <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.3. Extrapyrimidal symptoms (EPS, high = worse, skew)</HEADING>
<P>Parkinsonian and related extrapyramidal side effects were also measured using the EPS scale, which presented skewed data and are best viewed by inspection of the 'other data' table (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.4. Need for additional medication</HEADING>
<P>There was no significant difference in the number of people requiring additional medication (n = 346, 2 RCTs, <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.5. Side effects (LUNSERS, high = worse, skew)</HEADING>
<P>Side effects measured using LUNSERS presented skewed data and should be interpreted carefully (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.6. Side effects (UKU, high = worse, skew)</HEADING>
<P>Side effects measured using UKU presented skewed data and should be interpreted carefully (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>) .</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.7. Tardive dyskinesia</HEADING>
<P>By medium term, there was no significant difference when measuring prevalence of tardive dyskinesia at medium term (n = 43, 1 RCT) or by long term (n = 165, 4 RCTs, <LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7.8. Tardive dyskinesia (AIMS, high = worse, skew)</HEADING>
<P>Intermittent treatment groups generally scored lower on the AIMS at both medium and long term - these results, however, are skewed and should be interpreted with caution (<LINK REF="CMP-001.25" TYPE="ANALYSIS">Analysis 1.25</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Quality of life</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.8.1. Average score (LQLP, low = worse)</HEADING>
<P>There was no significant difference between groups when assessing quality of life scores at medium term, using LQLP (n = 27, 1 RCT) with lower scores in the intermittent treatment group in the one RCT that reported data (<LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.2. Average score (GLS, low = worse)</HEADING>
<P>Data reported from one RCT using the QLS demonstrated no significant difference between groups by long term (n = 26, 1 RCT, <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8.3. Average score (WHOQoL-Bref, low = worse)</HEADING>
<P>Using the WHOQoL-Bref, there was no difference between groups at both medium term (n = 128, 1 RCT) and long term (n = 128, 1 RCT, <LINK REF="CMP-001.28" TYPE="ANALYSIS">Analysis 1.28</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Leaving the study early/loss to follow-up</HEADING>
<P>There was no significant difference between groups when assessing people leaving the study early for any reason by short term (n = 31, 1 RCT), with equivocal results at medium term (n = 155, 3 RCTs, RR 1.40, 95% CI 0.25 to 7.82); there was a trend favouring maintenance therapy over intermittent therapy by long term (n = 996, 10 RCTs, RR 1.63, 95% CI 1.23 to 2.15, <LINK REF="CMP-001.29" TYPE="ANALYSIS">Analysis 1.29</LINK>). There was moderate heterogeneity between these results, however, and they are presented using a random-effects model (Chi² = 31.25, P = 0.003, I² = 58%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: INTERMITTENT (EARLY-BASED) versus MAINTENANCE THERAPY</HEADING>
<P>Five studies compared intermittent (early-based) therapy with maintenance therapy (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Schooler-1997" TYPE="STUDY">Schooler 1997</LINK>, n = 626).</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Relapse</HEADING>
<P>Data from two RCTs showed that people receiving intermittent (early-based) treatment were more likely to relapse, with significant favour of maintenance therapy at long term (n = 155, 2 RCTs, RR 2.33, 95% CI 1.32 to 4.12, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Hospitalisation</HEADING>
<P>At medium term, no significant difference between groups for rates of hospitalisation (n = 101, 1 RCT) but at long term, results displayed statistical significance in favour of maintenance treatment (n = 625, 5 RCTs, RR 1.66, 95% CI 1.33 to 2.08, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Death</HEADING>
<P>Only two studies reported the outcome of death, with people receiving maintenance therapy at greater risk in the long term (n = 155, 2 RCTs, RR 0.34, 95% CI 0.05 to 2.08, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.4.1. Average score (GAS, low = worse)</HEADING>
<P>Medium-term data for global state using the GAS showed an equivocal effect between intermittent (early) treatment and maintenance therapy at medium term (n = 75, 1 RCT, MD -0.15, 95% CI -4.78 to 4.48) and long term (n = 82, 2 RCTs, MD 0.99, 95% CI -4.24 to 6.22, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4.2. Prodromal episodes</HEADING>
<P>Instances of prodromal episodes were also significantly more prevalent in intermittent (early) treatment, with statistically significant favour of maintenance treatment by long term (n = 155, 2 RCTs, RR 3.19, 95% CI 1.87 to 5.44, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.5.1 Average score (BPRS, high = worse)</HEADING>
<P>One study reported data using the BPRS, which demonstrated an equivocal effect by long term (n = 26, 1 RCT, MD 0.10, 95% CI -0.33 to 0.53, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 General functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.6.1. Average endpoint (LOFS, low = worse)</HEADING>
<P>In the one RCT that assessed level of functioning using the LOFS, results were equivocal by long term (n = 26, 1 RCT, MD 2.60, 95% CI -2.63 to 7.83, <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6.2. Social (PAS, high = worse)</HEADING>
<P>There was no difference between groups in the one study that assessed functioning using the PAS, at medium (n = 75, 1 RCT) and long term (n = 56, 1 RCT, <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.7.1. Extrapyramidal side effects</HEADING>
<P>Only one trial reported data for specific extrapyramidal side effects, which demonstrated no significant difference between groups for instance of hypomimia for maintenance therapy at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference was found between groups instance of rigidity at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference was found between groups for instance of tremor for maintenance therapy at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference was found between groups for instance of akathisia at medium term (n = 43, 1 RCT), but with a significant outcome favouring intermittent (early) therapy at long term (n = 43, 1 RCT, RR 0.19, 95% CI 0.05 to 0.76); no significant difference was found between groups for instance of gait abnormality at medium term (n = 43, 1 RCT) and long term (n = 43, 1 RCT); no significant difference was found for instance of parkinsonism at medium term (n = 43, 1 RCT), but with a significant outcome favouring intermittent (early) therapy at long term (n = 43, 1 RCT, RR 0.13, 95% CI 0.02 to 0.96); and a significantly higher risk of global non-liveliness with maintenance therapy at both medium term (n = 43, 1 RCT, RR 0.24, 95% CI 0.08 to 0.73) and long term (n = 43, 1 RCT, RR 0.09, 95% CI 0.01 to 0.61, <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.2. Extrapyramidal symptoms (EPS, high = worse, skew)</HEADING>
<P>Parkinsonian and related extrapyramidal side effects were also measured using the EPS scale, which presented skewed data and are these are best viewed by inspection of the 'other' data table (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.3. Need for additional medication</HEADING>
<P>In the one RCT that compared intermittent (early) treatment with maintenance therapy, there was no difference in the amount of people who required additional medication (n = 313, 1 RCT, <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7.4. Tardive dyskinesia</HEADING>
<P>By medium term, there was no significant difference between groups when measuring prevalence of tardive dyskinesia at medium term (n = 43, 1 RCT) or by long term (n = 30, 1 RCT, <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Quality of life</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.8.1. Average score (QLS, low = worse)</HEADING>
<P>Data reported from one RCT using the QLS demonstrated no significant difference by long term (n = 26, 1 RCT, <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Leaving the study early/loss to follow-up</HEADING>
<P>There was a trend favouring maintenance therapy over intermittent therapy by long term (n = 562, 5 RCTs, RR 1.67, 95% CI 1.17 to 2.37, <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>). There was moderate heterogeneity between these results, however, and they are presented using a random-effects model (Chi² = 9.45, P = 0.05, I² = 58%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: INTERMITTENT (CRISIS INTERVENTION) versus MAINTENANCE THERAPY</HEADING>
<P>Only one study reported data for this comparison.<LINK REF="STD-Pietzcker-1993_x002a_" TYPE="STUDY">Pietzcker 1993*</LINK> had three treatment arms, and so this comparison assesses the outcomes of participants in that study receiving intermittent (crisis) and maintenance therapy (n = 237). As loss to follow-up was at 56%, only data for the outcome of leaving the study early are presented.</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Leaving the study early/loss to follow-up</HEADING>
<P>By long term, there was a significantly greater number of participants receiving intermittent (crisis) therapy that left the study early or were lost to follow-up (n = 237, 1 RCT, RR 1.57, 95% CI 1.23 to 2.00, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS) versus MAINTENANCE THERAPY</HEADING>
<P>Three studies provided data for this comparison (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>, n = 260).</P>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Relapse</HEADING>
<P>Data from three RCTs showed that people receiving intermittent (gradually increased drug-free) treatment were more likely to relapse, with no significant difference at short (n = 128, 1 RCT) and medium term (n = 128, 1 RCT), but with significant favour of maintenance therapy at long term (n = 219, 3 RCTs, RR 2.76, 95% CI 1.63 to 4.67, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). Heterogenity was present with long-term data, but this was only slight (Chi² = 2.89, P = 0.24, I² = 31%), and results remain in data and analysis using a fixed-effect model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.2.1. Average score (CGI-S, high = worse)</HEADING>
<P>Symptom severity was measured by one RCT using the CGI-S scale, which demonstrated no significant difference between groups by long term (n = 27, 1 RCT, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2.2. Average score (GAS, low = worse)</HEADING>
<P>Results were equivocal when using the GAS at medium term (n = 51, 1 RCT, MD -1.54, 95% CI -10.42 to 7.34) and long term (n = 51, 1 RCT, MD 1.83, 95% CI -4.66 to 8.32, <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1. Average score (BPRS, high = worse)</HEADING>
<P>Using the BPRS, there was little difference in levels of psychiatric symptoms between people receiving intermittent or maintenance therapy, with no significant difference between groups at medium term (n = 51, 1 RCT) or long term (n = 51, RCT, MD 0.20, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.2. Negative symptoms score (PANSS negative symptom subscale, high = worse)</HEADING>
<P>Negative symptom scores using PANSS tended to be slightly higher with maintenance therapy, but with no significant difference between groups at both medium (n = 128, 1 RCT) and long term (n = 128, 1 RCT, <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.3. Negative symptoms score (PANSS negative symptom subscale, high = worse, skew)</HEADING>
<P>Skewed data using PANSS in one RCT are presented in a separate table (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.4. Negative symptom score (SANS, high = worse, skew)</HEADING>
<P>Data assessing negative symptoms using SANS were also skewed (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.5. Positive symptoms score (PANSS positive symptoms subscale, high = worse)</HEADING>
<P>Positive symptoms were assessed using the PANSS positive symptom subscale; the one RCT that presented data at medium term demonstrated significant favour for intermittent treatment (n = 128, 1 RCT, MD -0.80, 95% CI -1.58 to -0.02), but an equivocal effect by long term (n = 155, 2 RCTs, MD 0.40, 95% CI -0.79 to 1.59, <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 General functioning</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.4.1. Social functioning score (GAF, low = worse)</HEADING>
<P>Social functioning scores using the GAF significantly favoured maintenance treatment at long term in the one RCT that reported data (n = 27, 1 RCT, MD -9.00, 95% CI -15.92 to -2.08, <LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4.2. Social functioning score (GSDS, high = worse, skew)</HEADING>
<P>Data presented were skewed with the GSDS (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>) and need interpreting with caution.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4.3. Social functioning score (SAS, high = worse)</HEADING>
<P>Results were equivocal at both medium term (n = 51, 1 RCT, MD 0.06, 95% CI -0.10 to 0.22) and long term (n = 51, 1 RCT, MD 0.05, 95% CI -0.08 to 0.18, <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>) when using the SAS.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.5.1. Akathisia (HAS, high = worse, skew)</HEADING>
<P>All data from scales used to assess adverse effects/events are skewed and are presented in separate tables (<LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.2. Extrapyramidal symptoms (EPS, high = worse, skew)</HEADING>
<P>There was little difference in EPS scores to measure extrapyramidal symptoms (<LINK REF="CMP-004.13" TYPE="ANALYSIS">Analysis 4.13</LINK>), with skewed data presented separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.3. Side effects (LUNSERS, high = worse, skew)</HEADING>
<P>Side effects scores were skewed when using LUNSERS in the one RCT that used the scale and are reported separately (<LINK REF="CMP-004.14" TYPE="ANALYSIS">Analysis 4.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.4. Side effects (UKU, high = worse, skew)</HEADING>
<P>Results for side effects using the UKU by long term were also skewed (<LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.5. Tardive dyskinesia</HEADING>
<P>The only binary outcome represents zero instances of tardive dyskinesia in either intermittent or maintenance groups throughout the period of the one study that reported such data (<LINK REF="CMP-004.16" TYPE="ANALYSIS">Analysis 4.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5.6. Tardive dyskinesia (AIMS, high = worse, skew)</HEADING>
<P>AIMS scores to measure tardive dyskinesia were skewed and are presented separately (<LINK REF="CMP-004.17" TYPE="ANALYSIS">Analysis 4.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.6 Quality of life</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.6.1. Average score (LQLP, low = worse)</HEADING>
<P>Quality of life scores were equivocal when using the LQLP by long term (n = 27, 1 RCT, MD -0.50, 95% CI -1.38 to 0.38, <LINK REF="CMP-004.18" TYPE="ANALYSIS">Analysis 4.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.6.2. Average score (WHOQoL-Bref, low = worse)</HEADING>
<P>Again, results were equivocal using the WHOQoL-Bref at both medium term (n = 128, 1 RCT, MD -0.70, 95% CI -4.27 to 2.87) and long term (n = 128, 1 RCT, MD -0.90, 95% CI -5.39 to 3.59, <LINK REF="CMP-004.19" TYPE="ANALYSIS">Analysis 4.19</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.7 Leaving the study early/loss to follow-up</HEADING>
<P>There was no difference between groups for numbers leaving the study early for any reason by long term (n = 257, 3 RCTs, <LINK REF="CMP-004.20" TYPE="ANALYSIS">Analysis 4.20</LINK>); these results displayed substantial heterogeneity (Chi² = 6.33, P = 0.04, I² = 68%) and are presented using a random-effects model of analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 5: INTERMITTENT (DRUG HOLIDAY) versus MAINTENANCE THERAPY</HEADING>
<P>Seven studies provided data for this comparison (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>, n = 627).</P>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Relapse</HEADING>
<P>Data demonstrate that there was a significantly greater risk of relapse for participants receiving intermittent drug therapy; results were homogenous, statistically significant in favour of maintenance therapy at medium term (n = 272, 3 RCTs, RR 2.15, 95% CI 1.25 to 3.68), however, results were equivocal by short term (n = 268, 3 RCTs, RR 1.59, 95% CI 0.94 to 2.70) and long term (n = 62, 2 RCTs, RR 1.70, 95% CI 0.54 to 5.38, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Hospitalisation</HEADING>
<P>There was no significant difference in numbers of hospitalisation between groups (n = 35, 1 RCT, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.3.1. Average score (CGI-S, high = worse)</HEADING>
<P>At medium term, CGI scores were not significantly different between groups (n = 35, 1 RCT, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.2. Average score (GAS, low = worse)</HEADING>
<P>In one RCT, results from the GAS significantly favoured maintenance therapy at short term (n = 31, 1 RCT, MD -3.61, 95% CI -5.67 to -1.55, <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3.3. Significant improvement</HEADING>
<P>In the one trial that measured 'significant improvement', there was a significantly higher instance of improvement with maintenance therapy at short term (n = 60, 1 RCT, RR 0.40, 95% CI 0.18 to 0.89) and medium term (n = 60, 1 RCT, RR 0.32, 95% CI 0.15 to 0.68, <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.4 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.4.1. Need for additional medication</HEADING>
<P>There was no significant difference between groups for instances of people requiring additional medication (n = 33, 1 RCT, <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.4.2. Tardive dyskinesia</HEADING>
<P>There was no significant difference between groups when assessing numbers of people who experienced tardive dyskinesia by long term (n = 50, 2 RCTs, <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.4.3. Tardive dyskinesia (AIMS, high = worse, skew)</HEADING>
<P>Tardive dyskinesia scores using the AIMS scale were skewed and are presented separately (<LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.5 Leaving the study early/loss to follow-up</HEADING>
<P>Overall, there was no significant difference in lost to follow-up numbers between groups (n = 248, 6 RCTs, <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>), however results demonstrated considerable heterogeneity (Chi² = 16.09, P = 0.007, I² = 69%) and are presented using a random-effects model.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 6: ANY INTERMITTENT DRUG TECHNIQUE versus PLACEBO</HEADING>
<P>Three studies reported data for this comparison (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>, n = 498).</P>
<SUBSECTION>
<HEADING LEVEL="4">6.1 Relapse</HEADING>
<P>Compared with placebo, there was significant favour for intermittent treatment at short term (n = 260, 1 RCT, RR 0.22, 95% CI 0.10 to 0.45) and medium term (n = 290, 2 RCTs, RR 0.37, 95% CI 0.24 to 0.58, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), however, heterogeneity is present for the medium term results (Chi² = 2.59, P = 0.11, I² = 61%), and so caution should be employed in interpreting this data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.2.1. Significant improvement</HEADING>
<P>There was no significant difference in the amount of people considered 'significantly improved' by medium term (n = 30, 1 RCT, <LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3 Leaving the study early/loss to follow-up</HEADING>
<P>People allocated to placebo were significantly more likely to remain in the study compared with the intermittent drug techniques used in two RCTS (n = 90, 2 RCTs, RR 1.97, 95% CI 1.28 to 3.01, <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 7: ANY INTERMITTENT DRUG TECHNIQUE (SPECIFIC DRUG) versus MAINTENANCE THERAPY (SPECIFIC DRUG)</HEADING>
<P>We compared the differences between the various antipsychotics used in intermittent treatment compared with maintenance therapy at short term, medium and long term for our two primary outcomes of relapse and hospitalisation. Twelve studies provided data for the outcome of relapse (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>; <LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>; <LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>; <LINK REF="STD-Prien-1973" TYPE="STUDY">Prien 1973</LINK>; <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>; <LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>, n = 1327); however, some studies did not provide adequate information regarding the types of antipsychotics used, instead converting dosages into milligrams of chlorpromazine (<LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>; <LINK REF="STD-Carpenter-1990_x002a_" TYPE="STUDY">Carpenter 1990*</LINK>; <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>; <LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>) or haloperidol (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>; <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>; <LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>) equivalents. Dosages were unclear in <LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">7.1 Relapse</HEADING>
<P>Results demonstrated homogeneity, with favour of maintenance therapy with each specific drug comparison; some results were statistically significant, however, and demonstrate a higher risk of relapse for people receiving intermittent drugs in the following comparisons: various intermittent typical antipsychotics (moderate dose) versus maintained typical antipsychotics (moderate dose) at medium term (n = 551, 2 RCTs, RR 3.75, 95% CI 1.42 to 9.94); intermittent chlorpromazine equivalents (low dose) versus maintained chlorpromazine equivalents (low dose) by long term (n = 148, 2 RCTs, RR 2.62, 95% CI 1.30 to 5.28) and intermittent haloperidol equivalents (low dose) versus maintained haloperidol equivalents (low dose) by long term (n = 226, 3 RCTs, RR 2.53, 95% CI 1.60 to 4.01, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7.2 Hospitalisation</HEADING>
<P>Data demonstrated statistical significance in favour of maintenance therapy when comparing intermittent fluphenazine decanoate (low dose) versus maintained fluphenazine decanoate (low + moderate dose) by long term (n = 313, 1 RCTs, RR 1.81, 95% CI 1.33 to 2.48), with overall statistically significant favour for maintenance therapy between all groups (n = 661, 6 RCTs, RR 1.58, 95% CI 1.28 to 1.97, <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">SENSITIVITY ANALYSIS: ANY INTERMITTENT DRUG TECHNIQUE versus MAINTENANCE THERAPY</HEADING>
<P>When included studies that implied randomisation or provided no further details regarding randomisation techniques were removed from the meta-analysis, this did not substantially alter the direction of effect or the precision of the effect estimates, with a significantly greater risk of relapse still demonstrated for people receiving any intermittent therapy by long term (n = 273, 3 RCTs, RR 2.19, 95% CI 1.41 to 3.42), and greater risk of hospitalisation for the same group by long term (n = 414, 2 RCTs, RR 1.76, 95% CI 1.31 to 2.36); therefore, where risk of bias for randomisation was 'unclear', all data have been employed from all studies. All of the included studies were judged to be at a high risk of bias across one or more of the domains of randomisation, allocation concealment, blinding and outcome reporting, which makes it difficult to draw meaningful conclusions from a sensitivity analyses, as we would need substantial power to show real differences with confidence.</P>
<P>When testing how prone the primary outcomes were to change when data only from people who complete the study to that point were compared to the intention to treat analysis, there was little difference in results - often showing results with greater significance. When comparing any intermittent drug technique to maintenance therapy, data still showed significantly greater relapses in the intermittent group at short term (n = 358, 3 RCTs, RR 2.12, 95% CI 1.12 to 3.98), medium term (n = 767, 5 RCTs, RR 2.94, 95% CI 1.71 to 5.05) and long term (n = 430, 7 RCTs, RR 2.51, 95% CI 1.72 to 3.67). Neither was there any significant difference in numbers of people hospitalised at long term (n = 620, 5 RCTs), with data still showing significant favour for maintenance therapy.<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-05-14 16:23:25 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-05-14 16:04:19 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">1. Specific</HEADING>
<P>The review includes studies that span over five decades. Over this period, the landscape of psychiatry has changed, as have the types of participants involved in the studies; the methods by which trials are carried out; treatment administered and even the level of quality by which results are reported (<LINK REF="REF-Thornley-1998" TYPE="REFERENCE">Thornley 1998</LINK>). All studies were included in the meta-analysis, however, and have been detailed in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for closer inspection. There were no differences in primary outcomes when a random-effects or fixed-effect model was used; results that displayed moderate heterogeneity were analysed using a random-effects model.</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1. ANY INTERMITTENT DRUG TECHNIQUE versus MAINTENANCE THERAPY</HEADING>
<P>This comparison encapsulates the various forms of intermittent antipsychotic treatment (which, for the purposes of this review, include intermittent treatment based on: prodrome/early-based intervention; crisis-based intervention; drug holidays; and gradually increased drug-free periods) and antipsychotic treatment (only a select few of included studies have provided adequate detail regarding types of antipsychotics and dosages administered). Therefore, one must remain mindful that these intermittent treatments, although uniformly meta-analysed within data and results, have employed differing: methods of administration; types of antipsychotics used; and methods by which trial authors determine when people receiving intermittent therapy (if receiving a form of early-based intermittent treatment that relies on recognition of prodromal symptoms, for example) are to re-start their treatment, if at all. With this in mind, the significance of the results for relapse at short, medium and long term indicates that any intermittent treatment (regardless of its administration), falls short to the stability of continuous maintenance therapy.</P>
<P>Only two studies reported death, with a higher (non-significant) rate in people receiving maintenance therapy. In <LINK REF="STD-Herz-1991_x002a_" TYPE="STUDY">Herz 1991*</LINK>, the deaths recorded were due to 'natural causes', with no further information given (n = 2 receiving maintenance therapy), and a 'possible suicide' (n = 1 receiving intermittent therapy) who drowned after ingesting large amounts of alcohol. It is unclear to what extent, if any, these deaths could be said to be attributable to either intermittent or maintenance treatments. This is also the case with the deaths recorded by <LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>, in which n = 2 participants receiving maintenance treatment died; one death was a suggested suicide, and the other reported as 'attributable to an acute physical illness'.</P>
<P>Many scales were employed to measure adverse effects; however, all presented skewed data and were not included within a meta-analysis due to high standard deviations. Specific adverse effects were measured in only one randomised controlled trial (RCT) (<LINK REF="STD-Jolley-1989_x002f_1990" TYPE="STUDY">Jolley 1989/1990</LINK>), and demonstrated significant favour for intermittent treatment when assessing extra-pyramidal symptoms (EPS) side effects including: akathisia; parkinsonism; and non-liveliness.<BR/>
<BR/>Most continuous outcomes demonstrated no significant difference between intervention groups; were considerably skewed; or used different scales to measure the same outcome, making a meaningful interpretation of these results difficult.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: INTERMITTENT (EARLY-BASED) versus MAINTENANCE THERAPY</HEADING>
<P>More people receiving intermittent treatment, given on the early/prodromal signs of relapse, were significantly more likely to experience full relapse compared to people receiving maintenance therapy. There was also a higher instance of hospitalisation with people receiving the early intermittent treatment; results were homogenous and demonstrated statistical significance by long term. These results from five RCTs, with a relatively large sample size (n = 620), demonstrate that maintenance therapy is more effective than early intermittent techniques at lowering the number of people hospitalised.</P>
<P>Results were equivocal when assessing general functioning; no two studies used the same scale to assess general functioning, and any real-life significance of these scale measurements have not been considered by trial authors.</P>
<P>We found that less specific adverse effects were experienced in people receiving intermittent treatment when given on the early/prodromal signs of relapse, demonstrating significant favour for intermittent treatment when assessing EPS symptoms including: akathisia; parkinsonism; and non-liveliness. Only one RCT with a small sample size (n = 43) reported data for this outcome. Data for extrapyramidal symptom scores using the EPS were highly skewed, making it difficult to draw any meaningful conclusions.</P>
<P>More people tended to leave the studies early when they were receiving intermittent treatment, with a significant favour of maintenance therapy; however, considerable heterogeneity (I² = 58%) was evident in the analysis. Upon visual inspection, removal of <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK> restored homogeneity; this RCT documented people who dropped out as: n = 9 in the maintenance group (one refused assignment to regimen; seven discontinued treatment; one was non-compliant); and n = 7 in the intermittent group (two were hospitalised; two were dropped while hospitalised; three dropped out during clinical stability while medication-free). Taking this into account, it is difficult to ascertain whether those who 'discontinued' the intermittent treatment did so for treatment-related reasons or due to other circumstances.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: INTERMITTENT (CRISIS INTERVENTION) versus MAINTENANCE THERAPY</HEADING>
<P>Only one study provided data for this comparison, and unfortunately, since attrition was over 50%, only data for the outcome of leaving the study early were included in the data and analysis. Maintenance therapy was significantly favoured, with a higher instance of people leaving the study early when given intermittent treatment. Numbers leaving the study early were adequately documented; a high number of participants in the intermittent treatment groups dropped-out due to difficulties of withdrawing antipsychotics, indicating that people who left the study early had negative outcomes. This finding would need to be confirmed through further research, using high-quality, randomised methods.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS) versus MAINTENANCE THERAPY</HEADING>
<P>Corresponding with the findings from Comparison 1 and 2, intermittent treatment, when employed via gradually increasing drug-free periods, had a higher instance of relapse, with a significant outcome by long term.</P>
<P>Due to the small amount of studies (three RCTs) and relatively small sample sizes (maximum of n = 128) providing data for this mental state outcomes, results are difficult to interpret meaningfully. Data for most continuous outcomes were either considerably skewed, or demonstrated no significant difference between the groups.</P>
<P>General functioning scores tend to favour maintenance treatment, using the SAS, and significantly when using the GAF - this judgement is based on a single study with only 27 participants. Furthermore, scores measuring social disabilities using the GSDS were considerably skewed.This makes the present results difficult to interpret - dichotomous data are a preferred method of reporting outcomes, particularly for adverse effects, in order to reflect the real-life significance of the outcome.</P>
<P>More people left the study early when receiving intermittent treatment via gradually increasing drug-free periods. Considerable heterogeneity associated with leaving the study early could be attributable to the different methods by which drug-free periods were gradually increased. Each of the three RCTs providing outcome data gradually decreased antipsychotic treatment in the intermittent group, however one trial sought complete removal over a period of three months at the most (<LINK REF="STD-Gaebel-2011" TYPE="STUDY">Gaebel 2011</LINK>), the second sought gradual decrease of the active drug after three months (<LINK REF="STD-Wiedemann-2001" TYPE="STUDY">Wiedemann 2001</LINK>), and the third trial was open-label, dosages were gradually tapered-off guided by symptom severity levels and the preference of the participant, discontinued only 'if feasible' (<LINK REF="STD-Wunderink-2007" TYPE="STUDY">Wunderink 2007</LINK>). These factors could well influence whether or not a person left the study early due to inaccurate identification of times when medication should be administered or a lack of effective treatment structure, for example.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 5: INTERMITTENT (DRUG HOLIDAY) versus MAINTENANCE THERAPY</HEADING>
<P>People who received intermittent drug treatment via drug holiday were significantly more likely to experience relapse in the short and medium term than people who received maintenance therapy, again confirming the results for the above comparisons that intermittent treatment is not as effective as continuous.</P>
<P>Only one RCT reported data for hospitalisation, in which intermittent therapy is favoured over maintenance; this contradicts results in the other comparisons, which was acknowledged by the trial authors, who stated their findings to be 'at odds' with the existing number of previous studies evaluating intermittent therapy. Further research is needed to clarify this issue.</P>
<P>There was no significant difference found when comparing instances of adverse effects between the two comparison groups, and numbers of people leaving the studies early were equivocal; reasons included: administrative (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>); refusal of medication (<LINK REF="STD-McCreadie-1980" TYPE="STUDY">McCreadie 1980</LINK>); exacerbation of positive symptoms, suicidal ideas and attempts, family requests to withdraw, tardive dyskinesia, complaints of tiredness (<LINK REF="STD-McCreadie-1982" TYPE="STUDY">McCreadie 1982</LINK>); 'behavioural' or 'inadvertent' attrition (<LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK>); withdrawal of consent (<LINK REF="STD-Remington-2011" TYPE="STUDY">Remington 2011</LINK>); and failure to attend appointments (<LINK REF="STD-Shenoy-1981" TYPE="STUDY">Shenoy 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 6: ANY INTERMITTENT DRUG TECHNIQUE versus PLACEBO</HEADING>
<P>It is understandable that placebo-controlled trials in this area are uncommon and it could be argued that in certain circumstances are unethical. We identified three trials undertaken in the 1960s that made this comparison; each trial was poorly reported, and failed to describe randomisation methods.</P>
<P>The two trials reporting data for relapse (<LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>; <LINK REF="STD-Caffey-1964" TYPE="STUDY">Caffey 1964</LINK>) both employed a drug holiday intermittent technique, in which antipsychotics were withdrawn and reintroduced on a regular or longer-term basis. Intermittent treatment was significantly favoured, with more people receiving placebo classified as relapsed. This finding goes some way to demonstrate that intermittent techniques are at least more effective than no treatment/placebo, the extent to which this result is applicable, however, could well be dependable on the type of intermittent therapy implemented.</P>
<P>Significantly more people receiving intermittent therapy left the study early when compared with placebo. Further, reasons for leaving were not made clear, described only as 'behavioural' or 'inadvertent' attrition, or 'lost for administrative reasons'. Whether this makes people leaving intermittent treatment likely to experience a negative outcome is difficult to establish. Differences between the study methods, however, may well have influenced favour for placebo - the two comparison groups in <LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK> examined the effects of placebo substituted for the first half of the study (eight weeks) then active medication reintroduced for the final half of the trial, versus placebo substituted for the full trial length; whereas <LINK REF="STD-Olson-1962_x002a_" TYPE="STUDY">Olson 1962*</LINK> compared active drugs alternated monthly (intermittent) versus active drugs alternated monthly with placebo. Placebo effect may well have been evident in <LINK REF="STD-Blackburn-1961" TYPE="STUDY">Blackburn 1961</LINK>, which made use of placebo in each treatment arm; this may have resulted in the much higher rate of attrition in the study that employed placebo in only one group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 7: ANY INTERMITTENT DRUG TECHNIQUE (SPECIFIC DRUG) versus MAINTENANCE THERAPY (SPECIFIC DRUG)</HEADING>
<P>Not all studies described the type of antipsychotic medication administered or the dosages used, therefore, this comparison measured outcome data only from those trials where adequate details regarding the type of medication were given. There was significant favour for maintenance therapy when comparing:</P>
<OL>
<LI>intermittent low/moderate dose typical antipsychotics versus maintained low/moderate dose typical antipsychotics at medium term;</LI>
<LI>intermittent low dose chlorpromazine/haloperidol equivalents versus maintained low dose chlorpromazine/haloperidol equivalents at long term.</LI>
</OL>
<P>Only chlorpromazine or haloperidol equivalents were reported in some trials, which make it difficult to ascertain efficacy of specific drugs, if at all, when given intermittently.</P>
<P>Meta-analysis overall demonstrated significant favour of maintenance therapy for preventing hospitalisation, with significance found particularly when comparing intermittent low dose fluphenazine decanoate with maintained low/moderate dose fluphenazine decanoate.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">2. General</HEADING>
<P>Futhermore, because 'relapse' was defined differently in each individual study, there was not a single, fixed assessment of measurement. Out of the 17 studies included in this update, 15 reported our two primary outcomes of interest. The majority of the included studies had a low level of participants; only seven studies had a sample size of 100+ participants.</P>
<SUBSECTION>
<HEADING LEVEL="3">2.1 Heterogeneity</HEADING>
<P>Some results are difficult to interpret due to high levels of heterogeneity; sources of heterogeneity have been explored and addressed in the above discussion, however, where results for the I<SUP>2</SUP> are statistically significant (when testing for homogeneity), caution should be employed when adding trial data together.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.2 Funnel plots</HEADING>
<P>It is clear from <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> that five small studies are scattered on the side of the plot, which suggests the possibility of publication bias. This is due to inequality of the scattered studies on both sides of the plot, as the left-hand side represents studies that are having or approaching either no effect or a negative effect. Therefore, it can be said that there is evidence of asymmetry.      </P>
<P>In <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, three studies (two on the right and one on the left) have no effect since their standard errors (SE) range between 1 and 1.5. The funnel plot shows that the majority of large studies are scattered around the top of the plot along a lower SE of less than one. It can be concluded that the funnel plot is, to a large extent, symmetrical, raising the possibility of some potentially moderate bias. In other words, there may be some negative results that have not been published.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-05-14 16:04:26 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">1. Completeness</HEADING>
<P>Twelve of the 17 included studies reported our primary outcome interest of relapse; however, only six trials reported our second primary outcome of interest of hospitalisation. No study reported economic outcomes, which would be of interest to managers and policy makers in measuring potential cost-effectiveness and efficiency of the intervention, nor was satisfaction with treatment addressed. Furthermore, it was disappointing that only two studies reported death and only four reported tardive dyskinesia as outcome measures; two outcomes that could offer greater insight into an intervention that aims to reduce the risk of typical adverse effects of continuous antipsychotic treatment. Patient-oriented outcomes were addressed in few small-scale included studies; with only three studies reporting data for quality of life; four studies reporting mental state scores; and five studies reporting scores for general and social functioning. Numerous scales were employed (in some instances by single studies), which made it difficult to make any meaningful interpretation of results, as trial authors did not address the real-life significance of scale measurements, and combining all similar scale data in meta-analysis could overestimate authority of potentially weak data.<BR/>
<BR/>The available evidence is relevant to the review question, however, intermittent antipsychotic techniques were not always referred to explicitly, as some studies did not specify their treatment as intermittent, but 'targeted intervention', 'guided discontinuation' or 'dose reduction and family treatment'. This made the trial search problematic and the intervention question more indirect, as many other studies were identified via handsearching. Consequently, we worked mainly with published reports, which may have the result of missing other potentially relevant RCTs from the current review. When presented with problematic or incomplete data, we made efforts to contact relevant trial authors to clarify these issues.<BR/>Poor reporting exacerbated the problem of scarce data; three trials were excluded due to unusable data, and the majority of included studies did not report all outcomes as per protocol. This was particularly the case with scale data, where scale measurements were taken at designated time intervals, but no data were ultimately reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">2. Applicability</HEADING>
<P>Settings were not uniform between studies, with six large multi-centre trials carried out in Germany, the Netherlands and the US; two studies carried out hostel wards in Scotland (UK); four trials undertaken in psychiatric hospitals/institutes in the US, one in Germany and one in London (UK); with a further trial conducted in a Centre for Addiction and Mental Health, Canada, setting and location were not made clear in two other included studies. As studies included both inpatients and outpatients from various countries, the international applicability of the present available evidence needs considering in relation to the methods of psychiatric treatment employed and the types of antipsychotic medication available or recommended in individual countries. Participants in seven of the total included studies were inpatients, and in the remaining 10 studies participants were outpatients. Of the inpatient studies, all were undertaken between 1961 and 1982 with the exception of a study undertaken in 2001. With this is mind, one must take into account the applicability of the evidence when considering results from studies that included inpatients, particularly because more psychiatric treatments are increasingly obliged to take place in outpatient or community settings. There was a disproportionate amount of male participants compared to female participants in the included studies (n = 1555 males and n = 540 females), and two included studies did not specify gender in their reports. Ages of participants were described in each study, with a range from all studies of 18-60; means were provided in most of the reports. Furthermore, ethnicity/racial origin was not described in the majority of studies, with only six trials providing appropriate details.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-04-03 14:15:04 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, most quality criteria were poorly reported in the trials included in this review; large, well-designed and clearly reported trials are possible in this area (as has been demonstrated in the recent TREC trials - <LINK REF="REF-TREC_x002d_Rio_x002d_I" TYPE="REFERENCE">TREC-Rio-I</LINK>; <LINK REF="REF-TREC_x002d_Vellore_x002d_I" TYPE="REFERENCE">TREC-Vellore-I</LINK>). Better reporting of the methods used to ensure trials of high quality as outlined in the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) could have resulted in this review being more transparent. Future trialists in this area need to ensure that attention is given to the adequate reporting of quality criteria. Some data reported by the included studies were skewed, and without access to individual patient data, it is difficult to present these results in a meaningful way, or likewise to comment upon them with a degree of certainty.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-05-14 16:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>The review protocol and process of study selection were strictly adhered to throughout the entire review process, and the process for searching for studies was thorough and data were extracted independently; however, this was made difficult due to numerical inconsistencies in parts of the reported data. Review authors adhered to the guidance from the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the <I>Methodological Expectations for Cochrane Intervention Reviews</I> (<A HREF="http://www.editorial-unit.cochrane.org/mecir">MECIR</A>).<BR/>
<BR/>The first study search was narrow, and failed to identify several studies that suited inclusion criteria. With the intention of correctly identifying all relevant published studies, another trial search was conducted (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for previous search term methods). Authors of included studies were contacted to obtain details of ongoing or unpublished studies, but there remains a possibility that other unpublished trials of the intervention exist which the review authors do not currently have access to. As a consequence, publication bias may have been perpetuated as we worked predominantly with published reports. Furthermore, it became clear that not all of the studies employing an intermittent technique of administering antipsychotics labelled it as such, referring instead to 'targeted intervention' or 'guided discontinuation'; it may therefore be that trials exist relying on essential elements of the intervention, but are not packaged and delivered in identical models.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-05-14 16:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>The findings from this review supports the existing evidence that intermittent antipsychotic treatment is not as effective as continuous, maintained antipsychotic therapy in preventing relapse in people with schizophrenia. The findings of this review largely agree with current clinical guidelines (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). These guidelines state that low-dose prescribing and use of intermittent dosing strategies may well minimise side effects in the long-term use of antipsychotic medication; however, the risk of symptom-worsening and relapse is stated to outweigh any benefits (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). Instead, it is suggested that patients who refuse maintenance therapy or where another contraindication to such therapy exists (e.g. side-effect sensitivity), then targeted, intermittent dosage maintenance strategies may be considered, baring in mind the 'reasonable targets' for intervention, including presence of persistent symptoms, poor adherence to treatment regimen, lack of insight and substance use (<LINK REF="REF-Marder-2003" TYPE="REFERENCE">Marder 2003</LINK>). WHO guidance makes no mention of intermittent or targeted approaches (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-05-14 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-05-14 16:07:54 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For people with schizophrenia</HEADING>
<P>The results suggested that intermittent drug techniques do not play a preventative role for relapse or (re)hospitalisation when compared with maintenance therapy, and the assumption that intermittent antipsychotic treatment may minimise potential adverse effects associated with continuous, long-term antipsychotic treatment is far from being concluded. The results of this review included data from small, poorly-reported trials, where randomisation methods were not specified, therefore making any significant findings susceptible to a high risk of bias, with the quality of the majority of the evidence ultimately rated as 'low' or 'very low'. The report of higher relapses in the intermittent techniques may suggest an intolerance to drug withdrawal by not controlling positive symptoms. Those who are on drugs intermittently are unlikely to permanently discontinue antipsychotic medication; loss of substance, motivation and sense of purposiveness to medication is lost by treating individuals intermittently, yet the stigma of assignment to long-term treatment can make compliance more problematic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>The evidence that any intermittent drug technique is superior to maintenance therapy is weak, with a significantly higher instance of relapse at each time interval evident among people receiving drugs on an intermittent schedule, and a significantly higher rate of hospitalisation in the long term. Until further evidence is available concerning the potential range and extent of both benefits and harms of intermittent antipsychotics, clinicians should employ this method of treatment only under heavily supervised settings. Effectiveness of any psychiatric treatment relies on good communication between healthcare professionals and service users at every stage of treatment and care, with the treatment provided and information supplied tailored to individual persons needs and culturally appropriate (<A HREF="http://guidance.nice.org.uk/CG82/Guidance/pdf/English">NICE</A>); all relevant and suitable treatment options should be determined on an individual basis, through full-disclosure and discussion with the recipient of care. If intermittent drug techniques are to be undertaken there must be a thorough assessment taken prior to this concerning patient characteristics and history of treatment compliance. Throughout the therapy, clinicians must carefully control and monitor the withdrawal of antipsychotics and the process should be one made gradually for patient safety. In such circumstances, the evidence favours early intervention in comparison to crisis intervention, as attrition rates are marginally lower; by intervening early, symptoms may be more effectively controlled and treatment adherence improved.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers or policy-makers</HEADING>
<P>The majority of the included studies provided insufficient information regarding the specific antipsychotic treatment employed and dosages administered in both intermittent and maintenance therapy groups. This makes it difficult to interpret any cost-effectiveness of intermittent treatment, on the assumption that similar antipsychotics (i.e. typical or atypical antipsychotics) and dosages would be administered on an intermittent as opposed to a continuous/maintained basis. There was no discussion of economic outcomes, specifically relating to potential cost-effectiveness of employing an intermittent antipsychotic regimen. Until further evidence is available concerning the potential range and extent of both benefits and harms of intermittent antipsychotic treatment, managers and policymakers should consider it an experimental therapy (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>: suggested design of future studies). Well-reported economic data need to be well balanced with patient-oriented outcomes to help equip policy makers with much needed information regarding any cost-benefits of intermittent treatment.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-05-14 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>Adherence to the CONSORT statement (<A HREF="http://archie.cochrane.org/sections/documents/view?version=70295506143093369579100414152212&amp;format=REVMAN#REF-Moher-2001">Moher 2001</A>) would probably have resulted in this review being more conclusive. Clear descriptions of randomisation would have reassured users of these trials that selection bias had been minimised and well-described and tested blinding could have encouraged greater confidence in the control of performance and detection bias. The use of binary outcomes should take preference over continuous results because they are easier to interpret and the use of validated rating scales would have provided more usable data. The reporting of outcomes with their means and standard deviations again would have provided more usable data and facilitated synthesis of findings. When presenting data in a graph, the exact numbers and standard deviations should also be reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1. Reviews</HEADING>
<P>The current review has sought to include all relevant randomised controlled trials comparing any form of intermittent drug treatment with the standard continuous/maintained antipsychotic therapy. However, the trial search failed to identify a number of relevant trials, owing in part to poor standards of reporting on behalf of trial authors. Future reviews would need to address the varying ways in which intermittent treatments are described and packaged to ensure completeness. Furthermore, the protocol to this review did not specify a comparison with specific named drugs (atypical or typical) nor dosages, which is certainly a comparison of interest for people receiving treatment as well as clinicians administering medication and was subsequently addressed in the current review (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for differences between protocol and review).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Research</HEADING>
<P>The results demonstrate the efficacy of continuous antipsychotic use for managing schizophrenia; having said this, there are some individuals who demonstrate reduced treatment adherence or a higher sensitivity to side effects; it is for this population that the need for further research surrounding intermittent techniques is certainly needed. Furthermore, evidence that has suggested that first-episode patients seem to be more suited to intermittent treatment than multiple-episode patients needs further research (<LINK REF="REF-Gaebel-2002" TYPE="REFERENCE">Gaebel 2002</LINK>). Future research using large, methodologically sound and clearly reported trials should consider comparing typical and atypical antipsychotics for differences in tolerability among men and women equally, with varying degrees of illness specified, to assess why some individuals are particularly treatment-resistant to some forms of drugs than others. Methods of the intervention should be clearly defined, with specific drugs identified and dosages reported clearly, in order to facilitate higher standards of care provided by professionals, and a greater level of understanding for people with schizophrenia and their family members. Health economic outcomes should be addressed, in order to ascertain any potential cost benefits associated with intermittently administered antipsychotics, as efficiency of treatment must be demonstrated before becoming a realistic option for managers and policy makers. Any outcomes of further studies in this area should include validated scales that are acceptable to clinicians working in the field, recipients of care, researchers and those working with regulatory authorities, taking into account, however, the real-life significance and practicality of use of standardised outcome measures in practice (<LINK REF="REF-Gilbody-2002" TYPE="REFERENCE">Gilbody 2002</LINK>). The landscape of psychiatric care has transformed dramatically over the past 50 years, with emphasis placed on a person-centred approach, where people with schizophrenia are increasingly treated in outpatient or community settings. People with schizophrenia who are prescribed pharmacological treatment are most likely to also receive psychological therapy, and any further research and subsequent reviews into intermittent antipsychotic therapy could shed light onto the effects of the intervention combined with some form of psychological/supportive therapy.</P>
</SUBSECTION>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-06-27 14:29:27 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Dr. Adib Essali and Professor Clive Adams for encouragement, continuous support and great help. We thank Gill Rizzello and Tessa Grant for their support and Judith Wright for assistance in the literature searches. We would also like to thank William Carpenter, Wolfgang Gaebel, Marvin Herz, Mathias Riesbeck and Hiroyuki Uchida for their assistance in clarifying characteristics of their included studies.</P>
<P>The Cochrane Schizophrenia Group maintains a standard template for its methods section of reviews and protocols.We have used this and adapted it.</P>
<P>We would like to thank and acknowledge the contributions made by Kajal Joshi (who helped with trial selection, data extraction and writing the review), Anas Alomar, Khaled Boobes and Mohamad Awf Mouchli (who helped write the protocol). We would also like to thank Beccy Dickenson and Muhammad Shahzad Ashraf for peer reviewing the review.<BR/>
<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-07-10 14:53:13 +0100" MODIFIED_BY="[Empty name]">
<P>Stephanie Sampson - none known.</P>
<P>Clive Elliot Adams - none known.</P>
<P>Mouhamad Mansour - none known.</P>
<P>Karla Soares-Weiser - I currently work for Enhance Reviews Ltd, a company that carries out systematic reviews mostly for the public sector, we currently do not provide services for the pharmaceutical industry.</P>
<P>Nicola Maayan - I currently work for Enhance Reviews Ltd, a company that carries out systematic reviews mostly for the public sector, we currently do not provide services for the pharmaceutical industry.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-10 13:35:39 +0100" MODIFIED_BY="[Empty name]">
<P>Stephanie Sampson - completed data extraction, helped with completion of risk of bias tables and writing the review.</P>
<P>Clive Elliot Adams - helped with data extraction and writing the review.</P>
<P>Mouhamad Mansour - helped write the protocol.</P>
<P>Karla Soares-Weiser - completion of risk of bias tables.</P>
<P>Nicola Maayan - completion of risk of bias tables.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-06-11 16:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> to review differences between protocol and review that have been classified as either 'minor' or 'major'.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-05-15 10:39:43 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-05-15 10:34:36 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-05-15 10:33:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Blackburn-1961" MODIFIED="2013-05-15 09:42:03 +0100" MODIFIED_BY="[Empty name]" NAME="Blackburn 1961" YEAR="1961">
<REFERENCE MODIFIED="2013-05-15 09:42:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn HL, Allen JL</AU>
<TI>Behavioural effects on interrupting and resuming tranquillizing medication among schizophrenics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1961</YR>
<VL>133</VL>
<NO>4</NO>
<PG>303-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caffey-1964" MODIFIED="2013-05-03 10:31:59 +0100" MODIFIED_BY="[Empty name]" NAME="Caffey 1964" YEAR="1964">
<REFERENCE MODIFIED="2013-05-03 10:31:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, et al</AU>
<TI>Discontinuation or reduction of chemotherapy in chronic schizophrenics</TI>
<SO>Journal of Chronic Diseases</SO>
<YR>1964</YR>
<VL>17</VL>
<NO>4</NO>
<PG>347-58</PG>
<IDENTIFIERS MODIFIED="2012-04-17 17:31:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1987" MODIFIED="2012-04-23 09:40:28 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-04-23 09:39:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Heinrichs DW, Hanlon TE</AU>
<TI>A comparative trial of pharmacologic strategies in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<NO>11</NO>
<PG>1466-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-23 09:40:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Heinrichs DW</AU>
<TI>Early intervention, time limited, targeted pharmacotherapy of schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>4</NO>
<PG>533-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpenter-1990_x002a_" MODIFIED="2013-05-15 10:30:43 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1990*" YEAR="1990">
<REFERENCE MODIFIED="2013-05-15 10:30:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt A, Kirkpatrick B, Levine J, et al</AU>
<TI>Continuous vs. targeted medication in schizophrenic outpatients: Outcome results</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<PG>1138-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-17 14:22:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Stephens JH, Rey AC, Hanlon TE, Heinrichs DW</AU>
<TI>Early intervention vs continuous pharmacotherapy of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1982</YR>
<VL>18</VL>
<NO>1</NO>
<PG>21-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaebel-2011" MODIFIED="2013-05-15 10:31:23 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-15 10:30:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Möller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, et al</AU>
<TI>Pharmacological long-term treatment strategies in first episode schizophrenia: study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2004</YR>
<VL>254</VL>
<PG>129-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1007/s00406-004-0509-y"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:31:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, Wilmsdorff M, et al</AU>
<TI>Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomised controlled trial within the German Research Network on Schizophrenia</TI>
<SO>The Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>11</NO>
<PG>1763-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:31:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, Wilmsdorff M, et al</AU>
<TI>Relapse prevention in first-episode schizophrenia - maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomised controlled trial within the German Research Network on Schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>February 2011</YR>
<VL>72</VL>
<NO>2</NO>
<PG>205-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:31:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Riedel M, Jäger M, Wickelmaier F, Maier W, Kühn KU, et al</AU>
<TI>Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>7</NO>
<PG>985-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herz-1991_x002a_" MODIFIED="2013-05-15 10:31:35 +0100" MODIFIED_BY="[Empty name]" NAME="Herz 1991*" YEAR="1991">
<REFERENCE MODIFIED="2013-05-15 10:31:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Herz MI, Glazer W, Mirza M, Mostert M, Hafez H, Smith P, et al</AU>
<TI>Intermittent medication in schizophrenia: a preliminary report</TI>
<SO>Schizophrenia: Scientific Progress</SO>
<YR>1989</YR>
<PG>333-40</PG>
<ED>Schulz SC, Tamminga CA</ED>
<PB>Oxford University Press</PB>
<CY>New York, USA</CY>
<IDENTIFIERS MODIFIED="2013-05-15 10:31:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-11 09:02:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herz MI, Glazer W</AU>
<TI>Intermittent medication in schizophrenia - preliminary results</TI>
<SO>Schizophrenia Research</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>2,3</NO>
<PG>224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-11 08:59:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al</AU>
<TI>Intermittent vs maintenance medication in schizophrenia. Two-year results</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1991</YR>
<VL>48</VL>
<NO>4</NO>
<PG>333-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1672588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-04 15:18:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herz MI, Szymanski HV, Simon JC</AU>
<TI>Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>918-22</PG>
<IDENTIFIERS MODIFIED="2012-04-04 15:18:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-04 15:18:36 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6124133"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jolley-1989_x002f_1990" MODIFIED="2013-05-15 10:32:00 +0100" MODIFIED_BY="[Empty name]" NAME="Jolley 1989/1990" YEAR="1989">
<REFERENCE MODIFIED="2012-03-28 15:23:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Hirsch SR, Jolley AG, Manchanda R, McRink A</AU>
<TI>Intermittent medication as an alternative to maintenance medication in the treatment of schizophrenia: a preliminary report</TI>
<TO>Fruehzeitige medikamentoese Intervention als Alternative zur Depot-Dauer-Medikation in der Schizophreniebehandlung Ein vorlaeufiger Bericht</TO>
<SO>Bewaltigung der Schizophrenie</SO>
<YR>1986</YR>
<PG>62-71</PG>
<ED>Boeker W, Brenner HD</ED>
<PB>Verlag Hans Huber</PB>
<CY>Bern, Switzerland</CY>
<IDENTIFIERS MODIFIED="2012-03-28 15:23:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:31:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jolley AG, Hirsch SR, McRink A, Manchanda R</AU>
<TI>Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>298</VL>
<NO>6679</NO>
<PG>985-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2567190"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:32:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L</AU>
<TI>Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<NO>6756</NO>
<PG>837-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2567190"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-11 09:42:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Jolley AG, Hirsch SR</AU>
<TI>Intermittent and low-dosage neuroleptic treatment: preventive strategies in schizophrenia</TI>
<TO>Intermittierende und niedrigdosierte Neuroleptika-Therapie: Prophylaktische Strategien bei der Schizophrenie</TO>
<SO>Therapie der Schizophrenie</SO>
<YR>1990</YR>
<PG>53-63</PG>
<PB>Kohlhammer</PB>
<CY>UK</CY>
<IDENTIFIERS MODIFIED="2012-04-11 09:42:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-03-28 15:23:32 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCreadie-1980" MODIFIED="2013-05-03 10:37:15 +0100" MODIFIED_BY="[Empty name]" NAME="McCreadie 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-05-03 10:37:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ</AU>
<TI>Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>510-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7011468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCreadie-1982" MODIFIED="2013-05-03 10:37:24 +0100" MODIFIED_BY="[Empty name]" NAME="McCreadie 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-05-03 10:37:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCreadie R, Mackie D, Morrison D, Kidd J</AU>
<TI>Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia</TI>
<SO>British Journal of Psyhciatry</SO>
<YR>1982</YR>
<VL>140</VL>
<PG>280-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olson-1962_x002a_" MODIFIED="2013-05-15 10:32:14 +0100" MODIFIED_BY="[Empty name]" NAME="Olson 1962*" YEAR="1962">
<REFERENCE MODIFIED="2013-05-15 10:32:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olson GW, Peterson DB</AU>
<TI>Intermittent chemotherapy for chronic psychiatric inpatients</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>February 1962</YR>
<VL>134</VL>
<PG>145-9</PG>
<IDENTIFIERS MODIFIED="2012-04-20 12:41:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-20 12:41:17 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14481933"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietzcker-1993_x002a_" MODIFIED="2013-05-15 10:32:59 +0100" MODIFIED_BY="[Empty name]" NAME="Pietzcker 1993*" YEAR="1986">
<REFERENCE MODIFIED="2013-05-15 10:32:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bandelow B, Müller P, Frick U, Gaebel W, Linden M, Müller-Spahn F, et al</AU>
<TI>Depressive syndromes in schizophrenic patients under neuroleptic therapy</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>1992</YR>
<VL>241</VL>
<NO>5</NO>
<PG>291-5</PG>
<IDENTIFIERS MODIFIED="2012-04-02 16:29:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-02 16:29:01 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1351405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-23 11:59:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Frick U, Köpcke W, Linden M, Müller P, Müller-Spahn F, et al</AU>
<TI>Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?</TI>
<SO>British Journal of Psychiatry Supplementum</SO>
<YR>1993</YR>
<VL>163(Suppl 21)</VL>
<PG>8-12</PG>
<IDENTIFIERS MODIFIED="2012-04-02 16:15:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-02 16:15:52 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8105814"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:32:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Janner M, Frommann N, Pietzcker A, Köpcke W, Linden M, et al</AU>
<TI>First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<PG>145-59</PG>
<IDENTIFIERS MODIFIED="2012-04-02 16:34:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-02 16:18:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W</AU>
<TI>Predictors of response to different neuroleptic long-term treatment strategies in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1,2</NO>
<PG>150</PG>
<IDENTIFIERS MODIFIED="2012-04-02 16:18:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-02 16:18:48 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="241181"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:32:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godemann F, Linden M, Gaebel W, Köpcke W, Müller P, Müller-Spahn F, et al</AU>
<TI>Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment?</TI>
<SO>European Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>82-4</PG>
<IDENTIFIERS MODIFIED="2012-04-04 09:59:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-04 09:59:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0924-9338(03)00008-7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:32:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Müller P, Bandelow B, Gaebel W, Köpcke W, Linden M, Müller-Spahn F, et al</AU>
<TI>Intermittent medication, coping and psychotherapy: interactions in relapse prevention and course modification</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>161</VL>
<NO>suppl. 18</NO>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-23 11:59:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, et al</AU>
<TI>A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1986</YR>
<VL>19</VL>
<NO>4</NO>
<PG>161-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2868467"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-23 11:58:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, et al</AU>
<TI>Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1993</YR>
<VL>27</VL>
<NO>4</NO>
<PG>321-39</PG>
<IDENTIFIERS MODIFIED="2012-04-02 16:19:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-02 16:19:56 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2868467"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:32:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pietzcker A</AU>
<TI>A German multi-centre study on the long-term treatment of schizophrenic outpatients</TI>
<SO>Pharmacopsychiat</SO>
<YR>1985</YR>
<VL>18</VL>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prien-1973" MODIFIED="2012-05-01 15:51:11 +0100" MODIFIED_BY="[Empty name]" NAME="Prien 1973" YEAR="1973">
<REFERENCE MODIFIED="2012-05-01 15:51:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien RF, Gillis RD, Caffey EM Jr</AU>
<TI>Intermittent pharmacotherapy in chronic schizophrenia</TI>
<SO>Hospital and Community Psychiatry</SO>
<YR>1973</YR>
<VL>24</VL>
<NO>5</NO>
<PG>317-22</PG>
<IDENTIFIERS MODIFIED="2012-05-01 15:51:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-01 15:51:11 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="4574574"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remington-2011" MODIFIED="2013-05-15 10:33:26 +0100" MODIFIED_BY="[Empty name]" NAME="Remington 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-15 10:33:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S</AU>
<TI>"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>August 2011</YR>
<VL>72</VL>
<NO>8</NO>
<PG>1042-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-15 10:33:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remington G, Seeman P, Shammi C, Mann S, Kapur S</AU>
<TI>"Extended" antipsychotic dosing: rationale and pilot data</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>6</NO>
<PG>611-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schooler-1997" MODIFIED="2013-05-15 10:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="Schooler 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-05-15 10:33:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al</AU>
<TI>Relapse and rehospitalisation during maintenance treatment of schizophrenia</TI>
<SO>Archives of General Psychology</SO>
<YR>1997</YR>
<VL>54</VL>
<PG>453-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shenoy-1981" MODIFIED="2012-04-17 17:59:55 +0100" MODIFIED_BY="[Empty name]" NAME="Shenoy 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-04-17 17:59:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Shenoy RS, Sadler A, Hamer R, Ross B</AU>
<TI>The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1981</YR>
<VL>17</VL>
<NO>1</NO>
<PG>116-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-17 14:26:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B</AU>
<TI>Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>3</NO>
<PG>141-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6117584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiedemann-2001" MODIFIED="2012-04-26 09:53:52 +0100" MODIFIED_BY="[Empty name]" NAME="Wiedemann 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-04-26 09:53:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiedemann G, Hahlweg K, Müller U, Feinstein E, Hank G, Dose M</AU>
<TI>Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2001</YR>
<VL>251</VL>
<PG>72-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wunderink-2007" MODIFIED="2012-05-08 09:03:53 +0100" MODIFIED_BY="[Empty name]" NAME="Wunderink 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-08 09:03:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D</AU>
<TI>Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>May 2007</YR>
<VL>68</VL>
<NO>5</NO>
<PG>654-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-05-15 10:34:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Caffey-1975" MODIFIED="2010-09-24 13:08:17 +0100" MODIFIED_BY="[Empty name]" NAME="Caffey 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-09-24 13:08:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caffey EM, Prien RF</AU>
<TI>Practical considerations on treatment with antipsychotic preparations</TI>
<TO>Prakticheskie soobrazheniia o lechenii antipsikhoticheskimi preparatami</TO>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova</SO>
<YR>1975</YR>
<VL>75</VL>
<NO>9</NO>
<PG>1399-401</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="241181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Docherty-2003" MODIFIED="2012-04-18 15:30:03 +0100" MODIFIED_BY="[Empty name]" NAME="Docherty 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-04-18 15:30:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Docherty JP, Grogg AL, Pharm D, Kozma C, Lasser R</AU>
<TI>Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome</TI>
<SO>Presented at the International Congress on Schizophrenia Research Biennial Meeting</SO>
<YR>March 29-April 2, 2003</YR>
<CY>Colorado Springs, Colorado, US</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engelhart-2002" MODIFIED="2012-04-23 11:57:25 +0100" MODIFIED_BY="[Empty name]" NAME="Engelhart 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-04-23 11:57:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Engelhart LM, Janagap C, White RE, Rothman M</AU>
<TI>The implications of antipsychotic treatment patterns on health outcomes in schizophrenia</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2012-04-23 11:57:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-23 11:57:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Engelhart LM, Janagap C, White RE</AU>
<TI>The implications of antipsychotic treatment patterns on health outcomes in schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2012-04-23 11:57:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hymowitz-1980" MODIFIED="2013-05-15 10:34:01 +0100" MODIFIED_BY="[Empty name]" NAME="Hymowitz 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-05-15 10:34:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hymowitz P, Spohn H</AU>
<TI>The effects of antipsychotic medication on the linguistic ability of schizophrenics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1980</YR>
<VL>168</VL>
<NO>5</NO>
<PG>287-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1980" MODIFIED="2013-05-15 10:34:06 +0100" MODIFIED_BY="[Empty name]" NAME="Levine 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-05-15 10:34:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine J, Schooler N, Severe J, Escobar J, Gelenberg A, Mandel M, et al</AU>
<TI>Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study</TI>
<SO>Advances in Biochemical Psychopharmacology</SO>
<YR>1980</YR>
<VL>24</VL>
<PG>483-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newton-1989" MODIFIED="2012-04-23 11:57:32 +0100" MODIFIED_BY="[Empty name]" NAME="Newton 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-04-23 11:57:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newton JE, Cannon DJ, Couch L, Fody EP, McMillan DE, Metzer WS, et al</AU>
<TI>Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>50</VL>
<NO>4</NO>
<PG>132-5</PG>
<IDENTIFIERS MODIFIED="2012-04-23 11:57:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strauss-1990" MODIFIED="2012-04-23 11:57:37 +0100" MODIFIED_BY="[Empty name]" NAME="Strauss 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-04-23 11:57:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Strauss WH, Tegeler J, Luthcke H</AU>
<TI>Cognitive functions in schizophrenic patients under long-term neuroleptic therapy</TI>
<SO>Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan</SO>
<YR>1990</YR>
<PG>304</PG>
<IDENTIFIERS MODIFIED="2012-04-23 11:57:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uchida-2008" MODIFIED="2013-05-15 10:34:36 +0100" MODIFIED_BY="[Empty name]" NAME="Uchida 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-15 10:34:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, et al</AU>
<TI>Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>8</NO>
<PG>1281-6</PG>
<IDENTIFIERS MODIFIED="2012-05-21 17:27:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-21 17:27:04 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18642974"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-06-11 15:51:31 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Uchida-2013" MODIFIED="2012-04-26 14:54:59 +0100" MODIFIED_BY="[Empty name]" NAME="Uchida 2013" YEAR="2013">
<REFERENCE MODIFIED="2012-04-26 14:54:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Uchida H</AU>
<TI>D2 Receptor Blockade and Remission in Schizophrenia</TI>
<SO>UMIN-CTR Clinical Trial Registry, trial number UMIN000006011</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-05-15 10:39:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-05-15 10:39:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-10-26 10:57:38 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-10-26 10:57:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1982" MODIFIED="2012-05-17 16:36:26 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Negative symptoms in schizophrenia: definition and reliability</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<NO>7</NO>
<PG>784-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1980" MODIFIED="2012-06-11 15:52:20 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1980" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1980</YR>
<VL>3</VL>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" MODIFIED="2012-06-11 15:51:58 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<VL>4</VL>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baldessarini-1988" MODIFIED="2012-01-19 16:34:17 +0000" MODIFIED_BY="[Empty name]" NAME="Baldessarini 1988" TYPE="JOURNAL_ARTICLE">
<AU>Baldessarini RJ, Cohen BM, Teicher MH</AU>
<TI>Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>79-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbui-1996" MODIFIED="2012-01-19 17:03:27 +0000" MODIFIED_BY="[Empty name]" NAME="Barbui 1996" TYPE="JOURNAL_ARTICLE">
<AU>Barbui C, Saraceno B, Liberati A, Garattini S</AU>
<TI>Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomised controlled trials</TI>
<SO>European Psychiatry</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>306-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bleuler-1908" MODIFIED="2012-06-11 15:30:18 +0100" MODIFIED_BY="[Empty name]" NAME="Bleuler 1908" TYPE="JOURNAL_ARTICLE">
<AU>Bleuler E</AU>
<TI>The prognosis of dementia praecox - schizophrenia group</TI>
<TO>Die Prognose der Dementia Praecox - Schizophreniegruppe</TO>
<SO>Allgemeine Zeitschrift fur Psychiatrie</SO>
<YR>1908</YR>
<VL>65</VL>
<PG>436-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2009-12-10 16:27:19 +0000" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borison-1998" MODIFIED="2012-01-24 09:36:08 +0000" MODIFIED_BY="[Empty name]" NAME="Borison 1998" TYPE="JOURNAL_ARTICLE">
<AU>Borison RL, Diamond BI, Sinha D, Gupta RP, Prince Ajiboye PA</AU>
<TI>Clozapine withdrawal rebound psychosis</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1998</YR>
<VL>24</VL>
<PG>260-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1983" MODIFIED="2012-05-21 14:33:30 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1983" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Heinrichs DW</AU>
<TI>Early intervention, time limited, targeted pharmacotherapy of schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>4</NO>
<PG>533-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Csernansky-2002" MODIFIED="2012-04-30 14:21:46 +0100" MODIFIED_BY="[Empty name]" NAME="Csernansky 2002" TYPE="JOURNAL_ARTICLE">
<AU>Csernansky JG, Mahmoud R, Brenner R</AU>
<TI>A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curson-1985" NAME="Curson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC</AU>
<TI>Long term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Reseach Council fluphenazine/placebo trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>146</VL>
<PG>464-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1976" MODIFIED="2012-01-19 15:46:29 +0000" MODIFIED_BY="[Empty name]" NAME="Davis 1976" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM</AU>
<TI>Recent developments in the drug treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>133</VL>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-1995" MODIFIED="2013-05-15 10:34:51 +0100" MODIFIED_BY="[Empty name]" NAME="Day 1995" TYPE="JOURNAL_ARTICLE">
<AU>Day JC, Wood G, Dewey M, Bentall RP</AU>
<TI>A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>166</VL>
<PG>650-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2011-07-07 10:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dencker-1980" NAME="Dencker 1980" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Lepp M, Malm U</AU>
<TI>Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1980</YR>
<VL>279</VL>
<PG>10-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-12-10 16:27:15 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-12-10 16:27:23 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1976" MODIFIED="2013-05-15 10:35:18 +0100" MODIFIED_BY="[Empty name]" NAME="Endicott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL, Fleiss JL, Cohen J</AU>
<TI>The Global Assessment Scale; A procedure for measuring overall severity of psychiatric disturbance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feighner-1972" MODIFIED="2012-04-19 16:14:48 +0100" MODIFIED_BY="[Empty name]" NAME="Feighner 1972" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munos R</AU>
<TI>Diagnostic criteria for the use in psychiatric research</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleischhacker-1989" MODIFIED="2013-05-15 10:35:10 +0100" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, et al</AU>
<TI>The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia</TI>
<SO>Psychopharmacological Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>2</NO>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2009-12-10 16:27:11 +0000" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2002" MODIFIED="2013-05-15 10:35:23 +0100" MODIFIED_BY="[Empty name]" NAME="Gaebel 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Janner M, Frommann N, Pietzcker A, Köpcke W, Linden M, et al</AU>
<TI>First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<PG>145-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gardos-1976" MODIFIED="2012-01-26 10:26:16 +0000" MODIFIED_BY="[Empty name]" NAME="Gardos 1976" TYPE="JOURNAL_ARTICLE">
<AU>Gardos G, Cole J</AU>
<TI>Maintenance antipsychotic therapy: is the cure worse than the disease?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>133</VL>
<NO>1</NO>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-1995" NAME="Gilbert 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert PL, Harris J, McAdam LA, Jeste DV</AU>
<TI>Neuroleptic withdrawal in schizophrenic patients - a review of the literature</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<PG>173-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbody-2002" MODIFIED="2012-05-23 12:18:00 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbody 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gilbody S, House A, Sheldon T</AU>
<TI>Psychiatrists in the UK do not use outcomes measures: National Survey</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>180</VL>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1970" MODIFIED="2012-05-11 14:37:59 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1970" TYPE="BOOK">
<AU>Guy W, Bonato RR</AU>
<TI>Clinical Global Impressions</TI>
<SO>Manual for the ECDEU Assessment Battery</SO>
<YR>1970</YR>
<VL>2. Rev</VL>
<PG>212-222</PG>
<PB>National Institute of Mental Health</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2013-05-15 10:35:50 +0100" MODIFIED_BY="Heather Maxwell" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haddad-2008" MODIFIED="2012-01-19 12:38:23 +0000" MODIFIED_BY="[Empty name]" NAME="Haddad 2008" TYPE="JOURNAL_ARTICLE">
<AU>Haddad P, Dursun S</AU>
<TI>Neurological complications of psychiatric drugs: clinical features and management</TI>
<SO>Human Psychopharmacology Clinical and Experimental</SO>
<YR>2008</YR>
<VL>23</VL>
<PG>15-26</PG>
<IDENTIFIERS MODIFIED="2012-01-19 12:38:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-19 12:38:23 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/hup.918"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hawk-1975" MODIFIED="2012-05-16 16:44:06 +0100" MODIFIED_BY="[Empty name]" NAME="Hawk 1975" TYPE="JOURNAL_ARTICLE">
<AU>Hawk AB, Carpenter WT, Strauss JS</AU>
<TI>Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1975</YR>
<VL>32</VL>
<PG>343-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heinrichs-1984" MODIFIED="2012-05-16 17:08:28 +0100" MODIFIED_BY="[Empty name]" NAME="Heinrichs 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon TE, Carpenter WT</AU>
<TI>The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>388-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herz-1980" MODIFIED="2013-05-15 10:36:00 +0100" MODIFIED_BY="[Empty name]" NAME="Herz 1980" TYPE="JOURNAL_ARTICLE">
<AU>Herz MI, Melville C</AU>
<TI>Relapse in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2009-10-26 11:00:34 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]</TI>
<SO>Availabel from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-10-26 10:57:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-21 11:59:39 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2011</YR>
<VL>Available from www.cochrane-handbook.org</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2013-05-15 10:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton Jane L</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICD_x002d_10" MODIFIED="2013-05-15 10:36:11 +0100" MODIFIED_BY="[Empty name]" NAME="ICD-10" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The ICD-10 Classification of Mental and Behavioural Disorders</SO>
<YR>1992</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1992" MODIFIED="2013-05-15 10:36:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jablensky 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al</AU>
<TI>Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study</TI>
<SO>Psychological Medicine (Monograph Supplement)</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>1-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM,Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnstone-1998" MODIFIED="2013-05-15 10:36:34 +0100" MODIFIED_BY="[Empty name]" NAME="Johnstone 1998" TYPE="BOOK_SECTION">
<AU>Johnstone EC</AU>
<TI>Psychiatry, its history and boundaries</TI>
<SO>Companion to Psychiatric Studies</SO>
<YR>1998</YR>
<PG>1-10</PG>
<ED>Johnstone EC, Freeman CPL, Zealley AK</ED>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1998" MODIFIED="2013-05-15 10:36:40 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kane 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, et al</AU>
<TI>Guidelines for depot antipsychotic treatment in schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>55-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2013-05-15 10:36:49 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" MODIFIED="2012-05-10 17:41:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A, and Opler LA</AU>
<TI>The positive and negative syndrome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<NO>2</NO>
<PG>261-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-1969" MODIFIED="2013-05-15 10:36:57 +0100" MODIFIED_BY="[Empty name]" NAME="Klein 1969" TYPE="BOOK">
<AU>Klein D, Davis JM</AU>
<SO>Diagnosis and Drug Treatment of Psychiatric Disorders</SO>
<YR>1969</YR>
<PB>Williams and Wilkins</PB>
<CY>Baltimore, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kraepelin-1896" MODIFIED="2013-05-03 12:04:17 +0100" MODIFIED_BY="[Empty name]" NAME="Kraepelin 1896" TYPE="BOOK_SECTION">
<AU>Kraepelin E</AU>
<TI>Textbook of Psychiatry</TI>
<TO>Lehrbuch der Psychiatrie</TO>
<SO>Psychiatrie</SO>
<YR>1896</YR>
<VL>5</VL>
<PB>Ferdinand Enke</PB>
<CY>Erlangen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lambert-2003" MODIFIED="2013-05-15 10:37:13 +0100" MODIFIED_BY="[Empty name]" NAME="Lambert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lambert TJ, Cock N, Alcock SJ, Kelly DL, Conley RR</AU>
<TI>Measurement of antipsychotic-induced side-effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement</TI>
<SO>Human Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leff-1971" MODIFIED="2012-01-19 14:34:58 +0000" MODIFIED_BY="[Empty name]" NAME="Leff 1971" TYPE="JOURNAL_ARTICLE">
<AU>Leff J, Wing J</AU>
<TI>Trial of maintenance therapy in schizophrenia</TI>
<SO>British Medical Journal</SO>
<YR>1971</YR>
<VL>3</VL>
<PG>559-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2009-12-10 16:27:02 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2011-07-07 10:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2011-07-07 10:14:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2011-07-07 10:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2011-07-07 10:14:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2005" MODIFIED="2013-05-15 10:37:21 +0100" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marder-2003" MODIFIED="2013-05-15 10:29:18 +0100" MODIFIED_BY="[Empty name]" NAME="Marder 2003" TYPE="BOOK_SECTION">
<AU>Marder SR, Wirshing DA</AU>
<TI>Maintenance treatment</TI>
<SO>Schizophrenia</SO>
<YR>2003</YR>
<EN>2nd</EN>
<ED>Hirsch SR, Weinberger DR</ED>
<PB>Blackwell</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2012-05-21 11:12:26 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>12</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morken-2008" MODIFIED="2012-06-11 15:26:10 +0100" MODIFIED_BY="[Empty name]" NAME="Morken 2008" TYPE="JOURNAL_ARTICLE">
<AU>Morken G, Widen J, Grawe R</AU>
<TI>Non-adherence to antipsychotic medication, relapse and re-hospitalisation in recent-onset schizophrenia</TI>
<SO>BMC Psychiatry</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>32</PG>
<IDENTIFIERS MODIFIED="2012-01-19 15:01:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-19 15:01:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-244X-8-3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neuchterlein-1986" MODIFIED="2012-04-26 11:34:05 +0100" MODIFIED_BY="[Empty name]" NAME="Neuchterlein 1986" TYPE="JOURNAL_ARTICLE">
<AU>Neuchterlein KH, Snyder KS, Dawson ME, Rappe S, Gitlin M, Fogelson D</AU>
<TI>Expressed emotion, fixed dose fluphenazine decanoate maintenance and relapse in recent onset schizophrenia</TI>
<SO>Psychopharamacology Bulletin</SO>
<YR>1986</YR>
<VL>22</VL>
<PG>633-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2013-04-24 12:49:22 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2010" TYPE="OTHER">
<TI>The NICE guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care</TI>
<SO>National Clinical Guideline: 82</SO>
<YR>2010</YR>
<EN>Updated edition</EN>
<PB>The British Psychological Society and The Royal College of Psychiatrists, British Library, Stanley Hunt</PB>
<CY>London, Leicester</CY>
<IDENTIFIERS MODIFIED="2013-04-03 15:29:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Nose-2003" MODIFIED="2009-10-26 11:01:26 +0000" MODIFIED_BY="[Empty name]" NAME="Nose 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nose M, Barbui C, Tansella M</AU>
<TI>How often do patients with psychosis fail to adhere to treatment programmes? A systematic review</TI>
<SO>Psychological Medicine</SO>
<YR>2003</YR>
<VL>33</VL>
<PG>1149-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Carroll-2000" MODIFIED="2013-05-15 10:38:43 +0100" MODIFIED_BY="[Empty name]" NAME="O'Carroll 2000" TYPE="JOURNAL_ARTICLE">
<AU>O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC</AU>
<TI>A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation</TI>
<SO>Quality of Life Research</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>1</NO>
<PG>121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliver-1991" MODIFIED="2012-05-11 16:52:30 +0100" MODIFIED_BY="[Empty name]" NAME="Oliver 1991" TYPE="JOURNAL_ARTICLE">
<AU>Oliver J</AU>
<TI>The social care directive: development of a quality of life profile for use in community services for the mentally ill</TI>
<SO>Social Work and Social Sciences Review</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>5-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2009-12-10 16:26:52 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perkins-2002" MODIFIED="2013-05-15 10:38:51 +0100" MODIFIED_BY="[Empty name]" NAME="Perkins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Perkins DO</AU>
<TI>Predictors of noncompliance in patients with schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<PG>1121-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prudo-1987" NAME="Prudo 1987" TYPE="JOURNAL_ARTICLE">
<AU>Prudo R, Blum HM</AU>
<TI>Five-year outcome and prognosis in schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>150</VL>
<PG>345-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ray-2009" MODIFIED="2012-01-24 09:52:55 +0000" MODIFIED_BY="[Empty name]" NAME="Ray 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ray WA, Chung CP, Murray KT, Hall K, Stein CM</AU>
<TI>Atypical antipsychotic drugs and the risk of sudden cardiac death</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>225-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RDC-criteria-1978" MODIFIED="2013-05-15 10:39:04 +0100" MODIFIED_BY="[Empty name]" NAME="RDC criteria 1978" TYPE="BOOK_SECTION">
<AU>Spitzer RL, Endicott J, Robins E</AU>
<TI>Research Diagnostic Criteria (RDC) for a selected group of functional disorders</TI>
<SO>Biometrics Research</SO>
<YR>1978</YR>
<PG>0-33</PG>
<PB>New York State Psychiatric Institute</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-1993" MODIFIED="2012-01-17 10:29:35 +0000" MODIFIED_BY="[Empty name]" NAME="Schooler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Keith SJ</AU>
<TI>The clinical research base for the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<PG>431-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-2004" MODIFIED="2012-01-24 12:01:13 +0000" MODIFIED_BY="[Empty name]" NAME="Schooler 2004" TYPE="JOURNAL_ARTICLE">
<AU>Schooler N</AU>
<TI>Maintenance medication for schizophrenia: strategies for dose reduction</TI>
<SO>FOCUS</SO>
<YR>Winter 2004</YR>
<VL>2</VL>
<NO>1</NO>
<PG>175-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2011-07-07 10:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2013-05-15 10:39:21 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica et Neurologica Scandinavica, Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spitzer-1971" MODIFIED="2012-05-11 14:53:25 +0100" MODIFIED_BY="[Empty name]" NAME="Spitzer 1971" TYPE="JOURNAL_ARTICLE">
<AU>Spitzer RL, Endicott J</AU>
<TI>An integrated group of forms for automated psychiatric case records: a progress report</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1971</YR>
<VL>24</VL>
<PG>448-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-1998" MODIFIED="2012-05-23 10:22:51 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thornley B, Adams CE</AU>
<TI>Content and quality of 2000 controlled trials in schizophrenia over 50 years</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>1181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TREC_x002d_Rio_x002d_I" MODIFIED="2012-05-21 11:14:17 +0100" MODIFIED_BY="[Empty name]" NAME="TREC-Rio-I" TYPE="JOURNAL_ARTICLE">
<AU>TREC Collaborative Group</AU>
<TI>Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7417</NO>
<PG>708-13</PG>
<IDENTIFIERS MODIFIED="2012-05-21 11:14:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-21 11:14:17 +0100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2003210869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-TREC_x002d_Vellore_x002d_I" MODIFIED="2012-06-07 16:48:00 +0100" MODIFIED_BY="[Empty name]" NAME="TREC-Vellore-I" TYPE="JOURNAL_ARTICLE">
<AU>Alexander J, Tharyan P, Adams CE, John T, Mol C, Philip J</AU>
<TI>Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol plus promethazine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>185</VL>
<PG>63-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-10-26 11:01:50 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2009-10-26 11:01:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-UKU-1987" MODIFIED="2012-05-11 15:49:23 +0100" MODIFIED_BY="[Empty name]" NAME="UKU 1987" TYPE="JOURNAL_ARTICLE">
<AU>Scandinavian Society of Psychopharmacology Committee of Clinical Investigations</AU>
<TI>The UKU side-effect rating scale: scale for the registration of unwanted effects of psychotropics</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1987</YR>
<VL>76(suppl)</VL>
<PG>81-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Nieuwenhuizen-2001" MODIFIED="2012-05-11 17:10:50 +0100" MODIFIED_BY="[Empty name]" NAME="van Nieuwenhuizen 2001" TYPE="JOURNAL_ARTICLE">
<AU>van Nieuwenhuizen C, Schene AH, Koeter MWJ, Huxley PJ</AU>
<TI>The Lancashire Quality of Life Profile: modification and psychometric evaluation</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2001</YR>
<VL>36</VL>
<PG>36-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weissman-1976" MODIFIED="2013-05-15 10:39:43 +0100" MODIFIED_BY="[Empty name]" NAME="Weissman 1976" TYPE="JOURNAL_ARTICLE">
<AU>Weissman MM, Bothwell S</AU>
<TI>Assessment of Social Adjustment by patient self-report</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2013-05-14 16:22:46 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2009" TYPE="OTHER">
<AU>World Health Organisation</AU>
<TI>Pharmacological treatment of mental health disorders in primary health care</TI>
<SO>http://whqlibdoc.who.int/publications/2009/9789241547697_eng.pdf</SO>
<YR>2009</YR>
<PG>9-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiersma-1990" MODIFIED="2012-05-11 13:59:26 +0100" MODIFIED_BY="[Empty name]" NAME="Wiersma 1990" TYPE="BOOK">
<AU>Wiersma D, de Jong A, Kraaijkamp HJM, et al</AU>
<TI>The Groningen Social Disabilities Schedule, second version</TI>
<SO>The Groningen Social Disabilities Schedule, second version</SO>
<YR>1990</YR>
<PB>Department of Psychiatry, Rijksuniversiteit Groningen</PB>
<CY>Groningen, Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2011-07-07 10:14:47 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-05-03 12:16:58 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mansour-2006" MODIFIED="2013-05-03 12:16:58 +0100" MODIFIED_BY="[Empty name]" NAME="Mansour 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Mansour M, Alomar A, Boobes K, Mouchli MA</AU>
<TI>Intermittent drug techniques for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2009-10-26 11:08:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006196"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-09-28 16:37:07 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-05-16 14:53:42 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-05-16 14:53:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-05-15 09:30:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blackburn-1961">
<CHAR_METHODS MODIFIED="2012-06-08 17:04:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: not stated.<BR/>Duration: 16 weeks.<BR/>Setting: inpatients, 'fully-privileged, open-ward', hospital.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 09:38:53 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 60.</P>
<P>Age: 20-40 years.<BR/>Sex: 60 M.</P>
<P>Racial origin: not stated.<BR/>Consent: not stated.<BR/>
</P>
<P>History: length of current hospitalisation ranged form three months to 129 months, with a mean of 45 months.</P>
<P>Inclusion: judged by psychiatric staff to be clinically tranquillised and to be making a satisfactory hospital adjustment on phenothiazine medication.</P>
<P>Exclusion: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-14 17:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>Initial daily drug dosages ranged from 15 mg to 150 mg prochlorperazine, 12 mg to 24 mg of perphenazine, 50 mg to 800 mg chlorpromazine, 200 mg to -400 mg promazine and 6 mg of trifluoperazine.</P>
<P>1. Intermittent: participants were further randomly subdivided into two groups of n = 15:</P>
<P>a. PD (placebo-drug): placebo (thiamine chloride) was substituted for phenothiazine for the first eight weeks, then drugs were re-introduced for the final eight weeks, n = 15.</P>
<P>b. PP (placebo-placebo): placebo was substituted for the whole 16 weeks of the study, n = 15.</P>
<P>2. Maintenance: DD (drug-drug) group remained on initial type and dosage of tranquillising medication throughout the period of the study, n = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:30:38 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: this included participants who were judged to have 'significantly deteriorated' indicated by a decrease in his adjustment score by at least one SE of measurement since initial evaluation, or if their behaviour had necessitated emergency resumption of drugs and/or transfer to a closed ward before the next scheduled rating period - by 8 and 16 weeks.</P>
<P>Global state: significant improvement: indicated by an increase in his adjustment score by at least one SE of measurement since initial evaluation, or if he was released from hospital in that period - by 8 and 16 weeks.</P>
<P>Leaving the study early.</P>
<P>Unable to use - Behaviour: Patient Adjustment Report; Taylor Manifest Anxiety Scale (no scale data reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 19:50:08 +0100" MODIFIED_BY="[Empty name]">
<P>Available data from eight weeks combines both PD and PP groups, where data from the full 16 weeks presents individual group results. Meta-analysed data will combine both intermittent groups, but will present data comparing ANY INTERMITTENT DRUG TECHNIQUE vs PLACEBO separately at the end of the 16 weeks study period (medium term).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-14 17:28:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caffey-1964">
<CHAR_METHODS MODIFIED="2012-05-01 11:44:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration: 16 weeks.<BR/>Setting: inpatients, 18-hospital collaborative study (hospitalised for two or more years).<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-14 17:28:17 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia (1/3 classified as paranoid sub-type).<BR/>N = 348.</P>
<P>Age: average 40 years.<BR/>Sex: 177 M.</P>
<P>Racial origin: not stated.<BR/>Consent: not stated.<BR/>
</P>
<P>History: average patient hospitalised for nearly 10 years; participants on chlorpromazine on average had been receiving a daily dosage of 400 mg over two years; participants on thioridazine on average had been receiving 350 mg daily for one year. All treated with fairly stable doses of at least 100 mg and not more than 800 mg daily of either chlorpromazine or thioridazine for at least three months immediately prior to the beginning of the study.</P>
<P>Inclusion: schizophrenia diagnosis.</P>
<P>Exclusion: CNS disease; history of seizures; prefrontal lobotomy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-14 17:28:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: reduced total dosage on an intermittent-schedule (received usual daily dosage on Monday, Wednesday and Friday; 3/7 of their usual dosage, medication administered in standard 100 mg tablets), n = 89.<BR/>2. Placebo: corresponding placebo group 1 - patients received the same number of tablets prior to the study (daily); corresponding placebo group 2 - patients received the same number of tablets prior to the study (Monday, Wednesday or Friday), n = 171.</P>
<P>3. Maintenance: continue to receive either chlorpromazine or thioridazine daily (participants on chlorpromazine had been receiving it for over two years at an average daily dose of 400mg; participants on thioridazine had been receiving it for one year at an average daily dose of 350 mg (medication administered in standard 100 mg tablets), n = 88.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-14 17:28:17 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: participants were judged clinically to have relapsed by the Principal Investigator and the rest of the treatment staff jointly - reported from 1-16 weeks.</P>
<P>Unable to use -</P>
<P>Mental state: PRP (no SD).</P>
<P>Adverse effects: IMPS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 17:28:17 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-14 17:28:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-1987">
<CHAR_METHODS MODIFIED="2012-04-23 10:45:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open label.<BR/>Duration: 2 years.<BR/>Setting: outpatients, Walnut Street Clinic, Maryland Psychiatric Research Center, Maryland, US.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 09:51:20 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (76% were considered chronically ill, and approximately 50% were diagnosed with paranoid schizophrenia, with the remaining diagnosis fairly evenly distributed between RDC undifferentiated schizophrenia and schizoaffective disorder, mainly schizophrenia).<BR/>N = 42.</P>
<P>Age: mean 31 years.<BR/>Sex: 20 M; 22 F.</P>
<P>Racial origin: n = 34 Black; n = 8 White.<BR/>Consent: written consent form required, 'meeting both NIMH and local institutional board regulations'.<BR/>
</P>
<P>History: all participants had recently experienced a psychiatric episode and were in some intermediate stage of recovery.</P>
<P>Inclusion: 18-50 years old; clinical diagnosis of schizophrenia.</P>
<P>Exclusion: organic brain disorder; recent evidence of alcoholism or clinically significant drug abuse; poor physical health or a major medical illness requiring treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-14 17:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>Upon referral and admission to the research clinic, all participants entered a 4-8 week stabilisation and evaluation period. When a participant was clinically stable, medication was withdrawn for a 4-week period during which baseline assessments were completed. Antipsychotic treatment was administered during this period only when there was an immediate need for symptom control. At the completion of the drug-free period, participants were then randomly assigned to a two-year treatment course, receiving one of two treatments:</P>
<P>1. Intermittent: targeted medication: medication administered on an 'as-needed basis' to participants who were otherwise drug-free. Antipsychotic treatment was initiated at moderate to high doses when prodromal experiences occurred, and discontinued when the participant returned to a stable clinical state. Participants were treated within context of psychosocial intervention and were assigned to a primary therapist (e.g. psychiatric social worker or masters-level psychologist) for weekly sessions of approximately 45 minutes - mean daily dose 196 mg ± 163 mg (chlorpromazine equivalents), n = 21.</P>
<P>2. Maintenance: continuous medication: minimum daily chlorpromazine-equivalent doses of 300mg* were administered combined with brief visits with a pharmacotherapist on alternate weeks - mean daily dose 720 mg ± 732 mg (chlorpromazine equivalents), n = 21.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-16 17:03:06 +0100" MODIFIED_BY="[Empty name]">
<P>Hospitalisation - by two years.</P>
<P>Leaving the study early - by two years.</P>
<P>Global state: BPRS; GAS - by two years.</P>
<P>General functioning: LOFS - by two years.</P>
<P>Quality of life: QLS - by two years.</P>
<P>Unable to use -</P>
<P>Global state: BPRS; GAS - taken at intervals of six months (no data reported for intervals).</P>
<P>General functioning: LFS - taken at intervals of six months (no data reported).</P>
<P>Quality of life: QLS - taken at intervals of six months (no data reported for intervals).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 17:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>*Adjustments in dose above 300 mg were made on the basis of psychotic symptom manifestation and side effect information - medication was increased if prodromal symptoms of relapse were detected.</P>
<P>Participants who failed to complete the drug-free period after two attempts were admitted to the experimental phase while taking medication. During the study, participants who decompensated and required inpatient treatment were admitted to their local hospital until they were again candidates for outpatient treatment. At discharge, they continued the study provided they had been hospitalised for fewer than six months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-14 17:28:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carpenter-1990_x002a_">
<CHAR_METHODS MODIFIED="2012-04-30 17:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: single.<BR/>Duration: 2 years.<BR/>Setting: outpatients, Walnut Street Clinic, Maryland Psychiatric Research Center, Maryland, US.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 09:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (RDC).<BR/>N = 116.</P>
<P>Age: mean 28.1 years.<BR/>Sex: 71 M; 45 F.</P>
<P>Racial origin: n = 73 Black; n = 43 White.<BR/>Consent: written consent form required.<BR/>
</P>
<P>History: all participants had recently experienced a psychiatric episode and were in some intermediate stage of recovery.</P>
<P>Inclusion: not stated.</P>
<P>Exclusion: organic brain disorder; recent evidence of alcoholism or clinically significant drug abuse; poor physical health; or a major medical illness requiring treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-14 17:28:39 +0100" MODIFIED_BY="[Empty name]">
<P>Upon referral and admission to the research clinic, all participants entered a 4 to 8 week stabilisation and evaluation period. When a participant was clinically stable, medication was withdrawn for a 4-week period during which baseline assessments were completed.</P>
<P>1. Intermittent: targeted administration of medication: medication administered on an 'as-needed basis' to participants who were otherwise drug-free. Participants remained drug-free until symptoms appeared that were suggestive of a prodromal phase of a psychotic episode, mean daily dose 173 mg ± 69 mg chlorpromazine/4.4 mg ± 1.1 mg haloperidol equivalents, n = 57.</P>
<P>2. Maintenance: continuous administration of medication: continued receiving medication - dose levels were raised when prodromal symptoms appeared and lowered when re-stabilisation occurred, mean daily dose of 433 mg ± 46 mg chlorpromazine/11.8 mg ± 4.4 mg haloperidol equivalents, n = 59.</P>
<P>Each group were further assigned to receive psychosocial treatment, involving individual therapy as well as involvement with the family or significant others (this was the same approach as in <LINK REF="STD-Carpenter-1987" TYPE="STUDY">Carpenter 1987</LINK>).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-14 17:28:39 +0100" MODIFIED_BY="[Empty name]">
<P>Hospitalisation - over two years.</P>
<P>Leaving the study early - by two years.</P>
<P>Unable to use -</P>
<P>Global state: BPRS, GAS - taken at intervals of six months (no data reported).</P>
<P>Quality of life: QLS - taken at intervals of six months (no data reported).</P>
<P>General functioning: LFS (no SD reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-14 17:28:39 +0100" MODIFIED_BY="[Empty name]">
<P>A variety of antipsychotics were administered: mean daily dose of haloperidol for targeted-medication group = 4.4 mg ± 1.1 mg; mean daily dose of haloperidol for continuous-medication group = 11.8 mg ± 4.4 mg.</P>
<P>Mean daily dose of chlorpromazine for targeted-medication group = 173 mg ± 69 mg; mean daily dose of chlorpromazine for continuous-medication group = 433 mg ± 46 mg.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:31:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaebel-2011">
<CHAR_METHODS MODIFIED="2013-05-15 09:31:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open.<BR/>Duration: 1 year.<BR/>Setting: outpatients, 8 German psychiatric university hospitals.<BR/>Design: 2x2.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-15 09:31:48 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-10).<BR/>N = 44.</P>
<P>Age: 18-56, mean 33.1 years.<BR/>Sex: 25 M; 19 F.</P>
<P>Racial origin: n = 44 White.<BR/>Consent: written informed consent required.<BR/>
</P>
<P>History: first episode schizophrenia - defined in the study as 'the first inpatient treatment of the respective symptoms and no prior treatment with antipsychotics'.</P>
<P>Inclusion: had just completed one year of antipsychotic maintenance treatment after the first episode (defined as the first inpatient treatment of the respective symptoms and no prior treatment with antipsychotics) of schizophrenia (diagnosed according to ICD-10); were sufficiently stable (i.e. had no relapse in the first postacute year and did not fulfil any criteria of the decision algorithm for early intervention at the beginning of the second year; additional clinical assessment was performed by the treating psychiatrist; had been sufficiently compliant in keeping the assigned biweekly appointments; were aged between 18 to 56 years; sufficiently proficient in German; gave written informed consent after receiving detailed information about the study.</P>
<P>Exclusion: pregnancy; contraindication for antipsychotic treatment; mental retardation; organic brain disease; substance dependence; suicidal behaviour in previous history; serious physical disease; and participation in other incompatible traits.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:31:38 +0100" MODIFIED_BY="[Empty name]">
<P>After an eight-week acute study and one year of double-blind antipsychotic maintenance treatment with low-dose haloperidol or risperidone (1 mg to 10 mg daily) plus either 8 weeks of psychoeducation vs 1 year CBT, stable first-episode participants were randomly assigned to 12 months of either:</P>
<P>1. Intermittent: respective antipsychotic treatment completely removed in a stepwise fashion over a period of three months (at the most) and restarted at occurrence of prodromal symptoms - mean daily dose of 1 mg/day haloperidol equivalent (the mean dose covers an initial maintenance phase of about 3-4 weeks (mean daily dose 2.9 mg ± 1.6 mg/day), a phase of about 10 weeks in which antipsychotics were tapered off (mean daily dose 1.7 mg ± 1.2 mg/day), a phase of six months where antipsychotics were withdrawn completely (0 mg ± 0 mg/d) and a 2-week phase in which drug treatment was restarted (4.5 mg ± 3.7 mg/day)), n = 21.</P>
<P>2. Maintenance: maintaining drug regimen from the end of the first year of treatment for the whole second year - mean daily dose of 3.1 mg ± 1.7 mg/day haloperidol equivalent, n = 23.</P>
<P>Participants received low dose atypical or typical antipsychotics throughout the course of the study - by the end of the trial, people in the maintenance group were receiving: risperidone (mean dose 2.2 mg ± 1.0 mg; n = 9); haloperidol (mean dose 2.7 mg ± 1.0 mg; n = 8); olanzapine (mean dose 11.8 mg ± 7.6 mg; n = 3); quetiapine (mean dose 495.1 mg ± 82.4 mg; n = 3). People in the intermittent treatment, when tapering off, received: risperidone (mean dose 1.5 mg ± 0.8 mg; n = 7); haloperidol (mean dose 1.3 mg ± 0.4 mg; n = 7); aripiprazole (mean dose 30.0 mg); n = 1); clozapine (mean dose 84.3 mg; n = 1); olanzapine (mean dose 4.5 mg ± 1.5 mg; n = 3); risperidone (open) (mean dose 1.0 mg; n = 1); ziprasidone (mean dose 38.7 mg ± 28.2 mg; n = 2).</P>
<P>In case of prodromal symptoms of an impending relapse, participants in both intervention groups received early drug intervention (MT = increased; IT = restarted), guided by a 'decision algorithm'.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: an increase in PANSS positive score &gt; 10, CGI change score &#8805; 6 and a decrease in GAF score &gt; 20 between two visits - by one year.</P>
<P>Global state: PANSS; SANS; CGI-S - by one year.</P>
<P>Leaving the study early - by one year.</P>
<P>Level of functioning: GAF - by one year.</P>
<P>Adverse effects: akathisia (HAS); extrapyramidal symptoms (EPS); side effects (UKU); tardive dyskinesia (AIMS) - by one year.</P>
<P>Quality of life: LQLP - by one year.</P>
<P>Unable to use-</P>
<P>Data from first year of study: concerned maintenance treatment - risperidone vs low-dose haloperidol (no intermittent treatment examined).</P>
<P>Attitude towards drugs: Drug Attitude Inventory (DAI) (not considered in this review).</P>
<P>Compliance: Compliance Rating Scale (CRS) (not considered in this review).</P>
<P>Depression ratings: Calgary Depression Rating Scale (CDSS) and Hamilton Depression Rating Scale (HDRS) (not considered in this review).</P>
<P>Stressful life events: Munich Event List (MEL) (not considered in this review).</P>
<P>'Marked clinical deterioration': defined as fulfilment of one of the three single relapse criteria or increase in PANSS positive score &#8805; 7 with decrease in GAF score &gt;15 between two visits (added post-hoc as a further outcome measure due to low prevalence of relapse).</P>
<P>Deterioration: according to <LINK REF="REF-Csernansky-2002" TYPE="REFERENCE">Csernansky 2002</LINK> - defined as an increase (from start of the second year of treatment) in the sum of the PANSS positive and negative scores &#8805; 25% or &#8805; 10 points or a CGI-change score &#8805; 6 (added post-hoc as a further outcome measure due to low prevalence of relapse).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-03 10:40:02 +0100" MODIFIED_BY="[Empty name]">
<P>*This study also had a 'secondary objective' of early drug intervention with antipsychotics vs benzodiazepines; the MT and IT groups were further split into subgroups (half of each group receiving either antipsychotics or benzodiazepines) but data were not reported individually, making a valuable and meaningful assessment of intermittent antipsychotic treatment difficult. The two results that have been presented (relapse and leaving the study early) represent the total group numbers.</P>
<P>**This study was subject to a sensitivity analysis: there was no substantive difference in the results when these data were included and they remain within the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:32:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herz-1991_x002a_">
<CHAR_METHODS MODIFIED="2012-06-07 11:48:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double-blind.<BR/>Duration: 2 years.<BR/>Setting: stable schizophrenic outpatients, Buffalo, New York and New Haven, Conneticut (US).<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-15 09:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (RDC; DSM-III).<BR/>N = 101.</P>
<P>Age: 19 to 60 (mean 36 years old).<BR/>Sex: 54 M; 47 F.</P>
<P>Racial origin: n = 45 Black; n = 56 White.<BR/>Consent: informed consent required.<BR/>
</P>
<P>History: Research and Diagnostic Criteria of schizophrenia or schizoaffective depression; n = 62 with less than three (&lt; 3) previous hospitalisations, n = 39 with three or more (&gt; 3) previous hospitalisations.</P>
<P>Inclusion: Research and Diagnostic Criteria of schizophrenia or schizoaffective depression based on the Schedule for Affective Disorders and Schizphrenia Lifetime Version interview; at least two years admission in a psychiatric hospital or DSM-III schizophrenia diagnosis; currently receiving chlorpromazine, fluphenazine, haloperidol, trifluoperazine as maintenance therapy; in a stable state for at least 3 months; a significant other willing to cooperate.</P>
<P>Exclusion: organic mental disorder; uncooperativeness with treatment in the past; hallucinations and delusions that interfere with functioning; Research and Diagnostic Criteria of alcohol and drug dependence in the past two years; serious suicidal/ assaultive behaviour in past two years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:32:36 +0100" MODIFIED_BY="[Empty name]">
<P>Stage one: eight-week 'washout period'; last two weeks are drug-free; drug withdrawal of oral medication was 25% dose reduction every two weeks; depot fluphenazine was 33% dose reduction every two weeks. Those who showed prodromal symptoms were excluded, only those who passed stage one entered stage two and were randomly assigned to one of two double-blind treatment groups.<BR/>
</P>
<P>1. Intermittent: received placebo injection, mean daily dose 149.7 mg ± 179.3 mg chlorpromazine equivalents (average cumulative antipsychotic drug dosage during prodromal episodes over two years = 487.19 mg ± 370.68 mg), n = 50.<BR/>2. Maintenance: usual dose of antipsychotic medication mean daily dose 290.0 mg ± 146.7 mg chlorpromazine equivalents (average cumulative antipsychotic drug dosage during prodromal episodes over two years = 424.84 mg ± 333.05 mg), n = 51.</P>
<P>Participants in stage two were expected to attend weekly supportive group therapy sessions, to allow for weekly monitoring. Open family group meetings were held monthly for family members who could attend on a regular or irregular basis according to their own needs.</P>
<P>When a participant was considered to be experiencing a prodromal* episode, administration of study medication was stopped and the active form of the participant's study antipsychotic medication was given openly. The dosage was given at the discretion of the psychiatrist, depending on severity of symptoms, but it was frequently twice the maintenance or baseline level. After an episode was declared, participants were seen every other day for continuing evaluation and treatment. Once clinically stabilised and considered in remission for two weeks, active medication was decreased while double-blind study medication (placebo or active) was simultaneously increased over a two-week period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-03 09:09:46 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: defined as an increase in any problem appraisal scale PAS; &#8804; 30 GAS; more than two days' duration of episode or consensus judgement of the clinical team where the above criteria is not met - by 24 months.</P>
<P>Hospitalisation - by 24 months.</P>
<P>Death - by 24 months.</P>
<P>Global state: GAS - by 6 months and 24 months .</P>
<P>Global state: prodromal episodes (worsening of symptoms of at least a days' duration; increase in any PAS; non psychotic and dysphoric symptoms + mild exacerbation of schizophrenia symptoms) - by 24 months .</P>
<P>Service outcomes: time to hospitalisation - by 6 months and 24 months.</P>
<P>General functioning: PAS social component average score - by 6 months and 24 months.</P>
<P>Leaving the study early - by 24 months.</P>
<P>Unable to use -</P>
<P>Global state: GAS (attrition rates were more than 50%).</P>
<P>Adverse effects: AIMS (no data reported).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-12 11:50:20 +0100" MODIFIED_BY="[Empty name]">
<P>*Symptoms were considered prodromal if there was an increase in any Problem Assessment Scale (PAS) role-functioning item or nonpsychotic symptom from a baseline of none, slight or mild to moderate or marked, or from a baseline of moderate to marked.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-16 14:51:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jolley-1989_x002f_1990">
<CHAR_METHODS MODIFIED="2013-05-16 14:51:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blinding: double.</P>
<P>Duration: 2 years.</P>
<P>Setting: psychiatric outpatients, Charing Cross Hospital, London, UK.</P>
<P>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-16 14:51:17 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III) - in remission.<BR/>N = 54.</P>
<P>Age: mean 41 years.<BR/>Sex: 23 M; 31 F.</P>
<P>Racial origin: not stated.<BR/>Consent: not stated.<BR/>
</P>
<P>History: all participants had been free of florid symptoms for at least six months and had been stabilised for at least two months on a fixed dose of depot fluphenazine decanoate.</P>
<P>Inclusion: schizophrenia (DSM-III), all participants were required to be free of florid symptoms for at least six months and be stabilised for at least two months on a fixed dose of depot fluphenazine decanoate.</P>
<P>Exclusion: participants in whom relapse had entailed a definite risk to self or others in the past were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-16 14:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: equivalent doses of placebo injections, with brief intermittent course of antipsychotics begun at the earliest sign of relapse (prodromal symptoms - appearance of non-psychotic symptoms), average cumulative antipsychotic drug dosage (haloperidol equivalents) over two years = 298 mg ± 249 mg, n = 27.<BR/>2. Maintenance: continued to receive fluphenazine decanoate in clinically optimal (pre-trial) doses, average cumulative antipsychotic drug dosage (mg haloperidol equivalents) over two years = 1616 mg ± 598 mg, n = 27.</P>
<P>Haloperidol (5 mg to -10 mg) was given to patients in both the intermittent and control groups who developed prodromal symptoms or relapse. Treatment of prodromal symptoms continued for up to two weeks unless relapse occurred and treatment for relapse continued until four weeks after.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-22 12:36:26 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: defined as the re-emergence of florid symptoms (delusions, hallucinations, bizarre behaviour, or thought disorder) or a deterioration of symptoms sufficient to warrant hospitalisation - by one and two years.</P>
<P>Hospitalisation - by one year.</P>
<P>Death - by two years.<BR/>Global state: prodromal symptoms: defined on a clinical basis - emergence of neurotic or dysphoric symptoms lasting for two days or more and causing distress to the patient - by one and two years.</P>
<P>Adverse effects: EPS, specific (including hypomimia; tremor; rigidity; gait abnormality; akathisia; global non-liveliness, global parkinsonism) - by six months, one and two years.<BR/>Leaving the study early.</P>
<P>Unable to use -</P>
<P>Global state: Early Signs Questionnaire (no data reported); GAS (no data reported); Manchester scale (no data reported); Symptom Checklist-90 (no SD reported).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:33:19 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-16 14:52:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCreadie-1980">
<CHAR_METHODS MODIFIED="2013-05-16 14:51:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blinding: double.</P>
<P>Duration: 9 months.</P>
<P>Setting: inpatients, hostel ward of the rehabilitation unit of Gartnavel Royal Hospital, Glasgow (UK) and day patients attending the hospital's industrial and occupational therapy departments.</P>
<P>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-16 14:52:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: 'definite schizophrenia' (<A HREF="http://archie.cochrane.org/sections/documents/view?version=z1305141729178547528171096235177&amp;format=REVMAN#REF-Feighner-1972">Feighner 1972</A> criteria).<BR/>N = 34.</P>
<P>Age: mean 51 years.<BR/>Sex: 34 M.</P>
<P>Racial origin: not stated.<BR/>Consent: consent required from participant or next of kin.<BR/>
</P>
<P>History: n = 9 inpatients (average length of illness as estimated from first hospital admission 26 years (mean)) and n = 26 day patients (average length of illness 18 years (mean)).</P>
<P>Inclusion: physically fit; fulfilled Feighner criteria for 'definite schizophrenia'; in the opinion of both medical and nursing staff was well-controlled on and benefiting from long-acting intramuscular antipsychotic medication; consent from participant/ next of kin.</P>
<P>Exclusion: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-16 14:52:10 +0100" MODIFIED_BY="[Empty name]">
<P>All participants were switched to fluphenazine decanoate (if not already receiving) at least three months before the trial began.</P>
<P>1. Intermittent: intermittent pimozide: mean dose 8 mg/oral, maximum 32 mg every 4 days/week, n = 16.</P>
<P>2. Maintenance: continued fluphenazine decanoate: mean dose 12.5 mg/IM, maximum 50 mg weekly, n = 18.</P>
<P>To ensure double-blind conditions, participants received active fluphenazine injections and placebo pimozide tablets, or placebo fluphenazine injections and active pimozide tablets.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: defined as exacerbation of positive symptoms - by 9 months.</P>
<P>Adverse effects: dyskinesia, need for additional antiparkinsonian medication - by 9 months.</P>
<P>Leaving the study early - by 9 months.</P>
<P>Unable to use -</P>
<P>Mental state: Hamilton-Lorr Scale, Kraweicka Scale (depression and anxiety) (outcome reported but no usable data presented).</P>
<P>Behaviour: Wing Ward Behaviour Scale (independent behaviour) (outcome reported but no usable data presented).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-16 14:52:30 +0100" MODIFIED_BY="[Empty name]">
<P>Number of participants differ in the abstract and the full paper.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:33:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCreadie-1982">
<CHAR_METHODS MODIFIED="2012-05-01 11:46:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration: 10 months.<BR/>Setting: inpatients, hostel wards of Crichton Royal Hospital, Dumfries (UK).<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-15 09:33:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: 'definite schizophrenia' (<LINK REF="REF-Feighner-1972" TYPE="REFERENCE">Feighner 1972</LINK> criteria).<BR/>N = 28.</P>
<P>Age: mean 55 years.<BR/>Sex: 28 M.</P>
<P>Racial origin: not stated.<BR/>Consent: consent required from participant or traceable next of kin.<BR/>
</P>
<P>History: average length of illness as estimated from first hospital admission 27 years (mean).</P>
<P>Inclusion: physically fit; fulfilled Feighner criteria for 'definite schizophrenia'; in the opinion of both medical and nursing staff was well-controlled on and benefiting from antipsychotic medication; consent from participant/ next of kin.</P>
<P>Exclusion: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: intermittent pimozide: once weekly, range 10 mg to 60 mg/oral, mean 40 mg/IM weekly, n = 13.</P>
<P>2. Maintenance: continued fluphenazine decanoate: range 2 mg to 25 mg/IM, mean 14 mg/IM biweekly, n = 15.</P>
<P>Pimozide was administered daily for the first week, four consecutive days weekly for the second, twice weekly for the third and once weekly thereafter on Monday mornings. The once weekly dose was four times the initial daily dose, subject to a maximum of 60 mg. The maximum of weekly dose of fluphenazine (which in most cases was given two-weekly, also on Monday mornings) was 50 mg.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-21 15:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: defined as exacerbation of positive symptoms - by 10 months.</P>
<P>Adverse effects: tardive dyskinesia - by 10 months.</P>
<P>Leaving the study early - by 10 months.</P>
<P>Unable to use -</P>
<P>Mental state: Hamilton-Lorr Scale, Kraweicka Scale (outcome reported but no usable data presented).</P>
<P>Behaviour: Wing Ward Behaviour Scale (outcome reported but no usable data presented).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>One participant was receiving fluphenazine decanoate and five participants were receiving daily pimozide before the study began; a further five participants were receiving intramuscular flupenthixol decanoate.</P>
<P>If participants were on anti-parkinsonian medication at the start of the trial, the dose of this was steadily reduced and the drug eventually discontinued if sign of parkinsonism were no more than 'mild'. Anti-parkinsonian medication was prescribed if signs were 'moderate' or 'severe'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:33:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olson-1962_x002a_">
<CHAR_METHODS MODIFIED="2012-06-07 11:48:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration: 6 months.<BR/>Setting: hospital inpatients.<BR/>Design: longitudinal evaluation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 10:37:16 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 90.</P>
<P>Age: mean 51 years.<BR/>Sex: not stated.</P>
<P>Racial origin: not stated.<BR/>Consent: not stated.<BR/>
</P>
<P>History: not stated.</P>
<P>Inclusion: successfully tranquillized for at least the last 60 days; no significant physical illness exhibited; chronically mentally ill in the same hospital for the last 18 months or more.</P>
<P>Exclusion: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-05 10:37:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: drug-nothing (DN): alternated monthly between active drug (one half received phenothiazine and one half received chlorpromazine) and nothing, n = 30.</P>
<P>2. Placebo: drug-placebo (DP): alternated monthly between active drug (one half received phenothiazine and one half received chlorpromazine) and placebo, n = 30.</P>
<P>3. Maintenance: control (C): routine treatment by the ward physician and received medication in standard form (continuous medication in different form), n = 30*.</P>
<P>'The study contained three phases of medication, each followed by a phase of no medication - that is, three cycles, each containing two 30-day phases.'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:33:49 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early - by six months.</P>
<P>Unable to use -</P>
<P>Behaviour: ward behaviour ratings, clinical behaviour ratings (no SD reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-10 11:16:09 +0100" MODIFIED_BY="[Empty name]">
<P>*Dosages were not specified.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:34:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pietzcker-1993_x002a_">
<CHAR_METHODS MODIFIED="2012-06-07 11:48:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: none - open treatment.<BR/>Duration: 2 years.<BR/>Setting: outpatients, Germany (multi-centre study): outpatient setting of the five psychiatric centres involved - university centres in Berlin, Düsseldorf, Göttingen and München (treatment observation lasted until September 1989).<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 10:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N = 364* (recruited between 1983-1987).</P>
<P>Age: 18-55, mean 34.7 years.<BR/>Sex: 169 M; 195 F.</P>
<P>Racial origin: not stated.<BR/>Consent: informed consent required.<BR/>
</P>
<P>History: average duration of illness: 7.2 years - 3 month stabilisation period.</P>
<P>Inclusion: 18-55 years of age; stable clinical condition for at least 3 months since the last acute episode or inpatient treatment; ICD-9 diagnosis pf schizophrenia</P>
<P>Exclusion: organic brain disease; drug and alcohol abuse; mental retardation; pregnancy; history of suicide attempts and/or serious legal violations during antipsychotic-free intervals; tutelage or treatment guardianship, or recent compulsory hospitalisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: antipsychotic crisis intervention (CI): antipsychotic treatment renewed after stabilisation only when relapse occurs, discontinued once stabilised (average cumulative antipsychotic drug dosage (mg chlorpromazine equivalents) over two years = 110 mg), n = 115.<BR/>2. Intermittent: prophylactic early intervention (EI): antipsychotic therapy resumed as soon as prodromal symptoms appear, discontinued once stabilised (average cumulative antipsychotic drug dosage (mg chlorpromazine equivalents) over two years = 90 mg), n = 127.</P>
<P>3. Maintenance: prophylactic maintenance medication (type and application of antipsychotic drugs used throughout the study was not restricted) (MT): continuous administration of medication, with doses individually adjusted in accordance with the patient's clinical demands at a given time; minimal dosage of 100mg chlorpromazine equivalents (average cumulative antipsychotic drug dosage over two years = 210 mg), n = 122.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse (definition included three criteria: i) an increase of &gt; 10 in the psychosis factor (HOST, THOT, ACTV) of the BPRS; ii) a decrease of &gt; 20 in the GAS; iii) and deterioration on the CGI scale indicated by a score of &gt; 7. Relapse predicted by prodromal symptoms) - by 2 years.</P>
<P>Hospitalisation - by 2 years.</P>
<P>Leaving the study early - by 2 years.</P>
<P>Unable to use -</P>
<P>AIMS, BPRS, CGI, ESS, GAS: (no data reported for full 2 years).</P>
<P>Negative attitudes toward treatment (not specified in protocol).</P>
<P>Relapse: &gt; 1 year - full participant numbers not available as study was still recruiting (incomplete data).</P>
<P>Rehospitalisation: &gt; 1 year - full participant numbers not available as study was still recruiting (incomplete data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>*n = 3,910 schizophrenia suspect cases screened, of which n = 3,481 (89%) were excluded during initial recruitment phase due to either administrative reasons, patient refusal, not fulfilling inclusion criteria of age, or fulfilling exclusion criteria. A further n = 65 dropped out because of 'implicit/explicit treatment refusal'.</P>
<P>Criteria for withdrawal from study: patient refusal or unsatisfactory treatment cooperation; occurrence of side effects; intercurrent somatic illnesses; occurrence of a fourth relapse under the assigned treatment strategy; therapeutic objections of the attending physician to treatment continuation, as well as impossibility to withdraw the antipsychotics within six months (according to the schedule) or to maintain a patient without drugs for a minimum of four weeks in the intermittent strategies.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:34:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prien-1973">
<CHAR_METHODS MODIFIED="2012-05-01 16:20:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration: 16 weeks<BR/>Setting: inpatients, 18 Veterans Administration hospitals.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 10:38:23 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia.<BR/>N = 375.</P>
<P>Age: mean 50.9 years.<BR/>Sex: 375 M.</P>
<P>Racial origin: not stated.<BR/>Consent: not stated.<BR/>
</P>
<P>History: mean duration of current hospitalisation was 10.3 years.</P>
<P>Inclusion: not stated.</P>
<P>Exclusion: organic brain disease; bedfast; had an incapacitating or terminal physical illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>All participants had received stable doses of antipsychotic medication during the six months preceding the study; 48% of participants were receiving chlorpromazine (mean daily dose 462 mg), 46% were receiving thioridazine (mean daily dose 362 mg), 27% were receiving trifluoperazine (mean daily dose 15 mg), and 4% were receiving perphenazine (mean daily dose 28 mg) - 25% of participants were receiving more than one drug.</P>
<P>Participants were assigned to one of five interventions:</P>
<P>1. Intermittent: five-day schedule A: participants received their pre-study dosage Monday through Friday and placebo on Saturday and Sunday.</P>
<P>2. Intermittent: five-day schedule B: participants received their pre-study dosage Monday, Wednesday, Thursday, Friday and Sunday, and placebo on Tuesday and Saturday.</P>
<P>3. Intermittent: four-day schedule A: participants received their pre-study dosage Monday through Thursday and placebo on Friday through Sunday.</P>
<P>4. Intermittent: four-day schedule B: participants received their pre-study dosage Monday, Wednesday, Friday and Sunday, and placebo on Tuesday, Thursday and Saturday.</P>
<P>5. Maintenance: daily schedule: participants continued on their pre-study regimen, n = 73.</P>
<P>Total participants for intermittent schedules: n = 301 (individual group data not reported).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-03 09:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: defined as 'regression' that required the participant to be returned to hs is pre-study dosage before the end of 16 weeks - 'that decision was usually made jointly by the principal investigator at each hospital and the rest of the study staff' - by 16 weeks.</P>
<P>Unable to use -</P>
<P>Global state: Global Change Scale (GCS); Global Severity of Illness (GSI); BPRS; Nurses Observation Scale for Inpatient Evaluation (NOISE) (no data reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>In the four intermittent schedules, there was no increase in daily dosage to compensate for the omission of two or three days of medication - The participant's weekly dosage was therefore reduced by two-sevenths (29%) or three-sevenths (43%) from the pre-study level.</P>
<P>*This study was subject to a sensitivity analysis and was considered only in the comparison ANY INTERMITTENT DRUG TECHNIQUE vs MAINTENANCE THERAPY: there was no substantive difference in the results when these data were included and they remain within the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-16 14:53:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Remington-2011">
<CHAR_METHODS MODIFIED="2013-05-16 14:53:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration: 6 months.<BR/>Setting: outpatients, from the 'Schizophrenia Program', which offers both acute inpatient and ongoing outpatient care to over 4,000 individuals - Centre for Addiction and Mental Health, Toronto, Ontario, Canada.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-16 14:53:23 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 35.</P>
<P>Age: mean 39 years.<BR/>Sex: 20 M; 15 F.</P>
<P>Racial origin: not stated.<BR/>Consent: written informed consent required.<BR/>
</P>
<P>History: stabilised outpatients with a single, oral antipsychotic (excluding clozapine and quetiapine as the authors state 'there is theoretical and anecdotal evidence that abrupt discontinuation of these drugs may result in an increased risk of symptom exacerbation').</P>
<P>Inclusion: DSM-IV diagnosis of schizophrenia based on clinical interview, collaborative history, and chart review; capacity to provide written, informed consent; stabilised as outpatients with a single, oral antipsychotic (with the exception of clozapine and quetiapine) &#8805; 3 months; evidence of adherence with current anti-psychotic treatment.</P>
<P>Exclusion: exposure to a depot antipsychotic &#8805; 1 year; current diagnosis of substance abuse according to DSM-IV criteria; participants receiving clozapine and quetiapine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-16 14:53:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: "same daily dose administered every other day" (n = 6 risperidone, n = 11 olanzapine), n = 17.</P>
<P>2. Maintenance: "treatment as usual" (n = 8 risperidone, n = 8 olanzapine, n = 2 loxapine), n = 18.</P>
<P>Dosages not specified.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:35:16 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse (20% increase in overall symptoms using BPRS) - by six months.</P>
<P>CGI-S - by six months.</P>
<P>Re-hospitalisation - by six months.</P>
<P>Side effects: (AIMS) tardive dyskinesia - by six months.</P>
<P>Leaving the study early - by six months.</P>
<P>Unable to use -</P>
<P>BPRS - by six months (no usable data were reported).</P>
<P>Simpson-Angus Rating Scale (SAS) - by six months (no usable data were reported).</P>
<P>Calgary depression scale - by six months (no usable data were reported).</P>
<P>Barnes Akathisia Scale - by six months (no usable data were reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:35:16 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:35:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schooler-1997">
<CHAR_METHODS MODIFIED="2013-05-08 20:50:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double blind.<BR/>Duration: 2 years.<BR/>Setting: outpatients, recruited form five centres; from Grady Memorial Hospital, Atlanta (Georgia) and San Francisco (California) (general public hospitals with psychiatric units), Hillside Hospital, New Hyde Park, New York (private psychiatric hospital in a medical centre), Whitney Clinic, New York (University hospital), Eastern Pennsylvania Psychiatric Institute (Philadelphia) (public psychiatric hospital in a medical centre).<BR/>Design: 3 X 2 factorial design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-08 20:31:24 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-III-R diagnosis of schizophrenia (n = 249) (any subtype), schizoaffective disorder (n = 41) or schizophreniform disorder (n = 23) (79% met this criteria at study entry).<BR/>N = 313.</P>
<P>Age: 18-55 years (mean 36.5 years).<BR/>Sex: 207 M; 106 F.</P>
<P>Racial origin: n = 124 White.<BR/>Consent: informed consent from the participant and at least one family member.<BR/>
</P>
<P>History: 93% of participants were recruited during hospitalisation; the remainder were outpatients experiencing acute exacerbations.</P>
<P>Inclusion: DSM-III-R diagnosis of schizophrenia or schizoaffective disorder; age between 18-55 years; living with, or having more than superficial contact with, family of origin defined as a minimum of 4 hours of regular face-to-face contact per week; living close enough to the clinic to permit home visits; informed consent.</P>
<P>Exclusion: unequivocal liver damage; acute or chronic organic brain syndrome; DSM-III-R diagnosis of psychoactive substance dependence or substance abuse; pregnancy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-05 10:39:38 +0100" MODIFIED_BY="[Empty name]">
<P>Following consent, a 16-24-week stabilisation phase was initiated, defined by hospital admission date or by study entry for outpatients. Participants were randomly assigned to 'applied family management' (AFM<SUP>1</SUP>) or 'supportive family management' (SFM<SUP>2</SUP>) and then discharged, with the goal of stabilization.* Successfully stabilised participants entered the maintenance phase at which time they were randomised to one of three medication conditions:</P>
<P>1. Intermittent: fluphenazine decanoate: targeted, early intervention - an injection of sesame oil or miglioil "vehicle" (placebo) every 2 weeks (if subjects showed prodromal signs of relapse, open-label rescue medication was added; either oral fluphenazine or fluphenazine decanoate), n = 51 (AFM) n = 49 (SFM), total n = 100.</P>
<P>Treatment with combination of medication and family management continued for 24 months.</P>
<P>2. Maintenance: fluphenazine decanoate: continuous standard dose - 12.5-50mg every 2 weeks, n = 52 (AFM) n = 55 (SFM), total n = 107.</P>
<P>3. Maintenance: fluphenazine decanoate: continuous low dose - 2.5-10mg every 2 weeks, n = 54 (AFM) n = 52 (SFM), total n = 106.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:35:27 +0100" MODIFIED_BY="[Empty name]">
<P>Hospitalisation - by two years.</P>
<P>Adverse effects: need for additional medication (fluphenazine decanoate) - by two years.</P>
<P>Unable to use -</P>
<P>Relapse: mean time to psychotic relapse (no SD).</P>
<P>Relapse: mean time to first rescue medication (no SD).</P>
<P>Time to re-hospitalisation (no SD).</P>
<P>Family management parameters (exceeds the scope of the review).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:35:32 +0100" MODIFIED_BY="[Empty name]">
<P>Benztropine mesylate was the preferred antiparkinsonian mediation and temazepam or lorazepam was used for sleep. Fluphenazine decanoate was used as rescue medication is compliance was a concern.</P>
<P>
<SUP>1</SUP>AFM: involved individual meetings (first weekly, then bi-weekly, then monthly) in home setting to assess functional status and knowledge of schizophrenia; maximum of 32 sessions; detailed treatment manual and educational material and training in communication skills and problem-solving.</P>
<P>
<SUP>2</SUP>SFM: involved monthly family group meetings throughout stabilisation and maintenance phases; lasted roughly 1.5 hours; Q&amp;A sessions provided by a clinician.</P>
<P>*Stabilistation criteria included: stable dosage of 12.5 mg to 50 mg fluphenazine decanoate every two weeks for four weeks without use of other antipsychotic or psychotropic medication; stable psychotic symptoms as assessed by BPRS for four weeks; no psychotic symptom (conceptual disorganisation, grandiosity, hallucinatory behaviour and unusual thought content) greater than moderate.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:35:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shenoy-1981">
<CHAR_METHODS MODIFIED="2012-06-07 11:49:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double.<BR/>Duration: 6 weeks*.<BR/>Setting: outpatients, McGuire VA Medical Center, Richmond, Virginia (US).<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 10:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-III) - average duration of illness mean 13 years.<BR/>N = 31.</P>
<P>Age: mean 37 years.<BR/>Sex: not stated.</P>
<P>Racial origin: n = 16 Black; n = 12 White.<BR/>Consent: written informed consent required.<BR/>
</P>
<P>History: for two years prior to the study, participants had been treated with fluphenazine decanoate, reporting to the clinic every three weeks for an injection. Prior to the two years on fluphenazine decanoate, participants had been treated with a variety of other antipsychotics for varying periods of time.</P>
<P>Inclusion: not stated.</P>
<P>Exclusion: not stated.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:35:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent: six-week drug discontinuation (drug-holiday): received a placebo injection (at the end of the study, participants were returned to their routine active medication), n = 17.<BR/>2. Maintenance: continued on regular medication, fluphenazine decanoate mean dose 39.3 mg, n = 14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:35:40 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse (no definition).<BR/>Global state: GAS.</P>
<P>Leaving the study early.</P>
<P>Unable to use -</P>
<P>Adverse effects: AIMS (no SDs/full data reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-12 10:46:53 +0100" MODIFIED_BY="[Empty name]">
<P>*Six weeks chosen as it is the 'best estimate of that period of discontinuation in which no relapse would occur'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:35:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiedemann-2001">
<CHAR_METHODS MODIFIED="2012-05-08 09:06:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open.<BR/>Duration: 18 months.<BR/>Setting: inpatients, Max Planck Institute of Psychiatry, Munich, Germany.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 10:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: ICD-9 diagnosis and RDC criteria for schizophrenia and schizoaffective disorder.<BR/>N = 85.</P>
<P>Age: 17-55 years, mean 30 years.<BR/>Sex: 31 M; 21 F.</P>
<P>Racial origin: not stated.<BR/>Consent: informed consent required.<BR/>
</P>
<P>History: not stated.</P>
<P>Inclusion: ICD-9 diagnosis and RDC criteria for schizophrenia and schizoaffective disorder; age range 17-55 years old; living with partner or in close contact with relative (at least 10 hours a week) for at least three months before admission and likely to return to that household after discharge; living close enough to the clinic to permit at least one home visit and; informed consent.</P>
<P>Exclusion: evidence of organic central nervous system disorder; unequivocal liver damage; mental retardation; ICD-9 diagnosis of psychoactive substance abuse/ dependence; history of more than three relapses per year after the withdrawal of maintenance antipsychotic medication; pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:35:49 +0100" MODIFIED_BY="[Empty name]">
<P>After hospital discharge, a 'recommended' dose was maintained for three months - participants were then assigned to one of two groups (type of antipsychotic drug was not restricted: dosages converted into milligrams of chlorpromazine equivalents (CPZ)):</P>
<P>1.Intermittent: targeted medication: gradual decrease after three months using a step-by-step discontinuation technique of 50% of antipsychotics every two weeks; where prodromal signs occurred, antipsychotic treatment was reintroduced; when re-stabilisation was attained, pharmacotherapy was again tapered off (mean daily dosage during first year after discharge 161 mg ± 144 mg chlorpromazine equivalent), n = 24.</P>
<P>2. Maintenance: continuous standard dose: the same antipsychotic dose level was maintained throughout the 18-month study period (mean daily dosage during first year after discharge 312 mg ± 152 mg chlorpromazine equivalent), n = 27.</P>
<P>Of the 51 participants completing the study, n = 25 received clozapine (with n = 16 receiving clozapine versus n = 11 receiving typical antipsychotics in the continuous standard dose group; and n = 9 receiving clozapine versus n = 15 on typical antipsychotics in the targeted medication group).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-15 09:35:49 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse: defined as reoccurrence of psychotic symptoms with or without subsequent hospitalisation and operationalised following recommendations of <LINK REF="REF-Neuchterlein-1986" TYPE="REFERENCE">Neuchterlein 1986</LINK>: a rating of 'moderately severe' (= 5) for significant exacerbation or a rating of 'severe' (= 6) or greater fro relapse, representing an increase of at least 2 scale points in any one of the psychosis items of the BPRS - by 18 months.</P>
<P>Global state: BPRS, GAS - by 18 months.</P>
<P>General functioning: SAS - by 18 months.</P>
<P>Adverse effects: tardive dyskinesia - by 18 months.</P>
<P>Leaving the study early - by 18 months.</P>
<P>Unable to use -</P>
<P>Family burden global rating (not considered in this review).</P>
<P>IMPS (no data reported).</P>
<P>EPS; AIMS (no data reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-15 09:35:49 +0100" MODIFIED_BY="[Empty name]">
<P>Both interventions were combined with behavioural family treatment (not considered in this review).</P>
<P>Relapsed participants were kept in the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-05-15 09:35:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wunderink-2007">
<CHAR_METHODS MODIFIED="2012-06-08 16:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open.<BR/>Duration: 2 years.<BR/>Setting: outpatients, seven district mental health care centres and the Department of Psychiatry of the University Medical Center Groningen, Netherlands<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-05 10:40:54 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: first episode schizophrenia or related psychotic disorder (DSM-IV diagnosis of schizophrenia, schizophreniform disorder, brief psychotic disorder, schizoaffective disorder, delusional disorder, or psychotic disorder not otherwise specified).<BR/>N = 131.</P>
<P>Age: 18-45 years.<BR/>Sex: 89 M; 39 F.</P>
<P>Racial origin: not stated.<BR/>Consent: written consent required.<BR/>
</P>
<P>History: participants received no prior antipsychotic medication for more than three months; spoke Dutch language; had estimated IQ score above 70.</P>
<P>Inclusion: participants had to show response of positive symptoms within six months of antipsychotic treatment and sustained remission during six months.</P>
<P>Exclusion: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-15 09:35:59 +0100" MODIFIED_BY="[Empty name]">
<P>1.<I> </I>Intermittent: guided discontinuation: dosage was gradually tapered and discontinued if feasible (tapering guided by symptom severity levels and preference of the participant - if early warning signs of relapse emerged or positive symptoms recurred, clinicians were to restart/ increase the dosage of anti-psychotics - mean daily dose 4.36 mg haloperidol equivalent), n = 65.</P>
<P>2. Maintenance: all participants were continuously treated with low-dose atypical/second-generation antipsychotics (mean daily dose 2.94 mg haloperidol equivalent), n = 63.</P>
<P>By the end of the trial, people in the drug discontinuation group were receiving: risperidone (mean dose 2.4 mg ± 1.5 mg; n = 18); olanzapine (mean dose 2.1 mg ± 1.0 mg; n = 16); quetiapine (mean dose 6.5 mg ± 4.1 mg; n = 4); clozapine (mean dose 6.3 mg ± 2.4 mg; n = 2); zuclopenthixol (mean dose 4.5 mg ± 6.5 mg; n = 3). People in the maintenance treatment group were receiving: risperidone (mean dose 2.9 mg ± 1.7 mg; n = 21); olanzapine (mean dose 2.0 mg ± 1.2 mg; n = 22); quetiapine (mean dose 4.8 mg ± 5.9 mg; n = 7); clozapine (mean dose 3.7 mg ± 1.9 mg; n = 5); zuclopenthixol (mean dose 1.3 mg ± 0.8 mg; n = 3).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-08 10:50:39 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: relapse (defined as clinical deterioration during at least one week, having consequences (augmentation of antipsychotic dosage, hospital admission or more frequent consultations) reported by the clinician and subsequently confirmed by PANSS positive subscale item scores assessed by a research team member, of at least one score of five (moderately severe)); PANNS (positive and negative symptoms) - by two years.</P>
<P>Social functioning: Groningen Social Disabilities Schedule (GSDS) - by two years.</P>
<P>Adverse effects: Liverpool University Neurolpetic Side Effect Rating Scale (LUNSERS) - by two years.</P>
<P>Quality of life: World Health Organisation Quality of Life Scale (WHOQoL-Bref) - by two years.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-05 10:41:31 +0100" MODIFIED_BY="[Empty name]">
<P>n = 45 were categorised as alcohol/cannabis dependent/ abusers.</P>
<P>The four most commonly used antipsychotics were all second-generation: risperidone, olanzapine, quetiapine, clozapine.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>General:</B>
</P>
<P>CBT - cognitive behavioural therapy.<BR/>EPS - extrapyramidal symptoms.<BR/>IM - intramuscular.<BR/>IV - intravenous.<BR/>ITT - intention-to-treat.<BR/>LOCF - last observation carried forward.<BR/>SD - standard deviation.<BR/>SE - standard error.<BR/>vs - versus.</P>
<P>
<B>Diagnostic tools:</B>
</P>
<P>DSM - Diagnostic and Statistical Manual of Mental Disorders.<BR/>ICD - The International Statistical Classification of Diseases and Related Health Problems.<BR/>RDC - Research Diagnostic Criteria.<BR/>
</P>
<P>
<B>Relevant rating scales:</B>
</P>
<P>Global state<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>CGI - Clinical Global Impression.<BR/>CGI-S - Clinical Global Impression Severity Scale.<BR/>GAS - Global Assessment Scale.<BR/>
</P>
<P>Mental state<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale.<BR/>NOSIE - Nurses' Observation Scale for Inpatient Evaluation.<BR/>PANSS - Positive and Negative syndrome Scale.<BR/>PRP - Psychotic Reaction Profile.<BR/>SANS - Scale for the Assessment of Negative Symptoms.</P>
<P>General functioning<BR/>GAF - Gloabal Assessment of Functioning.<BR/>GSDS - Groningen Social Disabilities Schedule.<BR/>LOFS - Level of Functioning Scale.<BR/>PAS - Problem Appraisal Scale.<BR/>SAS - Social Adjustment Scale.<BR/>
</P>
<P>Adverse Effects<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>EPS - Extrapyramidal Side Effects scale.<BR/>HAS - Hillside Akathisia Scale.<BR/>LUNSERS - Liverpool University Neuroleptic Side Effect Rating Scale.<BR/>SAS - Simpson-Angus Scale.<BR/>UKU - Udvalg for Kliniske Undersogelser Side Effects scale.</P>
<P>Quality of Life<BR/>LQLP - Lancashire Quality of Life Profile.<BR/>QLS - Quality of Life Scale.<BR/>WHOQoL-Bref - World Health Organisation Quality of Life Scale.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-05-04 15:47:37 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-04-18 14:45:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caffey-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-18 14:45:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: controlled design.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-18 15:31:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Docherty-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-18 15:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: chronic schizophrenia.<BR/>Interventions: continuous therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-24 14:24:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engelhart-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-23 11:57:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: continuous therapy vs intermittent therapy vs low exposure therapy.<BR/>Outcomes: quality of life, symptoms, hospitalisation (no usable data reported).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-18 14:45:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hymowitz-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-18 14:45:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: controlled design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-03 10:41:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-03 10:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: schizophrenia.</P>
<P>Interventions: abrupt discontinuation of antipsychotics vs continuous fluphenazine decanoate/ hydrochloride (not an intermittent technique).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-04 15:47:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newton-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-04 15:47:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, cross-over design.<BR/>Participants: schizophrenia.<BR/>Interventions: two-day drug holiday vs continuous medication.<BR/>Outcomes: serum haloperidol levels; tardive dyskinesia; mental state (no usable data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-24 14:24:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strauss-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-14 10:54:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: intermitted from drug therapy &#8805; 2 months vs long-term therapy.<BR/>Outcomes: cognitive function (no usable data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-21 17:27:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uchida-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-21 17:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: controlled design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-05-04 15:48:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-05-04 15:48:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uchida-2013">
<CHAR_STUDY_NAME MODIFIED="2012-04-26 14:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>Uchida 2013 </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-04-26 14:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: single (participant).<BR/>Duration: 1 year.<BR/>Setting: Japan<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-04 15:48:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>Target sample size: n = 60.</P>
<P>Age: (lower age limit) 20 years-old &lt;=.<BR/>Sex: male and female.</P>
<P>Inclusion: (1) DSM-IV diagnosis of schizophrenia or schizoaffective disorder, (2) having received a stable dose of risperidone or olanzapine for previous 3 months. </P>
<P>Exclusion: (1) receiving another antipsychotic drug, (2) history of treatment with long-acting risperidone within 6 months, (3) past history of vagus nerve reflection with a blood test. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-04 15:48:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Intermittent risperidone/ olanzapine: D2 blockade of &gt; 65%. Participants will be treated with an individually prepared regimen and observed for one year.</P>
<P>2. Continuous risperidone/ olanzapine: D2 blockade of &gt; 65%. Participants will be treated with an individually prepared regimen and observed for one year.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-03 10:41:41 +0100" MODIFIED_BY="[Empty name]">
<P>Adverse effects: Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale, Barnes Akathisia Rating Scale (BARS).</P>
<P>Global state: Positive and Negative Symptom Scale (PANSS), Global Assessment Functioning Scale (GAF), Japanese version of the Calgary Depression Scale for Schizophrenics (JCDSS), Subjective Well-Being under antipsychotic drug treatment short form Japanese version (SWNS-J), Clinical Global Impression (CGI).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-04-26 14:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>August 2011.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-04-26 14:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Hiroyuki Uchida </P>
<P>Keio University, School of Medicine</P>
<P>Department of Neuropsychiatry</P>
<P>Shinanomachi 35, Shinjuku-ku, Tokyo, Japan</P>
<P>Email: mcn41320@biglobe.ne.jp</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-04-26 15:01:21 +0100" MODIFIED_BY="[Empty name]">
<P>As of January 2012, participants were in the process of recruitment - with a target completion date of late 2013. </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-05-15 10:40:39 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-05-15 09:35:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-11 09:16:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blackburn-1961">
<DESCRIPTION>
<P>Randomised - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-19 16:31:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>Randomised - 'randomly assigned to one of four groups' - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 09:45:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1987">
<DESCRIPTION>
<P>Randomised - 'at the completion of the drug-free trial, the patients were randomly assigned using a stratification process involving age, sex and prognostic status'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 14:37:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1990_x002a_">
<DESCRIPTION>
<P>Randomised - 'at the completion of the drug-free trial, the patients were randomly assigned within age, sex and prognostic categories'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 10:20:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaebel-2011">
<DESCRIPTION>
<P>Randomised - 'openly randomly assigned' - randomisation for the 8-week initial treatment phase; randomisation for the first-year treatment phase; randomisation for the second year treatment phase; randomisation for 'lateral entry' participants who had originally dropped-out of the first year of the study and subsequently re-recruited to complete the second-year treatment phase. The randomisation for the second year (maintenance treatment vs intermittent treatment; for each: early intervention with the pre-given antipsychotic vs a benzodiazepine --&gt; 4 conditions with a ratio of  1:1:1:1) was conducted by an independent institution in a different city (Coordinating Center for Clinical Trials of the Mainz University) by an approved biostatistician/ mathematician. Block randomisation was conducted [regarding study site and pre-treatment (risperidone/haloperidol)]'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-04 15:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Herz-1991_x002a_">
<DESCRIPTION>
<P>Randomised - 'when a patient was deemed acceptable for randomisation, the coordinator called the statistician who consulted a table for randomisation. The table was in blocks in an attempt to have equal numbers of patients in each treatment group.There was no stratification used in the randomisation.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-19 16:31:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jolley-1989_x002f_1990">
<DESCRIPTION>
<P>'Randomised' - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-19 16:30:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1980">
<DESCRIPTION>
<P>Randomised - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:52:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1982">
<DESCRIPTION>
<P>Randomised - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 16:32:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olson-1962_x002a_">
<DESCRIPTION>
<P>Randomised - 'subjects were randomly selected from a roster of those on the continued-treatment service receiving ataractic medication, and were consecutively assigned to one of three groups'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 11:29:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pietzcker-1993_x002a_">
<DESCRIPTION>
<P>Randomised - 'centrally randomised... using an adaptive randomisation strategy'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-01 15:55:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1973">
<DESCRIPTION>
<P>Randomised - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-19 15:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remington-2011">
<DESCRIPTION>
<P>Randomised - 'participants were randomly assigned (1:1 ratio)', no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-15 09:35:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schooler-1997">
<DESCRIPTION>
<P>Randomised - an adaptive randomisation algorithm was use in an attempt to maximise equality of randomisation using the following parameters: family management assignment; gender; AIMS score at the end of stabilisation (mild or greater in any body area vs less than mild); diagnosis (DSM-III-R schizophrenia vs schizoaffective disorder vs schizophreniform disorder); length of stabilisation phase (16 weeks vs &gt; 16 weeks).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-12 10:22:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shenoy-1981">
<DESCRIPTION>
<P>Randomised - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-26 10:08:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiedemann-2001">
<DESCRIPTION>
<P>Randomised - stratified block randomisation was applied with 'expressed emotion' and sex as strata. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 09:35:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wunderink-2007">
<DESCRIPTION>
<P>Randomised - 'carried out by an independent agent, in separate blocks for the seven sites to prevent effects of site. Within these blocks a minimization procedure was applied for gender and age (under or over 25) - raters were blinded for the allotted strategy throughout.' </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-05-14 14:34:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-11 09:17:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blackburn-1961">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-03 16:00:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 10:12:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1987">
<DESCRIPTION>
<P>'Randomly assigned' - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 15:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1990_x002a_">
<DESCRIPTION>
<P>'Randomly assigned' - no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-14 14:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaebel-2011">
<DESCRIPTION>
<P>Unclear - it is stated that participants in the first year of treatment were randomly assigned under double-blind conditions, but participants in the second year of treatment were 'openly randomly assigned to either continued double-blind' maintenance or intermittent treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 16:28:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herz-1991_x002a_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-14 14:34:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jolley-1989_x002f_1990">
<DESCRIPTION>
<P>'Participating clinicians were requested to refer patients whom they thought might benefit from the brief intermittent treatment approach.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-19 16:30:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1980">
<DESCRIPTION>
<P>'Blindly allocated' - no further description. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 11:52:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1982">
<DESCRIPTION>
<P>'Blindly allocated' - no further description.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 14:36:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olson-1962_x002a_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 16:28:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pietzcker-1993_x002a_">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-01 16:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1973">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 16:28:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remington-2011">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 16:29:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schooler-1997">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 16:29:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shenoy-1981">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-26 10:55:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiedemann-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 09:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderink-2007">
<DESCRIPTION>
<P>'Randomly assigned' - no further description. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-14 15:19:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-11 09:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blackburn-1961">
<DESCRIPTION>
<P>Not described - 'the placebo was physically different from the phenothiazine' and thus identifiable to participants and staff as a change in medication. The nursing staff identified that this was indeed a placebo. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 15:19:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>Double blind - 'double blind control between corresponding active and placebo groups was maintained'...'the placebo tablets were identical in appearance to the commercial product'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-23 10:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carpenter-1987">
<DESCRIPTION>
<P>No blinding - 'open comparative trial'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 15:16:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1990_x002a_">
<DESCRIPTION>
<P>Single (assessor) blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-30 14:11:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gaebel-2011">
<DESCRIPTION>
<P>Unclear - it is stated that treatment procedures for the primary hypothesis were conducted in an open manner for all participants; however, a double blind condition was seemingly employed for participants who completed the first year of the study and for 'lateral entry' participants treatment was open (randomisation and blinding procedures for the second year of study were provided by the Johann-Gutenberg University, Mainz, Germany).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-26 09:00:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Herz-1991_x002a_">
<DESCRIPTION>
<P>Double blind - 'clinicians and research evaluators were blind regarding patients' treatment status'. However, when prodromal signs identified, antipsychotic medication was given openly.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 14:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jolley-1989_x002f_1990">
<DESCRIPTION>
<P>Double blind - 'placebo injections were substituted under double-blind conditions'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 14:54:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCreadie-1980">
<DESCRIPTION>
<P>Double blind - 'to ensure double-blind conditions, participants received active fluphenazine injections and placebo pimozide tablets, or placebo fluphenazine injections and active pimozide tablets.' </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 14:58:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCreadie-1982">
<DESCRIPTION>
<P>Double blind - 'to ensure double-blind conditions, participants received active fluphenazine injections and placebo pimozide tablets, or placebo fluphenazine injections and active pimozide tablets'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-20 14:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olson-1962_x002a_">
<DESCRIPTION>
<P>Double - 'the procedure was blind to nurses, clinical interview rater and patients. The physician was informed of the date but not the direction of change between active drug and placebo to preclude the possibility of continuing high dosages which may have developed during the placebo period.' </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-18 12:41:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pietzcker-1993_x002a_">
<DESCRIPTION>
<P>Open label - 'a double-blind, placebo-controlled strategy...was not chosen, since early intervention treatment requires the patient's full knowledge of and responsibility for drug treatment and is thus best accomplished under naturalistic, open conditions.' Further, it was stated that 'non-blindness towards treatment strategy may have biased treating psychiatrists to overestimate the base rate of impending relapses, particularly in early intervention treatment, in order to legitimise initiation of treatment'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-01 16:09:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1973">
<DESCRIPTION>
<P>Double - 'on drug-free days, placebo tablets identical in appearance were administered in place of the active medication'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-19 12:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Remington-2011">
<DESCRIPTION>
<P>Double blind - pharmacy.ca (a company specialising in the preparation of drugs for experimental trials - Toronto, Ontario, Canada) was employed to provide, on an individualized basis, all antipsychotics at the appropriate dose and placebo when necessary in matching gelatin capsules. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-17 14:28:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schooler-1997">
<DESCRIPTION>
<P>Double blind - blinding was maintained by administering the same volume of medication to all groups - if participants showed prodromal signs of relapse, open-label rescue medication was added. Participants who required rescue medication for a cumulative total of more than 140 days (20 weeks) were discontinued from receiving double blind medication and were treated openly. They continued with their assigned family management condition and received study assessments for the full two year maintenance phase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 14:48:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shenoy-1981">
<DESCRIPTION>
<P>Double blind 'fashion at 3 and 6 weeks' - placebo injection from 'a nurse not involved in the assessment'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-14 14:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiedemann-2001">
<DESCRIPTION>
<P>Non-blind: open label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-05-08 09:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wunderink-2007">
<DESCRIPTION>
<P>Non-blind - open label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-05-15 10:40:39 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 09:50:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blackburn-1961">
<DESCRIPTION>
<P>Follow-up: 88% - 'seven participants lost for administrative reasons unrelated to clinical condition' (n = 25 DD; n = 14 PD; n = 14 PP). ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 09:51:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>Follow-up: 73% (n = 254). Not all participants completed rating scales. ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 09:51:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1987">
<DESCRIPTION>
<P>Follow-up: 62% - drop outs were n = 9 continuous medication group (one refused assignment to regimen; seven discontinued treatment; one was non-compliant), n = 7 targeted medication group (two were hospitalised; two were dropped while hospitalised; three dropped out during clinical stability while medication-free) over the two-year period.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-15 10:40:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carpenter-1990_x002a_">
<DESCRIPTION>
<P>Follow-up: 66% - n = 29 in targeted treatment group (19 were treatment-related drop-outs including refusal to continue treatment; n = 10 were non-treatment-related drop-outs); n = 11 in continuous treatment group (8 were treatment-related; 3 were non treatment-related). ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:34:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaebel-2011">
<DESCRIPTION>
<P>First year of maintenance study: n = 159 - of these, n = 96 passed the first year and were assessed for eligibility; n = 37 (40%) were not eligible for inclusion in the second year of study (n =14 insufficient clinical stability, n = 8 unreliable attendance, n = 6 no consent, n = 6 wanted to remain on antipsychotic treatment, n = 1 wanted to discontinue antipsychotics treatment, n = 1 changed residence, n = 1 'lateral entry' not provided by study site).</P>
<P>Second year of study - n = 59 were included and further randomly allocated: however, n = 15 dropped out immediately after random assignment (in maintenance treatment, n = 6 withdrew consent: in intermittent treatment, n = 9 were not treated according to random allocation). Total n = 44 treated according to randomisation and included in ITT analysis (LOCF).</P>
<P>Follow-up: (for 1 year of IT vs MT) 61%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:35:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Herz-1991_x002a_">
<DESCRIPTION>
<P>Follow-up: 55% - protocol terminations: n = 7 participants from the maintenance group were dropped (n = 5 because their episodes lasted more than nine weeks, and n = 2 participants because they experienced three episodes in one year). n = 23 participants in the intermittent group were dropped (n = 10 participants because episodes lasted more than nine weeks and n = 13 participants because they had three episodes in the course of one year). A further n = 7 participants in the maintenance group an n = 8 from intermittent were dropped because of non-compliance or withdrawal from the study (of these n = 2 died of natural causes in the maintenance group, and n = 1 died in the intermittent group, classified as a 'possible suicide', who drowned after ingesting large amounts of alcohol). ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-08 20:20:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jolley-1989_x002f_1990">
<DESCRIPTION>
<P>Follow-up: 91% - 'of the 49 patients for whom two year follow-up data were available, 19 had been withdrawn from double blind treatment before the end of the two year study period. Thirteen of these were re-established on depot antipsychotic drugs, and two patients in the intermittent treatment group and four controls received no further antipsychotics'. Of the five participants not followed up, n = 2 died in the control group (one suggested suicide, and one attributable to an acute physical illness, and the participant was withdrawn from the study at the time of diagnosis), n = 2 disappeared in the intermittent group, and n = 1 refused all attempts at follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-04-20 09:31:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1980">
<DESCRIPTION>
<P>Follow-up: 97% - one participant on pimozide refused all medication from the sixth month and was therefore withdrawn from the trial; he was counted neither as a relapse nor as a non-relapse.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:37:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCreadie-1982">
<DESCRIPTION>
<P>Follow-up: 58% - n = 5/13 on pimozide and n = 6/15 on fluphenazine were withdrawn (reasons included: exacerbation of positive symptoms; depression; suicidal ideas and attempts; family request to withdraw; tardive dyskinesia; complaints of tiredness).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olson-1962_x002a_">
<DESCRIPTION>
<P>Follow-up: 52% - attrition described as either 'behavioural' or 'inadvertent': n = 26 in DN group; n = 13 in DP group; n = 4 in the control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:38:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pietzcker-1993_x002a_">
<DESCRIPTION>
<P>Follow-up: 44% (n = 159) at 2 years - n = 205 dropped-out.</P>
<P>Reasons for drop-outs fully addressed, and included: patients not showing up regularly (n = 107); impossible to withdraw antipsychotics within six months (n = 56); occurrence of exclusion criteria (n = 44); therapist refusal to continue treatment (n = 12); impossible to maintain patient withdrawn for &gt;4 weeks (n = 11); patient refusal to continue (n = 10) (Multiple occurrence)</P>
<P>Overall drop-out rate: 42.6% in MT group (n = 52) 59.8% in EI group (n = 76) 67% in CI group (n = 77).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-01 16:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prien-1973">
<DESCRIPTION>
<P>Follow-up: unclear - 'approximately 5% of the patients in each treatment group were dropped from the study for reasons other than relapse, such as intercurrent illness, AWOL status or discharge. None of the early terminations were considered to be related to study treatment.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:38:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Remington-2011">
<DESCRIPTION>
<P>Follow-up: 74% - a total of n = 38 consented to the study, but three withdrew consent before the first follow-up visit. n = 26 completed the study, with n = 9 'partial completers' (n = 4 withdrew consent; n = 5 were withdrawn by the investigator - reasons included failure to attend scheduled visits and readmission to hospital). ITT used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:39:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schooler-1997">
<DESCRIPTION>
<P>Follow-up: 59% - out of n = 528 acutely ill participants recruited at the beginning of the study, n = 215 did not enter the treatment phase. These numbers are accounted for; '105 could not be stabilised according to the study criteria, 21 were stable but only with the treatment above the study dose range (50mg of fluphenazine decanoate every 2 weeks), 80 withdrew consent and 9 were withdrawn for administrative reasons.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-04-12 10:49:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shenoy-1981">
<DESCRIPTION>
<P>Follow-up: 90% - 'three patients failed to complete the study for failure to appear for appointments'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:40:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiedemann-2001">
<DESCRIPTION>
<P>Follow-up: 55% - from n = 85 originally randomised, n = 25 dropped out before receiving any treatment; n = 9 received a maximum of six treatment sessions (four sessions of communication skills training and two psycho-educational sessions). After treatment, n = 4 dropped-out, the reasons for which are unclear. Not all data accounted for. Completer-only data used (no details as to treatment allocation).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-05 10:41:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wunderink-2007">
<DESCRIPTION>
<P>Follow-up: 98% - of the 131 participants included in the trial, n = 3 from the discontinuation group withdrew consent and were not included in the analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-05-15 09:35:36 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-11 09:34:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Blackburn-1961">
<DESCRIPTION>
<P>Not all outcomes reported. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-03 16:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>Not all expected outcomes reported - only data presented for either relapse or non-relapse are available without SD and overall scores for all participants are not available; 'relapse' was not defined in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-14 17:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1987">
<DESCRIPTION>
<P>Criterion instruments were completed at six-month intervals - however, only results by the full two years are available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-15 09:31:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carpenter-1990_x002a_">
<DESCRIPTION>
<P>Not all outcomes reported - including data from BPRS, GAS, QLS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 14:25:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaebel-2011">
<DESCRIPTION>
<P>In the first year of study, participants from 13 German psychiatric university hospitals were included; in the second year, however, participants from only 8 German psychiatric university hospitals were mentioned - 'there have been no formal or administrative reasons why 5 sites did not include patients in the second year'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-11 16:05:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Herz-1991_x002a_">
<DESCRIPTION>
<P>Not all expected outcomes reported - adverse effects using AIMS was mentioned but no data were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-16 12:35:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jolley-1989_x002f_1990">
<DESCRIPTION>
<P>AIMS; Early Signs Questionnaire; GAS; 'Manchester Rating Scale' and 'Symptom Checklist-90' were both mentioned as instruments used to measure psychotic symptoms at one year, but no data reported at either one or two years. Data reported at one year differs to data reported at two years. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 09:11:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCreadie-1980">
<DESCRIPTION>
<P>Not all data reported for listed outcomes. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 09:20:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCreadie-1982">
<DESCRIPTION>
<P>Not all data reported for listed outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 14:42:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olson-1962_x002a_">
<DESCRIPTION>
<P>Not all reported outcomes presented data. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 09:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pietzcker-1993_x002a_">
<DESCRIPTION>
<P>Not all reported outcomes presented data. AIMS, BPRS, CGI, ESS, GAS all mentioned as instruments of measurement to be taken throughout the course of the two-year study, but only data from the preliminary report (up to six months) were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-01 16:16:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prien-1973">
<DESCRIPTION>
<P>No data reported for rating scales used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-23 09:21:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remington-2011">
<DESCRIPTION>
<P>Not all reported outcomes presented data. No data for individual groups were reported for; Symptoms (Simpson-Angus Rating Scale), Calgary depression scale or the Barnes Akathisia Scale.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-15 09:35:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schooler-1997">
<DESCRIPTION>
<P>Hillside anchored version of the BPRS, modification of SANS, CGI severity and improvement scale, EPS symptoms - stated that scales will be used but no data were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-15 09:05:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shenoy-1981">
<DESCRIPTION>
<P>Weissman Social Adjustment Scale mentioned but no data were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-15 09:09:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wiedemann-2001">
<DESCRIPTION>
<P>AIMS, EPS and IMPS scale used but no data reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 10:06:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wunderink-2007">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-05-14 17:28:31 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-11 09:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blackburn-1961">
<DESCRIPTION>
<P>Funding source: not stated.</P>
<P>Rating scales: ratings completed independently by both the nurse and the aide on each ward at each of the three rating periods. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-15 10:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caffey-1964">
<DESCRIPTION>
<P>Funding source: drugs used in the study were donated by Sandoz (thioridazine-Mellaril) and Smith, Kline &amp; French (chlorpromazine-Thorazine).</P>
<P>Rating scales: IMPS was completed independently by two psychiatrists or psychologists. The PRP was completed by two nurses or nursing assistants.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-14 17:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carpenter-1987">
<DESCRIPTION>
<P>Funding source: supported in part by NIMH grant MH-35996.</P>
<P>Rating scales: 'criterion instruments were completed at six-month intervals by an evaluator who was independent of the treatment team and whose sole function during the experimental treatment phase was to make independent assessments of outcome'. Trial author developed two of the psychosocial measure scales, including the Level of Functioning Scale and the QLS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-15 10:09:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carpenter-1990_x002a_">
<DESCRIPTION>
<P>Funding source: supported in part by NIMH grant MH-35996 and MH-40279.</P>
<P>Rating scales: independent rater - 'to minimize bias in the evaluation of outcome, assessments were completed by an evaluator blind to the treatment administered in any given case'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-30 14:25:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gaebel-2011">
<DESCRIPTION>
<P>The original design was amended by addition of a 'lateral entry procedure' to allow first-episode participants to enter the second year after the initial first year of maintenance treatment'. The majority of the 'lateral entry' participants were patients who had participated in the first year of study but dropped-out for various reasons, then switched to another atypical antipsychotic at the discretion of the doctor and continued to attend the biweekly appointments.</P>
<P>Funding source: conducted within the framework of the German Research Network on Schizophrenia, funded by the German Federal Ministry for Education and Research BMBF (grants 01 GI 9932 and 01 GI 0232) risperidone and haloperidol were provided by Janssen Cilag, Germany. Lorazepam was provided by Wyeth-Pharma.</P>
<P>Rating scales: conducted by a study physician at every visit.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-12 12:06:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herz-1991_x002a_">
<DESCRIPTION>
<P>Funding: supported by grant MH37343 from the National Institute of Mental Health, Bethesda, Maryland.</P>
<P>Rating scales: unclear who administered the rating scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-15 10:04:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jolley-1989_x002f_1990">
<DESCRIPTION>
<P>Funding: funded by grants from the Department of Health and Social Services, North West Thames Regional Research Fund, and the Priory Hospital, Roehampton. Depot fluphenazine decanoate and placebo were supplied by ER Squibb and Sons.</P>
<P>Rating scales: made during interviews with the participants, conducted by the community psychiatric nurse during home visits.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 09:36:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1980">
<DESCRIPTION>
<P>Funding source: not stated - Janssen Pharmaceutical and ER Squibb acknowledged for supplying the medication and providing 'advice'.</P>
<P>Rating scales: participants' mental state was assessed independently by two psychiatrists.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 05:37:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McCreadie-1982">
<DESCRIPTION>
<P>Funding source: supported by a research grant from Dumfries and Galloway Health Board. Janssen Pharamceutical and ER Squibb provided 'advice', medication and 'other materials'.</P>
<P>Rating scales: participants' mental state was assessed independently by two psychiatrists.</P>
<P>Number of included participants differ in the abstract (N = 29). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-20 14:42:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olson-1962_x002a_">
<DESCRIPTION>
<P>Funding source: not stated. </P>
<P>Rating scales: clinical interview rater used - not stated whether an independent rater.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-12 12:06:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pietzcker-1993_x002a_">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Rating scales: unclear who administered the rating scales. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-01 16:36:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1973">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Rating scales: administered by physician and nurse.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-19 17:28:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remington-2011">
<DESCRIPTION>
<P>Funding source: supported through a National Alliance for Research on Schizophrenia and Depression (NARSAD) Independent Award to Dr. Remington.</P>
<P>Rating scales: not stated who administered rating scales. </P>
<P>Other potential conflicts of interest: Dr Remington has received grant/research support from Novartis and Merck (Germany). Dr Shammi has participated in speaker/ advisory boards for AstraZeneca, Pfizer, Novartis and Bristol-Myers Squibb. In the last three years, DR Kapur has received a grant/research support from AstraZeneca, Bioline, Bristol-Myers Squibb, Eli Lilly, Janssen (Johnson and Johnson), Lundbeck, Otsuka, Organon, Pfizer, Servier, and Solvay Wyeth.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-17 14:29:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schooler-1997">
<DESCRIPTION>
<P>Funding: not stated - all double-blind medication supplies as well as open label fluphenazine decanoate and fluphenazine hydrochloride were provided courtesy of Bristol-Myers Quibb Company, Princeton, New Jersey (US).</P>
<P>Rating scales: unclear who administered rating scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-12 12:08:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shenoy-1981">
<DESCRIPTION>
<P>Funding: not stated.</P>
<P>Rating scales (AIMS and 'side effects scale) were completed by the same rater, 'raising the possibility that the correlations are partly due to a halo effect'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-26 11:21:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wiedemann-2001">
<DESCRIPTION>
<P>Funding: supported by a grant from the German Ministry of Research and Technology. </P>
<P>Rating scales: unclear who administered rating scales. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-08 10:12:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderink-2007">
<DESCRIPTION>
<P>Funding: direct funding from the Netherlands Organisation for Health Research and Development (The Hague) (DO945-01-001), Foundation for the Support of the Society for Christian Care of the Nervously and Mentally Ill (Bennekom), Foundation 'De Open Ankh' (Soesterberg) and Eli Lilly Nederland B.V. (Houten).</P>
<P>Rating scales: unclear who administered rating scales. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-05-15 10:40:42 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-05-15 09:41:01 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-05-15 09:38:26 +0100" MODIFIED_BY="Grade Profiler">ANY INTERMITTENT DRUG TECHNIQUE compared with MAINTENANCE THERAPY for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="34">
<TR>
<TD COLSPAN="7">
<P>
<B>ANY INTERMITTENT DRUG TECHNIQUE compared with MAINTENANCE THERAPY for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> inpatients; outpatients; multi-centre (Germany, Netherlands, UK, US)<BR/>
<B>Intervention:</B> ANY INTERMITTENT DRUG TECHNIQUE<BR/>
<B>Comparison: </B>MAINTENANCE THERAPY</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MAINTENANCE THERAPY</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ANY INTERMITTENT DRUG TECHNIQUE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Relapse: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 17 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.46 </B>
<BR/>(1.70 to 3.54)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>436<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>369 per 1000</B>
<BR/>(255 to 531)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>738 per 1000</B>
<BR/>(510 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Hospitalisation: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 24 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.65 </B>
<BR/>(1.33 to 2.06)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>626<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>82 per 1000</B>
<BR/>(66 to 103)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>495 per 1000</B>
<BR/>(399 to 618)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>825 per 1000</B>
<BR/>(665 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: average score: long term (+ 26 weeks)</B>
<BR/>Global Assessment Scale (GAS). Scale from: 0 to 100.<BR/>Follow-up: mean 22 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global state: average score: long term (+ 26 weeks) in the control groups was<BR/>
<B>59 points</B>
<SUP>5</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global state: average score: long term (+26 weeks) in the intervention groups was<BR/>
<B>1.32 higher</B>
<BR/>(2.75 lower to 5.39 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>133<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: average score: long term (+ 26 weeks)</B>
<BR/>Brief Psychaitric Rating Scale (BPRS). Scale from: 0 to 126.<BR/>Follow-up: mean 21 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: average score: long term (+ 26 weeks) in the control groups was<BR/>
<B>11.95 points</B>
<SUP>7</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: average score: long term (+26 weeks) in the intervention groups was<BR/>
<B>0.1 higher</B>
<BR/>(0.32 lower to 0.53 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>77<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: tardive dyskinesia: by long term (+26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 15 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>9</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.15 </B>
<BR/>(0.58 to 2.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>165<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>9</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>230 per 1000</B>
<BR/>(116 to 460)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>9</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>690 per 1000</B>
<BR/>(348 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes: cost effectiveness</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Leaving the study early/ loss to follow-up: by long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 19 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>10</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.63 </B>
<BR/>(1.23 to 2.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>996<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,11</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>163 per 1000</B>
<BR/>(123 to 215)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>10</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>652 per 1000</B>
<BR/>(492 to 860)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>10</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>700 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(861 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (14%).<BR/>
<SUP>2</SUP> Imprecision: 'serious' - small sample size - confidence intervals for best estimate of effect include both no effect and appreciable benefit/ harm<BR/>
<SUP>3</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (26.1%).<BR/>
<SUP>4</SUP> Indirectness: 'serious' - intermittent drug techniques differ between studies, with some instead examining 'targeted intervention' or 'dose reduction and family treatment'<BR/>
<SUP>5</SUP> Denotes endpoint data<BR/>
<SUP>6</SUP> Risk of bias: 'serious' - only 30% of included studies adequately described randomisation methods, the remaining 70% provided no description of randomisation methods<BR/>
<SUP>7</SUP> Denotes endpoint and change data.<BR/>
<SUP>8</SUP> Risk of bias: 'serious' - 100% of included studies provided no description of randomisation methods<BR/>
<SUP>9</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (17.2%).<BR/>
<SUP>10</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (27.9%).<BR/>
<SUP>11</SUP> Indirectness: 'serious' - intermittent drug techniques differ between studies, with some instead examining 'targeted intervention' or 'guided discontinuation'</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-05-15 09:40:53 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-05-15 09:38:36 +0100" MODIFIED_BY="Grade Profiler">INTERMITTENT (EARLY-BASED) compared with MAINTENANCE THERAPY for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>INTERMITTENT (EARLY-BASED) compared with MAINTENANCE THERAPY for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> outpatients (Germany, UK, US)<BR/>
<B>Intervention:</B> INTERMITTENT (EARLY-BASED)<BR/>
<B>Comparison: </B>MAINTENANCE THERAPY</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MAINTENANCE THERAPY</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>INTERMITTENT (EARLY-BASED)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Relapse: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 24 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.33 </B>
<BR/>(1.32 to 4.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>155<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>349 per 1000</B>
<BR/>(198 to 618)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>756 per 1000</B>
<BR/>(396 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Hospitalisation: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 24 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.16 </B>
<BR/>(1.33 to 2.08)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>625<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>166 per 1000</B>
<BR/>(133 to 208)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>498 per 1000</B>
<BR/>(399 to 624)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>996 per 1000</B>
<BR/>(798 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: average score: long term (+ 26 weeks)</B>
<BR/>Global Assessment Scale (GAS). Scale from: 0 to 100.<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global state: average score: long term (+ 26 weeks) in the control groups was<BR/>
<B>47.5 points</B>
<SUP>6</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global state: average score: long term (+26 weeks) in the intervention groups was<BR/>
<B>0.99 higher</B>
<BR/>(4.24 lower to 6.22 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>82<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: average score: long term (+ 26 weeks)</B>
<BR/>Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126.<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: average score: long term (+ 26 weeks) in the control groups was<BR/>
<B>1.8 points</B>
<SUP>7</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: average score: long term (+26 weeks) in the intervention groups was<BR/>
<B>0.1 higher</B>
<BR/>(0.33 lower to 0.53 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>26<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: tardive dyskinesia: long term (+26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>444 per 1000</B>
<SUP>9</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>249 per 1000</B>
<BR/>(84 to 756)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.56 </B>
<BR/>(0.19 to 1.7)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes: cost effectiveness: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Leaving the study early/loss to follow-up: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 24 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.67 </B>
<BR/>(1.17 to 2.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>562<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,11</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
<SUP>10</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>334 per 1000</B>
<BR/>(234 to 474)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
<SUP>10</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>668 per 1000</B>
<BR/>(468 to 948)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
<SUP>10</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(702 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (16.7%).<BR/>
<SUP>2</SUP> Risk of bias: 'serious' - only 50% of included studies adequately described randomisation methods, the remaining 50% provided no description of randomisation methods<BR/>
<SUP>3</SUP> Imprecision: 'serious' - small sample size - confidence intervals for best estimate of effect include both no effect and appreciable benefit/ harm<BR/>
<SUP>4</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (25.9%).<BR/>
<SUP>5</SUP> Risk of bias: 'serious' - only 40% of included studies adequately described randomisation methods, the remaining 60% provided no description of randomisation methods<BR/>
<SUP>6</SUP> Denotes endpoint data<BR/>
<SUP>7</SUP> Denotes change data<BR/>
<SUP>8</SUP> Risk of bias: 'serious' - study provided no description of randomisation methods<BR/>
<SUP>9</SUP> Mean baseline risk presented for single study.<BR/>
<SUP>10</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (33.9%).<BR/>
<SUP>11</SUP> Risk of bias: 'serious' - only 20% of included studies adequately described randomisation methods, the remaining 80% provided no description of randomisation methods</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-05-15 09:40:46 +0100" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-05-15 09:39:04 +0100" MODIFIED_BY="Grade Profiler">INTERMITTENT (CRISIS INTERVENTION) compared with MAINTENANCE THERAPY for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>INTERMITTENT (CRISIS INTERVENTION) compared with MAINTENANCE THERAPY for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> outpatients (Germany)<BR/>
<B>Intervention:</B> INTERMITTENT (CRISIS INTERVENTION)<BR/>
<B>Comparison: </B>MAINTENANCE THERAPY</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MAINTENANCE THERAPY</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>INTERMITTENT (CRISIS INTERVENTION)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Relapse: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hospitalisation: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: average score: long term (+ 26 weeks)</B>
<BR/>Global Assessment Scale (GAS). Scale from: 0 to 100.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: average score: long term (+ 26 weeks)</B>
<BR/>Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: tardive dyskinesia: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes: cost effectiveness: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Leaving the study early/ loss to follow-up: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>426 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>669 per 1000</B>
<BR/>(524 to 852)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.57 </B>
<BR/>(1.23 to 2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>237<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Mean baseline risk presented for single study.<BR/>
<SUP>2</SUP> Risk of bias: 'serious' - study provided no description of randomisation methods<BR/>
<SUP>3</SUP> Imprecision: small sample size (n = 237) from single study.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-05-15 10:40:42 +0100" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-05-15 09:39:30 +0100" MODIFIED_BY="Grade Profiler">INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS) compared with MAINTENANCE THERAPY for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS) compared with MAINTENANCE THERAPY for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> inpatients; outpatients (Germany, Netherlands)<BR/>
<B>Intervention:</B> INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS)<BR/>
<B>Comparison: </B>MAINTENANCE THERAPY</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MAINTENANCE THERAPY</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Relapse: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 18 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.76 </B>
<BR/>(1.63 to 4.67)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>219<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>276 per 1000</B>
<BR/>(163 to 467)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>828 per 1000</B>
<BR/>(489 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hospitalisation: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: average score: long term (+26 weeks)</B>
<BR/>Global Assessment Scale (GAS). Scale from: 0 to 100.<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global state: average score: long term (+26 weeks) in the control groups was<BR/>
<B>82.17 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean global state: average score: long term (+ 26 weeks) in the intervention groups was<BR/>
<B>1.83 higher</B>
<BR/>(4.66 lower to 8.32 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>51<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: average score: long term (+ 26 weeks)</B>
<BR/>Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126.<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: average score: long term (+26 weeks) in the control groups was<BR/>
<B>22.1 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean mental state: average score: long term (+ 26 weeks) in the intervention groups was<BR/>
<B>0.2 higher</B>
<BR/>(2.77 lower to 3.17 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>51<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: tardive dyskinesia: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 18 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment<SUP>6</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>85<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes: cost effectiveness: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Leaving the study early/ loss to follow-up: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 18 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>7</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.12 </B>
<BR/>(0.7 to 6.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>257<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>424 per 1000</B>
<BR/>(140 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(350 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (12.7%).<BR/>
<SUP>2</SUP> Risk of bias: 'serious' - 66% of included studies adequately described randomisation methods, the remaining 34% provided no description of randomisation methods<BR/>
<SUP>3</SUP> Imprecision: 'serious' - small sample size - confidence intervals for best estimate of effect include both no effect and appreciable benefit/ harm<BR/>
<SUP>4</SUP> Denotes endpoint score.<BR/>
<SUP>5</SUP> Risk of bias: 'serious' - study provided no description of randomisation methods<BR/>
<SUP>6</SUP> Single included study reported no instances of tardive dyskinesia (0%).<BR/>
<SUP>7</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (17.2%).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-05-15 09:40:27 +0100" MODIFIED_BY="Grade Profiler" NO="5" READONLY="YES">
<TITLE MODIFIED="2013-05-15 09:40:18 +0100" MODIFIED_BY="Grade Profiler">INTERMITTENT (DRUG HOLIDAY) compared with MAINTENANCE THERAPY for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>INTERMITTENT (DRUG HOLIDAY) compared with MAINTENANCE THERAPY for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> inpatients; outpatients (Canada, UK)<BR/>
<B>Intervention:</B> INTERMITTENT (DRUG HOLIDAY)<BR/>
<B>Comparison: </B>MAINTENANCE THERAPY</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>MAINTENANCE THERAPY</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>INTERMITTENT (DRUG HOLIDAY)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Relapse: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 9.5 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.70 </B>
<BR/>(0.54 to 5.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>61<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>255 per 1000</B>
<BR/>(81 to 807)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>340 per 1000</B>
<BR/>(108 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hospitalisation: medium term (13-25 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 6 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>222 per 1000</B>
<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>58 per 1000</B>
<BR/>(7 to 476)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.26 </B>
<BR/>(0.03 to 2.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>35<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: average score: long term (+ 26 weeks)</B>
<BR/>Global Assessment Scale (GAS). Scale from: 0 to 100.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: average score: long term (+ 26 weeks)</B>
<BR/>Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: tardive dyskinesia: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 9.5 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>6</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.64 </B>
<BR/>(0.82 to 3.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>50<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>164 per 1000</B>
<BR/>(82 to 330)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>492 per 1000</B>
<BR/>(246 to 990)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>984 per 1000</B>
<BR/>(492 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes: cost effectiveness: long term (+ 26 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Leaving the study early/ loss to follow-up: long term (+ 26 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 9.5 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>6</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.01 </B>
<BR/>(0.46 to 2.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>62<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
<BR/>(46 to 220)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>303 per 1000</B>
<BR/>(138 to 660)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>404 per 1000</B>
<BR/>(184 to 880)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (12.1%).<BR/>
<SUP>2</SUP> Risk of bias: 'serious' - 100% of included studies provided no description of randomisation methods<BR/>
<SUP>3</SUP> Imprecision: 'serious' - small sample size - confidence intervals for best estimate of effect include both no effect and appreciable benefit/ harm<BR/>
<SUP>4</SUP> Mean baseline risk presented from single study.<BR/>
<SUP>5</SUP> No explanation was provided<BR/>
<SUP>6</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (27.3%).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2013-05-15 09:41:20 +0100" MODIFIED_BY="Grade Profiler" NO="6" READONLY="YES">
<TITLE MODIFIED="2013-05-15 09:41:16 +0100" MODIFIED_BY="Grade Profiler">ANY INTERMITTENT DRUG TECHNIQUE compared with PLACEBO for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>ANY INTERMITTENT DRUG TECHNIQUE compared with PLACEBO for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> inpatients<BR/>
<B>Intervention:</B> ANY INTERMITTENT DRUG TECHNIQUE<BR/>
<B>Comparison: </B>PLACEBO</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PLACEBO</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ANY INTERMITTENT DRUG TECHNIQUE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Relapse: medium term (13-25 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 16 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.36 </B>
<BR/>(0.23 to 0.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>288<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>74 per 1000</B>
<BR/>(48 to 116)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>148 per 1000</B>
<BR/>(96 to 232)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>296 per 1000</B>
<BR/>(192 to 464)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hospitalisation: medium term (13-25 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state: average score: medium term (13-25 weeks)</B>
<BR/>Global Assessment Scale (GAS). Scale from: 0 to 100.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: average score: medium term (13-25 weeks)</B>
<BR/>Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: tardive dyskinesia: medium term (13-25 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported provided useable data for this outcome by long term</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic outcomes: cost effectiveness: medium term (13-25 weeks)</B>
<BR/>as defined in each study</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Leaving the study early/ loss to follow-up: medium term (13-25 weeks)</B>
<BR/>as defined in each study<BR/>Follow-up: mean 11 months</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.97 </B>
<BR/>(1.28 to 3.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>90<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>197 per 1000</B>
<BR/>(128 to 301)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>591 per 1000</B>
<BR/>(384 to 903)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
<BR/>(768 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (46.2%).<BR/>
<SUP>2</SUP> Risk of bias: 'serious' - 100% of included studies provided no description of randomisation methods<BR/>
<SUP>3</SUP> Imprecision: 'serious' - small sample size - confidence intervals for best estimate of effect include both no effect and appreciable benefit/ harm<BR/>
<SUP>4</SUP> Assumed risk: calculated from the included studies - presents 3 risks based on the control group risks - 'moderate' risk equates with that of control group (31.1%).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-05-15 09:41:54 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-05-15 09:41:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-24 11:56:19 +0100" MODIFIED_BY="[Empty name]">Suggested design for future study</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised, fully described in terms of methods of randomisation and allocation concealment.</P>
<P>Blinding: double/single blind, with methods of maintenance of blinding fully described.<BR/>Duration: two years.<BR/>Setting: outpatients.<BR/>Design: parallel.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (DSM-IV/ICD-10/ RDC).<BR/>n =&gt; 300.<BR/>Sex: male and female.<BR/>Age: adults, with age specified in trial.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Any intermittent drug technique (n = 150):</P>
<P>a. Prodrome-based/early intervention (defined as treatment given on the early signs of relapse).</P>
<P>b. Crisis intervention (defined as treatment given only in case of full relapse and discontinued again after re-stabilisation).</P>
<P>c. Gradually increased drug-free period (defined as increasing the cessation period of the treatment constantly).</P>
<P>d. Drug holiday (defined as stopping medication for fixed periods, and then reintroducing it - repeating this more than once).</P>
<P>
<BR/>Secifiying types of typical or atypical antipsychotics:</P>
<P>i. High dose (as defined by each study).</P>
<P>ii. Low or moderate dose (as defined by each study).</P>
<P/>
<P>versus</P>
<P/>
<P>2. Maintenance therapy, as defined in each study (n = 150):</P>
<P/>
<P>Secifiying types of typical or atypical antipsychotics:</P>
<P>i. High dose (as defined by each study).</P>
<P>ii. Low or moderate dose (as defined by each study).</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Relapse (operationally defined using either PANSS, CGI or BPRS).</P>
<P>Hospitaliation (as defined in each study).</P>
<P>Global state: CGI (Clinical Global Impression) or GAS (Global Assessment Scale) - preferably dichotomous outcomes/dichotomised scale data).</P>
<P>Mental state: BPRS or PANSS (preferably dichotomous outcomes/dichotomised scale data).</P>
<P>General functioning: GAF (Global Assessment of Functioning Scale - preferably dichotomous outcomes/dichotomised scale data).</P>
<P>Quality of life: QLS (Quality of Life Scale - preferably dichotomous outcomes/dichotomised scale data).</P>
<P>Adverse effects: including specific adverse effects, extrapyramidal symptoms, tardive dyskinesia.</P>
<P>Economic outcomes: including any cost effectiveness of treatment.</P>
<P>Death.</P>
<P>Leaving the study early: specific reasons including - any reason; loss to follow-up; treatment-related; non-treatment related; death; adverse effects.<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>Notes</P>
</TH>
<TD>
<P>Any outcomes measured using scale-derived data should be interpreted in such a way as to make clear the real-life relevance of changes in scale score.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BPRS - Brief Psychiatric Rating Scale<BR/>CGI - Clinical Global Impression.<BR/>DSM - Diagnostic and Statistical Manual of Mental Disorders<BR/>ICD - The International Statistical Classification of Diseases and Related Health Problems<BR/>PANSS - Positive and Negative Syndrome Scale<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-05-15 09:41:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-06-11 16:12:51 +0100" MODIFIED_BY="[Empty name]">Differences between protocol and review</TITLE>
<TABLE COLS="2" ROWS="2">
<TR>
<TH>
<P>Major</P>
</TH>
<TH>
<P>Minor</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1. There have been additions to <LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK>: the protocol to the current review did not specify a comparison with specific named drugs (atypical or typical) nor dosages, which is certainly a comparison of interest for people receiving treatment as well as clinicians administering medication and was subsequently addressed in the final text.</P>
</TD>
<TD VALIGN="TOP">
<P>1. The data collection and analysis section has been updated to reflect changes in methodology that have occurred whilst writing this review, namely inclusion of 'Risk of bias' tables and 'Summary of findings' tables.</P>
<P/>
<P>2. Types of outcome measures have been modified/clarified from the original protocol - this decision was not influenced by the results. Economic outcomes of direct and indirect costs have been qualified as 'defined by each study', to take into account that what may constitute a direct and indirect cost can differ between trial authors. A further sub-category of 'cost-effectiveness' has been added, again a factor that would be 'defined by each study'.</P>
<P/>
<P>3. Further, the protocol specified a global state outcome of 'no clinically important change in global state (as defined by individual studies)'; this has been changed to 'any clinically important change in global state (as defined by individual studies)'. The direction of the graphs have been modified to represent an unfavourable outcome for intermittent treatment when results are presented to the left of the line of no effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-05-15 10:40:53 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-05-15 09:44:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ANY INTERMITTENT DRUG TECHNIQUE versus MAINTENANCE THERAPY</NAME>
<DICH_OUTCOME CHI2="7.47269796600132" CI_END="2.909173156044367" CI_START="1.7554438074914174" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2598429152705166" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.46376957153118864" LOG_CI_START="0.24438693207138404" LOG_EFFECT_SIZE="0.3540782518012864" METHOD="MH" MODIFIED="2013-01-21 09:49:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9149522420226419" P_Q="0.46294095226143717" P_Z="2.505106664170865E-10" Q="1.5403121007543292" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="918" TOTAL_2="688" WEIGHT="300.0" Z="6.326668536291152">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.31622635822624245" CI_END="2.8085990879507845" CI_START="1.0026296669367576" DF="2" EFFECT_SIZE="1.6780896186172467" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.4484897504806771" LOG_CI_START="0.0011405508618255063" LOG_EFFECT_SIZE="0.2248151506712513" MODIFIED="2013-01-21 09:42:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8537531684299491" P_Z="0.0488431682903255" STUDIES="4" TAU2="0.0" TOTAL_1="201" TOTAL_2="195" WEIGHT="100.0" Z="1.9699581395027486">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="2.7188323904830174" CI_START="0.8784762754874332" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4343824351961736" LOG_CI_START="-0.056269962756075785" LOG_EFFECT_SIZE="0.18905623622004888" MODIFIED="2013-01-21 09:42:06 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.2882116473256918" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.08306595365418895" WEIGHT="68.58614824885376"/>
<DICH_DATA CI_END="5.702648095864593" CI_START="0.5250308901101693" EFFECT_SIZE="1.7303370786516854" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7560765725776436" LOG_CI_START="-0.27981514419454295" LOG_EFFECT_SIZE="0.2381307141915503" MODIFIED="2013-01-21 08:41:24 +0000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.6084879221786795" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="88" VAR="0.37025755143732675" WEIGHT="25.0813238588515"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-21 09:41:28 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.0" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="27.217111396832962" CI_START="0.31063820230374717" EFFECT_SIZE="2.9076923076923076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4348420308237835" LOG_CI_START="-0.5077451357630062" LOG_EFFECT_SIZE="0.46354844753038854" MODIFIED="2012-05-08 10:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.1410853176146392" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="1.3020757020757021" WEIGHT="6.332527892294736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.930243676359856" CI_END="3.8574019633095826" CI_START="1.5019968417535607" DF="4" EFFECT_SIZE="2.4070325228930702" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="21" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.586294897188921" LOG_CI_START="0.17666901947877336" LOG_EFFECT_SIZE="0.3814819583338472" MODIFIED="2013-01-21 09:46:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7485872743543095" P_Z="2.6162451925993004E-4" STUDIES="5" TAU2="0.0" TOTAL_1="502" TOTAL_2="272" WEIGHT="99.99999999999999" Z="3.6506038303332886">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="3.749267815044464" CI_START="0.9376830819855172" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5739464637455769" LOG_CI_START="-0.027943919618101734" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2013-01-21 09:46:36 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.125" WEIGHT="36.9948436423561"/>
<DICH_DATA CI_END="9.474271020259568" CI_START="1.08994918004535" EFFECT_SIZE="3.2134831460674156" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9765458039637874" LOG_CI_START="0.03740624900447311" LOG_EFFECT_SIZE="0.5069760264841302" MODIFIED="2013-01-21 08:41:22 +0000" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.5516552233988733" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="88" VAR="0.3043234855032608" WEIGHT="18.601927029207307"/>
<DICH_DATA CI_END="37.24789041280546" CI_START="0.6963853683199257" EFFECT_SIZE="5.093023255813954" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" LOG_CI_END="1.5711016808958063" LOG_CI_START="-0.15715036237474259" LOG_EFFECT_SIZE="0.7069756592605319" MODIFIED="2013-01-21 08:41:21 +0000" MODIFIED_BY="[Empty name]" ORDER="743" O_E="0.0" SE="1.0151838052027076" STUDY_ID="STD-Prien-1973" TOTAL_1="301" TOTAL_2="73" VAR="1.0305981583458488" WEIGHT="7.4434812408751245"/>
<DICH_DATA CI_END="5.403400157551767" CI_START="0.36885655821539853" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7326671311115547" LOG_CI_START="-0.43314249044489045" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2013-01-21 08:41:20 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="13.476693041144008"/>
<DICH_DATA CI_END="6.22303716472749" CI_START="0.869509786418459" EFFECT_SIZE="2.3261538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7940023946511705" LOG_CI_START="-0.060725525606506105" LOG_EFFECT_SIZE="0.3666384345223322" MODIFIED="2013-01-21 08:41:19 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.5020714113308007" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="0.25207570207570207" WEIGHT="23.483055046417448"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.808163723445132" CI_END="3.538374407842774" CI_START="1.704771718834526" DF="6" EFFECT_SIZE="2.4560375854490144" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="31" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.548803785231981" LOG_CI_START="0.23166623207452594" LOG_EFFECT_SIZE="0.39023500865325356" MODIFIED="2013-01-21 09:49:09 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7026183705408937" P_Z="1.4110508880610135E-6" STUDIES="7" TAU2="0.0" TOTAL_1="215" TOTAL_2="221" WEIGHT="100.00000000000003" Z="4.82343736875157">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="172.109750484579" CI_START="0.5600885129602998" EFFECT_SIZE="9.818181818181818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.235805474985875" LOG_CI_START="-0.2517433343284256" LOG_EFFECT_SIZE="0.9920310703287246" MODIFIED="2012-05-01 16:56:11 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="1.461198484156417" STUDY_ID="STD-Gaebel-2011" TOTAL_1="21" TOTAL_2="23" VAR="2.1351010101010104" WEIGHT="1.5263806085792158"/>
<DICH_DATA CI_END="4.1070038258056885" CI_START="0.8905899300647625" EFFECT_SIZE="1.9125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6135251074130694" LOG_CI_START="-0.05032221976175894" LOG_EFFECT_SIZE="0.2816014438256552" MODIFIED="2012-04-11 15:08:03 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.3899472060797612" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.15205882352941175" WEIGHT="25.279390817153526"/>
<DICH_DATA CI_END="7.090456930116108" CI_START="1.2693117084984007" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8506742233119523" LOG_CI_START="0.10356828612737265" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-21 09:49:09 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.43885372573625553" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.1925925925925926" WEIGHT="15.957615453328165">
<FOOTNOTE>by 2 years</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.710927782353705" CI_START="0.3939815185463059" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7567066683203335" LOG_CI_START="-0.404524150208971" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-01-21 09:49:09 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.6821127309893708" STUDY_ID="STD-McCreadie-1980" TOTAL_1="16" TOTAL_2="18" VAR="0.4652777777777777" WEIGHT="9.011359314820611"/>
<DICH_DATA CI_END="22.62194860474717" CI_START="0.23541048032726553" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.354530011369287" LOG_CI_START="-0.6281742065436359" LOG_EFFECT_SIZE="0.3631779024128256" MODIFIED="2013-01-21 08:41:18 +0000" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-McCreadie-1982" TOTAL_1="13" TOTAL_2="15" VAR="1.3564102564102565" WEIGHT="2.963557155618088"/>
<DICH_DATA CI_END="61.59870228703997" CI_START="1.1312933193518502" EFFECT_SIZE="8.347826086956522" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7895715628865971" LOG_CI_START="0.05357522248531644" LOG_EFFECT_SIZE="0.9215733926859567" MODIFIED="2013-01-21 08:41:16 +0000" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.0197328436721884" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="23" TOTAL_2="24" VAR="1.039855072463768" WEIGHT="3.1236183440557257"/>
<DICH_DATA CI_END="3.651449239334383" CI_START="1.1934891522797948" EFFECT_SIZE="2.0875739644970412" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.5624652676694573" LOG_CI_START="0.07681847602275987" LOG_EFFECT_SIZE="0.31964187184610854" MODIFIED="2012-05-08 10:35:44 +0100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.2852713294036598" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="0.08137973137973138" WEIGHT="42.13807830644468"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.9077288801205" CI_END="2.0051315351231254" CI_START="1.300366948564392" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6147466599433775" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="102" I2="13.140771675808232" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3021428672826006" LOG_CI_START="0.11406592249855804" LOG_EFFECT_SIZE="0.20810439489057933" METHOD="MH" MODIFIED="2013-05-14 15:09:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3294649546097449" P_Q="0.459886362239483" P_Z="1.442154150260928E-5" Q="0.5461714505918277" RANDOM="NO" SCALE="150.13411227935356" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="322" TOTAL_2="440" WEIGHT="200.0" Z="4.3373430962351875">
<NAME>Hospitalisation</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.192301620340255" CI_END="3.4771804470454746" CI_START="0.3107290862209591" DF="1" EFFECT_SIZE="1.0394523091204457" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="68.67463921239955" ID="CMP-001.02.01" LOG_CI_END="0.5412272288261035" LOG_CI_START="-0.5076180921134633" LOG_EFFECT_SIZE="0.016804568356320146" MODIFIED="2012-05-16 09:58:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07398582139724952" P_Z="0.9499218092648751" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="69" WEIGHT="100.00000000000001" Z="0.06280496865757901">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="35.247926780870635" CI_START="0.4722660740725935" EFFECT_SIZE="4.08" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5471335776648154" LOG_CI_START="-0.3258132514850554" LOG_EFFECT_SIZE="0.6106601630898799" MODIFIED="2012-05-16 09:58:09 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="1.100178238678963" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="1.2103921568627451" WEIGHT="20.306335576699933"/>
<DICH_DATA CI_END="2.1372282551634014" CI_START="0.03278508225921429" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32985090712626963" LOG_CI_START="-1.4843237223321302" LOG_EFFECT_SIZE="-0.5772364076029303" MODIFIED="2012-05-15 12:19:38 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.0656551576531124" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="1.1356209150326797" WEIGHT="79.69366442330008"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3438212383859134" CI_END="2.056346933419145" CI_START="1.3257887780338697" DF="4" EFFECT_SIZE="1.6511455684074203" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="97" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.31309638783231963" LOG_CI_START="0.12247433866809121" LOG_EFFECT_SIZE="0.2177853632502054" MODIFIED="2013-01-21 13:28:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5020194636289887" P_Z="7.516551148654765E-6" STUDIES="5" TAU2="0.0" TOTAL_1="255" TOTAL_2="371" WEIGHT="100.0" Z="4.478510961369701">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="2.0168589294794694" CI_START="0.5999428032937777" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.30467552226272765" LOG_CI_START="-0.22189015194627745" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-01-21 13:28:04 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.30930728357249476" STUDY_ID="STD-Carpenter-1987" TOTAL_1="21" TOTAL_2="21" VAR="0.09567099567099568" WEIGHT="12.97630914205117"/>
<DICH_DATA CI_END="2.2560608187073528" CI_START="0.9691866620973163" EFFECT_SIZE="1.4786967418546366" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.3533508031450696" LOG_CI_START="-0.013592571234277696" LOG_EFFECT_SIZE="0.16987911595539598" MODIFIED="2013-01-21 08:42:36 +0000" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.21554435450942633" STUDY_ID="STD-Carpenter-1990_x002a_" TOTAL_1="57" TOTAL_2="59" VAR="0.04645936876088526" WEIGHT="26.780417315578017"/>
<DICH_DATA CI_END="3.4224156342808483" CI_START="0.6839905640192335" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5343327511762583" LOG_CI_START="-0.16494988954106068" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2012-04-11 15:15:24 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.41076208466225117" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.1687254901960784" WEIGHT="10.278264666971223"/>
<DICH_DATA CI_END="7.568851914749338" CI_START="0.9991607822664673" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8790300083107804" LOG_CI_START="-3.646206502552156E-4" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-01-21 13:28:04 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.5165607581253312" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.26683501683501687" WEIGHT="5.190523656820468"/>
<DICH_DATA CI_END="2.482201132294917" CI_START="1.3263262993243017" EFFECT_SIZE="1.8144444444444445" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="54" LOG_CI_END="0.39483696938942986" LOG_CI_START="0.12265038120525673" LOG_EFFECT_SIZE="0.2587436752973433" MODIFIED="2013-01-21 08:42:00 +0000" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="0.15988374924472454" STUDY_ID="STD-Schooler-1997" TOTAL_1="100" TOTAL_2="213" VAR="0.02556281327254995" WEIGHT="44.77448521857912"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.234455641609705" CI_END="2.0794372165023987" CI_START="0.05462063035328199" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3370165745856354" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3179458124440726" LOG_CI_START="-1.2626432921609074" LOG_EFFECT_SIZE="-0.47234873985841747" METHOD="MH" MODIFIED="2012-05-16 15:52:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6282395629085809" P_Q="1.0" P_Z="0.24142001615494657" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="1.1714448942715565">
<NAME>Death</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.234455641609705" CI_END="2.0794372165023987" CI_START="0.05462063035328199" DF="1" EFFECT_SIZE="0.3370165745856354" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.3179458124440726" LOG_CI_START="-1.2626432921609074" LOG_EFFECT_SIZE="-0.47234873985841747" MODIFIED="2012-04-16 11:00:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6282395629085809" P_Z="0.24142001615494657" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="1.1714448942715565">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="5.447773390636908" CI_START="0.047744276670361144" EFFECT_SIZE="0.51" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7362190340657451" LOG_CI_START="-1.3210786818698723" LOG_EFFECT_SIZE="-0.2924298239020636" MODIFIED="2012-04-11 14:55:51 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.2084668621285175" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="1.4603921568627451" WEIGHT="44.19889502762431"/>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-04-16 11:00:59 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="55.80110497237569"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.3824902266979207" CI_END="0.6522827508626722" CI_START="-0.758637885021599" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05317756707946343" ESTIMABLE="YES" I2="58.02711008867481" I2_Q="58.02711008867481" ID="CMP-001.04" MODIFIED="2012-05-22 10:19:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12270199170127216" P_Q="0.12270199170127216" P_Z="0.8825463864447918" Q="2.3824902266979207" RANDOM="YES" SCALE="6.530797343076039" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.150406269349845" TOTALS="YES" TOTAL_1="25" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.1477419971193336">
<NAME>Global state: 1. Average score (CGI-S, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.240905791115129" CI_START="-1.080905791115129" DF="0" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2012-05-22 10:19:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2129331931924816" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="49.052439872147694" Z="1.245540415250235">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="0.240905791115129" CI_START="-1.080905791115129" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="2.83" MEAN_2="3.25" MODIFIED="2012-05-22 10:19:31 +0100" MODIFIED_BY="[Empty name]" ORDER="390" SD_1="0.84" SD_2="1.14" SE="0.3372030283863731" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" WEIGHT="49.052439872147694"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9317094330109384" CI_START="-0.3317094330109388" DF="0" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2012-04-30 12:04:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3519619096525507" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="19" WEIGHT="50.947560127852306" Z="0.9307905892103947">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.9317094330109384" CI_START="-0.3317094330109388" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.1" MODIFIED="2012-04-30 12:04:36 +0100" MODIFIED_BY="[Empty name]" ORDER="1023" SD_1="0.7" SD_2="0.9" SE="0.3223066535884241" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="50.947560127852306"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.796503406551505" CI_END="-0.5674256851346984" CI_START="-3.9221600955735134" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.244792890354106" ESTIMABLE="YES" I2="13.741101327590973" I2_Q="62.7400076698509" ID="CMP-001.05" MODIFIED="2012-05-21 09:21:33 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.32652652478099164" P_Q="0.06830028492024687" P_Z="0.008716246953500007" Q="5.367687632028014" RANDOM="NO" SCALE="38.19" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="161" UNITS="" WEIGHT="300.0" Z="2.622987503365499">
<NAME>Global state: 2. Average score (GAS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7855590876847417E-31" CI_END="-1.5501708542620216" CI_START="-5.669829145737976" DF="0" EFFECT_SIZE="-3.609999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.05.01" MODIFIED="2012-05-15 14:27:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="5.925996164510572E-4" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="3.4349790606806163">
<NAME>short term (&#8804;12 weeks)</NAME>
<CONT_DATA CI_END="-1.550170854262022" CI_START="-5.669829145737976" EFFECT_SIZE="-3.6099999999999994" ESTIMABLE="YES" MEAN_1="63.56" MEAN_2="67.17" MODIFIED="2012-05-15 14:27:06 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="2.68" SD_2="3.09" SE="1.0509525491211302" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.07409829965770373" CI_END="3.6551996085033647" CI_START="-4.549127010774855" DF="1" EFFECT_SIZE="-0.44696370113574524" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2012-04-26 12:23:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7854605379310762" P_Z="0.8308949937720715" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="71" WEIGHT="100.0" Z="0.21355384720162557">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="4.4759725741190355" CI_START="-4.775972574119033" EFFECT_SIZE="-0.14999999999999858" ESTIMABLE="YES" MEAN_1="54.42" MEAN_2="54.57" MODIFIED="2012-04-11 15:20:33 +0100" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="9.74" SD_2="10.51" SE="2.3602334586799123" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="31" TOTAL_2="44" WEIGHT="78.63570495426295"/>
<CONT_DATA CI_END="7.335006144072986" CI_START="-10.415006144072999" EFFECT_SIZE="-1.5400000000000063" ESTIMABLE="YES" MEAN_1="77.83" MEAN_2="79.37" MODIFIED="2012-04-26 12:23:29 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="19.3" SD_2="11.6" SE="4.528147564995025" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="21.36429504573705"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.35471747486578553" CI_END="5.391076603988197" CI_START="-2.753028771125872" DF="2" EFFECT_SIZE="1.3190239164311623" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.03" MODIFIED="2012-04-26 12:24:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.837479332597417" P_Z="0.5255107605239887" STUDIES="3" TAU2="0.0" TOTAL_1="57" TOTAL_2="76" WEIGHT="100.0" Z="0.6348737527026014">
<NAME>long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="16.985229657624124" CI_START="-8.385229657624132" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="42.5" MODIFIED="2012-04-23 10:55:33 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="17.6" SD_2="15.4" SE="6.472174875499551" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="10.304575575191187"/>
<CONT_DATA CI_END="6.048030340531144" CI_START="-5.42803034053114" EFFECT_SIZE="0.3100000000000023" ESTIMABLE="YES" MEAN_1="52.78" MEAN_2="52.47" MODIFIED="2012-04-11 16:09:20 +0100" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="10.19" SD_2="10.72" SE="2.927620295980943" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="19" TOTAL_2="37" WEIGHT="50.36178291289867"/>
<CONT_DATA CI_END="8.322789319930465" CI_START="-4.662789319930468" EFFECT_SIZE="1.8299999999999983" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="82.17" MODIFIED="2012-04-26 12:24:18 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="10.21" SD_2="13.38" SE="3.3127084840051957" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="39.33364151191014"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.04198662309114322" CI_END="5.440280345092874" CI_START="1.8685890852698328" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1883614088820833" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.7356212800639479" LOG_CI_START="0.27151380773493916" LOG_EFFECT_SIZE="0.5035675438994435" METHOD="MH" MODIFIED="2013-01-21 06:22:54 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8376453866574814" P_Q="1.0" P_Z="2.1072381642226892E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="4.253214217273062">
<NAME>Global state: 3. Prodromal episodes</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04198662309114322" CI_END="5.440280345092874" CI_START="1.8685890852698328" DF="1" EFFECT_SIZE="3.1883614088820833" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.7356212800639479" LOG_CI_START="0.27151380773493916" LOG_EFFECT_SIZE="0.5035675438994435" MODIFIED="2013-01-21 06:22:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8376453866574814" P_Z="2.1072381642226892E-5" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="4.253214217273062">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="7.100403111726087" CI_START="1.5818923647924086" EFFECT_SIZE="3.3514285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.8512830056526707" LOG_CI_START="0.19917692987783656" LOG_EFFECT_SIZE="0.5252299677652537" MODIFIED="2012-04-11 14:22:47 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.3830503368872728" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.1467275605894532" WEIGHT="53.59877488514548"/>
<DICH_DATA CI_END="6.378945350016858" CI_START="1.4108915355382716" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.8047488814594771" LOG_CI_START="0.14949362797984786" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-21 06:22:54 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.3849001794597505" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.14814814814814814" WEIGHT="46.40122511485452"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17504718316191634" CI_END="0.6131570362388439" CI_START="0.20315753825895916" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.21242828365799143" LOG_CI_START="-0.692167058331269" LOG_EFFECT_SIZE="-0.45229767099463025" METHOD="MH" MODIFIED="2013-01-21 06:18:36 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6756649341640024" P_Q="0.6756994216307255" P_Z="2.192751215578483E-4" Q="0.1750077088185661" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="60" WEIGHT="200.0" Z="3.6957077152855002">
<NAME>Global state: 4. Significant improvement</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.890351646543475" CI_START="0.1797042782154134" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-01-21 06:17:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0248038000478183" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.244444749133034">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-01-21 06:17:56 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.67911894972813" CI_START="0.14684171562238474" DF="0" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.16805415107126048" LOG_CI_START="-0.8331505500671103" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2013-01-21 06:18:36 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0031732454959754294" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.9504371972936214">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="0.6791189497281301" CI_START="0.14684171562238474" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.1680541510712604" LOG_CI_START="-0.8331505500671103" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2013-01-21 06:18:36 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.39068091705043445" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.15263157894736842" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4927626466659372" CI_END="0.5379194233325286" CI_START="-0.3076359047157935" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.11514175930836754" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-05-21 09:21:56 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7816241253957747" P_Q="0.4845972828853188" P_Z="0.593488124951705" Q="0.48849988063317945" RANDOM="NO" SCALE="10.084144381106293" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="66" UNITS="" WEIGHT="200.0" Z="0.5337881363289879">
<NAME>Mental state: 1. Average score (BPRS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.733302154004129" CI_START="-3.033302154004126" DF="0" EFFECT_SIZE="1.8500000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2012-04-26 12:07:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4577743468674129" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.00000000000001" Z="0.7425166940419552">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="6.733302154004129" CI_START="-3.033302154004126" EFFECT_SIZE="1.8500000000000014" ESTIMABLE="YES" MEAN_1="25.26" MEAN_2="23.41" MODIFIED="2012-04-26 12:07:46 +0100" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="10.31" SD_2="6.93" SE="2.4915264732020543" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0042627660327577855" CI_END="0.5264111165430647" CI_START="-0.3223310404831396" DF="1" EFFECT_SIZE="0.10204003802996253" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2012-05-16 17:15:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.947943214401077" P_Z="0.6374455126642105" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.4712733964354014">
<NAME>long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.5287671204299488" CI_START="-0.32876712042994904" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.8" MODIFIED="2012-05-16 16:52:43 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="0.5" SD_2="0.6" SE="0.21876275473019363" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="97.95996197003733"/>
<CONT_DATA CI_END="3.171164153099063" CI_START="-2.7711641530990643" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="22.1" MODIFIED="2012-05-16 17:15:27 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="5.91" SD_2="4.77" SE="1.515927933643285" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="2.0400380299626777"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.09297837316228659" CI_END="0.2999940222364327" CI_START="-2.222941175554252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9614735766589096" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2012-05-21 09:22:04 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.7604243953150834" P_Q="0.7604243953150833" P_Z="0.13521271362856752" Q="0.09297837316228663" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="126" UNITS="" WEIGHT="200.0" Z="1.4938580935321493">
<NAME>Mental state: 2. Negative symptom score (PANSS negative symptom subscale, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.774356763590305E-32" CI_END="0.8335703706337515" CI_START="-2.4335703706337526" DF="0" EFFECT_SIZE="-0.8000000000000006" ESTIMABLE="YES" I2="100.0" ID="CMP-001.09.01" MODIFIED="2012-05-08 10:55:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.3371342176457278" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.9598430626675372">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="0.8335703706337514" CI_START="-2.4335703706337526" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="13.3" MODIFIED="2012-05-08 10:55:18 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="4.4" SD_2="5.0" SE="0.8334695859307348" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7854335812110498" CI_START="-3.185433581211052" DF="0" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2012-05-08 10:55:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.23617323521418887" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.1846061251837239">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.7854335812110498" CI_START="-3.185433581211052" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="13.3" MODIFIED="2012-05-08 10:55:37 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="5.2" SD_2="6.2" SE="1.0129949309639859" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.10" MODIFIED="2013-01-15 01:09:09 +0000" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 3. Negative symptom score (PANSS negative symptom subscale, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.10.01" MODIFIED="2012-04-30 12:11:44 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:11:44 +0100" MODIFIED_BY="[Empty name]" ORDER="461" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>2.8</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.11" MODIFIED="2013-01-15 01:09:15 +0000" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 4. Negative symptom score (SANS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.11.01" MODIFIED="2012-04-30 12:13:12 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:13:12 +0100" MODIFIED_BY="[Empty name]" ORDER="462" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>17.6</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>9.7</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="2.9949182964010537" CI_END="0.21852428523238016" CI_START="-1.0907962439477858" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4361359793577028" ESTIMABLE="YES" I2="33.220214975367824" I2_Q="63.28556682190075" ID="CMP-001.12" MODIFIED="2012-05-21 09:22:57 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.22369788870736684" P_Q="0.0988671499915007" P_Z="0.19164373500656987" Q="2.72372446865533" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="145" UNITS="" WEIGHT="200.0" Z="1.3057319317194909">
<NAME>Mental state: 5. Positive symptom score (PANSS positive symptom subscale, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.015583763144736418" CI_START="-1.5844162368552615" DF="0" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2012-05-08 10:52:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04561895790852645" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.9989020037602272">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="-0.015583763144736418" CI_START="-1.5844162368552615" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.6" MODIFIED="2012-05-08 10:52:33 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="1.7" SD_2="2.7" SE="0.4002197198737516" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.27119382774572337" CI_END="1.5873894736497232" CI_START="-0.7893793003733969" DF="1" EFFECT_SIZE="0.39900508663816314" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2012-05-08 10:53:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6025321169127799" P_Z="0.5104955968640796" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="82" WEIGHT="100.00000000000001" Z="0.658066201480209">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="3.128814214170191" CI_START="-1.3288142141701922" EFFECT_SIZE="0.8999999999999995" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="7.2" MODIFIED="2012-04-30 12:07:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1024" SD_1="3.2" SD_2="0.5" SE="1.1371710050545794" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="28.429298091166256"/>
<CONT_DATA CI_END="1.6047184906553784" CI_START="-1.2047184906553798" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.8" MODIFIED="2012-05-08 10:53:00 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="4.3" SD_2="3.8" SE="0.7167062771232631" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="71.57070190883375"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.827912095300201" CI_START="-2.6279120953002053" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2012-05-21 09:23:09 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.32968438757511986" Q="0.0" RANDOM="NO" SCALE="39.86" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.9747498173095265">
<NAME>General functioning: 1. Average endpoint (LOFS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.827912095300201" CI_START="-2.6279120953002053" DF="0" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2012-05-16 16:09:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32968438757511986" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="0.9747498173095265">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="7.827912095300201" CI_START="-2.6279120953002053" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" MEAN_1="22.9" MEAN_2="20.3" MODIFIED="2012-05-16 16:09:30 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="7.4" SD_2="6.2" SE="2.6673511026413275" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.083038333088048" CI_START="-15.916961666911952" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2012-05-21 09:23:18 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.01076593418038009" Q="0.0" RANDOM="NO" SCALE="55.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="2.5502058143883928">
<NAME>General functioning: 2. Social functioning score (GAF, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.083038333088048" CI_START="-15.916961666911952" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2012-04-30 12:15:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01076593418038009" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0" Z="2.5502058143883928">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="-2.083038333088048" CI_START="-15.916961666911952" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="71.8" MEAN_2="80.8" MODIFIED="2012-04-30 12:15:27 +0100" MODIFIED_BY="[Empty name]" ORDER="1027" SD_1="8.0" SD_2="9.2" SE="3.5291269234904634" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.15" MODIFIED="2013-01-15 01:15:32 +0000" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>General functioning: 3. Social functioning score (GSDS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.15.01" MODIFIED="2012-05-08 11:05:51 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-08 11:05:41 +0100" MODIFIED_BY="[Empty name]" ORDER="468" STUDY_ID="STD-Wunderink-2007">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>4.2</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="9.846901493023807E-5" CI_END="1.4164627904328184" CI_START="-0.5246135530368775" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4459246186979704" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2013-01-15 01:15:39 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9920825973798154" P_Q="0.9920825973798154" P_Z="0.3678396737451475" Q="9.846901493023807E-5" RANDOM="NO" SCALE="6.654322137572321" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="81" UNITS="" WEIGHT="200.0" Z="0.9005273753483599">
<NAME>General functioning: 4. Social functioning score (PAS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7109051502756396" CI_START="-0.8109051502756393" DF="0" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" MODIFIED="2012-04-30 10:44:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48424920986040376" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="44" WEIGHT="100.0" Z="0.699484646287803">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="1.7109051502756396" CI_START="-0.8109051502756393" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" MEAN_1="8.16" MEAN_2="7.71" MODIFIED="2012-04-11 15:49:46 +0100" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="2.76" SD_2="2.72" SE="0.6433307755762342" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="31" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9602972040078703" CI_START="-1.0802972040078713" DF="0" EFFECT_SIZE="0.4399999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" MODIFIED="2012-04-30 10:44:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5705463267796963" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="37" WEIGHT="100.0" Z="0.5672470822969153">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="1.9602972040078703" CI_START="-1.0802972040078713" EFFECT_SIZE="0.4399999999999995" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.56" MODIFIED="2012-04-11 16:16:45 +0100" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="2.7" SD_2="2.84" SE="0.7756760920097415" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="19" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.009226826142674498" CI_END="0.15477424198551176" CI_START="-0.046435070691193236" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05416958564715926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2012-05-21 09:23:35 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.9234758035892191" P_Q="0.9234758035892191" P_Z="0.29127750837496014" Q="0.00922682614267451" RANDOM="NO" SCALE="0.7874291977214868" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="54" UNITS="" WEIGHT="200.0" Z="1.0553232900952292">
<NAME>General functioning: 5. Social functioning score (SAS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.619621730303372E-33" CI_END="0.21580149918996253" CI_START="-0.09580149918996242" DF="0" EFFECT_SIZE="0.06000000000000006" ESTIMABLE="YES" I2="100.0" ID="CMP-001.17.01" MODIFIED="2012-04-26 12:04:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.4503733621562299" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.7547927310315614">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="0.21580149918996253" CI_START="-0.09580149918996242" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.37" MEAN_2="2.31" MODIFIED="2012-04-26 12:04:47 +0100" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="0.31" SD_2="0.25" SE="0.07949202149575442" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1817553842261879" CI_START="-0.08175538422618825" DF="0" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" MODIFIED="2012-04-26 12:05:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.45700417054635967" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="0.743788952554426">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.1817553842261879" CI_START="-0.08175538422618825" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" MEAN_1="2.32" MEAN_2="2.27" MODIFIED="2012-04-26 12:05:06 +0100" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="0.23" SD_2="0.25" SE="0.06722337005447943" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.18" MODIFIED="2013-01-15 01:44:09 +0000" MODIFIED_BY="[Empty name]" NO="18" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 1. Akathisia (HAS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.18.01" MODIFIED="2012-04-30 12:23:55 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:23:55 +0100" MODIFIED_BY="[Empty name]" ORDER="473" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="3.725163848870329" CI_END="0.31045186494154503" CI_START="0.12215316358601146" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19473745773165183" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-0.5080057269232021" LOG_CI_START="-0.9130952809610619" LOG_EFFECT_SIZE="-0.710550503942132" METHOD="MH" MODIFIED="2012-05-21 09:24:56 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.9937790074108406" P_Q="0.9949326451052114" P_Z="6.165143400741339E-12" Q="3.57458287720002" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="308" WEIGHT="1400.0" Z="6.875780345563821">
<NAME>Adverse effects: 2. Extrapyramidal side effects</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0938370831300013" CI_START="0.06270961678507815" DF="0" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.03895264268620937" LOG_CI_START="-1.20266585316556" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:01:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06621193998076161" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.8369861503297906">
<NAME>hypomimia: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.0938370831300013" CI_START="0.06270961678507815" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03895264268620937" LOG_CI_START="-1.20266585316556" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:01:31 +0100" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.7293328505740071" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.5319264069264069" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.330512525265881" CI_START="0.022913176691376512" DF="0" EFFECT_SIZE="0.1746031746031746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.12401896729646611" LOG_CI_START="-1.6399146958871793" LOG_EFFECT_SIZE="-0.7579478642953567" MODIFIED="2012-04-13 15:01:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0921119271110325" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.684360979308879">
<NAME>hypomimia: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.330512525265881" CI_START="0.022913176691376512" EFFECT_SIZE="0.1746031746031746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12401896729646611" LOG_CI_START="-1.6399146958871793" LOG_EFFECT_SIZE="-0.7579478642953567" MODIFIED="2012-04-13 15:01:40 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="1.0361433653665277" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.0735930735930737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.106165080466761" CI_START="0.014981398530378208" DF="0" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="0.9088154438179327" LOG_CI_START="-1.824447642866484" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2012-04-13 15:03:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5114509562061094" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="0.6565800935750086">
<NAME>rigidity: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="8.106165080466761" CI_START="0.014981398530378208" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9088154438179327" LOG_CI_START="-1.824447642866484" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2012-04-13 15:03:02 +0100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.6055322669889123" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="2.5777338603425557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9292834525095068" CI_START="0.091018718271318" DF="0" EFFECT_SIZE="0.41904761904761906" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.19.04" LOG_CI_END="0.28539603936870833" LOG_CI_START="-1.0408692845362095" LOG_EFFECT_SIZE="-0.3777366225837506" MODIFIED="2012-04-13 15:03:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.26423234355328273" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.1164435389536391">
<NAME>rigidity: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.9292834525095064" CI_START="0.091018718271318" EFFECT_SIZE="0.41904761904761906" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2853960393687082" LOG_CI_START="-1.0408692845362095" LOG_EFFECT_SIZE="-0.3777366225837506" MODIFIED="2012-04-13 15:03:32 +0100" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.7790548163809828" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.6069264069264069" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.156255130476228" CI_START="0.031811682828664346" DF="0" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.19.05" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:03:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2129111051972713" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.2456005476418743">
<NAME>tremor: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:03:52 +0100" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6473556828286111" CI_START="0.026648906010382792" DF="0" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.19.06" LOG_CI_END="0.21678737841234125" LOG_CI_START="-1.5743206149078048" LOG_EFFECT_SIZE="-0.6787666182477319" MODIFIED="2012-04-13 15:03:59 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.13740768038674603" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.4855141405600456">
<NAME>tremor: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.6473556828286111" CI_START="0.026648906010382792" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21678737841234125" LOG_CI_START="-1.5743206149078048" LOG_EFFECT_SIZE="-0.6787666182477319" MODIFIED="2012-04-13 15:03:59 +0100" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="1.0521057014038118" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.1069264069264069" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3443796738917988" CI_START="0.004810626819534818" DF="0" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-001.19.07" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:04:18 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.07942650546531799" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.754023354374729">
<NAME>akathisia: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.3443796738917988" CI_START="0.004810626819534818" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:04:18 +0100" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="1.436980635750546" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="2.064913347522043" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.903634190546396E-32" CI_END="0.7593235577294558" CI_START="0.047780921280528514" DF="0" EFFECT_SIZE="0.19047619047619044" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="100.0" ID="CMP-001.19.08" LOG_CI_END="-0.11957312608915716" LOG_CI_START="-1.3207454807227568" LOG_EFFECT_SIZE="-0.720159303405957" MODIFIED="2012-04-13 15:04:21 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.01876427771800993" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.3501811249022344">
<NAME>akathisia: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.7593235577294561" CI_START="0.047780921280528514" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11957312608915698" LOG_CI_START="-1.3207454807227568" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2012-04-13 15:04:21 +0100" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.7055745870108262" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.4978354978354979" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1149039925532027" CI_START="0.020089689359633504" DF="0" EFFECT_SIZE="0.14965986394557823" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-001.19.09" LOG_CI_END="0.047237470702949536" LOG_CI_START="-1.6970267785548891" LOG_EFFECT_SIZE="-0.8248946539259698" MODIFIED="2012-04-13 15:04:42 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.0637669120247977" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.8538060542402843">
<NAME>gait abnormality: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.1149039925532027" CI_START="0.020089689359633504" EFFECT_SIZE="0.14965986394557823" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.047237470702949536" LOG_CI_START="-1.6970267785548891" LOG_EFFECT_SIZE="-0.8248946539259698" MODIFIED="2012-04-13 15:04:42 +0100" MODIFIED_BY="[Empty name]" ORDER="545" O_E="0.0" SE="1.0245894542613396" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.0497835497835497" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3443796738917988" CI_START="0.004810626819534818" DF="0" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-001.19.10" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:04:49 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.07942650546531799" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.754023354374729">
<NAME>gait abnormality: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.3443796738917988" CI_START="0.004810626819534818" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:04:49 +0100" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="1.436980635750546" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="2.064913347522043" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5408044221997768" CI_START="0.07914377228482253" DF="0" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-001.19.11" LOG_CI_END="0.18774751623308447" LOG_CI_START="-1.1015832534958354" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2012-04-13 15:05:22 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.1647844791409474" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.3891587596231592">
<NAME>global parkinsonism: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.5408044221997768" CI_START="0.07914377228482253" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18774751623308447" LOG_CI_START="-1.1015832534958354" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2012-04-13 15:05:22 +0100" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.75735927642901" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.5735930735930737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9589502792763" CI_START="0.017882601890516304" DF="0" EFFECT_SIZE="0.13095238095238096" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-001.19.12" LOG_CI_END="-0.018203910030305873" LOG_CI_START="-1.7475692917770074" LOG_EFFECT_SIZE="-0.8828866009036566" MODIFIED="2012-04-13 15:05:30 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.0453679832636189" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.001226529070893">
<NAME>global parkinsonism: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.9589502792763" CI_START="0.017882601890516304" EFFECT_SIZE="0.13095238095238096" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.018203910030305873" LOG_CI_START="-1.7475692917770074" LOG_EFFECT_SIZE="-0.8828866009036566" MODIFIED="2012-04-13 15:05:30 +0100" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="1.015837785734714" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.031926406926407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5544286734768364E-31" CI_END="0.7290702306815794" CI_START="0.08016655323232245" DF="0" EFFECT_SIZE="0.24175824175824173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="100.00000000000001" ID="CMP-001.19.13" LOG_CI_END="-0.13723063446890355" LOG_CI_START="-1.0960067885288713" LOG_EFFECT_SIZE="-0.6166187114988874" MODIFIED="2012-04-13 15:05:42 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Z="0.011701274758900532" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.5210273776911714">
<NAME>global non-liveliness: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="0.7290702306815795" CI_START="0.08016655323232245" EFFECT_SIZE="0.24175824175824176" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.13723063446890346" LOG_CI_START="-1.0960067885288713" LOG_EFFECT_SIZE="-0.6166187114988874" MODIFIED="2012-04-13 15:05:42 +0100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.5631898589133305" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.31718281718281716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6138582221646011" CI_START="0.012415842730755198" DF="0" EFFECT_SIZE="0.0873015873015873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-001.19.14" LOG_CI_END="-0.21193192273760775" LOG_CI_START="-1.9060237971810678" LOG_EFFECT_SIZE="-1.0589778599593378" MODIFIED="2012-04-13 15:05:49 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="0.014271766841632401" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.450349355022391">
<NAME>global non-liveliness: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.6138582221646011" CI_START="0.012415842730755198" EFFECT_SIZE="0.0873015873015873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.21193192273760775" LOG_CI_START="-1.9060237971810678" LOG_EFFECT_SIZE="-1.0589778599593378" MODIFIED="2012-04-13 15:05:49 +0100" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="0.9951179529381129" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.9902597402597402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.20" MODIFIED="2013-01-15 01:45:09 +0000" MODIFIED_BY="[Empty name]" NO="20" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Adverse effects: 3. Extrapyramidal symptoms (EPS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.20.01" MODIFIED="2012-05-16 11:42:39 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by medium term (13-25 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-16 11:42:39 +0100" MODIFIED_BY="[Empty name]" ORDER="488" STUDY_ID="STD-Jolley-1989_x002f_1990">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>1.4</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>2.8</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.20.02" MODIFIED="2012-05-16 11:43:10 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="2">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:19:49 +0100" MODIFIED_BY="[Empty name]" ORDER="489" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-16 11:43:10 +0100" MODIFIED_BY="[Empty name]" ORDER="490" STUDY_ID="STD-Jolley-1989_x002f_1990">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.0225292488579867" CI_END="2.477091036412926" CI_START="0.19704601396770582" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6986421938018776" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="155" I2="50.55695730656819" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.3939419677829567" LOG_CI_START="-0.7054323460271993" LOG_EFFECT_SIZE="-0.1557451891221213" METHOD="MH" MODIFIED="2012-05-21 09:25:06 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.15498120430082085" P_Q="1.0" P_Z="0.5786724578253545" Q="0.0" RANDOM="YES" SCALE="77.66846359300334" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5541260421608573" TOTALS="SUB" TOTAL_1="115" TOTAL_2="231" WEIGHT="100.0" Z="0.5553248927324852">
<NAME>Adverse effects: 4. Need for additional medication</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0225292488579867" CI_END="2.477091036412926" CI_START="0.19704601396770582" DF="1" EFFECT_SIZE="0.6986421938018776" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="155" I2="50.55695730656819" ID="CMP-001.21.01" LOG_CI_END="0.3939419677829567" LOG_CI_START="-0.7054323460271993" LOG_EFFECT_SIZE="-0.1557451891221213" MODIFIED="2012-05-16 12:50:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15498120430082085" P_Z="0.5786724578253545" STUDIES="2" TAU2="0.5541260421608573" TOTAL_1="115" TOTAL_2="231" WEIGHT="100.0" Z="0.5553248927324852">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.8360955943866473" CI_START="0.0313709156408283" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2638952885394375" LOG_CI_START="-1.5034728051162254" LOG_EFFECT_SIZE="-0.619788758288394" MODIFIED="2012-05-16 12:50:53 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.0381607668264958" STUDY_ID="STD-McCreadie-1980" TOTAL_1="15" TOTAL_2="18" VAR="1.0777777777777777" WEIGHT="25.554760581787463"/>
<DICH_DATA CI_END="1.174327702846464" CI_START="0.8655737555506655" EFFECT_SIZE="1.0082" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="150" LOG_CI_END="0.06978930617781062" LOG_CI_START="-0.06269591997354716" LOG_EFFECT_SIZE="0.003546693102131761" MODIFIED="2012-04-17 14:34:28 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.07782247765375383" STUDY_ID="STD-Schooler-1997" TOTAL_1="100" TOTAL_2="213" VAR="0.006056338028169014" WEIGHT="74.44523941821254"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.22" MODIFIED="2013-01-15 01:45:39 +0000" MODIFIED_BY="[Empty name]" NO="22" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 5. Side effects (LUNSERS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.22.01" MODIFIED="2012-05-08 11:09:30 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by medium term (13-25 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-08 11:09:30 +0100" MODIFIED_BY="[Empty name]" ORDER="493" STUDY_ID="STD-Wunderink-2007">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>18.7</P>
</TD>
<TD>
<P>15.3</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.22.02" MODIFIED="2012-05-08 11:09:00 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-08 11:08:29 +0100" MODIFIED_BY="[Empty name]" ORDER="494" STUDY_ID="STD-Wunderink-2007">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>24.5</P>
</TD>
<TD>
<P>36.6</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>22.2</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.23" MODIFIED="2013-01-15 01:46:08 +0000" MODIFIED_BY="[Empty name]" NO="23" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 6. Side effects (UKU, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.23.01" MODIFIED="2012-04-30 12:22:30 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:22:30 +0100" MODIFIED_BY="[Empty name]" ORDER="495" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="3.2234206835111827" CI_END="1.6635893846647858" CI_START="0.5881724607248114" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9891801969378289" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" I2="6.931167397853164" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.22104614047612767" LOG_CI_START="-0.23049531378890092" LOG_EFFECT_SIZE="-0.004724586656386628" METHOD="MH" MODIFIED="2013-05-14 11:13:02 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.35844411036634305" P_Q="0.5192888061970888" P_Z="0.9672838200137017" Q="0.4153056242679489" RANDOM="YES" SCALE="485.8318171582511" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017587717120107958" TOTALS="SUB" TOTAL_1="99" TOTAL_2="109" WEIGHT="200.0" Z="0.041015147561274536">
<NAME>Adverse effects: 7. Tardive dyskinesia</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7885048734193667" CI_START="0.3712168707555011" DF="0" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.25249012787680014" LOG_CI_START="-0.43037229455036236" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2012-05-16 12:24:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6096587808253924" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.5105605883728666">
<NAME>by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.7885048734193667" CI_START="0.3712168707555011" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.25249012787680014" LOG_CI_START="-0.43037229455036236" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2012-05-16 12:24:18 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.4011167671572218" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.16089466089466087" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.689476800211491" CI_END="2.299698234494416" CI_START="0.5751085962858551" DF="2" EFFECT_SIZE="1.150033140183857" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="25.636093985167406" ID="CMP-001.24.02" LOG_CI_END="0.36167085180366815" LOG_CI_START="-0.24025014085017937" LOG_EFFECT_SIZE="0.06071035547674441" MODIFIED="2013-05-14 11:13:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2606080649000456" P_Z="0.6925714189188564" STUDIES="4" TAU2="0.10370041063318375" TOTAL_1="78" TOTAL_2="87" WEIGHT="99.99999999999999" Z="0.3953678694554912">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.7030079387207948" CI_START="0.1857925866380088" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.2312166724691181" LOG_CI_START="-0.7309716189023179" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-05-16 12:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.565194165260439" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="12" TOTAL_2="18" VAR="0.3194444444444444" WEIGHT="29.54371597277563"/>
<DICH_DATA CI_END="11.340674842317624" CI_START="0.5079062824821158" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0546388986110724" LOG_CI_START="-0.2942164151878605" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2012-05-16 13:05:09 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.7923242882669809" STUDY_ID="STD-McCreadie-1980" TOTAL_1="15" TOTAL_2="18" VAR="0.6277777777777778" WEIGHT="17.09042266989818"/>
<DICH_DATA CI_END="2.740904667531958" CI_START="0.6649264462164116" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.43789393043741" LOG_CI_START="-0.1772263934473977" LOG_EFFECT_SIZE="0.13033376849500614" MODIFIED="2012-05-16 12:36:25 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.3613247231446467" STUDY_ID="STD-McCreadie-1982" TOTAL_1="8" TOTAL_2="9" VAR="0.1305555555555556" WEIGHT="53.365861357326175"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-14 11:13:02 +0100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="43" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.25" MODIFIED="2013-01-15 01:47:28 +0000" MODIFIED_BY="[Empty name]" NO="25" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Adverse effects: 8. Tardive dyskinesia (AIMS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.25.01" MODIFIED="2012-04-30 12:20:55 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by medium term (13-25 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:20:55 +0100" MODIFIED_BY="[Empty name]" ORDER="501" STUDY_ID="STD-Remington-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.33</P>
</TD>
<TD>
<P>0.78</P>
</TD>
<TD>
<P>18</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.25.02" MODIFIED="2012-04-30 12:21:09 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-30 12:21:09 +0100" MODIFIED_BY="[Empty name]" ORDER="502" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.378250815420482" CI_START="-1.378250815420482" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2012-05-21 09:25:58 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.2644932776530988" Q="0.0" RANDOM="NO" SCALE="5.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="1.115833854137487">
<NAME>Quality of life: 1. Average score (LQLP, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.378250815420482" CI_START="-1.378250815420482" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.26.01" MODIFIED="2012-04-30 12:30:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2644932776530988" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0" Z="1.115833854137487">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.378250815420482" CI_START="-1.378250815420482" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="5.2" MODIFIED="2012-04-30 12:30:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1032" SD_1="1.0" SD_2="1.2" SE="0.44809538458258025" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3481502790352677" CI_START="-0.34815027903526774" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" MODIFIED="2012-05-21 09:26:03 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="1.0" P_Q="1.0" P_Z="0.24791260942545534" Q="0.0" RANDOM="NO" SCALE="5.616691005747495" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1554343805495317">
<NAME>Quality of life: 2. Average score (QLS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3481502790352677" CI_START="-0.34815027903526774" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.27.01" MODIFIED="2012-05-16 17:10:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24791260942545534" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="1.1554343805495317">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="1.3481502790352677" CI_START="-0.34815027903526774" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="2.9" MODIFIED="2012-05-16 17:10:15 +0100" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="1.1" SD_2="1.1" SE="0.4327376858581938" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00466889470046194" CI_END="2.016998319477301" CI_START="-3.571870174279803" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7774359274012511" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2012-05-21 09:26:09 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.9455234921376476" P_Q="0.9455234921376476" P_Z="0.5855616212003699" Q="0.00466889470046194" RANDOM="NO" SCALE="15.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="126" UNITS="" WEIGHT="200.0" Z="0.5452790380364142">
<NAME>Quality of life: 3. Average score (WHOQoL-Bref, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.8696636862232756" CI_START="-4.269663686223281" DF="0" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.01" MODIFIED="2012-05-08 10:59:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7007243379964612" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.384342870862885">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="2.8696636862232756" CI_START="-4.269663686223281" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" MEAN_1="89.6" MEAN_2="90.3" MODIFIED="2012-05-08 10:59:40 +0100" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="10.7" SD_2="9.9" SE="1.821290449406382" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5909440134700734" CI_START="-5.390944013470056" DF="0" EFFECT_SIZE="-0.8999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-001.28.02" MODIFIED="2012-05-08 11:00:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6944795777908159" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="0.3927832502020101">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="3.5909440134700734" CI_START="-5.390944013470056" EFFECT_SIZE="-0.8999999999999915" ESTIMABLE="YES" MEAN_1="96.9" MEAN_2="97.8" MODIFIED="2012-05-08 11:00:04 +0100" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="12.6" SD_2="13.3" SE="2.2913400699676414" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="31.245590192129765" CI_END="2.2393835875891126" CI_START="1.1829757781804895" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6276168290395767" ESTIMABLE="YES" EVENTS_1="310" EVENTS_2="139" I2="58.39412883526047" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.3501284909460389" LOG_CI_START="0.07297585239610581" LOG_EFFECT_SIZE="0.21155217167107232" METHOD="MH" MODIFIED="2012-05-17 10:11:56 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.0031036409452258606" P_Q="0.5016518606027245" P_Z="0.0027706265746875428" Q="1.3796980186589805" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1633217147241908" TOTALS="YES" TOTAL_1="649" TOTAL_2="533" WEIGHT="100.00000000000001" Z="2.992103120474779">
<NAME>Leaving the study early/ loss to follow-up</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.08190891390962" CI_START="0.04153698100234844" DF="0" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.29.01" LOG_CI_END="0.6108633093884327" LOG_CI_START="-1.3815650721164667" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2012-04-12 10:52:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44836476511609336" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="1.7288263102095662" Z="0.7581440375927344">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="4.08190891390962" CI_START="0.04153698100234844" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6108633093884327" LOG_CI_START="-1.3815650721164667" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2012-04-12 10:52:32 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.1703622939755296" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" VAR="1.3697478991596639" WEIGHT="1.7288263102095662"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.686800822467465" CI_END="7.81680929681277" CI_START="0.2521017142287204" DF="2" EFFECT_SIZE="1.4037916595868125" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" I2="84.23558446304182" ID="CMP-001.29.02" LOG_CI_END="0.893029516798852" LOG_CI_START="-0.598424201219457" LOG_EFFECT_SIZE="0.1473026577896974" MODIFIED="2012-05-11 09:57:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0017583171909963946" P_Z="0.6986454119495118" STUDIES="3" TAU2="1.918236151612476" TOTAL_1="77" TOTAL_2="78" WEIGHT="15.52108072569227" Z="0.3871496656006743">
<NAME>by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-05-11 09:57:58 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="3.326924357446425"/>
<DICH_DATA CI_END="16.360161984644304" CI_START="2.5824927674711273" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="4" LOG_CI_END="1.2137875993774132" LOG_CI_START="0.4120391139082979" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2012-04-20 15:30:37 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.47095102908356806" STUDY_ID="STD-Olson-1962_x002a_" TOTAL_1="30" TOTAL_2="30" VAR="0.22179487179487178" WEIGHT="6.882100581076995"/>
<DICH_DATA CI_END="2.6365647790076467" CI_START="0.2721376907678665" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42103844618519687" LOG_CI_START="-0.5652113047512454" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2012-04-19 13:35:32 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.5793279857150695" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="0.33562091503267977" WEIGHT="5.31205578716885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.480653626902996" CI_END="2.152595206625927" CI_START="1.2306980174857907" DF="9" EFFECT_SIZE="1.6276346805238404" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="123" I2="45.39051542647306" ID="CMP-001.29.03" LOG_CI_END="0.3329623688587414" LOG_CI_START="0.09015150099904949" LOG_EFFECT_SIZE="0.21155693492889546" MODIFIED="2012-05-17 10:11:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05749789124276228" P_Z="6.369639597644358E-4" STUDIES="10" TAU2="0.07533538302863028" TOTAL_1="555" TOTAL_2="441" WEIGHT="82.75009296409817" Z="3.4153658507569">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.6981746081346563" CI_START="0.35622854605594834" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22998234282825936" LOG_CI_START="-0.44827128167839536" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2012-04-30 10:47:01 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.3984095364447979" STUDY_ID="STD-Carpenter-1987" TOTAL_1="21" TOTAL_2="21" VAR="0.15873015873015872" WEIGHT="8.229764526555135"/>
<DICH_DATA CI_END="4.9273670681299535" CI_START="1.5112976979778532" EFFECT_SIZE="2.7288676236044656" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="11" LOG_CI_END="0.6926149165930084" LOG_CI_START="0.1793500208277591" LOG_EFFECT_SIZE="0.4359824687103838" MODIFIED="2012-04-23 15:28:49 +0100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.30149434047471746" STUDY_ID="STD-Carpenter-1990_x002a_" TOTAL_1="57" TOTAL_2="59" VAR="0.09089883733828487" WEIGHT="10.425636567785757"/>
<DICH_DATA CI_END="9.22043701004002" CI_START="1.3741441687384728" EFFECT_SIZE="3.5595238095238093" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.964751505278271" LOG_CI_START="0.13803229924682495" LOG_EFFECT_SIZE="0.551391902262548" MODIFIED="2012-04-25 15:31:24 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.48561895394894145" STUDY_ID="STD-Gaebel-2011" TOTAL_1="21" TOTAL_2="23" VAR="0.2358257684344641" WEIGHT="6.6401798725904335"/>
<DICH_DATA CI_END="3.7094130454026026" CI_START="1.3751892376292456" EFFECT_SIZE="2.2585714285714285" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" LOG_CI_END="0.5693051949763678" LOG_CI_START="0.13836246485953663" LOG_EFFECT_SIZE="0.3538338299179522" MODIFIED="2012-04-11 16:01:06 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.25313789287154453" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.06407879280744555" WEIGHT="11.655255797951547"/>
<DICH_DATA CI_END="3.133009332159136" CI_START="0.8866165029465304" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4959616884977859" LOG_CI_START="-0.05226418926507314" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-04-12 17:21:21 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.3220305943597653" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.10370370370370369" WEIGHT="9.925688346335933">
<FOOTNOTE>30% of the patients in the intermittent group withdres because of prolonged or frequent relapse</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="76.92616453299082" CI_START="0.1461429229069466" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8860740794586417" LOG_CI_START="-0.835222210870207" LOG_EFFECT_SIZE="0.5254259342942175" MODIFIED="2012-05-16 12:41:13 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-McCreadie-1980" TOTAL_1="16" TOTAL_2="18" VAR="2.5552115583075334" WEIGHT="0.9749415650555843"/>
<DICH_DATA CI_END="2.426597970640073" CI_START="0.3810092253451765" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.38499783006278143" LOG_CI_START="-0.4190645086603421" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2012-04-25 12:12:52 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.47231019793873086" STUDY_ID="STD-McCreadie-1982" TOTAL_1="13" TOTAL_2="15" VAR="0.22307692307692312" WEIGHT="6.859266116847548"/>
<DICH_DATA CI_END="1.8616798649961173" CI_START="1.1818438568141894" EFFECT_SIZE="1.4833121424030515" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="52" LOG_CI_END="0.26990500166195597" LOG_CI_START="0.07256010209227724" LOG_EFFECT_SIZE="0.1712325518771166" MODIFIED="2012-04-25 12:12:49 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.11592137088023695" STUDY_ID="STD-Pietzcker-1993_x002a_" TOTAL_1="242" TOTAL_2="122" VAR="0.013437764226753445" WEIGHT="14.994449517475628"/>
<DICH_DATA CI_END="1.7434090600979935" CI_START="0.6755808836034639" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.2413992985845667" LOG_CI_START="-0.17032264782658862" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2012-04-26 11:05:58 +0100" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.24184750937841676" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="43" TOTAL_2="42" VAR="0.058490217792543375" WEIGHT="11.948911196043404"/>
<DICH_DATA CI_END="128.80616147577632" CI_START="0.3577103603665718" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1099366381086377" LOG_CI_START="-0.44646848119608723" LOG_EFFECT_SIZE="0.8317340784562753" MODIFIED="2012-05-17 10:11:56 +0100" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="1.5016450214890238" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="2.2549377705627704" WEIGHT="1.0959994574571967"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-05-15 09:44:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>INTERMITTENT (EARLY-BASED) versus MAINTENANCE THERAPY</NAME>
<DICH_OUTCOME CHI2="0.5880759695939066" CI_END="4.116785643808652" CI_START="1.322498890033902" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.6145582543828" LOG_CI_START="0.1213953162063888" LOG_EFFECT_SIZE="0.36797678529459443" METHOD="MH" MODIFIED="2013-01-21 06:34:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4431642404850622" P_Q="1.0" P_Z="0.003445888996726832" Q="0.0" RANDOM="NO" SCALE="38.82" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="2.9248801582337984">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5880759695939066" CI_END="4.116785643808652" CI_START="1.322498890033902" DF="1" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.6145582543828" LOG_CI_START="0.1213953162063888" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2013-01-21 06:34:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4431642404850622" P_Z="0.003445888996726832" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="2.9248801582337984">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="4.1070038258056885" CI_START="0.8905899300647625" EFFECT_SIZE="1.9125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6135251074130694" LOG_CI_START="-0.05032221976175894" LOG_EFFECT_SIZE="0.2816014438256552" MODIFIED="2012-04-11 16:38:58 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.3899472060797612" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.15205882352941175" WEIGHT="61.30268199233717"/>
<DICH_DATA CI_END="7.090456930116108" CI_START="1.2693117084984007" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8506742233119523" LOG_CI_START="0.10356828612737265" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-21 06:34:43 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.43885372573625553" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.1925925925925926" WEIGHT="38.69731800766284">
<FOOTNOTE>by 2 years</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5136596913384217" CI_END="2.1127520012310472" CI_START="1.3606064580561692" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6954716208613043" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="97" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3248485217480517" LOG_CI_START="0.13373252798828658" LOG_EFFECT_SIZE="0.22929052486816912" METHOD="MH" MODIFIED="2013-01-21 06:11:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6213218907973194" P_Q="0.41754481113941955" P_Z="2.5647276623579095E-6" Q="0.6572160086736976" RANDOM="NO" SCALE="56.03" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="305" TOTAL_2="421" WEIGHT="200.0" Z="4.702915354146648">
<NAME>Hospitalisation</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.247926780870635" CI_START="0.4722660740725935" DF="0" EFFECT_SIZE="4.08" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="1.5471335776648154" LOG_CI_START="-0.3258132514850554" LOG_EFFECT_SIZE="0.6106601630898799" MODIFIED="2012-05-16 09:59:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.20122727518649441" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="1.2780628983394897">
<NAME>by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="35.247926780870635" CI_START="0.4722660740725935" EFFECT_SIZE="4.08" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5471335776648154" LOG_CI_START="-0.3258132514850554" LOG_EFFECT_SIZE="0.6106601630898799" MODIFIED="2012-05-16 09:59:06 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="1.100178238678963" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="1.2103921568627451" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8045804258781963" CI_END="2.075450197368538" CI_START="1.3349556631476118" DF="4" EFFECT_SIZE="1.664522152017797" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="96" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.31711231648228977" LOG_CI_START="0.12546684205258768" LOG_EFFECT_SIZE="0.22128957926743872" MODIFIED="2013-01-21 06:11:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5910423423129356" P_Z="6.003379701217723E-6" STUDIES="5" TAU2="0.0" TOTAL_1="255" TOTAL_2="370" WEIGHT="100.0" Z="4.526270258234508">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="2.1927748068600104" CI_START="0.6179135522946962" EFFECT_SIZE="1.164021164021164" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.34099403288143654" LOG_CI_START="-0.2090722795835124" LOG_EFFECT_SIZE="0.06596087664896207" MODIFIED="2012-04-23 12:19:18 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.32311167481407166" STUDY_ID="STD-Carpenter-1987" TOTAL_1="21" TOTAL_2="20" VAR="0.1044011544011544" WEIGHT="12.085928522004455"/>
<DICH_DATA CI_END="2.2560608187073528" CI_START="0.9691866620973163" EFFECT_SIZE="1.4786967418546366" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.3533508031450696" LOG_CI_START="-0.013592571234277696" LOG_EFFECT_SIZE="0.16987911595539598" MODIFIED="2012-04-23 16:42:24 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.21554435450942633" STUDY_ID="STD-Carpenter-1990_x002a_" TOTAL_1="57" TOTAL_2="59" VAR="0.04645936876088526" WEIGHT="27.054420455866293"/>
<DICH_DATA CI_END="3.4224156342808483" CI_START="0.6839905640192335" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5343327511762583" LOG_CI_START="-0.16494988954106068" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2012-04-11 16:41:29 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.41076208466225117" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.1687254901960784" WEIGHT="10.383426463453983"/>
<DICH_DATA CI_END="7.568851914749338" CI_START="0.9991607822664673" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8790300083107804" LOG_CI_START="-3.646206502552156E-4" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-01-21 06:11:33 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.5165607581253312" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.26683501683501687" WEIGHT="5.243630364044261"/>
<DICH_DATA CI_END="2.482201132294917" CI_START="1.3263262993243017" EFFECT_SIZE="1.8144444444444445" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="54" LOG_CI_END="0.39483696938942986" LOG_CI_START="0.12265038120525673" LOG_EFFECT_SIZE="0.2587436752973433" MODIFIED="2012-04-17 14:44:33 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.15988374924472454" STUDY_ID="STD-Schooler-1997" TOTAL_1="100" TOTAL_2="213" VAR="0.02556281327254995" WEIGHT="45.232594194631005"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.234455641609705" CI_END="2.0794372165023987" CI_START="0.05462063035328199" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3370165745856354" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.3179458124440726" LOG_CI_START="-1.2626432921609074" LOG_EFFECT_SIZE="-0.47234873985841747" METHOD="MH" MODIFIED="2012-05-17 12:38:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6282395629085809" P_Q="1.0" P_Z="0.24142001615494657" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="1.1714448942715565">
<NAME>Death</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.234455641609705" CI_END="2.0794372165023987" CI_START="0.05462063035328199" DF="1" EFFECT_SIZE="0.3370165745856354" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.3179458124440726" LOG_CI_START="-1.2626432921609074" LOG_EFFECT_SIZE="-0.47234873985841747" MODIFIED="2012-04-13 15:24:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6282395629085809" P_Z="0.24142001615494657" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="1.1714448942715565">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="5.447773390636908" CI_START="0.047744276670361144" EFFECT_SIZE="0.51" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7362190340657451" LOG_CI_START="-1.3210786818698723" LOG_EFFECT_SIZE="-0.2924298239020636" MODIFIED="2012-04-11 16:41:42 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.2084668621285175" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="1.4603921568627451" WEIGHT="44.19889502762431"/>
<DICH_DATA CI_END="3.9804702774957645" CI_START="0.010049063857139322" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5999343853540574" LOG_CI_START="-1.9978743940260948" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2012-04-13 15:24:27 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.5259657363687524" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="2.3285714285714287" WEIGHT="55.80110497237569"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.41753633858439865" CI_END="3.8140631758063606" CI_START="-3.1148473608182785" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3496079074940408" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2012-05-21 09:27:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8115834599613927" P_Q="0.7493987605481606" P_Z="0.8432129163609128" Q="0.10203698448801403" RANDOM="NO" SCALE="27.28" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="93" UNITS="" WEIGHT="200.0" Z="0.19778546822817822">
<NAME>Global state: 1. Average score (GAS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (early)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.4759725741190355" CI_START="-4.775972574119033" DF="0" EFFECT_SIZE="-0.14999999999999858" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" MODIFIED="2012-04-30 15:11:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9493261286036416" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.06355303516623062">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="4.4759725741190355" CI_START="-4.775972574119033" EFFECT_SIZE="-0.14999999999999858" ESTIMABLE="YES" MEAN_1="54.42" MEAN_2="54.57" MODIFIED="2012-04-11 16:42:14 +0100" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="9.74" SD_2="10.51" SE="2.3602334586799123" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="31" TOTAL_2="44" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3154993540963845" CI_END="6.215773751746583" CI_START="-4.240318848248964" DF="1" EFFECT_SIZE="0.9877274517488098" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" MODIFIED="2012-04-30 15:11:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5743251235360335" P_Z="0.711164006803412" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="49" WEIGHT="100.0" Z="0.37029324548445874">
<NAME>long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="16.985229657624124" CI_START="-8.385229657624132" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="42.5" MODIFIED="2012-04-23 12:21:04 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="17.6" SD_2="15.4" SE="6.472174875499551" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="16.985650419769634"/>
<CONT_DATA CI_END="6.048030340531144" CI_START="-5.42803034053114" EFFECT_SIZE="0.3100000000000023" ESTIMABLE="YES" MEAN_1="52.78" MEAN_2="52.47" MODIFIED="2012-04-11 16:42:14 +0100" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="10.19" SD_2="10.72" SE="2.927620295980943" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="19" TOTAL_2="37" WEIGHT="83.01434958023036"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.04198662309114322" CI_END="5.440280345092874" CI_START="1.8685890852698328" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1883614088820833" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.7356212800639479" LOG_CI_START="0.27151380773493916" LOG_EFFECT_SIZE="0.5035675438994435" METHOD="MH" MODIFIED="2013-01-21 06:38:07 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8376453866574814" P_Q="1.0" P_Z="2.1072381642226892E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="4.253214217273062">
<NAME>Global state: 2. Prodromal episodes</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04198662309114322" CI_END="5.440280345092874" CI_START="1.8685890852698328" DF="1" EFFECT_SIZE="3.1883614088820833" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="13" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.7356212800639479" LOG_CI_START="0.27151380773493916" LOG_EFFECT_SIZE="0.5035675438994435" MODIFIED="2013-01-21 06:38:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8376453866574814" P_Z="2.1072381642226892E-5" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="100.0" Z="4.253214217273062">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="7.100403111726087" CI_START="1.5818923647924086" EFFECT_SIZE="3.3514285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.8512830056526707" LOG_CI_START="0.19917692987783656" LOG_EFFECT_SIZE="0.5252299677652537" MODIFIED="2012-04-11 16:42:41 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.3830503368872728" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.1467275605894532" WEIGHT="53.59877488514548"/>
<DICH_DATA CI_END="6.378945350016858" CI_START="1.4108915355382716" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.8047488814594771" LOG_CI_START="0.14949362797984786" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-21 06:38:07 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.3849001794597505" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.14814814814814814" WEIGHT="46.40122511485452"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.0243312270778066E-33" CI_END="0.5287671204299488" CI_START="-0.32876712042994904" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999988" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2012-05-21 09:27:40 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.6475875254360253" Q="0.0" RANDOM="NO" SCALE="1.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.4571162039138369">
<NAME>Mental state: 1. Average score (BPRS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.0243312270778066E-33" CI_END="0.5287671204299488" CI_START="-0.32876712042994904" DF="0" EFFECT_SIZE="0.09999999999999988" ESTIMABLE="YES" I2="100.0" ID="CMP-002.06.01" MODIFIED="2012-05-16 16:54:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.6475875254360253" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="0.4571162039138369">
<NAME>long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.5287671204299488" CI_START="-0.32876712042994904" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.8" MODIFIED="2012-05-16 16:54:28 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="0.5" SD_2="0.6" SE="0.21876275473019363" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.827912095300201" CI_START="-2.6279120953002053" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2012-05-21 09:27:49 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.32968438757511986" Q="0.0" RANDOM="NO" SCALE="39.86" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.9747498173095265">
<NAME>General functioning: 1. Average endpoint (LOFS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (early)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.827912095300201" CI_START="-2.6279120953002053" DF="0" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" MODIFIED="2012-04-30 10:45:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32968438757511986" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="0.9747498173095265">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="7.827912095300201" CI_START="-2.6279120953002053" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" MEAN_1="22.9" MEAN_2="20.3" MODIFIED="2012-04-23 12:22:18 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="7.4" SD_2="6.2" SE="2.6673511026413275" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.846901493023807E-5" CI_END="1.4164627904328184" CI_START="-0.5246135530368775" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4459246186979704" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2012-05-21 09:27:56 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9920825973798154" P_Q="0.9920825973798154" P_Z="0.3678396737451475" Q="9.846901493023807E-5" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="50" TOTAL_2="81" UNITS="" WEIGHT="200.0" Z="0.9005273753483599">
<NAME>General functioning: 2. Social (PAS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7109051502756396" CI_START="-0.8109051502756393" DF="0" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" MODIFIED="2012-04-30 10:45:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48424920986040376" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="44" WEIGHT="100.0" Z="0.699484646287803">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="1.7109051502756396" CI_START="-0.8109051502756393" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" MEAN_1="8.16" MEAN_2="7.71" MODIFIED="2012-04-11 16:43:33 +0100" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="2.76" SD_2="2.72" SE="0.6433307755762342" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="31" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9602972040078703" CI_START="-1.0802972040078713" DF="0" EFFECT_SIZE="0.4399999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.02" MODIFIED="2012-04-30 10:45:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5705463267796963" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="37" WEIGHT="100.0" Z="0.5672470822969153">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="1.9602972040078703" CI_START="-1.0802972040078713" EFFECT_SIZE="0.4399999999999995" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.56" MODIFIED="2012-04-11 16:43:33 +0100" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="2.7" SD_2="2.84" SE="0.7756760920097415" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="19" TOTAL_2="37" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.7251638488703294" CI_END="0.310451864941545" CI_START="0.12215316358601146" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.1947374577316518" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.5080057269232022" LOG_CI_START="-0.9130952809610619" LOG_EFFECT_SIZE="-0.7105505039421322" METHOD="MH" MODIFIED="2012-05-21 09:28:07 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9937790074108406" P_Q="0.9949326451052114" P_Z="6.165143400741295E-12" Q="3.5745828772000205" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="308" WEIGHT="1400.0" Z="6.875780345563822">
<NAME>Adverse effects: 1. Extrapyramidal side effects</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0938370831300013" CI_START="0.06270961678507815" DF="0" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.03895264268620937" LOG_CI_START="-1.20266585316556" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06621193998076161" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.8369861503297906">
<NAME>hypomimia: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.0938370831300013" CI_START="0.06270961678507815" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.03895264268620937" LOG_CI_START="-1.20266585316556" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.7293328505740071" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.5319264069264069" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.330512525265881" CI_START="0.022913176691376512" DF="0" EFFECT_SIZE="0.1746031746031746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.12401896729646611" LOG_CI_START="-1.6399146958871793" LOG_EFFECT_SIZE="-0.7579478642953567" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0921119271110325" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.684360979308879">
<NAME>hypomimia: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.330512525265881" CI_START="0.022913176691376512" EFFECT_SIZE="0.1746031746031746" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12401896729646611" LOG_CI_START="-1.6399146958871793" LOG_EFFECT_SIZE="-0.7579478642953567" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="1.0361433653665277" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.0735930735930737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.106165080466761" CI_START="0.014981398530378208" DF="0" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="0.9088154438179327" LOG_CI_START="-1.824447642866484" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5114509562061094" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="0.6565800935750086">
<NAME>rigidity: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="8.106165080466761" CI_START="0.014981398530378208" EFFECT_SIZE="0.3484848484848485" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9088154438179327" LOG_CI_START="-1.824447642866484" LOG_EFFECT_SIZE="-0.45781609952427577" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.6055322669889123" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="2.5777338603425557" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9292834525095068" CI_START="0.091018718271318" DF="0" EFFECT_SIZE="0.41904761904761906" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.09.04" LOG_CI_END="0.28539603936870833" LOG_CI_START="-1.0408692845362095" LOG_EFFECT_SIZE="-0.3777366225837506" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.26423234355328273" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.1164435389536391">
<NAME>rigidity: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.9292834525095064" CI_START="0.091018718271318" EFFECT_SIZE="0.41904761904761906" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2853960393687082" LOG_CI_START="-1.0408692845362095" LOG_EFFECT_SIZE="-0.3777366225837506" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.7790548163809828" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.6069264069264069" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.156255130476228" CI_START="0.031811682828664346" DF="0" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.09.05" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2129111051972713" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.2456005476418743">
<NAME>tremor: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="2.156255130476228" CI_START="0.031811682828664346" EFFECT_SIZE="0.2619047619047619" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337001457552575" LOG_CI_START="-1.4974133562346084" LOG_EFFECT_SIZE="-0.5818566052396754" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="1.075605135226867" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.156926406926407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6473556828286111" CI_START="0.026648906010382792" DF="0" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-002.09.06" LOG_CI_END="0.21678737841234125" LOG_CI_START="-1.5743206149078048" LOG_EFFECT_SIZE="-0.6787666182477319" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.13740768038674603" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.4855141405600456">
<NAME>tremor: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.6473556828286111" CI_START="0.026648906010382792" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21678737841234125" LOG_CI_START="-1.5743206149078048" LOG_EFFECT_SIZE="-0.6787666182477319" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="1.0521057014038118" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.1069264069264069" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3443796738917988" CI_START="0.004810626819534818" DF="0" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-002.09.07" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.07942650546531799" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.754023354374729">
<NAME>akathisia: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.3443796738917988" CI_START="0.004810626819534818" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="1.436980635750546" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="2.064913347522043" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.903634190546396E-32" CI_END="0.7593235577294558" CI_START="0.047780921280528514" DF="0" EFFECT_SIZE="0.19047619047619044" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="100.0" ID="CMP-002.09.08" LOG_CI_END="-0.11957312608915716" LOG_CI_START="-1.3207454807227568" LOG_EFFECT_SIZE="-0.720159303405957" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.01876427771800993" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.3501811249022344">
<NAME>akathisia: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.7593235577294561" CI_START="0.047780921280528514" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.11957312608915698" LOG_CI_START="-1.3207454807227568" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.7055745870108262" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.4978354978354979" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1149039925532027" CI_START="0.020089689359633504" DF="0" EFFECT_SIZE="0.14965986394557823" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-002.09.09" LOG_CI_END="0.047237470702949536" LOG_CI_START="-1.6970267785548891" LOG_EFFECT_SIZE="-0.8248946539259698" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.0637669120247977" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.8538060542402843">
<NAME>gait abnormality: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.1149039925532027" CI_START="0.020089689359633504" EFFECT_SIZE="0.14965986394557823" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.047237470702949536" LOG_CI_START="-1.6970267785548891" LOG_EFFECT_SIZE="-0.8248946539259698" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="545" O_E="0.0" SE="1.0245894542613396" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.0497835497835497" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3443796738917988" CI_START="0.004810626819534818" DF="0" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-002.09.10" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.07942650546531799" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.754023354374729">
<NAME>gait abnormality: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.3443796738917988" CI_START="0.004810626819534818" EFFECT_SIZE="0.08041958041958042" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12852193760927927" LOG_CI_START="-2.3177983318321798" LOG_EFFECT_SIZE="-1.09463819711145" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="1.436980635750546" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="2.064913347522043" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5408044221997768" CI_START="0.07914377228482253" DF="0" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-002.09.11" LOG_CI_END="0.18774751623308447" LOG_CI_START="-1.1015832534958354" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.1647844791409474" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="1.3891587596231592">
<NAME>global parkinsonism: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.5408044221997768" CI_START="0.07914377228482253" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18774751623308447" LOG_CI_START="-1.1015832534958354" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.75735927642901" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.5735930735930737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9589502792763" CI_START="0.017882601890516304" DF="0" EFFECT_SIZE="0.13095238095238096" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-002.09.12" LOG_CI_END="-0.018203910030305873" LOG_CI_START="-1.7475692917770074" LOG_EFFECT_SIZE="-0.8828866009036566" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.0453679832636189" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.001226529070893">
<NAME>global parkinsonism: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.9589502792763" CI_START="0.017882601890516304" EFFECT_SIZE="0.13095238095238096" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.018203910030305873" LOG_CI_START="-1.7475692917770074" LOG_EFFECT_SIZE="-0.8828866009036566" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="1.015837785734714" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="1.031926406926407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5544286734768364E-31" CI_END="0.7290702306815794" CI_START="0.08016655323232245" DF="0" EFFECT_SIZE="0.24175824175824173" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="100.00000000000001" ID="CMP-002.09.13" LOG_CI_END="-0.13723063446890355" LOG_CI_START="-1.0960067885288713" LOG_EFFECT_SIZE="-0.6166187114988874" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Z="0.011701274758900532" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.5210273776911714">
<NAME>global non-liveliness: by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="0.7290702306815795" CI_START="0.08016655323232245" EFFECT_SIZE="0.24175824175824176" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.13723063446890346" LOG_CI_START="-1.0960067885288713" LOG_EFFECT_SIZE="-0.6166187114988874" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.5631898589133305" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.31718281718281716" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6138582221646011" CI_START="0.012415842730755198" DF="0" EFFECT_SIZE="0.0873015873015873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" ID="CMP-002.09.14" LOG_CI_END="-0.21193192273760775" LOG_CI_START="-1.9060237971810678" LOG_EFFECT_SIZE="-1.0589778599593378" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="0.014271766841632401" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="2.450349355022391">
<NAME>global non-liveliness: by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.6138582221646011" CI_START="0.012415842730755198" EFFECT_SIZE="0.0873015873015873" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.21193192273760775" LOG_CI_START="-1.9060237971810678" LOG_EFFECT_SIZE="-1.0589778599593378" MODIFIED="2012-04-13 15:25:55 +0100" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="0.9951179529381129" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.9902597402597402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.10" MODIFIED="2013-01-15 02:02:04 +0000" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 2. Extrapyramidal symptoms (EPS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.10.01" MODIFIED="2012-05-16 11:43:48 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by medium term (13-25 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-16 11:43:48 +0100" MODIFIED_BY="[Empty name]" ORDER="554" STUDY_ID="STD-Jolley-1989_x002f_1990">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>1.4</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>2.8</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.10.02" MODIFIED="2012-05-16 12:44:27 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-16 12:44:27 +0100" MODIFIED_BY="[Empty name]" ORDER="555" STUDY_ID="STD-Jolley-1989_x002f_1990">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>3.0</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.174327702846464" CI_START="0.8655737555506655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0082" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="150" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.06978930617781062" LOG_CI_START="-0.06269591997354716" LOG_EFFECT_SIZE="0.003546693102131761" METHOD="MH" MODIFIED="2012-05-21 09:28:21 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.9164247253235287" Q="0.0" RANDOM="NO" SCALE="4.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="100" TOTAL_2="213" WEIGHT="100.0" Z="0.10493835345011636">
<NAME>Adverse effects: 3. Need for additional medication</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.174327702846464" CI_START="0.8655737555506655" DF="0" EFFECT_SIZE="1.0082" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="150" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.06978930617781062" LOG_CI_START="-0.06269591997354716" LOG_EFFECT_SIZE="0.003546693102131761" MODIFIED="2012-04-17 14:46:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9164247253235287" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="213" WEIGHT="100.0" Z="0.10493835345011636">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.174327702846464" CI_START="0.8655737555506655" EFFECT_SIZE="1.0082" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="150" LOG_CI_END="0.06978930617781062" LOG_CI_START="-0.06269591997354716" LOG_EFFECT_SIZE="0.003546693102131761" MODIFIED="2012-04-17 14:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.07782247765375383" STUDY_ID="STD-Schooler-1997" TOTAL_1="100" TOTAL_2="213" VAR="0.006056338028169014" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.28817952690218773" CI_END="1.3451122546054415" CI_START="0.37319500221781976" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7085119412124924" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.12875852933575455" LOG_CI_START="-0.42806418090559173" LOG_EFFECT_SIZE="-0.1496528257849186" METHOD="MH" MODIFIED="2012-05-21 09:28:27 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.5913895733785917" P_Q="0.5928694929565168" P_Z="0.29209909929684597" Q="0.2858853775157156" RANDOM="NO" SCALE="485.83" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="33" TOTAL_2="40" WEIGHT="200.0" Z="1.0535279661849823">
<NAME>Adverse effects: 4. Tardive dyskinesia</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.788504873419367" CI_START="0.371216870755501" DF="0" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="0.2524901278768002" LOG_CI_START="-0.4303722945503624" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2012-05-17 09:35:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6096587808253924" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="100.0" Z="0.5105605883728666">
<NAME>by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.7885048734193667" CI_START="0.3712168707555011" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.25249012787680014" LOG_CI_START="-0.43037229455036236" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2012-05-17 09:35:26 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.4011167671572218" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="21" TOTAL_2="22" VAR="0.16089466089466087" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7030079387207948" CI_START="0.1857925866380088" DF="0" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.12.02" LOG_CI_END="0.2312166724691181" LOG_CI_START="-0.7309716189023179" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-04-13 15:26:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3086809259417379" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="18" WEIGHT="100.0" Z="1.01799378031165">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.7030079387207948" CI_START="0.1857925866380088" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.2312166724691181" LOG_CI_START="-0.7309716189023179" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-04-13 15:26:25 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.565194165260439" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="12" TOTAL_2="18" VAR="0.3194444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3481502790352677" CI_START="-0.34815027903526774" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2012-05-21 09:28:32 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.24791260942545534" Q="0.0" RANDOM="NO" SCALE="5.62" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="1.1554343805495317">
<NAME>Quality of life: 1. Average score (QLS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (early)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3481502790352677" CI_START="-0.34815027903526774" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.01" MODIFIED="2012-05-16 17:10:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24791260942545534" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="1.1554343805495317">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="1.3481502790352677" CI_START="-0.34815027903526774" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="2.9" MODIFIED="2012-05-16 17:10:39 +0100" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="1.1" SD_2="1.1" SE="0.4327376858581938" STUDY_ID="STD-Carpenter-1987" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.45273887820372" CI_END="2.3676519574709882" CI_START="1.1748516476850759" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6678248719153896" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="95" I2="57.684221985405046" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.3743178618773428" LOG_CI_START="0.06998303030189876" LOG_EFFECT_SIZE="0.22215044608962078" METHOD="MH" MODIFIED="2012-05-17 12:41:27 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.050727501464474245" P_Q="1.0" P_Z="0.004218179964829683" Q="0.0" RANDOM="YES" SCALE="11.17" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0867246631942176" TOTALS="SUB" TOTAL_1="282" TOTAL_2="280" WEIGHT="100.0" Z="2.8613673382780513">
<NAME>Leaving the study early/ loss to follow-up</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (early)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.45273887820372" CI_END="2.3676519574709882" CI_START="1.1748516476850759" DF="4" EFFECT_SIZE="1.6678248719153896" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="95" I2="57.684221985405046" ID="CMP-002.14.01" LOG_CI_END="0.3743178618773428" LOG_CI_START="0.06998303030189876" LOG_EFFECT_SIZE="0.22215044608962078" MODIFIED="2012-04-23 16:42:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.050727501464474245" P_Z="0.004218179964829683" STUDIES="5" TAU2="0.0867246631942176" TOTAL_1="282" TOTAL_2="280" WEIGHT="100.0" Z="2.8613673382780513">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.6981746081346563" CI_START="0.35622854605594834" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.22998234282825936" LOG_CI_START="-0.44827128167839536" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2012-04-23 12:21:28 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.3984095364447979" STUDY_ID="STD-Carpenter-1987" TOTAL_1="21" TOTAL_2="21" VAR="0.15873015873015872" WEIGHT="13.019879282518566"/>
<DICH_DATA CI_END="4.9273670681299535" CI_START="1.5112976979778532" EFFECT_SIZE="2.7288676236044656" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="11" LOG_CI_END="0.6926149165930084" LOG_CI_START="0.1793500208277591" LOG_EFFECT_SIZE="0.4359824687103838" MODIFIED="2012-04-23 16:42:50 +0100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.30149434047471746" STUDY_ID="STD-Carpenter-1990_x002a_" TOTAL_1="57" TOTAL_2="59" VAR="0.09089883733828487" WEIGHT="17.991944428449592"/>
<DICH_DATA CI_END="3.7094130454026026" CI_START="1.3751892376292456" EFFECT_SIZE="2.2585714285714285" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="14" LOG_CI_END="0.5693051949763678" LOG_CI_START="0.13836246485953663" LOG_EFFECT_SIZE="0.3538338299179522" MODIFIED="2012-04-11 16:44:11 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.25313789287154453" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.06407879280744555" WEIGHT="21.191769973310336"/>
<DICH_DATA CI_END="3.133009332159136" CI_START="0.8866165029465304" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.4959616884977859" LOG_CI_START="-0.05226418926507314" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-04-13 15:27:22 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.3220305943597653" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.10370370370370369" WEIGHT="16.782122342521422">
<FOOTNOTE>30% of the patients in the intermittent group withdres because of prolonged or frequent relapse</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8034339476350825" CI_START="1.093030992036715" EFFECT_SIZE="1.4039975772259237" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="52" LOG_CI_END="0.2561002405257863" LOG_CI_START="0.038632476203780776" LOG_EFFECT_SIZE="0.14736635836478354" MODIFIED="2012-04-04 14:32:32 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.12774164124554072" STUDY_ID="STD-Pietzcker-1993_x002a_" TOTAL_1="127" TOTAL_2="122" VAR="0.01631792690810443" WEIGHT="31.01428397320008"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-05-15 09:44:42 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>INTERMITTENT (CRISIS INTERVENTION) versus MAINTENANCE THERAPY</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0022789311430227" CI_START="1.2324637834167307" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.570903010033445" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.3015245775479753" LOG_CI_START="0.09077416616966323" LOG_EFFECT_SIZE="0.19614937185881928" METHOD="MH" MODIFIED="2012-05-17 12:44:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.6392921608259397E-4" Q="0.0" RANDOM="NO" SCALE="5.09" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="115" TOTAL_2="122" WEIGHT="100.0" Z="3.6483506904604117">
<NAME>Leaving the study early/ loss to follow-up</NAME>
<GROUP_LABEL_1>Crisis intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (crisis)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0022789311430227" CI_START="1.2324637834167307" DF="0" EFFECT_SIZE="1.570903010033445" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="52" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.3015245775479753" LOG_CI_START="0.09077416616966323" LOG_EFFECT_SIZE="0.19614937185881928" MODIFIED="2012-04-12 09:08:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.6392921608259397E-4" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="122" WEIGHT="100.0" Z="3.6483506904604117">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="2.0022789311430227" CI_START="1.2324637834167307" EFFECT_SIZE="1.570903010033445" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="52" LOG_CI_END="0.3015245775479753" LOG_CI_START="0.09077416616966323" LOG_EFFECT_SIZE="0.19614937185881928" MODIFIED="2012-04-04 14:33:41 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.12379583487498184" STUDY_ID="STD-Pietzcker-1993_x002a_" TOTAL_1="115" TOTAL_2="122" VAR="0.015325408732393771" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-05-15 10:40:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>INTERMITTENT (GRADUALLY INCREASED DRUG-FREE PERIODS) versus MAINTENANCE THERAPY</NAME>
<DICH_OUTCOME CHI2="2.854900612376092" CI_END="4.192044444932848" CI_START="1.6871743589340147" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6594566924472516" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.6224258784810999" LOG_CI_START="0.2271599665310472" LOG_EFFECT_SIZE="0.42479292250607353" METHOD="MH" MODIFIED="2012-05-17 12:44:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5823935905883099" P_Q="0.953411066324549" P_Z="2.5227688548389347E-5" Q="0.09541826226804369" RANDOM="NO" SCALE="631.77" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="239" TOTAL_2="236" WEIGHT="300.0" Z="4.212753004132702">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.217111396832962" CI_START="0.31063820230374717" DF="0" EFFECT_SIZE="2.9076923076923076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="1.4348420308237835" LOG_CI_START="-0.5077451357630062" LOG_EFFECT_SIZE="0.46354844753038854" MODIFIED="2012-05-08 10:38:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.34958738230644093" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="0.9353899561123509">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="27.217111396832962" CI_START="0.31063820230374717" EFFECT_SIZE="2.9076923076923076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4348420308237835" LOG_CI_START="-0.5077451357630062" LOG_EFFECT_SIZE="0.46354844753038854" MODIFIED="2012-05-08 10:37:52 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.1410853176146392" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="1.3020757020757021" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.22303716472749" CI_START="0.869509786418459" DF="0" EFFECT_SIZE="2.3261538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.7940023946511705" LOG_CI_START="-0.060725525606506105" LOG_EFFECT_SIZE="0.3666384345223322" MODIFIED="2012-05-08 10:38:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09267236322100512" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.6814663707142754">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="6.22303716472749" CI_START="0.869509786418459" EFFECT_SIZE="2.3261538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7940023946511705" LOG_CI_START="-0.060725525606506105" LOG_EFFECT_SIZE="0.3666384345223322" MODIFIED="2012-05-08 10:38:00 +0100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.5020714113308007" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="0.25207570207570207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8873802477492987" CI_END="4.667546080387713" CI_START="1.6293310186319823" DF="2" EFFECT_SIZE="2.7577123870465226" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="14" I2="30.733058052918665" ID="CMP-004.01.03" LOG_CI_END="0.6690886142181852" LOG_CI_START="0.21200932553688648" LOG_EFFECT_SIZE="0.44054896987753583" MODIFIED="2012-05-17 10:37:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.23605545823438245" P_Z="1.5798922361044741E-4" STUDIES="3" TAU2="0.0" TOTAL_1="109" TOTAL_2="110" WEIGHT="100.0" Z="3.778163376762601">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="172.109750484579" CI_START="0.5600885129602998" EFFECT_SIZE="9.818181818181818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.235805474985875" LOG_CI_START="-0.2517433343284256" LOG_EFFECT_SIZE="0.9920310703287246" MODIFIED="2012-05-15 10:40:08 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="1.461198484156417" STUDY_ID="STD-Gaebel-2011" TOTAL_1="21" TOTAL_2="23" VAR="2.1351010101010104" WEIGHT="3.262328135706856"/>
<DICH_DATA CI_END="61.59870228703997" CI_START="1.1312933193518502" EFFECT_SIZE="8.347826086956522" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7895715628865971" LOG_CI_START="0.05357522248531644" LOG_EFFECT_SIZE="0.9215733926859567" MODIFIED="2012-04-26 12:28:38 +0100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.0197328436721884" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="23" TOTAL_2="24" VAR="1.039855072463768" WEIGHT="6.676098970169929"/>
<DICH_DATA CI_END="3.651449239334383" CI_START="1.1934891522797948" EFFECT_SIZE="2.0875739644970412" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.5624652676694573" LOG_CI_START="0.07681847602275987" LOG_EFFECT_SIZE="0.31964187184610854" MODIFIED="2012-05-17 10:37:47 +0100" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.2852713294036598" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="0.08137973137973138" WEIGHT="90.06157289412322"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9317094330109384" CI_START="-0.3317094330109388" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2012-05-21 09:29:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3519619096525507" Q="0.0" RANDOM="YES" SCALE="6.53" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.9307905892103947">
<NAME>Global state: 1. Average score (CGI-S, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9317094330109384" CI_START="-0.3317094330109388" DF="0" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2012-05-15 10:41:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3519619096525507" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0" Z="0.9307905892103947">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.9317094330109384" CI_START="-0.3317094330109388" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.1" MODIFIED="2012-05-15 10:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="1023" SD_1="0.7" SD_2="0.9" SE="0.3223066535884241" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3607866777582307" CI_END="5.895329865709574" CI_START="-4.585054810053338" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6551375278281182" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2012-05-21 09:29:19 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5480699011382434" P_Q="0.5480699011382433" P_Z="0.8064270514944806" Q="0.36078667775823076" RANDOM="NO" SCALE="38.19" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="54" UNITS="" WEIGHT="200.0" Z="0.24503794453904393">
<NAME>Global state: 2. Average score (GAS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (gradual)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.404580429968606E-33" CI_END="7.335006144072986" CI_START="-10.415006144072999" DF="0" EFFECT_SIZE="-1.5400000000000065" ESTIMABLE="YES" I2="100.0" ID="CMP-004.03.01" MODIFIED="2012-04-30 10:45:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.7337850451837178" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.34009492356322946">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="7.335006144072986" CI_START="-10.415006144072999" EFFECT_SIZE="-1.5400000000000063" ESTIMABLE="YES" MEAN_1="77.83" MEAN_2="79.37" MODIFIED="2012-04-26 12:29:20 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="19.3" SD_2="11.6" SE="4.528147564995025" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.4927681882181675E-33" CI_END="8.322789319930465" CI_START="-4.662789319930468" DF="0" EFFECT_SIZE="1.829999999999998" ESTIMABLE="YES" I2="100.0" ID="CMP-004.03.02" MODIFIED="2012-04-30 10:45:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.5806619611917869" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="0.5524180617871499">
<NAME>long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="8.322789319930465" CI_START="-4.662789319930468" EFFECT_SIZE="1.8299999999999983" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="82.17" MODIFIED="2012-04-26 12:29:20 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="10.21" SD_2="13.38" SE="3.3127084840051957" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.32007790815811754" CI_END="3.184048230183916" CI_START="-1.8924712170094826" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6457885065872169" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2012-05-21 09:29:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5715609562105395" P_Q="0.5715609562105395" P_Z="0.6180207010773662" Q="0.32007790815811754" RANDOM="NO" SCALE="29.75347356400709" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="54" UNITS="" WEIGHT="200.0" Z="0.49865748677102734">
<NAME>Mental state: 1. Average score (BPRS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.733302154004129" CI_START="-3.033302154004126" DF="0" EFFECT_SIZE="1.8500000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" MODIFIED="2012-04-26 12:29:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4577743468674129" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.00000000000001" Z="0.7425166940419552">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="6.733302154004129" CI_START="-3.033302154004126" EFFECT_SIZE="1.8500000000000014" ESTIMABLE="YES" MEAN_1="25.26" MEAN_2="23.41" MODIFIED="2012-04-26 12:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="10.31" SD_2="6.93" SE="2.4915264732020543" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.171164153099063" CI_START="-2.7711641530990643" DF="0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.02" MODIFIED="2012-04-30 10:45:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.895037766638298" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="0.1319323930652376">
<NAME>long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="3.171164153099063" CI_START="-2.7711641530990643" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="22.3" MEAN_2="22.1" MODIFIED="2012-04-26 12:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="5.91" SD_2="4.77" SE="1.515927933643285" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.09297837316228659" CI_END="0.2999940222364327" CI_START="-2.222941175554252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9614735766589096" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2012-05-21 09:29:32 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7604243953150834" P_Q="0.7604243953150833" P_Z="0.13521271362856752" Q="0.09297837316228663" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="126" UNITS="" WEIGHT="200.0" Z="1.4938580935321493">
<NAME>Mental state: 2. Negative symptom score (PANSS negative symptom subscale, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.774356763590305E-32" CI_END="0.8335703706337515" CI_START="-2.4335703706337526" DF="0" EFFECT_SIZE="-0.8000000000000006" ESTIMABLE="YES" I2="100.0" ID="CMP-004.05.01" MODIFIED="2012-05-08 11:13:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.3371342176457278" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.9598430626675372">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="0.8335703706337514" CI_START="-2.4335703706337526" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="13.3" MODIFIED="2012-05-08 11:13:01 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="4.4" SD_2="5.0" SE="0.8334695859307348" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7854335812110498" CI_START="-3.185433581211052" DF="0" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" MODIFIED="2012-05-08 11:13:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.23617323521418887" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.1846061251837239">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.7854335812110498" CI_START="-3.185433581211052" EFFECT_SIZE="-1.200000000000001" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="13.3" MODIFIED="2012-05-08 11:13:01 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="5.2" SD_2="6.2" SE="1.0129949309639859" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.06" MODIFIED="2013-01-15 02:07:41 +0000" MODIFIED_BY="[Empty name]" NO="6" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 3. Negative symptom score (PANSS negative symptom subscale, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.06.01" MODIFIED="2012-05-15 10:41:59 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-15 10:41:59 +0100" MODIFIED_BY="[Empty name]" ORDER="578" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>9.1</P>
</TD>
<TD>
<P>2.8</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.07" MODIFIED="2013-01-15 02:08:24 +0000" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Mental state: 4. Negative symptom score (SANS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.07.01" MODIFIED="2012-05-15 10:41:59 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-15 10:41:59 +0100" MODIFIED_BY="[Empty name]" ORDER="579" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>17.6</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>9.7</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="2.9949182964010537" CI_END="0.21852428523238016" CI_START="-1.0907962439477858" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4361359793577028" ESTIMABLE="YES" I2="33.220214975367824" I2_Q="63.28556682190075" ID="CMP-004.08" MODIFIED="2012-05-21 09:30:24 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.22369788870736684" P_Q="0.0988671499915007" P_Z="0.19164373500656987" Q="2.72372446865533" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="145" UNITS="" WEIGHT="200.0" Z="1.3057319317194909">
<NAME>Mental state: 5. Positive symptom score (PANSS positive symptom subscale, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.015583763144736418" CI_START="-1.5844162368552615" DF="0" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" I2="0.0" ID="CMP-004.08.01" MODIFIED="2012-05-08 10:53:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04561895790852645" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.9989020037602272">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="-0.015583763144736418" CI_START="-1.5844162368552615" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="9.6" MODIFIED="2012-05-08 10:53:39 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="1.7" SD_2="2.7" SE="0.4002197198737516" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.27119382774572337" CI_END="1.5873894736497232" CI_START="-0.7893793003733969" DF="1" EFFECT_SIZE="0.39900508663816314" ESTIMABLE="YES" I2="0.0" ID="CMP-004.08.02" MODIFIED="2012-05-15 10:43:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6025321169127799" P_Z="0.5104955968640796" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="82" WEIGHT="100.00000000000001" Z="0.658066201480209">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="3.128814214170191" CI_START="-1.3288142141701922" EFFECT_SIZE="0.8999999999999995" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="7.2" MODIFIED="2012-05-15 10:43:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1024" SD_1="3.2" SD_2="0.5" SE="1.1371710050545794" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="28.429298091166256"/>
<CONT_DATA CI_END="1.6047184906553784" CI_START="-1.2047184906553798" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="11.0" MEAN_2="10.8" MODIFIED="2012-05-08 10:53:39 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="4.3" SD_2="3.8" SE="0.7167062771232631" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="71.57070190883375"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.083038333088048" CI_START="-15.916961666911952" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2012-05-21 09:32:19 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.01076593418038009" Q="0.0" RANDOM="NO" SCALE="55.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="2.5502058143883928">
<NAME>General functioning: 1. Social functioning score (GAF, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (gradual)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.083038333088048" CI_START="-15.916961666911952" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.09.01" MODIFIED="2012-05-15 10:43:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01076593418038009" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0" Z="2.5502058143883928">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="-2.083038333088048" CI_START="-15.916961666911952" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="71.8" MEAN_2="80.8" MODIFIED="2012-05-15 10:43:49 +0100" MODIFIED_BY="[Empty name]" ORDER="1027" SD_1="8.0" SD_2="9.2" SE="3.5291269234904634" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.10" MODIFIED="2013-01-15 02:11:13 +0000" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>General functioning: 2. Social functioning score (GSDS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.10.01" MODIFIED="2012-05-08 11:13:48 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-08 11:13:48 +0100" MODIFIED_BY="[Empty name]" ORDER="584" STUDY_ID="STD-Wunderink-2007">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>4.5</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>6.4</P>
</TD>
<TD>
<P>4.2</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.009226826142674498" CI_END="0.15477424198551176" CI_START="-0.046435070691193236" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05416958564715926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.11" MODIFIED="2012-05-21 09:32:45 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9234758035892191" P_Q="0.9234758035892191" P_Z="0.29127750837496014" Q="0.00922682614267451" RANDOM="NO" SCALE="0.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="54" UNITS="" WEIGHT="200.0" Z="1.0553232900952292">
<NAME>General functioning: 3. Social functioning score (SAS, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.619621730303372E-33" CI_END="0.21580149918996253" CI_START="-0.09580149918996242" DF="0" EFFECT_SIZE="0.06000000000000006" ESTIMABLE="YES" I2="100.0" ID="CMP-004.11.01" MODIFIED="2012-04-26 12:33:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.4503733621562299" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.7547927310315614">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="0.21580149918996253" CI_START="-0.09580149918996242" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.37" MEAN_2="2.31" MODIFIED="2012-04-26 12:33:16 +0100" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="0.31" SD_2="0.25" SE="0.07949202149575442" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1817553842261879" CI_START="-0.08175538422618825" DF="0" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.02" MODIFIED="2012-04-26 12:33:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.45700417054635967" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0" Z="0.743788952554426">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.1817553842261879" CI_START="-0.08175538422618825" EFFECT_SIZE="0.04999999999999982" ESTIMABLE="YES" MEAN_1="2.32" MEAN_2="2.27" MODIFIED="2012-04-26 12:33:16 +0100" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="0.23" SD_2="0.25" SE="0.06722337005447943" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="24" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.12" MODIFIED="2013-01-15 02:14:47 +0000" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 1. Akathisia (HAS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.12.01" MODIFIED="2012-05-15 10:44:29 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-15 10:44:29 +0100" MODIFIED_BY="[Empty name]" ORDER="587" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.13" MODIFIED="2013-01-15 02:15:26 +0000" MODIFIED_BY="[Empty name]" NO="13" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 2. Extrapyramidal symptoms (EPS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.13.02" MODIFIED="2012-05-15 10:45:20 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-15 10:45:02 +0100" MODIFIED_BY="[Empty name]" ORDER="588" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.14" MODIFIED="2013-01-15 02:15:31 +0000" MODIFIED_BY="[Empty name]" NO="14" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 3. Side effects (LUNSERS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.14.01" MODIFIED="2012-05-08 11:13:17 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by medium term (13-25 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-08 11:13:17 +0100" MODIFIED_BY="[Empty name]" ORDER="589" STUDY_ID="STD-Wunderink-2007">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>18.7</P>
</TD>
<TD>
<P>15.3</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>20.3</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-004.14.02" MODIFIED="2012-05-08 11:13:17 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-08 11:13:17 +0100" MODIFIED_BY="[Empty name]" ORDER="590" STUDY_ID="STD-Wunderink-2007">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>24.5</P>
</TD>
<TD>
<P>36.6</P>
</TD>
<TD>
<P>65</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>22.2</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.15" MODIFIED="2013-01-15 02:16:32 +0000" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 4. Side effects (UKU, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.15.01" MODIFIED="2012-05-15 10:45:57 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-15 10:45:57 +0100" MODIFIED_BY="[Empty name]" ORDER="591" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-05-21 09:35:57 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="485.8318171582511" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 5. Tardive dyskinesia</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-04-30 10:45:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-26 12:33:34 +0100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="43" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-004.17" MODIFIED="2013-01-15 02:17:11 +0000" MODIFIED_BY="[Empty name]" NO="17" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 6. Tardive dyskinesia (AIMS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.17.02" MODIFIED="2012-05-15 10:46:50 +0100" MODIFIED_BY="[Empty name]" NO="2" STUDIES="1">
<NAME>by long term (&#8805;26 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-05-15 10:46:50 +0100" MODIFIED_BY="[Empty name]" ORDER="593" STUDY_ID="STD-Gaebel-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.378250815420482" CI_START="-1.378250815420482" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.18" MODIFIED="2012-05-21 09:36:06 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.2644932776530988" Q="0.0" RANDOM="NO" SCALE="5.72" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="1.115833854137487">
<NAME>Quality of life: 1. Average score (LQLP, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (gradual)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.378250815420482" CI_START="-1.378250815420482" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-004.18.01" MODIFIED="2012-05-15 10:47:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2644932776530988" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0" Z="1.115833854137487">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="0.378250815420482" CI_START="-1.378250815420482" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="5.2" MODIFIED="2012-05-15 10:47:40 +0100" MODIFIED_BY="[Empty name]" ORDER="1032" SD_1="1.0" SD_2="1.2" SE="0.44809538458258025" STUDY_ID="STD-Gaebel-2011" TOTAL_1="8" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00466889470046194" CI_END="2.016998319477301" CI_START="-3.571870174279803" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7774359274012511" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.19" MODIFIED="2012-05-21 09:36:12 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.9455234921376476" P_Q="0.9455234921376476" P_Z="0.5855616212003699" Q="0.00466889470046194" RANDOM="NO" SCALE="15.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="126" UNITS="" WEIGHT="200.0" Z="0.5452790380364142">
<NAME>Quality of life: 2. Average score (WHOQoL-Bref, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (gradual)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.8696636862232756" CI_START="-4.269663686223281" DF="0" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-004.19.01" MODIFIED="2012-05-08 11:14:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7007243379964612" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.384342870862885">
<NAME>by medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="2.8696636862232756" CI_START="-4.269663686223281" EFFECT_SIZE="-0.7000000000000028" ESTIMABLE="YES" MEAN_1="89.6" MEAN_2="90.3" MODIFIED="2012-05-08 11:14:31 +0100" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="10.7" SD_2="9.9" SE="1.821290449406382" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.5909440134700734" CI_START="-5.390944013470056" DF="0" EFFECT_SIZE="-0.8999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-004.19.02" MODIFIED="2012-05-08 11:14:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6944795777908159" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="0.3927832502020101">
<NAME>by long term (&#8805;26 weeks)</NAME>
<CONT_DATA CI_END="3.5909440134700734" CI_START="-5.390944013470056" EFFECT_SIZE="-0.8999999999999915" ESTIMABLE="YES" MEAN_1="96.9" MEAN_2="97.8" MODIFIED="2012-05-08 11:14:31 +0100" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="12.6" SD_2="13.3" SE="2.2913400699676414" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.328674350219587" CI_END="6.367005916709366" CI_START="0.7029848071926414" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1156342847364575" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="22" I2="68.3978051433377" I2_Q="0.0" ID="CMP-004.20" LOG_CI_END="0.8039352534437122" LOG_CI_START="-0.15305406078913633" LOG_EFFECT_SIZE="0.325440596327288" METHOD="MH" MODIFIED="2012-05-17 13:08:23 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.04224217764126814" P_Q="1.0" P_Z="0.1825191368735791" Q="0.0" RANDOM="YES" SCALE="485.83" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.575167126921043" TOTALS="SUB" TOTAL_1="129" TOTAL_2="128" WEIGHT="100.0" Z="1.3330386001646086">
<NAME>Leaving the study early/ loss to follow-up</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (gradual)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.328674350219587" CI_END="6.367005916709366" CI_START="0.7029848071926414" DF="2" EFFECT_SIZE="2.1156342847364575" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="22" I2="68.3978051433377" ID="CMP-004.20.01" LOG_CI_END="0.8039352534437122" LOG_CI_START="-0.15305406078913633" LOG_EFFECT_SIZE="0.325440596327288" MODIFIED="2012-05-17 10:14:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04224217764126814" P_Z="0.1825191368735791" STUDIES="3" TAU2="0.575167126921043" TOTAL_1="129" TOTAL_2="128" WEIGHT="100.0" Z="1.3330386001646086">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="9.22043701004002" CI_START="1.3741441687384728" EFFECT_SIZE="3.5595238095238093" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.964751505278271" LOG_CI_START="0.13803229924682495" LOG_EFFECT_SIZE="0.551391902262548" MODIFIED="2012-05-15 10:48:04 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.48561895394894145" STUDY_ID="STD-Gaebel-2011" TOTAL_1="21" TOTAL_2="23" VAR="0.2358257684344641" WEIGHT="38.96478922570664"/>
<DICH_DATA CI_END="1.7434090600979935" CI_START="0.6755808836034639" EFFECT_SIZE="1.0852713178294573" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.2413992985845667" LOG_CI_START="-0.17032264782658862" LOG_EFFECT_SIZE="0.03553832537898904" MODIFIED="2012-04-26 12:33:56 +0100" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.24184750937841676" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="43" TOTAL_2="42" VAR="0.058490217792543375" WEIGHT="49.869487814989654"/>
<DICH_DATA CI_END="128.80616147577632" CI_START="0.3577103603665718" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1099366381086377" LOG_CI_START="-0.44646848119608723" LOG_EFFECT_SIZE="0.8317340784562753" MODIFIED="2012-05-17 10:14:45 +0100" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="1.5016450214890238" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="2.2549377705627704" WEIGHT="11.16572295930371"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-05-15 09:45:03 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>INTERMITTENT (DRUG HOLIDAY) versus MAINTENANCE THERAPY</NAME>
<DICH_OUTCOME CHI2="1.6918091359345704" CI_END="2.649950823661807" CI_START="1.292072369604818" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.850385970565317" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.4232378146120976" LOG_CI_START="0.11128683938647746" LOG_EFFECT_SIZE="0.26726232699928754" METHOD="MH" MODIFIED="2013-05-14 15:56:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9457518883828244" P_Q="0.7372270530595265" P_Z="7.840152239366551E-4" Q="0.6097188145826271" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="301" TOTAL_2="301" WEIGHT="300.0" Z="3.3583772896629775">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (holiday)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.02989390640800524" CI_END="2.6982394866584984" CI_START="0.9427995719907479" DF="1" EFFECT_SIZE="1.5949605114704777" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.4310804935636284" LOG_CI_START="-0.025580623307343217" LOG_EFFECT_SIZE="0.2027499351281426" MODIFIED="2013-05-14 15:56:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.862731211079763" P_Z="0.08179182819963313" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="132" WEIGHT="99.99999999999999" Z="1.7403827741755">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="2.7188323904830174" CI_START="0.8784762754874332" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4343824351961736" LOG_CI_START="-0.056269962756075785" LOG_EFFECT_SIZE="0.18905623622004888" MODIFIED="2013-01-21 06:12:58 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.2882116473256918" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.08306595365418895" WEIGHT="73.22301617149303"/>
<DICH_DATA CI_END="5.702648095864593" CI_START="0.5250308901101693" EFFECT_SIZE="1.7303370786516854" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7560765725776436" LOG_CI_START="-0.27981514419454295" LOG_EFFECT_SIZE="0.2381307141915503" MODIFIED="2012-05-10 11:32:52 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.6084879221786795" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="88" VAR="0.37025755143732675" WEIGHT="26.776983828506957"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-05-14 15:56:25 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.0" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.054850234122735" CI_END="3.684202657168364" CI_START="1.248947571617465" DF="2" EFFECT_SIZE="2.1450818077679554" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.5663435114458832" LOG_CI_START="0.09654420792166954" LOG_EFFECT_SIZE="0.3314438596837764" MODIFIED="2013-01-21 06:14:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5901226045418242" P_Z="0.005683334918180683" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="136" WEIGHT="99.99999999999999" Z="2.765512945651557">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="3.749267815044464" CI_START="0.9376830819855172" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5739464637455769" LOG_CI_START="-0.027943919618101734" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2013-01-21 06:14:12 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.125" WEIGHT="53.55869194025979"/>
<DICH_DATA CI_END="9.474271020259568" CI_START="1.08994918004535" EFFECT_SIZE="3.2134831460674156" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9765458039637874" LOG_CI_START="0.03740624900447311" LOG_EFFECT_SIZE="0.5069760264841302" MODIFIED="2012-04-12 12:46:05 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.5516552233988733" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="88" VAR="0.3043234855032608" WEIGHT="26.930641710074134"/>
<DICH_DATA CI_END="5.403400157551767" CI_START="0.36885655821539853" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7326671311115547" LOG_CI_START="-0.43314249044489045" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2012-04-19 15:19:18 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="19.510666349666067"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10252482521775086" CI_END="5.377605515243795" CI_START="0.5373431102871142" DF="1" EFFECT_SIZE="1.6998880179171334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.730588940535756" LOG_CI_START="-0.26974831519392567" LOG_EFFECT_SIZE="0.23042031267091517" MODIFIED="2013-01-21 07:40:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.748820557064878" P_Z="0.3665649093272084" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.9029265111435394">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="5.710927782353705" CI_START="0.3939815185463059" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7567066683203335" LOG_CI_START="-0.404524150208971" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-01-21 07:40:41 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.6821127309893708" STUDY_ID="STD-McCreadie-1980" TOTAL_1="16" TOTAL_2="18" VAR="0.4652777777777777" WEIGHT="75.25195968645018"/>
<DICH_DATA CI_END="22.62194860474717" CI_START="0.23541048032726553" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.354530011369287" LOG_CI_START="-0.6281742065436359" LOG_EFFECT_SIZE="0.3631779024128256" MODIFIED="2012-05-15 10:57:47 +0100" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-McCreadie-1982" TOTAL_1="13" TOTAL_2="15" VAR="1.3564102564102565" WEIGHT="24.748040313549833"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1372282551634014" CI_START="0.03278508225921429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.32985090712626963" LOG_CI_START="-1.4843237223321302" LOG_EFFECT_SIZE="-0.5772364076029303" METHOD="MH" MODIFIED="2012-05-17 12:48:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.21230671083036567" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0" Z="1.2472477027250468">
<NAME>Hospitalisation</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (holiday)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1372282551634014" CI_START="0.03278508225921429" DF="0" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.32985090712626963" LOG_CI_START="-1.4843237223321302" LOG_EFFECT_SIZE="-0.5772364076029303" MODIFIED="2012-05-15 12:19:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21230671083036567" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0" Z="1.2472477027250468">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="2.1372282551634014" CI_START="0.03278508225921429" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32985090712626963" LOG_CI_START="-1.4843237223321302" LOG_EFFECT_SIZE="-0.5772364076029303" MODIFIED="2012-05-15 12:19:29 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.0656551576531124" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="1.1356209150326797" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.240905791115129" CI_START="-1.080905791115129" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2012-05-21 09:37:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2129331931924816" Q="0.0" RANDOM="NO" SCALE="1.8870482054118094" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.245540415250235">
<NAME>Global state: 1. Average score (CGI-S, high = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (holiday)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.240905791115129" CI_START="-1.080905791115129" DF="0" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.01" MODIFIED="2012-04-19 15:34:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2129331931924816" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0" Z="1.245540415250235">
<NAME>medium term (13-25 weeks)</NAME>
<CONT_DATA CI_END="0.240905791115129" CI_START="-1.080905791115129" EFFECT_SIZE="-0.41999999999999993" ESTIMABLE="YES" MEAN_1="2.83" MEAN_2="3.25" MODIFIED="2012-04-19 15:34:08 +0100" MODIFIED_BY="[Empty name]" ORDER="390" SD_1="0.84" SD_2="1.14" SE="0.3372030283863731" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7855590876847417E-31" CI_END="-1.5501708542620216" CI_START="-5.669829145737976" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.609999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2012-05-21 09:38:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="5.925996164510572E-4" Q="0.0" RANDOM="NO" SCALE="13.11" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="3.4349790606806163">
<NAME>Global state: 2. Average score (GAS, low = worse)</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (holiday)</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7855590876847417E-31" CI_END="-1.5501708542620216" CI_START="-5.669829145737976" DF="0" EFFECT_SIZE="-3.609999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-005.04.01" MODIFIED="2012-04-12 10:56:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="5.925996164510572E-4" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="3.4349790606806163">
<NAME>short term (&#8804;12 weeks)</NAME>
<CONT_DATA CI_END="-1.550170854262022" CI_START="-5.669829145737976" EFFECT_SIZE="-3.6099999999999994" ESTIMABLE="YES" MEAN_1="63.56" MEAN_2="67.17" MODIFIED="2012-04-12 10:56:46 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="2.68" SD_2="3.09" SE="1.0509525491211302" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.17504718316191634" CI_END="0.6131570362388439" CI_START="0.20315753825895916" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-0.21242828365799143" LOG_CI_START="-0.692167058331269" LOG_EFFECT_SIZE="-0.45229767099463025" METHOD="MH" MODIFIED="2013-01-21 06:44:16 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6756649341640024" P_Q="0.6756994216307255" P_Z="2.192751215578483E-4" Q="0.1750077088185661" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="60" WEIGHT="200.0" Z="3.6957077152855002">
<NAME>Global state: 3. Significant improvement</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours maintenance</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Intermittent (holiday)</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.890351646543475" CI_START="0.1797042782154134" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-01-21 06:43:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0248038000478183" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.244444749133034">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="0.890351646543475" CI_START="0.1797042782154134" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.05043843381437064" LOG_CI_START="-0.7454415835297045" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-01-21 06:43:51 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.408248290463863" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.16666666666666669" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.67911894972813" CI_START="0.14684171562238474" DF="0" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" I2="0.0" ID="CMP-005.05.02" LOG_CI_END="-0.16805415107126048" LOG_CI_START="-0.8331505500671103" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2013-01-21 06:44:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0031732454959754294" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.9504371972936214">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="0.6791189497281301" CI_START="0.14684171562238474" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="19" LOG_CI_END="-0.1680541510712604" LOG_CI_START="-0.8331505500671103" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2013-01-21 06:44:16 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.39068091705043445" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.15263157894736842" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0677613751634427" CI_START="0.021072123906482297" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.02847420678525765" LOG_CI_START="-1.6762916886738952" LOG_EFFECT_SIZE="-0.8239087409443188" METHOD="MH" MODIFIED="2012-05-21 09:40:17 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.05815992451801418" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="18" WEIGHT="100.0" Z="1.8944905726937669">
<NAME>Adverse effects: 1. Need for additional medication</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (holiday)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0677613751634427" CI_START="0.021072123906482297" DF="0" EFFECT_SIZE="0.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.02847420678525765" LOG_CI_START="-1.6762916886738952" LOG_EFFECT_SIZE="-0.8239087409443188" MODIFIED="2012-05-16 12:49:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05815992451801418" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="100.0" Z="1.8944905726937669">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="1.0677613751634423" CI_START="0.021072123906482318" EFFECT_SIZE="0.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.02847420678525747" LOG_CI_START="-1.6762916886738948" LOG_EFFECT_SIZE="-0.8239087409443188" MODIFIED="2012-05-16 12:49:12 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.0013879257199867" STUDY_ID="STD-McCreadie-1980" TOTAL_1="15" TOTAL_2="18" VAR="1.0027777777777778" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5238394819957213" CI_END="3.3033812385304095" CI_START="0.8168025316266228" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6426229508196721" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.5189586978923199" LOG_CI_START="-0.08788292485140005" LOG_EFFECT_SIZE="0.21553788652045988" METHOD="MH" MODIFIED="2012-05-21 09:40:27 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4692085181967841" P_Q="1.0" P_Z="0.16383785726638883" Q="0.0" RANDOM="NO" SCALE="89.94852926794049" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="23" TOTAL_2="27" WEIGHT="100.0" Z="1.3922792341565844">
<NAME>Adverse effects: 2. Tardive dyskinesia</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (holiday)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5238394819957213" CI_END="3.3033812385304095" CI_START="0.8168025316266228" DF="1" EFFECT_SIZE="1.6426229508196721" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="0.5189586978923199" LOG_CI_START="-0.08788292485140005" LOG_EFFECT_SIZE="0.21553788652045988" MODIFIED="2012-05-16 13:05:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4692085181967841" P_Z="0.16383785726638883" STUDIES="2" TAU2="0.0" TOTAL_1="23" TOTAL_2="27" WEIGHT="100.0" Z="1.3922792341565844">
<NAME>by long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="11.340674842317624" CI_START="0.5079062824821158" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0546388986110724" LOG_CI_START="-0.2942164151878605" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2012-05-16 13:05:14 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.7923242882669809" STUDY_ID="STD-McCreadie-1980" TOTAL_1="15" TOTAL_2="18" VAR="0.6277777777777778" WEIGHT="27.86885245901639"/>
<DICH_DATA CI_END="2.740904667531958" CI_START="0.6649264462164116" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.43789393043741" LOG_CI_START="-0.1772263934473977" LOG_EFFECT_SIZE="0.13033376849500614" MODIFIED="2012-05-16 12:37:04 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.3613247231446467" STUDY_ID="STD-McCreadie-1982" TOTAL_1="8" TOTAL_2="9" VAR="0.1305555555555556" WEIGHT="72.1311475409836"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-005.08" MODIFIED="2013-01-15 02:25:50 +0000" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 3. Tardive dyskinesia (AIMS, high = worse, skew)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.08.01" MODIFIED="2012-04-19 15:44:21 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>by medium term (13-25 weeks)</NAME>
<OTHER_DATA MODIFIED="2012-04-19 15:44:21 +0100" MODIFIED_BY="[Empty name]" ORDER="616" STUDY_ID="STD-Remington-2011">
<TR>
<TD>
<P>Intermittent</P>
</TD>
<TD>
<P>0.00</P>
</TD>
<TD>
<P>0.00</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance</P>
</TD>
<TD>
<P>0.33</P>
</TD>
<TD>
<P>0.78</P>
</TD>
<TD>
<P>18</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="16.094828131764974" CI_END="2.904854223188191" CI_START="0.4531480679958647" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1473138537677288" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="25" I2="68.9341199603621" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="0.46312434269760483" LOG_CI_START="-0.34375986728865643" LOG_EFFECT_SIZE="0.059682237704474235" METHOD="MH" MODIFIED="2012-05-17 15:56:38 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.006578503636649802" P_Q="0.6971316849617362" P_Z="0.7718601822126125" Q="0.7215622405299067" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8772782258939862" TOTALS="YES" TOTAL_1="123" TOTAL_2="125" WEIGHT="100.0" Z="0.2899425592168167">
<NAME>Leaving the study early/ loss to follow-up</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Intermittent (holiday)</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.08190891390962" CI_START="0.04153698100234844" DF="0" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="0.6108633093884327" LOG_CI_START="-1.3815650721164667" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2012-04-20 11:56:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44836476511609336" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="9.9974563316426" Z="0.7581440375927344">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="4.08190891390962" CI_START="0.04153698100234844" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6108633093884327" LOG_CI_START="-1.3815650721164667" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2012-04-12 10:57:16 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.1703622939755296" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" VAR="1.3697478991596639" WEIGHT="9.9974563316426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.686800822467465" CI_END="7.81680929681277" CI_START="0.2521017142287204" DF="2" EFFECT_SIZE="1.4037916595868125" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" I2="84.23558446304182" ID="CMP-005.09.02" LOG_CI_END="0.893029516798852" LOG_CI_START="-0.598424201219457" LOG_EFFECT_SIZE="0.1473026577896974" MODIFIED="2012-05-11 10:06:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0017583171909963946" P_Z="0.6986454119495118" STUDIES="3" TAU2="1.918236151612476" TOTAL_1="77" TOTAL_2="78" WEIGHT="53.832060106277446" Z="0.3871496656006743">
<NAME>by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-05-11 10:06:47 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="14.87115958041166"/>
<DICH_DATA CI_END="16.360161984644304" CI_START="2.5824927674711273" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="4" LOG_CI_END="1.2137875993774132" LOG_CI_START="0.4120391139082979" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2012-05-10 11:13:20 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.47095102908356806" STUDY_ID="STD-Olson-1962_x002a_" TOTAL_1="30" TOTAL_2="30" VAR="0.22179487179487178" WEIGHT="20.439537286939895"/>
<DICH_DATA CI_END="2.6365647790076467" CI_START="0.2721376907678665" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42103844618519687" LOG_CI_START="-0.5652113047512454" LOG_EFFECT_SIZE="-0.07208642928302428" MODIFIED="2012-04-19 13:39:18 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.5793279857150695" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="0.33562091503267977" WEIGHT="18.521363238925893"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.032601305302172756" CI_END="2.1961161478677407" CI_START="0.46099889559085205" DF="1" EFFECT_SIZE="1.0061844357553265" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-005.09.03" LOG_CI_END="0.34165530528813015" LOG_CI_START="-0.3363001150428318" LOG_EFFECT_SIZE="0.002677595122649152" MODIFIED="2012-05-03 12:09:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8567143243520228" P_Z="0.9876477927347719" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="33" WEIGHT="36.170483562079944" Z="0.015481814432608492">
<NAME>long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="4.804220397680052" CI_START="0.2634402452916539" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.681622922815106" LOG_CI_START="-0.5793178779203434" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2012-05-03 12:09:46 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.7406828681096324" STUDY_ID="STD-McCreadie-1980" TOTAL_1="16" TOTAL_2="18" VAR="0.548611111111111" WEIGHT="15.754760890819146"/>
<DICH_DATA CI_END="2.426597970640073" CI_START="0.3810092253451765" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.38499783006278143" LOG_CI_START="-0.4190645086603421" LOG_EFFECT_SIZE="-0.017033339298780342" MODIFIED="2012-04-20 12:22:07 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.47231019793873086" STUDY_ID="STD-McCreadie-1982" TOTAL_1="13" TOTAL_2="15" VAR="0.22307692307692312" WEIGHT="20.4157226712608"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-05-15 09:45:12 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>ANY INTERMITTENT DRUG TECHNIQUE versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="4.981918478393373" CI_END="0.45519220460036686" CI_START="0.21135001777076123" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31016911601801933" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="148" I2="59.85482282229188" I2_Q="34.99867657472792" ID="CMP-006.01" LOG_CI_END="-0.34180518406472943" LOG_CI_START="-0.6749977113185525" LOG_EFFECT_SIZE="-0.5084014476916409" METHOD="MH" MODIFIED="2013-01-21 06:47:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08283054026471681" P_Q="0.21485206978926252" P_Z="2.2147558035494314E-9" Q="1.5384302154242089" RANDOM="NO" SCALE="45.32227486227949" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="193" TOTAL_2="357" WEIGHT="200.0" Z="5.981217738443184">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.453899152177385" CI_START="0.10367296921271095" DF="0" EFFECT_SIZE="0.21692642261689019" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="62" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-0.3430406284601189" LOG_CI_START="-0.9843344630133931" LOG_EFFECT_SIZE="-0.6636875457367559" MODIFIED="2012-05-10 11:36:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.9747475218020964E-5" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="171" WEIGHT="100.0" Z="4.0568102063166185">
<NAME>short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="0.453899152177385" CI_START="0.10367296921271095" EFFECT_SIZE="0.21692642261689019" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="62" LOG_CI_END="-0.3430406284601189" LOG_CI_START="-0.9843344630133931" LOG_EFFECT_SIZE="-0.6636875457367559" MODIFIED="2012-05-10 11:36:30 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.3766991728722713" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="171" VAR="0.1419022668426533" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.588070839043999" CI_END="0.5840150420004881" CI_START="0.23989049852435093" DF="1" EFFECT_SIZE="0.37429889068926836" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="86" I2="61.36118127394892" ID="CMP-006.01.02" LOG_CI_END="-0.2335759669737651" LOG_CI_START="-0.6199869530332628" LOG_EFFECT_SIZE="-0.4267814600035139" MODIFIED="2013-01-21 06:47:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10767179538930449" P_Z="1.4947247619347247E-5" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="186" WEIGHT="100.0" Z="4.329464332297799">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="1.4041551637319367" CI_START="0.3165208916536036" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.1474151014043323" LOG_CI_START="-0.49959761951569487" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-01-21 06:47:21 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.3800584750330461" STUDY_ID="STD-Blackburn-1961" TOTAL_1="15" TOTAL_2="15" VAR="0.1444444444444445" WEIGHT="14.583073663218247"/>
<DICH_DATA CI_END="0.5505119596163701" CI_START="0.19113961350560205" EFFECT_SIZE="0.3243834816868525" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="77" LOG_CI_END="-0.25923324174404366" LOG_CI_START="-0.7186492964927643" LOG_EFFECT_SIZE="-0.488941269118404" MODIFIED="2012-05-10 11:33:33 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.2698632647055465" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="171" VAR="0.07282618163753588" WEIGHT="85.41692633678176"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.1843664851249125" CI_START="0.23898480296955818" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-01-21 06:19:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Global state: 1. significant improvement</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intermittent</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.1843664851249125" CI_START="0.23898480296955818" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-21 06:19:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="4.1843664851249125" CI_START="0.23898480296955818" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.62162971493598" LOG_CI_START="-0.6216297149359801" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-21 06:19:15 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Blackburn-1961" TOTAL_1="15" TOTAL_2="15" VAR="0.5333333333333333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2582335901486295" CI_END="3.011944431763364" CI_START="1.2820341563435171" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9650485079328954" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.4788469551776812" LOG_CI_START="0.10789959594247486" LOG_EFFECT_SIZE="0.2933732755600781" METHOD="MH" MODIFIED="2012-05-17 17:10:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6113363474077703" P_Q="1.0" P_Z="0.0019340566810017701" Q="0.0" RANDOM="YES" SCALE="53.792869566343235" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="3.100176021254311">
<NAME>Leaving the study early/ loss to follow-up</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2582335901486295" CI_END="3.011944431763364" CI_START="1.2820341563435171" DF="1" EFFECT_SIZE="1.9650485079328954" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="14" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.4788469551776812" LOG_CI_START="0.10789959594247486" LOG_EFFECT_SIZE="0.2933732755600781" MODIFIED="2012-05-17 17:10:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6113363474077703" P_Z="0.0019340566810017701" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="3.100176021254311">
<NAME>by medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-17 17:10:15 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Blackburn-1961" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="2.543507362784472"/>
<DICH_DATA CI_END="3.0825378340098912" CI_START="1.2976320860907768" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.48890841568168286" LOG_CI_START="0.1131515756462795" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-05-17 17:10:18 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.22072142786315227" STUDY_ID="STD-Olson-1962_x002a_" TOTAL_1="30" TOTAL_2="30" VAR="0.04871794871794873" WEIGHT="97.45649263721553"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-05-15 09:45:19 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>ANY INTERMITTENT DRUG TECHNIQUE (SPECIFIC DRUG) versus MAINTENANCE THERAPY (SPECIFIC DRUG)</NAME>
<DICH_OUTCOME CHI2="7.909478936893324" CI_END="3.2686446956566826" CI_START="1.8908585969394198" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4860701766287434" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.5143677149817064" LOG_CI_START="0.27665905244890343" LOG_EFFECT_SIZE="0.3955133837153049" METHOD="MH" MODIFIED="2013-04-03 10:43:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9273604773008738" P_Q="0.9293300653072394" P_Z="6.928250170597828E-11" Q="4.365988925773622" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="912" TOTAL_2="685" WEIGHT="1100.0" Z="6.52220225570109">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-05-18 12:53:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>intermittent fluphenazine decanoate (low dose) vs maintained fluphenazine decanoate (moderate dose) - short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-10 12:20:49 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.0" STUDY_ID="STD-Shenoy-1981" TOTAL_1="17" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.217111396832962" CI_START="0.31063820230374717" DF="0" EFFECT_SIZE="2.9076923076923076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="1.4348420308237835" LOG_CI_START="-0.5077451357630062" LOG_EFFECT_SIZE="0.46354844753038854" MODIFIED="2012-05-18 12:53:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34958738230644093" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="0.9353899561123509">
<NAME>intermittent haloperidol equivalents (low dose) vs maintained haloperidol equivalents (low dose) - short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="27.217111396832962" CI_START="0.31063820230374717" EFFECT_SIZE="2.9076923076923076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4348420308237835" LOG_CI_START="-0.5077451357630062" LOG_EFFECT_SIZE="0.46354844753038854" MODIFIED="2012-05-10 12:20:51 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.1410853176146392" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="1.3020757020757021" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.702648095864593" CI_START="0.5250308901101693" DF="0" EFFECT_SIZE="1.7303370786516854" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-007.01.03" LOG_CI_END="0.7560765725776436" LOG_CI_START="-0.27981514419454295" LOG_EFFECT_SIZE="0.2381307141915503" MODIFIED="2013-04-03 10:43:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3675283777796786" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="88" WEIGHT="100.0" Z="0.9011127627944584">
<NAME>various intermittent typical antipsychotics (moderate dose) vs maintained typical antipsychotics (moderate dose) - short term (&#8804;12 weeks)</NAME>
<DICH_DATA CI_END="5.702648095864593" CI_START="0.5250308901101693" EFFECT_SIZE="1.7303370786516854" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7560765725776436" LOG_CI_START="-0.27981514419454295" LOG_EFFECT_SIZE="0.2381307141915503" MODIFIED="2012-05-10 12:20:52 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.6084879221786795" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="88" VAR="0.37025755143732675" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.22303716472749" CI_START="0.869509786418459" DF="0" EFFECT_SIZE="2.3261538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-007.01.04" LOG_CI_END="0.7940023946511705" LOG_CI_START="-0.060725525606506105" LOG_EFFECT_SIZE="0.3666384345223322" MODIFIED="2012-05-18 12:55:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09267236322100512" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="100.0" Z="1.6814663707142754">
<NAME>intermittent haloperidol equivalents (low dose) vs maintained haloperidol equivalents (low dose) - medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="6.22303716472749" CI_START="0.869509786418459" EFFECT_SIZE="2.3261538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7940023946511705" LOG_CI_START="-0.060725525606506105" LOG_EFFECT_SIZE="0.3666384345223322" MODIFIED="2012-05-10 12:03:43 +0100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.5020714113308007" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="0.25207570207570207" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.913879935155344E-32" CI_END="5.4034001575517685" CI_START="0.36885655821539853" DF="0" EFFECT_SIZE="1.4117647058823533" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="100.0" ID="CMP-007.01.05" LOG_CI_END="0.7326671311115549" LOG_CI_START="-0.43314249044489045" LOG_EFFECT_SIZE="0.1497623203333322" MODIFIED="2013-04-03 10:43:27 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.6145691530480213" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="99.99999999999999" Z="0.5035620716572888">
<NAME>various intermittent atypical antipsychotics (dosage unclear) vs maintained atypical/typical antipsychotics (dosage unclear) - medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="5.403400157551767" CI_START="0.36885655821539853" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7326671311115547" LOG_CI_START="-0.43314249044489045" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2012-05-10 11:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.6848023425529537" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="0.46895424836601296" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.749267815044464" CI_START="0.9376830819855172" DF="0" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" ID="CMP-007.01.06" LOG_CI_END="0.5739464637455769" LOG_CI_START="-0.027943919618101734" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2013-04-03 10:43:34 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.07540816081328747" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.7779737831605824">
<NAME>various intermittent typical antipsychotics (low dose) vs maintained typical antipsychotics (low dose) - medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="3.749267815044464" CI_START="0.9376830819855172" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5739464637455769" LOG_CI_START="-0.027943919618101734" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2013-01-21 06:19:40 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Blackburn-1961" TOTAL_1="30" TOTAL_2="30" VAR="0.125" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.16933200362248857" CI_END="9.940407006357873" CI_START="1.4151591348805055" DF="1" EFFECT_SIZE="3.750634316949271" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="5" I2="0.0" ID="CMP-007.01.07" LOG_CI_END="0.9974041667913349" LOG_CI_START="0.15080527909320088" LOG_EFFECT_SIZE="0.5741047229422679" MODIFIED="2013-04-03 10:43:42 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6807064272786421" P_Z="0.007855375126051898" STUDIES="2" TAU2="0.0" TOTAL_1="390" TOTAL_2="161" WEIGHT="100.00000000000001" Z="2.658223620823856">
<NAME>various intermittent typical antipsychotics (moderate dose) vs maintained typical antipsychotics (moderate dose) - medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="9.474271020259568" CI_START="1.08994918004535" EFFECT_SIZE="3.2134831460674156" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9765458039637874" LOG_CI_START="0.03740624900447311" LOG_EFFECT_SIZE="0.5069760264841302" MODIFIED="2012-05-18 12:22:29 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.5516552233988733" STUDY_ID="STD-Caffey-1964" TOTAL_1="89" TOTAL_2="88" VAR="0.3043234855032608" WEIGHT="71.421138176493"/>
<DICH_DATA CI_END="37.24789041280546" CI_START="0.6963853683199257" EFFECT_SIZE="5.093023255813954" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" LOG_CI_END="1.5711016808958063" LOG_CI_START="-0.15715036237474259" LOG_EFFECT_SIZE="0.7069756592605319" MODIFIED="2012-05-18 12:33:31 +0100" MODIFIED_BY="[Empty name]" ORDER="743" O_E="0.0" SE="1.0151838052027076" STUDY_ID="STD-Prien-1973" TOTAL_1="301" TOTAL_2="73" VAR="1.0305981583458488" WEIGHT="28.57886182350701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9431362220428077" CI_END="5.282712359616574" CI_START="1.2996308408803774" DF="1" EFFECT_SIZE="2.62022439994319" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" I2="48.53680412849769" ID="CMP-007.01.08" LOG_CI_END="0.7228569642678294" LOG_CI_START="0.11382000881732829" LOG_EFFECT_SIZE="0.4183384865425788" MODIFIED="2012-05-18 13:29:06 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.16332869183919418" P_Z="0.007090989982011498" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="75" WEIGHT="100.0" Z="2.6925406073723472">
<NAME>intermittent chlorpromazine equivalents (low dose) vs maintained chlorpromazine equivalents (low dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="4.1070038258056885" CI_START="0.8905899300647625" EFFECT_SIZE="1.9125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6135251074130694" LOG_CI_START="-0.05032221976175894" LOG_EFFECT_SIZE="0.2816014438256552" MODIFIED="2012-05-10 11:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.3899472060797612" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.15205882352941175" WEIGHT="89.00250911328884"/>
<DICH_DATA CI_END="61.59870228703997" CI_START="1.1312933193518502" EFFECT_SIZE="8.347826086956522" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7895715628865971" LOG_CI_START="0.05357522248531644" LOG_EFFECT_SIZE="0.9215733926859567" MODIFIED="2012-05-18 13:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.0197328436721884" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="23" TOTAL_2="24" VAR="1.039855072463768" WEIGHT="10.997490886711168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="255.5070437722075" CI_START="0.916178264771043" DF="0" EFFECT_SIZE="15.300000000000002" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-007.01.09" LOG_CI_END="2.4074028771878946" LOG_CI_START="-0.038020015552696934" LOG_EFFECT_SIZE="1.1846914308175989" MODIFIED="2012-05-18 13:29:22 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.057561948966645564" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="16" WEIGHT="100.0" Z="1.8990192200200606">
<NAME>intermittent clozapine (low dose) vs maintained clozapine (low dose) long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="255.5070437722075" CI_START="0.9161782647710427" EFFECT_SIZE="15.3" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.4074028771878946" LOG_CI_START="-0.03802001555269709" LOG_EFFECT_SIZE="1.1846914308175989" MODIFIED="2012-05-18 10:46:22 +0100" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="1.4364535122343702" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="9" TOTAL_2="16" VAR="2.0633986928104577" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.465773095682255" CI_END="4.011466045285497" CI_START="1.595262551385099" DF="2" EFFECT_SIZE="2.529691988799592" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="18" I2="0.0" ID="CMP-007.01.10" LOG_CI_END="0.6033031205052213" LOG_CI_START="0.202832170298563" LOG_EFFECT_SIZE="0.4030676454018922" MODIFIED="2013-01-21 06:19:41 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.4805200295911807" P_Z="7.968510160516995E-5" STUDIES="3" TAU2="0.0" TOTAL_1="113" TOTAL_2="113" WEIGHT="99.99999999999999" Z="3.945345188775371">
<NAME>intermittent haloperidol equivalents (low dose) vs maintained haloperidol equivalents (low dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="172.109750484579" CI_START="0.5600885129602998" EFFECT_SIZE="9.818181818181818" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.235805474985875" LOG_CI_START="-0.2517433343284256" LOG_EFFECT_SIZE="0.9920310703287246" MODIFIED="2012-05-10 12:07:10 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="1.461198484156417" STUDY_ID="STD-Gaebel-2011" TOTAL_1="21" TOTAL_2="23" VAR="2.1351010101010104" WEIGHT="2.560093094294338"/>
<DICH_DATA CI_END="7.090456930116108" CI_START="1.2693117084984007" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8506742233119523" LOG_CI_START="0.10356828612737265" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-21 06:19:41 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.43885372573625553" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.1925925925925926" WEIGHT="26.764609622168077">
<FOOTNOTE>by 2 years</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.651449239334383" CI_START="1.1934891522797948" EFFECT_SIZE="2.0875739644970412" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.5624652676694573" LOG_CI_START="0.07681847602275987" LOG_EFFECT_SIZE="0.31964187184610854" MODIFIED="2012-05-10 12:07:10 +0100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.2852713294036598" STUDY_ID="STD-Wunderink-2007" TOTAL_1="65" TOTAL_2="63" VAR="0.08137973137973138" WEIGHT="70.67529728353757"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10252482521775086" CI_END="5.377605515243795" CI_START="0.5373431102871142" DF="1" EFFECT_SIZE="1.6998880179171334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-007.01.11" LOG_CI_END="0.730588940535756" LOG_CI_START="-0.26974831519392567" LOG_EFFECT_SIZE="0.23042031267091517" MODIFIED="2013-01-21 06:19:51 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.748820557064878" P_Z="0.3665649093272084" STUDIES="2" TAU2="0.0" TOTAL_1="29" TOTAL_2="33" WEIGHT="100.00000000000001" Z="0.9029265111435394">
<NAME>intermittent pimozide (high dose) vs fluphenazine decanoate (low dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="5.710927782353705" CI_START="0.3939815185463059" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7567066683203335" LOG_CI_START="-0.404524150208971" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-01-21 06:19:51 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.6821127309893708" STUDY_ID="STD-McCreadie-1980" TOTAL_1="16" TOTAL_2="18" VAR="0.4652777777777777" WEIGHT="75.25195968645018"/>
<DICH_DATA CI_END="22.62194860474717" CI_START="0.23541048032726553" EFFECT_SIZE="2.3076923076923075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.354530011369287" LOG_CI_START="-0.6281742065436359" LOG_EFFECT_SIZE="0.3631779024128256" MODIFIED="2012-05-10 12:07:08 +0100" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-McCreadie-1982" TOTAL_1="13" TOTAL_2="15" VAR="1.3564102564102565" WEIGHT="24.748040313549833"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.75252583003219" CI_START="0.3781753511114361" DF="0" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-007.01.12" LOG_CI_END="1.3570296160768578" LOG_CI_START="-0.42230678121584553" LOG_EFFECT_SIZE="0.46736141743050613" MODIFIED="2013-04-03 10:43:47 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.3031929900535558" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="11" WEIGHT="100.0" Z="1.0296103056410386">
<NAME>various intermittent typical antipsychotics (low dose) vs maintained typical antipsychotics - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="22.75252583003219" CI_START="0.3781753511114361" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.3570296160768578" LOG_CI_START="-0.42230678121584553" LOG_EFFECT_SIZE="0.46736141743050613" MODIFIED="2012-05-18 10:55:28 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="1.0451910076269517" STUDY_ID="STD-Wiedemann-2001" TOTAL_1="15" TOTAL_2="11" VAR="1.0924242424242425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.179326959059419" CI_END="1.9689464539987098" CI_START="1.2752696939567993" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5845938728293316" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="101" I2="19.08503898358098" I2_Q="19.072726317303093" ID="CMP-007.02" LOG_CI_END="0.2942339055494465" LOG_CI_START="0.1056020390534286" LOG_EFFECT_SIZE="0.19991797230143754" METHOD="MH" MODIFIED="2013-04-03 10:44:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28915877685528535" P_Q="0.2892462000881181" P_Z="3.2605281454955734E-5" Q="6.178386806411164" RANDOM="NO" SCALE="40.76571989714406" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="272" TOTAL_2="389" WEIGHT="100.00000000000001" Z="4.154462688109653">
<NAME>Hospitalisation</NAME>
<GROUP_LABEL_1>Intermittent</GROUP_LABEL_1>
<GROUP_LABEL_2>Maintenance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intermittent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours maintenance</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1372282551634014" CI_START="0.03278508225921429" DF="0" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.32985090712626963" LOG_CI_START="-1.4843237223321302" LOG_EFFECT_SIZE="-0.5772364076029303" MODIFIED="2013-04-03 10:44:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.21230671083036567" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="18" WEIGHT="4.800186856125089" Z="1.2472477027250468">
<NAME>various intermittent atypical antipsychotics (dosage unclear) vs maintained atypical/typical antipsychotics (dosage unclear) - medium term (13-25 weeks)</NAME>
<DICH_DATA CI_END="2.1372282551634014" CI_START="0.03278508225921429" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32985090712626963" LOG_CI_START="-1.4843237223321302" LOG_EFFECT_SIZE="-0.5772364076029303" MODIFIED="2012-05-15 12:19:23 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="1.0656551576531124" STUDY_ID="STD-Remington-2011" TOTAL_1="17" TOTAL_2="18" VAR="1.1356209150326797" WEIGHT="4.800186856125089"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4224156342808483" CI_START="0.6839905640192335" DF="0" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="0.5343327511762583" LOG_CI_START="-0.16494988954106068" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2012-05-18 15:17:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3005223102197022" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="9.784888757389522" Z="1.035313996310103">
<NAME>intermittent chlorpromazine equivalents (low dose) vs maintained chlorpromazine equivalents (low dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="3.4224156342808483" CI_START="0.6839905640192335" EFFECT_SIZE="1.53" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5343327511762583" LOG_CI_START="-0.16494988954106068" LOG_EFFECT_SIZE="0.1846914308175988" MODIFIED="2012-05-10 11:57:14 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.41076208466225117" STUDY_ID="STD-Herz-1991_x002a_" TOTAL_1="50" TOTAL_2="51" VAR="0.1687254901960784" WEIGHT="9.784888757389522"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2560608187073528" CI_START="0.9691866620973162" DF="0" EFFECT_SIZE="1.4786967418546366" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="0.0" ID="CMP-007.02.03" LOG_CI_END="0.3533508031450696" LOG_CI_START="-0.013592571234277744" LOG_EFFECT_SIZE="0.16987911595539598" MODIFIED="2012-05-18 15:17:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.06956090891845602" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="59" WEIGHT="25.494907243580197" Z="1.8147592911917123">
<NAME>intermittent chlorpromazine equivalents (low dose) vs maintained chlorpromazine equivalents (moderate dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="2.2560608187073528" CI_START="0.9691866620973163" EFFECT_SIZE="1.4786967418546366" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.3533508031450696" LOG_CI_START="-0.013592571234277696" LOG_EFFECT_SIZE="0.16987911595539598" MODIFIED="2012-05-18 15:17:21 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.21554435450942633" STUDY_ID="STD-Carpenter-1990_x002a_" TOTAL_1="57" TOTAL_2="59" VAR="0.04645936876088526" WEIGHT="25.494907243580197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.016858929479469" CI_START="0.5999428032937777" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-007.02.04" LOG_CI_END="0.3046755222627276" LOG_CI_START="-0.22189015194627745" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-01-21 06:54:53 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7579752316198016" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="12.353422056204273" Z="0.3081407547326197">
<NAME>intermittent chlorpromazine equivalents (low dose) vs maintained chlorpromazine equivalents (high dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="2.0168589294794694" CI_START="0.5999428032937777" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.30467552226272765" LOG_CI_START="-0.22189015194627745" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2013-01-21 06:54:53 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.30930728357249476" STUDY_ID="STD-Carpenter-1987" TOTAL_1="21" TOTAL_2="21" VAR="0.09567099567099568" WEIGHT="12.353422056204273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.482201132294917" CI_START="1.3263262993243017" DF="0" EFFECT_SIZE="1.8144444444444445" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="54" I2="0.0" ID="CMP-007.02.05" LOG_CI_END="0.39483696938942986" LOG_CI_START="0.12265038120525673" LOG_EFFECT_SIZE="0.2587436752973433" MODIFIED="2012-05-18 15:18:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="1.9428936152276344E-4" STUDIES="1" TAU2="0.0" TOTAL_1="100" TOTAL_2="213" WEIGHT="42.62522626421922" Z="3.7263282382390877">
<NAME>intermittent fluphenazine decanoate (low dose) v maintained fluphenazine decanoate (low+moderate dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="2.482201132294917" CI_START="1.3263262993243017" EFFECT_SIZE="1.8144444444444445" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="54" LOG_CI_END="0.39483696938942986" LOG_CI_START="0.12265038120525673" LOG_EFFECT_SIZE="0.2587436752973433" MODIFIED="2012-05-10 12:10:12 +0100" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="0.15988374924472454" STUDY_ID="STD-Schooler-1997" TOTAL_1="100" TOTAL_2="213" VAR="0.02556281327254995" WEIGHT="42.62522626421922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.568851914749338" CI_START="0.9991607822664675" DF="0" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-007.02.06" LOG_CI_END="0.8790300083107804" LOG_CI_START="-3.64620650255119E-4" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-01-21 06:55:13 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.05019028525880644" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="4.941368822481709" Z="1.9583386770410445">
<NAME>intermittent haloperidol equivalents (low dose) vs maintained haloperidol equivalents (low dose) - long term (&#8805;26 weeks)</NAME>
<DICH_DATA CI_END="7.568851914749338" CI_START="0.9991607822664673" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8790300083107804" LOG_CI_START="-3.646206502552156E-4" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-01-21 06:55:13 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.5165607581253312" STUDY_ID="STD-Jolley-1989_x002f_1990" TOTAL_1="27" TOTAL_2="27" VAR="0.26683501683501687" WEIGHT="4.941368822481709"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-05-15 10:41:03 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-05-21 17:28:55 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK8CAYAAADFzDkhAAA+JElEQVR42u3dD6QV+d/A8R9ZSZIl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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-05-15 10:41:02 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-05-15 10:40:40 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAS8AAAMYCAIAAAAVXPazAAAniUlEQVR42u3dvY4ex3a24QEMGA4Y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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-05-15 10:28:24 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 ANY INTERMITTENT DRUG TECHNIQUE versus MAINTENANCE THERAPY, outcome: 1.1 Relapse.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-05-15 10:41:03 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.29" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 ANY INTERMITTENT DRUG TECHNIQUE versus MAINTENANCE THERAPY, outcome: 1.29 Leaving the study early/loss to follow-up.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-05-15 10:26:54 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-06-12 16:57:13 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-06-12 16:57:13 +0100" MODIFIED_BY="[Empty name]">Previous search term</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-12 16:55:01 +0100" MODIFIED_BY="[Empty name]">
<P>We searched The Cochrane Schizophrenia Group Trials Register (March 2006) using the phrase:<BR/>[(intermit* or drug?holiday* or drug?free* or internal?med*) in title, abstract and index fields in REFERENCE) OR (intermittent medication or drug-free period in interventions field in STUDY)]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-05-15 10:26:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-07-07 10:31:05 +0100" MODIFIED_BY="[Empty name]">Previous data collection and analysis</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-15 10:26:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Selection of trials<BR/>Material downloaded from electronic sources will include details of author, institution or journal of publication.</P>
<P>We (MM and AA) will inspect each report in order to ensure reliable selection. We will resolve any disagreement by discussion, and where there is still doubt, we will acquire the full article for further inspection. Once the full articles are obtained, we (MM and AA) will independently decide whether the studies meet the review criteria. If disagreement cannot be resolved by discussion, we will seek further information and add these trials to the list of those awaiting assessment.</P>
<P>2. Assessment of methodological quality<BR/>We will assess the methodological quality of each of included trials in this review using the criteria described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>) and the Jadad Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The former is based on the evidence of a strong relationship between allocation concealment and direction of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). The categories are defined below:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results) <BR/>C. High risk of bias (inadequate allocation concealment). For the purpose of the analysis in this review, trials will be included if they met the Cochrane Handbook criteria A or B.</P>
<P>The Jadad Scale measures a wider range of factors that impact on the quality of a trial. The scale includes three items:<BR/>1. Was the study described as randomised?<BR/>2. Was the study described as double-blind? <BR/>3. Was there a description of withdrawals and drop outs?</P>
<P>Each item receives one point if the answer is positive. In addition, a point can be deducted if either the randomisation or the blinding/masking procedures described are inadequate. For this review we will use a cut-off of two points on the Jadad scale to check the assessment made by the Handbook criteria. However, we will not use the Jadad Scale to exclude trials.</P>
<P>3. Data collection <BR/>We (MM and AA) will independently extract data from selected trials, while KB and MAM will separately re-extract information from the same trials. When disputes arise we will attempt to resolve these by discussion. When this is not possible and further information is necessary to resolve the dilemma, we will not enter data but we will add the trial to the list of those awaiting assessment.</P>
<P>4. Data synthesis <BR/>4.1 Data types<BR/>We will assess outcomes using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous (for example, either 'no important changes' or 'important changes' in a person's behaviour) measures. Currently RevMan does not support categorical data so we will be unable to analyse these.</P>
<P>4.2 Incomplete data <BR/>We will not include trial outcomes if more than 50% of people are not reported in the final analysis.</P>
<P>4.3 Dichotomous - yes/no - data <BR/>We will carry out an intention-to-treat analysis. On the condition that more than 50% of people complete the study, we will count everyone allocated to the intervention, whether they completed the follow-up or not. We will assume that those who dropped out had the negative outcome, with the exception of death. Where possible, we will make efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study have used a predefined cut-off point for determining clinical effectiveness, we will use this where appropriate. Otherwise, we will generally assume that if there has been a 50% reduction in a scale-derived score, this could be considered as a clinically significant response. Similarly, we will consider a rating of 'at least much improved' according to the Clinical Global Impression Scale (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Guy-1976">Guy 1976</A>) as a clinically significant response.</P>
<P>We will calculate the relative risk (RR) and its 95% confidence interval (CI) based on the fixed-effect model. We will calculate the relative risk of statistically significantly heterogeneous outcomes using a random-effects model. When the overall results are significant, we will calculate the number needed to treat (NNT) and the number needed to harm (NNH) as the inverse of the risk difference.</P>
<P>4.4 Continuous data <BR/>4.4.1 Normally distributed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we will apply the following standards to all data before inclusion: (a) standard deviations (SDs) and means are reported in the paper or are obtainable from the authors; (b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Altman-1996">Altman 1996</A>); (c) if a scale started from a positive value (such as PANSS which can have values from 30 to 210), the calculation described above will be modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-Smin), where S is the mean score and Smin is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied to them. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale), it is difficult to tell whether data are non-normally distributed (skewed) or not. We will enter skewed data from studies of less than 200 participants in additional tables rather than into an analysis. Skewed data poses less of a problem when looking at means if the sample size is large and we will enter these into a synthesis.</P>
<P>For change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we have decided to present change data in MetaView in order to summarise available information. In doing this, we will assume either that data are not skewed or that the analyses could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. Where both change and endpoint data are available for the same outcome category, we will only present endpoint data. We acknowledge that by doing this we will exclude much of the published change data, but argue that endpoint data is more clinically relevant and that if we present change data along with endpoint data, it would be given undeserved equal prominence. We will contact authors of studies reporting only change data for endpoint figures. We will report non-normally distributed data in the 'other data types' tables.</P>
<P>4.4.2 Rating scales: A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. It has been shown that the use of rating scales which have not been described in a peer-reviewed journal (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Marshall-2000">Marshall 2000</A>) are associated with bias, therefore we will exclude the results of such scales. Furthermore, we stipulate that the instrument should either be a self-report or be completed by an independent rater or relative (not the therapist), and that the instrument could be considered a global assessment of an area of functioning. However, as it is expected that therapists would frequently also be the rater, we will include such data but comment on the data as 'prone to bias'.</P>
<P>Whenever possible we will take the opportunity to make direct comparisons between trials that use the same measurement instrument to quantify specific outcomes. Where continuous data are presented from different scales rating the same effect, we will present both sets of data and inspect the general direction of effect.</P>
<P>4.4.3 Summary statistic<BR/>For continuous outcomes, we will estimate a weighted mean difference (WMD) between groups, again based on the fixed-effect model. Afterwards, we will carry out a sensitivity analysis to find heterogeneous data. We will re-assess heterogeneous data using a random-effects model.</P>
<P>4.5 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Divine-1992">Divine 1992</A>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Bland-1997">Bland 1997</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Gulliford-1999">Gulliford 1999</A>).</P>
<P>Where clustering is not accounted for in primary studies, we will present the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients (ICCs) of their clustered data and to adjust for this using accepted methods (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Gulliford-1999">Gulliford 1999</A>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjust for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Donner-2002">Donner 2002</A>). If the ICC is not reported it will be assumed to be 0.1 (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Ukoumunne-1999">Ukoumunne 1999</A>).</P>
<P>If cluster studies are appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies will be possible using the generic inverse variance technique.</P>
<P>5. Investigation for heterogeneity<BR/>Firstly, we will consider all the included studies within any comparison to judge clinical heterogeneity. Then we will visually inspect graphs to investigate the possibility of statistical heterogeneity. This will be supplemented using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate is greater than or equal to 75%, we will interpret this as indicating the presence of high levels of heterogeneity (<A HREF="http://archie.cochrane.org/sections/documents/view?version=42CD293082E26AA201A0DF304D10969F&amp;format=REVMAN#REF-Higgins-2003">Higgins 2003</A>). If inconsistency is high, we will not summate data, but present this separately and investigate the reasons for heterogeneity.</P>
<P>6. Addressing publication bias <BR/>We will enter data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias.</P>
<P>7. Subgroup analyses<BR/>We will carry out a subgroup analysis to compare results between different interventions, as defined in 'Types of interventions'.</P>
<P>8. General <BR/>Where possible, we will enter data in such a way that the area to the left of the line of no effect indicates a favourable outcome for intermittent treatment.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;233 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;233 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;230 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;11 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;208 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;8 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>